CN105102003B - Tall and erect-anti-PSMA antibody conjugates of Pyrrolobenzodiazepines - Google Patents
Tall and erect-anti-PSMA antibody conjugates of Pyrrolobenzodiazepines Download PDFInfo
- Publication number
- CN105102003B CN105102003B CN201380065405.7A CN201380065405A CN105102003B CN 105102003 B CN105102003 B CN 105102003B CN 201380065405 A CN201380065405 A CN 201380065405A CN 105102003 B CN105102003 B CN 105102003B
- Authority
- CN
- China
- Prior art keywords
- seq
- group
- antibody
- pairs
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 title claims abstract description 21
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 title description 10
- 229940127121 immunoconjugate Drugs 0.000 title description 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims abstract description 20
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims abstract description 20
- 150000001875 compounds Chemical class 0.000 claims description 127
- 239000003814 drug Substances 0.000 claims description 78
- 239000000203 mixture Substances 0.000 claims description 78
- 229940079593 drug Drugs 0.000 claims description 74
- 239000000611 antibody drug conjugate Substances 0.000 claims description 63
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 63
- 239000000562 conjugate Substances 0.000 claims description 55
- 206010028980 Neoplasm Diseases 0.000 claims description 37
- 238000002360 preparation method Methods 0.000 claims description 31
- 238000011282 treatment Methods 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 201000011510 cancer Diseases 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 20
- 210000004408 hybridoma Anatomy 0.000 claims description 11
- 230000002062 proliferating effect Effects 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000011068 loading method Methods 0.000 claims description 3
- OMRPLUKQNWNZAV-CONSDPRKSA-N (6as)-3-[3-[[(6as)-2-methoxy-8-(4-methoxyphenyl)-11-oxo-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxy]propoxy]-8-(4-aminophenyl)-2-methoxy-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-11-one Chemical compound C1=CC(OC)=CC=C1C1=CN2C(=O)C3=CC(OC)=C(OCCCOC=4C(=CC=5C(=O)N6C=C(C[C@H]6C=NC=5C=4)C=4C=CC(N)=CC=4)OC)C=C3N=C[C@@H]2C1 OMRPLUKQNWNZAV-CONSDPRKSA-N 0.000 abstract description 4
- -1 carbinolamine methyl ethers Chemical class 0.000 description 191
- 239000002585 base Substances 0.000 description 161
- MTHSVFCYNBDYFN-UHFFFAOYSA-N anhydrous diethylene glycol Natural products OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 152
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 137
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 132
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 99
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 96
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 81
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 77
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 72
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 69
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 67
- 238000000034 method Methods 0.000 description 62
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 62
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 61
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 61
- 239000000243 solution Substances 0.000 description 61
- 210000004027 cell Anatomy 0.000 description 59
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 56
- 238000006243 chemical reaction Methods 0.000 description 56
- 239000000047 product Substances 0.000 description 53
- 230000002829 reductive effect Effects 0.000 description 52
- 239000002904 solvent Substances 0.000 description 52
- 235000019439 ethyl acetate Nutrition 0.000 description 51
- 125000001424 substituent group Chemical group 0.000 description 51
- 229940024606 amino acid Drugs 0.000 description 50
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 50
- 239000011541 reaction mixture Substances 0.000 description 50
- 150000003839 salts Chemical class 0.000 description 50
- 235000001014 amino acid Nutrition 0.000 description 47
- 230000014509 gene expression Effects 0.000 description 47
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 43
- 238000002390 rotary evaporation Methods 0.000 description 39
- 239000003153 chemical reaction reagent Substances 0.000 description 38
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 36
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 35
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 34
- 150000001413 amino acids Chemical class 0.000 description 34
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 33
- 108010016626 Dipeptides Proteins 0.000 description 33
- 125000003275 alpha amino acid group Chemical group 0.000 description 33
- 125000000217 alkyl group Chemical group 0.000 description 32
- 229910052799 carbon Inorganic materials 0.000 description 32
- 238000005160 1H NMR spectroscopy Methods 0.000 description 31
- 125000003118 aryl group Chemical group 0.000 description 31
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 30
- 238000003756 stirring Methods 0.000 description 29
- 125000004429 atom Chemical group 0.000 description 26
- 150000002148 esters Chemical class 0.000 description 26
- 125000005647 linker group Chemical group 0.000 description 26
- 229910052739 hydrogen Inorganic materials 0.000 description 25
- 239000007787 solid Substances 0.000 description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- 229910052736 halogen Inorganic materials 0.000 description 24
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 24
- 239000000741 silica gel Substances 0.000 description 24
- 229910002027 silica gel Inorganic materials 0.000 description 24
- 229960001866 silicon dioxide Drugs 0.000 description 24
- 238000005406 washing Methods 0.000 description 24
- 239000002253 acid Substances 0.000 description 23
- 150000001721 carbon Chemical group 0.000 description 23
- 239000001257 hydrogen Substances 0.000 description 22
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 239000012043 crude product Substances 0.000 description 21
- 150000002367 halogens Chemical class 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- 102000004190 Enzymes Human genes 0.000 description 20
- 108090000790 Enzymes Proteins 0.000 description 20
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 20
- 239000000427 antigen Substances 0.000 description 20
- 229910052786 argon Inorganic materials 0.000 description 20
- 150000004702 methyl esters Chemical group 0.000 description 20
- 102000036639 antigens Human genes 0.000 description 19
- 108091007433 antigens Proteins 0.000 description 19
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 19
- 239000000725 suspension Substances 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 239000012044 organic layer Substances 0.000 description 18
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 18
- 108060003951 Immunoglobulin Proteins 0.000 description 17
- 229910021529 ammonia Inorganic materials 0.000 description 17
- 102000018358 immunoglobulin Human genes 0.000 description 17
- 150000002576 ketones Chemical class 0.000 description 17
- 239000012074 organic phase Substances 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 16
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 16
- 238000003818 flash chromatography Methods 0.000 description 16
- 238000001819 mass spectrum Methods 0.000 description 16
- 239000007858 starting material Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 15
- 125000000524 functional group Chemical group 0.000 description 15
- 150000002466 imines Chemical class 0.000 description 15
- 239000007788 liquid Substances 0.000 description 15
- 229910052760 oxygen Inorganic materials 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 125000003396 thiol group Chemical group [H]S* 0.000 description 15
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 14
- 235000018417 cysteine Nutrition 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 230000027455 binding Effects 0.000 description 13
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 13
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 13
- 229960002433 cysteine Drugs 0.000 description 13
- 238000013461 design Methods 0.000 description 13
- 239000000539 dimer Substances 0.000 description 13
- 238000001704 evaporation Methods 0.000 description 13
- 125000001841 imino group Chemical group [H]N=* 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 239000012071 phase Substances 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- OCAAZRFBJBEVPS-UHFFFAOYSA-N prop-2-enyl carbamate Chemical compound NC(=O)OCC=C OCAAZRFBJBEVPS-UHFFFAOYSA-N 0.000 description 13
- 238000004809 thin layer chromatography Methods 0.000 description 13
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 12
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- 150000001412 amines Chemical class 0.000 description 12
- 125000000539 amino acid group Chemical group 0.000 description 12
- 239000003242 anti bacterial agent Substances 0.000 description 12
- 229940088710 antibiotic agent Drugs 0.000 description 12
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 238000001035 drying Methods 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- 235000019341 magnesium sulphate Nutrition 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 12
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 230000000903 blocking effect Effects 0.000 description 11
- 239000003480 eluent Substances 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 11
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- XMYQHJDBLRZMLW-UHFFFAOYSA-N methanolamine Chemical compound NCO XMYQHJDBLRZMLW-UHFFFAOYSA-N 0.000 description 11
- 238000010898 silica gel chromatography Methods 0.000 description 11
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 11
- 125000001544 thienyl group Chemical group 0.000 description 11
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- 230000008020 evaporation Effects 0.000 description 10
- 229910052731 fluorine Inorganic materials 0.000 description 10
- 239000007789 gas Substances 0.000 description 10
- 125000004076 pyridyl group Chemical group 0.000 description 10
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 9
- 239000004472 Lysine Substances 0.000 description 9
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 9
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 9
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 9
- 235000011089 carbon dioxide Nutrition 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 229960003646 lysine Drugs 0.000 description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 9
- 239000012299 nitrogen atmosphere Substances 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 229960000575 trastuzumab Drugs 0.000 description 9
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 8
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 8
- 239000012300 argon atmosphere Substances 0.000 description 8
- 150000001768 cations Chemical class 0.000 description 8
- 238000004140 cleaning Methods 0.000 description 8
- 238000005520 cutting process Methods 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 125000005842 heteroatom Chemical group 0.000 description 8
- 239000000178 monomer Substances 0.000 description 8
- 230000000269 nucleophilic effect Effects 0.000 description 8
- 239000005416 organic matter Substances 0.000 description 8
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- LJRNQPWPGBDBNV-UHFFFAOYSA-N 26-hydroxyhexacosanamide Chemical compound OCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N LJRNQPWPGBDBNV-UHFFFAOYSA-N 0.000 description 7
- 102000005600 Cathepsins Human genes 0.000 description 7
- 108010084457 Cathepsins Proteins 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 108091092195 Intron Proteins 0.000 description 7
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 7
- 150000001335 aliphatic alkanes Chemical class 0.000 description 7
- 125000001118 alkylidene group Chemical group 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000000460 chlorine Chemical group 0.000 description 7
- 238000006073 displacement reaction Methods 0.000 description 7
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 7
- 125000000623 heterocyclic group Chemical group 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 239000001301 oxygen Chemical group 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 7
- 239000003643 water by type Substances 0.000 description 7
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Chemical compound CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 6
- 150000001336 alkenes Chemical class 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 150000001408 amides Chemical group 0.000 description 6
- 229940125644 antibody drug Drugs 0.000 description 6
- 230000001363 autoimmune Effects 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 6
- 229910052805 deuterium Inorganic materials 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 125000004185 ester group Chemical group 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 229960000485 methotrexate Drugs 0.000 description 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- 150000003053 piperidines Chemical class 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 6
- 238000010792 warming Methods 0.000 description 6
- 229910052727 yttrium Inorganic materials 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 235000011054 acetic acid Nutrition 0.000 description 5
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 150000001767 cationic compounds Chemical class 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical class C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 5
- 239000011737 fluorine Substances 0.000 description 5
- 229960002949 fluorouracil Drugs 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 150000003951 lactams Chemical class 0.000 description 5
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 150000002825 nitriles Chemical group 0.000 description 5
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 5
- 150000003235 pyrrolidines Chemical class 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 229960001153 serine Drugs 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 5
- 229930192474 thiophene Natural products 0.000 description 5
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 5
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical group SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000005864 Sulphur Substances 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 206010047115 Vasculitis Diseases 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 125000004423 acyloxy group Chemical group 0.000 description 4
- 125000002723 alicyclic group Chemical group 0.000 description 4
- 150000001409 amidines Chemical class 0.000 description 4
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 229960003121 arginine Drugs 0.000 description 4
- 235000009697 arginine Nutrition 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- 230000002902 bimodal effect Effects 0.000 description 4
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- DMEGYFMYUHOHGS-UHFFFAOYSA-N cycloheptane Chemical compound C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 4
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 4
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 4
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 229960002449 glycine Drugs 0.000 description 4
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 4
- 150000002373 hemiacetals Chemical class 0.000 description 4
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 4
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000003999 initiator Substances 0.000 description 4
- 229910001411 inorganic cation Inorganic materials 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- BDJAEZRIGNCQBZ-UHFFFAOYSA-N methylcyclobutane Chemical compound CC1CCC1 BDJAEZRIGNCQBZ-UHFFFAOYSA-N 0.000 description 4
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methylcyclopentane Chemical compound CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 4
- 239000002808 molecular sieve Substances 0.000 description 4
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- WPHGSKGZRAQSGP-UHFFFAOYSA-N norcarane Chemical compound C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 150000004880 oxines Chemical class 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000001294 propane Substances 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000005493 quinolyl group Chemical group 0.000 description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 4
- 229960002930 sirolimus Drugs 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 229940124530 sulfonamide Drugs 0.000 description 4
- 150000003456 sulfonamides Chemical class 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 229960004295 valine Drugs 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- BMQDAIUNAGXSKR-UHFFFAOYSA-N (3-hydroxy-2,3-dimethylbutan-2-yl)oxyboronic acid Chemical compound CC(C)(O)C(C)(C)OB(O)O BMQDAIUNAGXSKR-UHFFFAOYSA-N 0.000 description 3
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- ARKUDJPBDMAVBL-UHFFFAOYSA-N 3-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid Chemical compound OC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCNC(=O)CCN1C(=O)C=CC1=O ARKUDJPBDMAVBL-UHFFFAOYSA-N 0.000 description 3
- 241001093575 Alma Species 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 229940126062 Compound A Drugs 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000012828 PI3K inhibitor Substances 0.000 description 3
- FADYJNXDPBKVCA-STQMWFEESA-N Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 FADYJNXDPBKVCA-STQMWFEESA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 229910007262 Si2M Inorganic materials 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 101710183280 Topoisomerase Proteins 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 125000004419 alkynylene group Chemical group 0.000 description 3
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 3
- 229960003437 aminoglutethimide Drugs 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 150000001491 aromatic compounds Chemical class 0.000 description 3
- 229960005261 aspartic acid Drugs 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 3
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 229910052801 chlorine Chemical group 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 229960002173 citrulline Drugs 0.000 description 3
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- IBAHLNWTOIHLKE-UHFFFAOYSA-N cyano cyanate Chemical compound N#COC#N IBAHLNWTOIHLKE-UHFFFAOYSA-N 0.000 description 3
- 229960000640 dactinomycin Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 150000002085 enols Chemical group 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000002532 enzyme inhibitor Substances 0.000 description 3
- 229940125532 enzyme inhibitor Drugs 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 229960002989 glutamic acid Drugs 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 150000002460 imidazoles Chemical class 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 3
- 125000001967 indiganyl group Chemical group [H][In]([H])[*] 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000005956 isoquinolyl group Chemical group 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000002891 organic anions Chemical class 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 3
- 150000008300 phosphoramidites Chemical class 0.000 description 3
- 229960005141 piperazine Drugs 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 125000001453 quaternary ammonium group Chemical group 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 229910001923 silver oxide Inorganic materials 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 150000003453 sulfinic acid esters Chemical class 0.000 description 3
- 150000003457 sulfones Chemical class 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- BPLUKJNHPBNVQL-UHFFFAOYSA-N triphenylarsine Chemical compound C1=CC=CC=C1[As](C=1C=CC=CC=1)C1=CC=CC=C1 BPLUKJNHPBNVQL-UHFFFAOYSA-N 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 229960000281 trometamol Drugs 0.000 description 3
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 2
- XXAFQSGWAGUKDT-UHFFFAOYSA-N (4-aminophenyl)boronic acid;2,3-dimethylbutane-2,3-diol Chemical compound CC(C)(O)C(C)(C)O.NC1=CC=C(B(O)O)C=C1 XXAFQSGWAGUKDT-UHFFFAOYSA-N 0.000 description 2
- XRBSKUSTLXISAB-XVVDYKMHSA-N (5r,6r,7r,8r)-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(O)=O)=C1 XRBSKUSTLXISAB-XVVDYKMHSA-N 0.000 description 2
- JEZZKSQFJNWDCY-NSIKDUERSA-N (8z)-2-[3,4-dihydroxy-4,6-dimethyl-5-(methylamino)oxan-2-yl]oxy-8-propylidene-7,9-dihydro-6ah-pyrrolo[2,1-c][1,4]benzodiazepin-11-one Chemical compound C1=C2C(=O)N3CC(=C/CC)\CC3C=NC2=CC=C1OC1OC(C)C(NC)C(C)(O)C1O JEZZKSQFJNWDCY-NSIKDUERSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- UQVNRKBFAXNOGA-OHLDGCSVSA-N (Z)-tomaymycin Chemical compound CO[C@H]1NC2=CC(O)=C(OC)C=C2C(=O)N2C\C(=C/C)C[C@@H]12 UQVNRKBFAXNOGA-OHLDGCSVSA-N 0.000 description 2
- VMOHRPRQENZZPX-GQCTYLIASA-N (e)-3-(4,6-dihydroxy-3-methyl-11-oxo-5,6,6a,9-tetrahydropyrrolo[2,1-c][1,4]benzodiazepin-8-yl)-n-methylprop-2-enamide Chemical compound OC1NC2=C(O)C(C)=CC=C2C(=O)N2CC(/C=C/C(=O)NC)=CC21 VMOHRPRQENZZPX-GQCTYLIASA-N 0.000 description 2
- OFZYBEBWCZBCPM-UHFFFAOYSA-N 1,1-dimethylcyclobutane Chemical compound CC1(C)CCC1 OFZYBEBWCZBCPM-UHFFFAOYSA-N 0.000 description 2
- YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- AAQTWLBJPNLKHT-UHFFFAOYSA-N 1H-perimidine Chemical compound N1C=NC2=CC=CC3=CC=CC1=C32 AAQTWLBJPNLKHT-UHFFFAOYSA-N 0.000 description 2
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 2
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical class CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- ZPVFWPFBNIEHGJ-UHFFFAOYSA-N 2-octanone Chemical compound CCCCCCC(C)=O ZPVFWPFBNIEHGJ-UHFFFAOYSA-N 0.000 description 2
- FXMOIYLVKOALHC-UHFFFAOYSA-N 3,9-dihydroxy-2-methoxy-6a,7,8,9-tetrahydropyrrolo[2,1-c][1,4]benzodiazepin-11-one Chemical compound N1=CC2CCC(O)N2C(=O)C2=C1C=C(O)C(OC)=C2 FXMOIYLVKOALHC-UHFFFAOYSA-N 0.000 description 2
- PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 2
- FQWNGSKQHPNIQG-UHFFFAOYSA-N 3-[[bis(2-chloroethyl)amino-(2-chloroethoxy)phosphoryl]amino]propan-1-ol Chemical compound OCCCNP(=O)(OCCCl)N(CCCl)CCCl FQWNGSKQHPNIQG-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 239000001142 4-methyl-2-oxopentanoic acid Substances 0.000 description 2
- ODVBBZFQPGORMJ-UHFFFAOYSA-N 4-nitrobenzylamine Chemical class NCC1=CC=C([N+]([O-])=O)C=C1 ODVBBZFQPGORMJ-UHFFFAOYSA-N 0.000 description 2
- TWSIYGATPWEKBK-UHFFFAOYSA-N 4h-1,3-benzodioxine Chemical compound C1=CC=C2OCOCC2=C1 TWSIYGATPWEKBK-UHFFFAOYSA-N 0.000 description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- XCRAFUWHEIINMU-UHFFFAOYSA-N CC(C)[Si]([O])(C(C)C)C(C)C Chemical compound CC(C)[Si]([O])(C(C)C)C(C)C XCRAFUWHEIINMU-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000004225 Cathepsin B Human genes 0.000 description 2
- 108090000712 Cathepsin B Proteins 0.000 description 2
- 241000254173 Coleoptera Species 0.000 description 2
- 229930188224 Cryptophycin Natural products 0.000 description 2
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-CBPJZXOFSA-N D-Gulose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-CBPJZXOFSA-N 0.000 description 2
- WQZGKKKJIJFFOK-WHZQZERISA-N D-aldose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 241000790917 Dioxys <bee> Species 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000003807 Graves Disease Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 241000288105 Grus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 2
- 101000945318 Homo sapiens Calponin-1 Chemical group 0.000 description 2
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 2
- 101000652736 Homo sapiens Transgelin Chemical group 0.000 description 2
- 241001062009 Indigofera Species 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 208000005777 Lupus Nephritis Diseases 0.000 description 2
- FSNCEEGOMTYXKY-JTQLQIEISA-N Lycoperodine 1 Natural products N1C2=CC=CC=C2C2=C1CN[C@H](C(=O)O)C2 FSNCEEGOMTYXKY-JTQLQIEISA-N 0.000 description 2
- 229940124647 MEK inhibitor Drugs 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 229930126263 Maytansine Natural products 0.000 description 2
- 229930184247 Mazethramycin Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- JEZZKSQFJNWDCY-UHFFFAOYSA-N Sibanomicin Natural products C1=C2C(=O)N3CC(=CCC)CC3C=NC2=CC=C1OC1OC(C)C(NC)C(C)(O)C1O JEZZKSQFJNWDCY-UHFFFAOYSA-N 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102100031013 Transgelin Human genes 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 2
- HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 description 2
- PVNFMCBFDPTNQI-UIBOPQHZSA-N [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] acetate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 3-methylbutanoate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 2-methylpropanoate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] propanoate Chemical compound CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(C)=O)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2.CCC(=O)O[C@H]1CC(=O)N(C)c2cc(C\C(C)=C\C=C\[C@@H](OC)[C@@]3(O)C[C@H](OC(=O)N3)[C@@H](C)C3O[C@@]13C)cc(OC)c2Cl.CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2.CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)CC(C)C)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 PVNFMCBFDPTNQI-UIBOPQHZSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- ZOZKYEHVNDEUCO-XUTVFYLZSA-N aceglatone Chemical compound O1C(=O)[C@H](OC(C)=O)[C@@H]2OC(=O)[C@@H](OC(=O)C)[C@@H]21 ZOZKYEHVNDEUCO-XUTVFYLZSA-N 0.000 description 2
- 229950002684 aceglatone Drugs 0.000 description 2
- CWRYPZZKDGJXCA-UHFFFAOYSA-N acenaphthene Chemical compound C1=CC(CC2)=C3C2=CC=CC3=C1 CWRYPZZKDGJXCA-UHFFFAOYSA-N 0.000 description 2
- 125000004036 acetal group Chemical group 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229910001413 alkali metal ion Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000005336 allyloxy group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 150000001449 anionic compounds Chemical class 0.000 description 2
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 2
- 150000003851 azoles Chemical class 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- SHOMMGQAMRXRRK-UHFFFAOYSA-N bicyclo[3.1.1]heptane Chemical compound C1C2CC1CCC2 SHOMMGQAMRXRRK-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- BEWYHVAWEKZDPP-UHFFFAOYSA-N bornane Chemical compound C1CC2(C)CCC1C2(C)C BEWYHVAWEKZDPP-UHFFFAOYSA-N 0.000 description 2
- 150000001642 boronic acid derivatives Chemical class 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 2
- 229930195731 calicheamicin Natural products 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- SKOLWUPSYHWYAM-UHFFFAOYSA-N carbonodithioic O,S-acid Chemical compound SC(S)=O SKOLWUPSYHWYAM-UHFFFAOYSA-N 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 2
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 108010006226 cryptophycin Proteins 0.000 description 2
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 2
- PSNOPSMXOBPNNV-UHFFFAOYSA-N cryptophycin-327 Natural products C1=C(Cl)C(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 PSNOPSMXOBPNNV-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 2
- 229950004239 defosfamide Drugs 0.000 description 2
- 229960005052 demecolcine Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000004807 desolvation Methods 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 229940043237 diethanolamine Drugs 0.000 description 2
- QWHNJUXXYKPLQM-UHFFFAOYSA-N dimethyl cyclopentane Natural products CC1(C)CCCC1 QWHNJUXXYKPLQM-UHFFFAOYSA-N 0.000 description 2
- HGGNZMUHOHGHBJ-UHFFFAOYSA-N dioxepane Chemical compound C1CCOOCC1 HGGNZMUHOHGHBJ-UHFFFAOYSA-N 0.000 description 2
- 150000002019 disulfides Chemical class 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 2
- 229950007432 endomycin Drugs 0.000 description 2
- 229940031098 ethanolamine Drugs 0.000 description 2
- 229940012017 ethylenediamine Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000000893 fibroproliferative effect Effects 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000001976 hemiacetal group Chemical group 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 102000054751 human RUNX1T1 Human genes 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- DOUHZFSGSXMPIE-UHFFFAOYSA-N hydroxidooxidosulfur(.) Chemical compound [O]SO DOUHZFSGSXMPIE-UHFFFAOYSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000003454 indenyl group Chemical class C1(C=CC2=CC=CC=C12)* 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 2
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- 150000004715 keto acids Chemical class 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229910000474 mercury oxide Inorganic materials 0.000 description 2
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 229940087646 methanolamine Drugs 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 125000006518 morpholino carbonyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])N(C(*)=O)C1([H])[H] 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- GTWJETSWSUWSEJ-UHFFFAOYSA-N n-benzylaniline Chemical compound C=1C=CC=CC=1CNC1=CC=CC=C1 GTWJETSWSUWSEJ-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 229930188317 neothramycin Natural products 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- HKKDKUMUWRTAIA-UHFFFAOYSA-N nitridooxidocarbon(.) Chemical class [O]C#N HKKDKUMUWRTAIA-UHFFFAOYSA-N 0.000 description 2
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 150000002892 organic cations Chemical class 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 150000004893 oxazines Chemical class 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- RPGWZZNNEUHDAQ-UHFFFAOYSA-N phenylphosphine Chemical compound PC1=CC=CC=C1 RPGWZZNNEUHDAQ-UHFFFAOYSA-N 0.000 description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000008301 phosphite esters Chemical class 0.000 description 2
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 2
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical group [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 150000003214 pyranose derivatives Chemical class 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 150000003233 pyrroles Chemical class 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 2
- RAGFPHFDFVNLCG-INYQBOQCSA-N sibiromycin Chemical compound O[C@@H]1[C@@](O)(C)[C@@H](NC)[C@H](C)O[C@H]1OC(C(=C1O)C)=CC(C2=O)=C1N[C@H](O)[C@H]1N2C=C(\C=C\C)C1 RAGFPHFDFVNLCG-INYQBOQCSA-N 0.000 description 2
- RAGFPHFDFVNLCG-UHFFFAOYSA-N sibiromycin Natural products OC1C(O)(C)C(NC)C(C)OC1OC(C(=C1O)C)=CC(C2=O)=C1NC(O)C1N2C=C(C=CC)C1 RAGFPHFDFVNLCG-UHFFFAOYSA-N 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 229950006315 spirogermanium Drugs 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical group C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 150000003459 sulfonic acid esters Chemical class 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 125000003666 tauryl group Chemical group [H]N([H])C([H])([H])C([H])([H])S(*)(=O)=O 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- DTMHTVJOHYTUHE-UHFFFAOYSA-N thiocyanogen Chemical compound N#CSSC#N DTMHTVJOHYTUHE-UHFFFAOYSA-N 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 125000005323 thioketone group Chemical group 0.000 description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 206010043778 thyroiditis Diseases 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- 229960005267 tositumomab Drugs 0.000 description 2
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- QWPXBEHQFHACTK-KZVYIGENSA-N (10e,12e)-86-chloro-12,14,4-trihydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-15,16-dihydro-14h-7-aza-1(6,4)-oxazina-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-6-one Chemical compound CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-KZVYIGENSA-N 0.000 description 1
- JKHVDAUOODACDU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCN1C(=O)C=CC1=O JKHVDAUOODACDU-UHFFFAOYSA-N 0.000 description 1
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 1
- BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical group C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 description 1
- PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical group O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 description 1
- VLARLSIGSPVYHX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-(2,5-dioxopyrrol-1-yl)hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O VLARLSIGSPVYHX-UHFFFAOYSA-N 0.000 description 1
- WCMOHMXWOOBVMZ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoate Chemical group O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCN1C(=O)C=CC1=O WCMOHMXWOOBVMZ-UHFFFAOYSA-N 0.000 description 1
- IHVODYOQUSEYJJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]amino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)C(CC1)CCC1CN1C(=O)C=CC1=O IHVODYOQUSEYJJ-UHFFFAOYSA-N 0.000 description 1
- AEELXMHQIJJMKP-QWWZWVQMSA-N (2r,3r)-3-sulfanylbutane-1,2,4-triol Chemical compound OC[C@@H](O)[C@H](S)CO AEELXMHQIJJMKP-QWWZWVQMSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- SVNJBEMPMKWDCO-KCHLEUMXSA-N (2s)-2-[[(2s)-3-carboxy-2-[[2-[[(2s)-5-(diaminomethylideneamino)-2-[[4-oxo-4-[[4-(4-oxo-8-phenylchromen-2-yl)morpholin-4-ium-4-yl]methoxy]butanoyl]amino]pentanoyl]amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoate Chemical compound C=1C(=O)C2=CC=CC(C=3C=CC=CC=3)=C2OC=1[N+]1(COC(=O)CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C([O-])=O)CCOCC1 SVNJBEMPMKWDCO-KCHLEUMXSA-N 0.000 description 1
- FLWWDYNPWOSLEO-HQVZTVAUSA-N (2s)-2-[[4-[1-(2-amino-4-oxo-1h-pteridin-6-yl)ethyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1C(C)N(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FLWWDYNPWOSLEO-HQVZTVAUSA-N 0.000 description 1
- LMGGOGHEVZMZCU-FGJMKEJPSA-N (2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,7,12-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-2-carboxylic acid Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(O)=O)C1 LMGGOGHEVZMZCU-FGJMKEJPSA-N 0.000 description 1
- CGMTUJFWROPELF-YPAAEMCBSA-N (3E,5S)-5-[(2S)-butan-2-yl]-3-(1-hydroxyethylidene)pyrrolidine-2,4-dione Chemical compound CC[C@H](C)[C@@H]1NC(=O)\C(=C(/C)O)C1=O CGMTUJFWROPELF-YPAAEMCBSA-N 0.000 description 1
- TVIRNGFXQVMMGB-OFWIHYRESA-N (3s,6r,10r,13e,16s)-16-[(2r,3r,4s)-4-chloro-3-hydroxy-4-phenylbutan-2-yl]-10-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(2-methylpropyl)-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H](O)[C@@H](Cl)C=2C=CC=CC=2)C/C=C/C(=O)N1 TVIRNGFXQVMMGB-OFWIHYRESA-N 0.000 description 1
- LTDQGCFMTVHZKP-UHFFFAOYSA-N (4-bromophenyl)-(4,6-dimethoxy-3-methyl-1-benzofuran-2-yl)methanone Chemical compound O1C2=CC(OC)=CC(OC)=C2C(C)=C1C(=O)C1=CC=C(Br)C=C1 LTDQGCFMTVHZKP-UHFFFAOYSA-N 0.000 description 1
- FZWQGZDXQUCCFS-UHFFFAOYSA-N (4-methyl-2,3-dihydro-1H-pyrrol-2-yl)methanol Chemical class OCC1NC=C(C1)C FZWQGZDXQUCCFS-UHFFFAOYSA-N 0.000 description 1
- ZYMCBJWUWHHVRX-UHFFFAOYSA-N (4-nitrophenyl)-phenylmethanone Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(=O)C1=CC=CC=C1 ZYMCBJWUWHHVRX-UHFFFAOYSA-N 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- GYUDGZRJHSDPLH-KJQCOJPZSA-N (6as,8e)-8-ethylidene-7,9-dihydro-6ah-pyrrolo[2,1-c][1,4]benzodiazepin-11-one Chemical compound C1=NC2=CC=CC=C2C(=O)N2CC(=C/C)/C[C@H]21 GYUDGZRJHSDPLH-KJQCOJPZSA-N 0.000 description 1
- XRBSKUSTLXISAB-UHFFFAOYSA-N (7R,7'R,8R,8'R)-form-Podophyllic acid Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C(CO)C2C(O)=O)=C1 XRBSKUSTLXISAB-UHFFFAOYSA-N 0.000 description 1
- JXVAMODRWBNUSF-KZQKBALLSA-N (7s,9r,10r)-7-[(2r,4s,5s,6s)-5-[[(2s,4as,5as,7s,9s,9ar,10ar)-2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl]oxy]-4-(dimethylamino)-6-methyloxan-2-yl]oxy-10-[(2s,4s,5s,6s)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2 Chemical compound O([C@@H]1C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C2[C@@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@H]4O[C@@H]5O[C@@H](C)C(=O)C[C@@H]5O[C@H]4C3)[C@H](C2)N(C)C)C[C@]1(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 JXVAMODRWBNUSF-KZQKBALLSA-N 0.000 description 1
- INAUWOVKEZHHDM-PYBHCKQVSA-N (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-(5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl)oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)C(OC(C)C1O)CC1N1CCOCC1 INAUWOVKEZHHDM-PYBHCKQVSA-N 0.000 description 1
- RCFNNLSZHVHCEK-IMHLAKCZSA-N (7s,9s)-7-(4-amino-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound [Cl-].O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)C1CC([NH3+])CC(C)O1 RCFNNLSZHVHCEK-IMHLAKCZSA-N 0.000 description 1
- DIPVWSTVQDONTF-NUAZBEIESA-N (8E)-2-[(2S,3R,4R,5R,6S)-3,4-dihydroxy-6-methyl-5-(methylamino)oxan-2-yl]oxy-6-methoxy-8-propylidene-6,6a,7,9-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-11-one Chemical compound CC\C=C1/CC2C(Nc3ccc(O[C@@H]4O[C@@H](C)[C@H](NC)[C@@H](O)[C@H]4O)cc3C(=O)N2C1)OC DIPVWSTVQDONTF-NUAZBEIESA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006593 (C2-C3) alkynyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- OQMYRVPMCIOFHL-GCOHUWJYSA-N (e)-3-[(6r)-6-hydroxy-4-methoxy-11-oxo-5,6,6a,7-tetrahydropyrrolo[2,1-c][1,4]benzodiazepin-8-yl]-n,n-dimethylprop-2-enamide Chemical compound N1[C@H](O)C2CC(\C=C\C(=O)N(C)C)=CN2C(=O)C2=C1C(OC)=CC=C2 OQMYRVPMCIOFHL-GCOHUWJYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- PBIJFSCPEFQXBB-UHFFFAOYSA-N 1,1-dimethylcyclopropane Chemical compound CC1(C)CC1 PBIJFSCPEFQXBB-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- OQQIAKKDWPPRHE-UHFFFAOYSA-N 1,2-benzodiazepin-2-yl trifluoromethanesulfonate Chemical compound FC(S(=O)(=O)ON1N=C2C(=CC=C1)C=CC=C2)(F)F OQQIAKKDWPPRHE-UHFFFAOYSA-N 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- SZZWLAZADBEDQP-UHFFFAOYSA-N 1,2-dimethylcyclopentene Chemical compound CC1=C(C)CCC1 SZZWLAZADBEDQP-UHFFFAOYSA-N 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- BGJSXRVXTHVRSN-UHFFFAOYSA-N 1,3,5-trioxane Chemical compound C1OCOCO1 BGJSXRVXTHVRSN-UHFFFAOYSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- RMJHGWFYNDUDRZ-UHFFFAOYSA-N 1,3-benzodioxol-5-yloxyboronic acid Chemical compound OB(O)OC1=CC=C2OCOC2=C1 RMJHGWFYNDUDRZ-UHFFFAOYSA-N 0.000 description 1
- 150000000183 1,3-benzoxazoles Chemical class 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- GUJAGMICFDYKNR-UHFFFAOYSA-N 1,4-benzodiazepine Chemical compound N1C=CN=CC2=CC=CC=C12 GUJAGMICFDYKNR-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- SGVWDRVQIYUSRA-UHFFFAOYSA-N 1-[2-[2-(2,5-dioxopyrrol-1-yl)ethyldisulfanyl]ethyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1CCSSCCN1C(=O)C=CC1=O SGVWDRVQIYUSRA-UHFFFAOYSA-N 0.000 description 1
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 description 1
- MUPYMRJBEZFVMT-UHFFFAOYSA-N 1-chloro-4-dimethoxyphosphorylsulfanylbenzene Chemical compound COP(=O)(OC)SC1=CC=C(Cl)C=C1 MUPYMRJBEZFVMT-UHFFFAOYSA-N 0.000 description 1
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 1
- BLXSFCHWMBESKV-UHFFFAOYSA-N 1-iodopentane Chemical class CCCCCI BLXSFCHWMBESKV-UHFFFAOYSA-N 0.000 description 1
- OCINXEZVIIVXFU-UHFFFAOYSA-N 1-methyl-3-[3-methyl-4-[4-(trifluoromethylthio)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(SC(F)(F)F)C=C1 OCINXEZVIIVXFU-UHFFFAOYSA-N 0.000 description 1
- ATQUFXWBVZUTKO-UHFFFAOYSA-N 1-methylcyclopentene Chemical compound CC1=CCCC1 ATQUFXWBVZUTKO-UHFFFAOYSA-N 0.000 description 1
- SHDPRTQPPWIEJG-UHFFFAOYSA-N 1-methylcyclopropene Chemical compound CC1=CC1 SHDPRTQPPWIEJG-UHFFFAOYSA-N 0.000 description 1
- 125000004806 1-methylethylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- RUFPHBVGCFYCNW-UHFFFAOYSA-N 1-naphthylamine Chemical compound C1=CC=C2C(N)=CC=CC2=C1 RUFPHBVGCFYCNW-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- DGHHQBMTXTWTJV-BQAIUKQQSA-N 119413-54-6 Chemical compound Cl.C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 DGHHQBMTXTWTJV-BQAIUKQQSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- BTOTXLJHDSNXMW-POYBYMJQSA-N 2,3-dideoxyuridine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 1
- FJRPOHLDJUJARI-UHFFFAOYSA-N 2,3-dihydro-1,2-oxazole Chemical compound C1NOC=C1 FJRPOHLDJUJARI-UHFFFAOYSA-N 0.000 description 1
- ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical compound C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 description 1
- FLNPFFMWAPTGOT-UHFFFAOYSA-N 2,3-dihydro-1h-pyrazole Chemical compound C1NNC=C1.C1NNC=C1 FLNPFFMWAPTGOT-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 description 1
- BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
- YOYAIZYFCNQIRF-UHFFFAOYSA-N 2,6-dichlorobenzonitrile Chemical compound ClC1=CC=CC(Cl)=C1C#N YOYAIZYFCNQIRF-UHFFFAOYSA-N 0.000 description 1
- BSRGOPQVDCJHIW-UHFFFAOYSA-N 2-(2-aminophenyl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=CC=C1N BSRGOPQVDCJHIW-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- ZDEIVOHRTZOREU-UHFFFAOYSA-N 2-[2-(2-hydroxyethoxy)ethoxy]ethanol pyrrole-2,5-dione Chemical group O=C1NC(=O)C=C1.O=C1NC(=O)C=C1.OCCOCCOCCO ZDEIVOHRTZOREU-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- QINPEPAQOBZPOF-UHFFFAOYSA-N 2-amino-n-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C(C)(C)N)C=CC=2)=C1 QINPEPAQOBZPOF-UHFFFAOYSA-N 0.000 description 1
- WAMWSIDTKSNDCU-UHFFFAOYSA-N 2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)C(N)C1CCCCC1 WAMWSIDTKSNDCU-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- VNBAOSVONFJBKP-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)propan-1-amine;hydrochloride Chemical compound Cl.CC(Cl)CN(CCCl)CCCl VNBAOSVONFJBKP-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- QXHPJWAXVTUDBA-UHFFFAOYSA-N 2-oxo-2-sulfanylacetic acid Chemical compound OC(=O)C(S)=O QXHPJWAXVTUDBA-UHFFFAOYSA-N 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- JZIBVTUXIVIFGC-UHFFFAOYSA-N 2H-pyrrole Chemical class C1C=CC=N1 JZIBVTUXIVIFGC-UHFFFAOYSA-N 0.000 description 1
- CMLFRMDBDNHMRA-UHFFFAOYSA-N 2h-1,2-benzoxazine Chemical compound C1=CC=C2C=CNOC2=C1 CMLFRMDBDNHMRA-UHFFFAOYSA-N 0.000 description 1
- JKSIXVZIFHKAPJ-UHFFFAOYSA-N 2h-benzotriazole;hydrate Chemical compound O.C1=CC=C2NN=NC2=C1 JKSIXVZIFHKAPJ-UHFFFAOYSA-N 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- YIMDLWDNDGKDTJ-QLKYHASDSA-N 3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-QLKYHASDSA-N 0.000 description 1
- FKIAGKIPWUJFBM-UHFFFAOYSA-N 3-(2,5-dioxopyrrolidin-1-yl)pyrrole-2,5-dione Chemical compound O=C1NC(=O)C(N2C(CCC2=O)=O)=C1 FKIAGKIPWUJFBM-UHFFFAOYSA-N 0.000 description 1
- VAJVDSVGBWFCLW-UHFFFAOYSA-N 3-Phenyl-1-propanol Chemical compound OCCCC1=CC=CC=C1 VAJVDSVGBWFCLW-UHFFFAOYSA-N 0.000 description 1
- IWCQHVUQEFDRIW-UHFFFAOYSA-N 3-[1-[[4-(6-phenyl-8H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one Chemical compound O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(cc2)-c2[nH]c3cc4ncnc4cc3nc2-c2ccccc2)CC1 IWCQHVUQEFDRIW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- OROGUZVNAFJPHA-UHFFFAOYSA-N 3-hydroxy-2,4-dimethyl-2H-thiophen-5-one Chemical compound CC1SC(=O)C(C)=C1O OROGUZVNAFJPHA-UHFFFAOYSA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- WPPHMBKSJVDIFZ-UHFFFAOYSA-N 3H-1,2-benzodioxole Chemical compound C1=CC=C2COOC2=C1 WPPHMBKSJVDIFZ-UHFFFAOYSA-N 0.000 description 1
- VXIKDBJPBRMXBP-UHFFFAOYSA-N 3H-pyrrole Chemical class C1C=CN=C1 VXIKDBJPBRMXBP-UHFFFAOYSA-N 0.000 description 1
- RELAJOWOFXGXHI-UHFFFAOYSA-N 3h-oxathiole Chemical compound C1SOC=C1 RELAJOWOFXGXHI-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
- ZMRMMAOBSFSXLN-UHFFFAOYSA-N 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanehydrazide Chemical compound C1=CC(CCCC(=O)NN)=CC=C1N1C(=O)C=CC1=O ZMRMMAOBSFSXLN-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- WCVPFJVXEXJFLB-UHFFFAOYSA-N 4-aminobutanamide Chemical compound NCCCC(N)=O WCVPFJVXEXJFLB-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 1
- JTSFIVQMXUDGAB-UHFFFAOYSA-N 4-thiomorpholin-4-ylmorpholine Chemical compound C1COCCN1N1CCSCC1 JTSFIVQMXUDGAB-UHFFFAOYSA-N 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- HCXJFMDOHDNDCC-UHFFFAOYSA-N 5-$l^{1}-oxidanyl-3,4-dihydropyrrol-2-one Chemical group O=C1CCC(=O)[N]1 HCXJFMDOHDNDCC-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- WOJKKJKETHYEAC-UHFFFAOYSA-N 6-Maleimidocaproic acid Chemical compound OC(=O)CCCCCN1C(=O)C=CC1=O WOJKKJKETHYEAC-UHFFFAOYSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- NVWKYNBWYYJZTK-UHFFFAOYSA-N 8-(2,5-dioxopyrrolidin-1-yl)oxy-8-oxooctanoic acid Chemical class OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O NVWKYNBWYYJZTK-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- PQJUJGAVDBINPI-UHFFFAOYSA-N 9H-thioxanthene Chemical compound C1=CC=C2CC3=CC=CC=C3SC2=C1 PQJUJGAVDBINPI-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- UIXMXBXOHWLGDO-CHJDUVSTSA-N 9h-fluoren-9-ylmethyl n-[(2s)-3-methyl-1-oxo-1-[[(2s)-1-oxo-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)anilino]propan-2-yl]amino]butan-2-yl]carbamate Chemical compound O=C([C@H](C)NC(=O)[C@@H](NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(C)C)NC(C=C1)=CC=C1B1OC(C)(C)C(C)(C)O1 UIXMXBXOHWLGDO-CHJDUVSTSA-N 0.000 description 1
- XPKVSFHMZHXKIX-UHFFFAOYSA-N 9h-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1.C1=CC=C2CC3=CC=CC=C3OC2=C1 XPKVSFHMZHXKIX-UHFFFAOYSA-N 0.000 description 1
- 230000035502 ADME Effects 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- OMNVYXHOSHNURL-WPRPVWTQSA-N Ala-Phe Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMNVYXHOSHNURL-WPRPVWTQSA-N 0.000 description 1
- 241000124001 Alcyonacea Species 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N Alternaria alternata Crofton-weed toxin Natural products CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- 241000432824 Asparagus densiflorus Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 108020003591 B-Form DNA Proteins 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical group C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OILZUWBYPXWFIU-UHFFFAOYSA-N C1(C=CC(N1)=O)=O.C1(C=CC(N1)=O)=O.C(COCCO)O Chemical compound C1(C=CC(N1)=O)=O.C1(C=CC(N1)=O)=O.C(COCCO)O OILZUWBYPXWFIU-UHFFFAOYSA-N 0.000 description 1
- YUZYMAADQYSENF-UHFFFAOYSA-N C1=CC=CC=2OC3=CC=CC=C3NC12.C1=CC=CC=2OC3=CC=CC=C3SC12.S1C=CC=C1 Chemical compound C1=CC=CC=2OC3=CC=CC=C3NC12.C1=CC=CC=2OC3=CC=CC=C3SC12.S1C=CC=C1 YUZYMAADQYSENF-UHFFFAOYSA-N 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 244000132059 Carica parviflora Species 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000003902 Cathepsin C Human genes 0.000 description 1
- 108090000267 Cathepsin C Proteins 0.000 description 1
- 102000003908 Cathepsin D Human genes 0.000 description 1
- 108090000258 Cathepsin D Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 229930184471 Chicamycin Natural products 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- XCDXSSFOJZZGQC-UHFFFAOYSA-N Chlornaphazine Chemical compound C1=CC=CC2=CC(N(CCCl)CCCl)=CC=C21 XCDXSSFOJZZGQC-UHFFFAOYSA-N 0.000 description 1
- 238000007445 Chromatographic isolation Methods 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-AGQMPKSLSA-N D-lyxofuranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@H]1O HMFHBZSHGGEWLO-AGQMPKSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- AUGQEEXBDZWUJY-ZLJUKNTDSA-N Diacetoxyscirpenol Chemical compound C([C@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)C)O2 AUGQEEXBDZWUJY-ZLJUKNTDSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- XTAHYROJKCXMOF-UHFFFAOYSA-N Dihydroaceanthrylene Chemical compound C1=CC=C2C(CCC3=CC=C4)=C3C4=CC2=C1 XTAHYROJKCXMOF-UHFFFAOYSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- 229930193152 Dynemicin Natural products 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000289695 Eutheria Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 1
- 208000032041 Hearing impaired Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 1
- 101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 1
- 101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- WQZGKKKJIJFFOK-YIDFTEPTSA-N IDOSE Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-YIDFTEPTSA-N 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000027601 Inner ear disease Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- XETQTCAMTVHYPO-UHFFFAOYSA-N Isocamphan von ungewisser Konfiguration Natural products C1CC2C(C)(C)C(C)C1C2 XETQTCAMTVHYPO-UHFFFAOYSA-N 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 1
- HMFHBZSHGGEWLO-HWQSCIPKSA-N L-arabinofuranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@H]1O HMFHBZSHGGEWLO-HWQSCIPKSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- JLERVPBPJHKRBJ-UHFFFAOYSA-N LY 117018 Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCC3)=CC=2)C2=CC=C(O)C=C2S1 JLERVPBPJHKRBJ-UHFFFAOYSA-N 0.000 description 1
- 208000017119 Labyrinth disease Diseases 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 241000289581 Macropus sp. Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- VJRAUFKOOPNFIQ-UHFFFAOYSA-N Marcellomycin Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C=C2C(C(=O)OC)C(CC)(O)CC1OC(OC1C)CC(N(C)C)C1OC(OC1C)CC(O)C1OC1CC(O)C(O)C(C)O1 VJRAUFKOOPNFIQ-UHFFFAOYSA-N 0.000 description 1
- QWPXBEHQFHACTK-UHFFFAOYSA-N Maytansinol Natural products CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- IVDYZAAPOLNZKG-KWHRADDSSA-N Mepitiostane Chemical compound O([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C[C@H]5S[C@H]5C[C@@H]4CC[C@H]3[C@@H]2CC1)C)C1(OC)CCCC1 IVDYZAAPOLNZKG-KWHRADDSSA-N 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 1
- 241000289390 Monotremata Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical compound C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- AFLXUQUGROGEFA-UHFFFAOYSA-N Nitrogen mustard N-oxide Chemical class ClCC[N+]([O-])(C)CCCl AFLXUQUGROGEFA-UHFFFAOYSA-N 0.000 description 1
- 102000004459 Nitroreductase Human genes 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000289371 Ornithorhynchus anatinus Species 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- SUDAHWBOROXANE-SECBINFHSA-N PD 0325901 Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-SECBINFHSA-N 0.000 description 1
- SUDAHWBOROXANE-VIFPVBQESA-N PD 0325901-Cl Chemical compound OC[C@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-VIFPVBQESA-N 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 241000209046 Pennisetum Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropyl alcohol Natural products CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 229930187104 Porothramycin Natural products 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- GYUDGZRJHSDPLH-UHFFFAOYSA-N Prothracarcin Natural products C1=NC2=CC=CC=C2C(=O)N2CC(=CC)CC21 GYUDGZRJHSDPLH-UHFFFAOYSA-N 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- WLMPICXKNVFCSV-UHFFFAOYSA-N S1SCC=C1.[O] Chemical compound S1SCC=C1.[O] WLMPICXKNVFCSV-UHFFFAOYSA-N 0.000 description 1
- 108010040181 SF 1126 Proteins 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920000519 Sizofiran Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041826 Squamous cell carcinoma of lung Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- BXFOFFBJRFZBQZ-QYWOHJEZSA-N T-2 toxin Chemical compound C([C@@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@H]1[C@]3(COC(C)=O)C[C@@H](C(=C1)C)OC(=O)CC(C)C)O2 BXFOFFBJRFZBQZ-QYWOHJEZSA-N 0.000 description 1
- YSMRWXYRXBRSND-UHFFFAOYSA-N TOTP Chemical compound CC1=CC=CC=C1OP(=O)(OC=1C(=CC=CC=1)C)OC1=CC=CC=C1C YSMRWXYRXBRSND-UHFFFAOYSA-N 0.000 description 1
- 229940126624 Tacatuzumab tetraxetan Drugs 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- CGMTUJFWROPELF-UHFFFAOYSA-N Tenuazonic acid Natural products CCC(C)C1NC(=O)C(=C(C)/O)C1=O CGMTUJFWROPELF-UHFFFAOYSA-N 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- 241001061127 Thione Species 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000003441 Transfusion reaction Diseases 0.000 description 1
- UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000009311 VIPoma Diseases 0.000 description 1
- 101150030763 Vegfa gene Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 241000289674 Vombatidae Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N Xylose Natural products O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FZWQGZDXQUCCFS-LURJTMIESA-N [(2S)-4-methyl-2,3-dihydro-1H-pyrrol-2-yl]methanol Chemical class OC[C@H]1NC=C(C1)C FZWQGZDXQUCCFS-LURJTMIESA-N 0.000 description 1
- MBHRHUJRKGNOKX-UHFFFAOYSA-N [(4,6-diamino-1,3,5-triazin-2-yl)amino]methanol Chemical compound NC1=NC(N)=NC(NCO)=N1 MBHRHUJRKGNOKX-UHFFFAOYSA-N 0.000 description 1
- IFJUINDAXYAPTO-UUBSBJJBSA-N [(8r,9s,13s,14s,17s)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
- BBHBYGXZJZWYMF-FYWRMAATSA-N [(e)-1-phenylbut-1-en-2-yl]benzene Chemical compound C=1C=CC=CC=1C(/CC)=C/C1=CC=CC=C1 BBHBYGXZJZWYMF-FYWRMAATSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- IHGLINDYFMDHJG-UHFFFAOYSA-N [2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone Chemical compound C1=CC(OC)=CC=C1C(CCC1=CC=CC=C11)=C1C(=O)C(C=C1)=CC=C1OCCN1CCCC1 IHGLINDYFMDHJG-UHFFFAOYSA-N 0.000 description 1
- XZSRRNFBEIOBDA-CFNBKWCHSA-N [2-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 2,2-diethoxyacetate Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)C(OCC)OCC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 XZSRRNFBEIOBDA-CFNBKWCHSA-N 0.000 description 1
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 description 1
- IBXPAFBDJCXCDW-MHFPCNPESA-A [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].Cc1cn([C@H]2C[C@H](O)[C@@H](COP([S-])(=O)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3CO)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].Cc1cn([C@H]2C[C@H](O)[C@@H](COP([S-])(=O)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3CO)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O IBXPAFBDJCXCDW-MHFPCNPESA-A 0.000 description 1
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 1
- SSMFXCDUJJPFBJ-UWJYBYFXSA-N abbeymycin Chemical compound CO[C@@H]1NC2=CC=CC=C2C(=O)N2C[C@@H](O)C[C@@H]12 SSMFXCDUJJPFBJ-UWJYBYFXSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OSWRVYBYIGOAEZ-UHFFFAOYSA-N acetic acid;2-hydroxypropanoic acid Chemical compound CC(O)=O.CC(O)C(O)=O OSWRVYBYIGOAEZ-UHFFFAOYSA-N 0.000 description 1
- HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 1
- 229930188522 aclacinomycin Natural products 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229950004955 adozelesin Drugs 0.000 description 1
- BYRVKDUQDLJUBX-JJCDCTGGSA-N adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-JJCDCTGGSA-N 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 108010011559 alanylphenylalanine Proteins 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 125000000320 amidine group Chemical group 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-N anhydrous cyanic acid Natural products OC#N XLJMAIOERFSOGZ-UHFFFAOYSA-N 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 201000005000 autoimmune gastritis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000004339 autoimmune neuropathy Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 229950011321 azaserine Drugs 0.000 description 1
- OSNDUYDDOHEKEE-UHFFFAOYSA-N azepane-2,7-dione Chemical compound O=C1CCCCC(=O)N1 OSNDUYDDOHEKEE-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 150000001545 azulenes Chemical class 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 229950001863 bapineuzumab Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229950005567 benzodepa Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- VFIUCBTYGKMLCM-UHFFFAOYSA-N benzyl n-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NP(=O)(N1CC1)N1CC1 VFIUCBTYGKMLCM-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- 229960005522 bivatuzumab mertansine Drugs 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 229930006742 bornane Natural products 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229960005520 bryostatin Drugs 0.000 description 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- ZPFKRQXYKULZKP-UHFFFAOYSA-N butylidene Chemical group [CH2+]CC[CH-] ZPFKRQXYKULZKP-UHFFFAOYSA-N 0.000 description 1
- 229960001921 calcium levofolinate Drugs 0.000 description 1
- KVUAALJSMIVURS-QNTKWALQSA-L calcium;(2s)-2-[[4-[[(6s)-2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioate Chemical compound [Ca+2].C([C@@H]1N(C=O)C=2C(=O)N=C(NC=2NC1)N)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-QNTKWALQSA-L 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229950007296 cantuzumab mertansine Drugs 0.000 description 1
- JHRWWRDRBPCWTF-OLQVQODUSA-N captafol Chemical group C1C=CC[C@H]2C(=O)N(SC(Cl)(Cl)C(Cl)Cl)C(=O)[C@H]21 JHRWWRDRBPCWTF-OLQVQODUSA-N 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000005488 carboaryl group Chemical group 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- 229930188550 carminomycin Natural products 0.000 description 1
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- BBZDXMBRAFTCAA-AREMUKBSSA-N carzelesin Chemical compound C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 1
- 229950007509 carzelesin Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 229940060038 chlorine Drugs 0.000 description 1
- 229950008249 chlornaphazine Drugs 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- WDECIBYCCFPHNR-UHFFFAOYSA-N chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 150000001854 cinnolines Chemical class 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-L clondronate(2-) Chemical compound OP([O-])(=O)C(Cl)(Cl)P(O)([O-])=O ACSIXWWBWUQEHA-UHFFFAOYSA-L 0.000 description 1
- 229960002271 cobimetinib Drugs 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 108010090203 cryptophycin 8 Proteins 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexediene Natural products C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 1
- FNIATMYXUPOJRW-UHFFFAOYSA-N cyclohexylidene Chemical group [C]1CCCCC1 FNIATMYXUPOJRW-UHFFFAOYSA-N 0.000 description 1
- MCFZBCCYOPSZLG-UHFFFAOYSA-N cyclopent-4-ene-1,3-dione Chemical compound O=C1CC(=O)C=C1 MCFZBCCYOPSZLG-UHFFFAOYSA-N 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 229950006418 dactolisib Drugs 0.000 description 1
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 229950003913 detorubicin Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
- 229950002389 diaziquone Drugs 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000004826 dibenzofurans Chemical class 0.000 description 1
- IYYZUPMFVPLQIF-UHFFFAOYSA-N dibenzothiophene Chemical class C1=CC=C2C3=CC=CC=C3SC2=C1 IYYZUPMFVPLQIF-UHFFFAOYSA-N 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- YDVNLQGCLLPHAH-UHFFFAOYSA-N dichloromethane;hydrate Chemical compound O.ClCCl YDVNLQGCLLPHAH-UHFFFAOYSA-N 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- OBISXEJSEGNNKL-UHFFFAOYSA-N dinitrogen-n-sulfide Chemical compound [N-]=[N+]=S OBISXEJSEGNNKL-UHFFFAOYSA-N 0.000 description 1
- 150000002012 dioxanes Chemical class 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- VURFVHCLMJOLKN-UHFFFAOYSA-N diphosphane Chemical compound PP VURFVHCLMJOLKN-UHFFFAOYSA-N 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
- 229950006700 edatrexate Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- XOPYFXBZMVTEJF-PDACKIITSA-N eleutherobin Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O XOPYFXBZMVTEJF-PDACKIITSA-N 0.000 description 1
- XOPYFXBZMVTEJF-UHFFFAOYSA-N eleutherobin Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(=CCC1C(C)C)C)C1C=C2COC1OCC(O)C(O)C1OC(C)=O XOPYFXBZMVTEJF-UHFFFAOYSA-N 0.000 description 1
- 229950000549 elliptinium acetate Drugs 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- JOZGNYDSEBIJDH-UHFFFAOYSA-N eniluracil Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
- 229950010213 eniluracil Drugs 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- 229950009760 epratuzumab Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229950007655 esilate Drugs 0.000 description 1
- ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
- 229950002017 esorubicin Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 229960005237 etoglucid Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 229950011548 fadrozole Drugs 0.000 description 1
- 229950001563 felvizumab Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 150000002220 fluorenes Chemical class 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000003682 fluorination reaction Methods 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229940064302 folacin Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 229950004923 fontolizumab Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 150000002243 furanoses Chemical class 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229960003082 galactose Drugs 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 150000002391 heterocyclic compounds Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000006289 hydroxybenzyl group Chemical group 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 229950004101 inotuzumab ozogamicin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000001261 isocyanato group Chemical group *N=C=O 0.000 description 1
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 description 1
- 150000002518 isoindoles Chemical class 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 229940033355 lauric acid Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229950002950 lintuzumab Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- DHMTURDWPRKSOA-RUZDIDTESA-N lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- YROQEQPFUCPDCP-UHFFFAOYSA-N losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
- 229950008745 losoxantrone Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
- 229950008612 mannomustine Drugs 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229950008001 matuzumab Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 229950009246 mepitiostane Drugs 0.000 description 1
- 229960005108 mepolizumab Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000002740 methanolamines Chemical class 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- UYVXZUTYZGILQG-UHFFFAOYSA-N methoxyboronic acid Chemical compound COB(O)O UYVXZUTYZGILQG-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- VJRAUFKOOPNFIQ-TVEKBUMESA-N methyl (1r,2r,4s)-4-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-5-[(2s,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylat Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1 VJRAUFKOOPNFIQ-TVEKBUMESA-N 0.000 description 1
- QRMNENFZDDYDEF-GOSISDBHSA-N methyl (8s)-8-(bromomethyl)-2-methyl-4-(4-methylpiperazine-1-carbonyl)oxy-6-(5,6,7-trimethoxy-1h-indole-2-carbonyl)-7,8-dihydro-3h-pyrrolo[3,2-e]indole-1-carboxylate Chemical compound C1([C@H](CBr)CN(C1=C1)C(=O)C=2NC3=C(OC)C(OC)=C(OC)C=C3C=2)=C2C(C(=O)OC)=C(C)NC2=C1OC(=O)N1CCN(C)CC1 QRMNENFZDDYDEF-GOSISDBHSA-N 0.000 description 1
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- BVWTXUYLKBHMOX-UHFFFAOYSA-N methyl vanillate Chemical group COC(=O)C1=CC=C(O)C(OC)=C1 BVWTXUYLKBHMOX-UHFFFAOYSA-N 0.000 description 1
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 1
- VNXBKJFUJUWOCW-UHFFFAOYSA-N methylcyclopropane Chemical compound CC1CC1 VNXBKJFUJUWOCW-UHFFFAOYSA-N 0.000 description 1
- HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- QTFKTBRIGWJQQL-UHFFFAOYSA-N meturedepa Chemical compound C1C(C)(C)N1P(=O)(NC(=O)OCC)N1CC1(C)C QTFKTBRIGWJQQL-UHFFFAOYSA-N 0.000 description 1
- 229950009847 meturedepa Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 229940087004 mustargen Drugs 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 230000002151 myoclonic effect Effects 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- ZOGSYTPLAROSTP-UHFFFAOYSA-N n-[bis(ethylamino)phosphoryl]ethanamine Chemical compound CCNP(=O)(NCC)NCC ZOGSYTPLAROSTP-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229950002366 nafoxidine Drugs 0.000 description 1
- 150000005054 naphthyridines Chemical class 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 1
- 229950010159 nemorubicin Drugs 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- IHRSXGONVFFQQF-SDXDJHTJSA-N nitrazine Chemical compound OS(=O)(=O)C1=CC2=CC(S(O)(=O)=O)=CC=C2C(=O)\C1=N/NC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O IHRSXGONVFFQQF-SDXDJHTJSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 108020001162 nitroreductase Proteins 0.000 description 1
- KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001736 nosyl group Chemical group S(=O)(=O)(C1=CC=C([N+](=O)[O-])C=C1)* 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 229960000435 oblimersen Drugs 0.000 description 1
- 229950005751 ocrelizumab Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical class O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 229950011093 onapristone Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 150000005063 oxadiazines Chemical class 0.000 description 1
- 150000004866 oxadiazoles Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- OYSMISPYDVWGPI-UHFFFAOYSA-N oxane thiophene Chemical compound O1CCCCC1.S1C=CC=C1 OYSMISPYDVWGPI-UHFFFAOYSA-N 0.000 description 1
- NFBOHOGPQUYFRF-UHFFFAOYSA-N oxanthrene Chemical compound C1=CC=C2OC3=CC=CC=C3OC2=C1 NFBOHOGPQUYFRF-UHFFFAOYSA-N 0.000 description 1
- OZQGLZFAWYKKLQ-UHFFFAOYSA-N oxazinane Chemical class C1CCONC1 OZQGLZFAWYKKLQ-UHFFFAOYSA-N 0.000 description 1
- ATYBXHSAIOKLMG-UHFFFAOYSA-N oxepin Chemical compound O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 150000002921 oxetanes Chemical class 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- AUONHKJOIZSQGR-UHFFFAOYSA-N oxophosphane Chemical compound P=O AUONHKJOIZSQGR-UHFFFAOYSA-N 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 208000030940 penile carcinoma Diseases 0.000 description 1
- 201000008174 penis carcinoma Diseases 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- RFPMGSKVEAUNMZ-UHFFFAOYSA-N pentylidene Chemical group [CH2+]CCC[CH-] RFPMGSKVEAUNMZ-UHFFFAOYSA-N 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 150000005053 phenanthridines Chemical class 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical group [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 125000000394 phosphonato group Chemical group [O-]P([O-])(*)=O 0.000 description 1
- 150000003009 phosphonic acids Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical group NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
- 229940061584 phosphoramidic acid Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Chemical group 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 125000005545 phthalimidyl group Chemical group 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- CLSUSRZJUQMOHH-UHFFFAOYSA-L platinum dichloride Chemical compound Cl[Pt]Cl CLSUSRZJUQMOHH-UHFFFAOYSA-L 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229950004406 porfiromycin Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 238000005036 potential barrier Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- CAEWJEXPFKNBQL-UHFFFAOYSA-N prop-2-enyl carbonochloridate Chemical compound ClC(=O)OCC=C CAEWJEXPFKNBQL-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229940117820 purinethol Drugs 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- IOXGEAHHEGTLMQ-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1.C1=CC=NN=C1 IOXGEAHHEGTLMQ-UHFFFAOYSA-N 0.000 description 1
- RDRCCJPEJDWSRJ-UHFFFAOYSA-N pyridine;1h-pyrrole Chemical compound C=1C=CNC=1.C1=CC=NC=C1 RDRCCJPEJDWSRJ-UHFFFAOYSA-N 0.000 description 1
- YMXFJTUQQVLJEN-UHFFFAOYSA-N pyrimidine Chemical compound C1=CN=CN=C1.C1=CN=CN=C1 YMXFJTUQQVLJEN-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 1
- 229960000460 razoxane Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229950004892 rodorubicin Drugs 0.000 description 1
- NSFWWJIQIKBZMJ-PAGWOCKZSA-N roridin a Chemical compound C([C@@]12[C@]3(C)[C@H]4C[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)[C@@H](O)[C@H](C)CCO[C@H](\C=C\C=C/C(=O)O4)[C@H](O)C)O2 NSFWWJIQIKBZMJ-PAGWOCKZSA-N 0.000 description 1
- 229950009092 rovelizumab Drugs 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 229950005374 ruplizumab Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 229930182947 sarcodictyin Natural products 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000005920 sec-butoxy group Chemical group 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 229950008684 sibrotuzumab Drugs 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229950003804 siplizumab Drugs 0.000 description 1
- 229950001403 sizofiran Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000011973 solid acid Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- ICXJVZHDZFXYQC-UHFFFAOYSA-N spongistatin 1 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C ICXJVZHDZFXYQC-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAZLUNIWYYOJPC-UHFFFAOYSA-M sulfenamide Chemical compound [Cl-].COC1=C(C)C=[N+]2C3=NC4=CC=C(OC)C=C4N3SCC2=C1C QAZLUNIWYYOJPC-UHFFFAOYSA-M 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- BUUPQKDIAURBJP-UHFFFAOYSA-N sulfinic acid Chemical compound OS=O BUUPQKDIAURBJP-UHFFFAOYSA-N 0.000 description 1
- 150000003451 sulfinic acid amides Chemical class 0.000 description 1
- 125000000213 sulfino group Chemical group [H]OS(*)=O 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- IWOKCMBOJXYDEE-UHFFFAOYSA-N sulfinylmethane Chemical compound C=S=O IWOKCMBOJXYDEE-UHFFFAOYSA-N 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003447 supported reagent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- GVIJJXMXTUZIOD-UHFFFAOYSA-N thianthrene Chemical compound C1=CC=C2SC3=CC=CC=C3SC2=C1 GVIJJXMXTUZIOD-UHFFFAOYSA-N 0.000 description 1
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- JWCVYQRPINPYQJ-UHFFFAOYSA-N thiepane Chemical compound C1CCCSCC1 JWCVYQRPINPYQJ-UHFFFAOYSA-N 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- VOVUARRWDCVURC-UHFFFAOYSA-N thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
- 150000003566 thiocarboxylic acids Chemical class 0.000 description 1
- 125000005031 thiocyano group Chemical group S(C#N)* 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 1
- WEMNATFLVGEPEW-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1.C=1C=CSC=1 WEMNATFLVGEPEW-UHFFFAOYSA-N 0.000 description 1
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 229960000898 toltrazuril Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229950001802 toralizumab Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
- 229930013292 trichothecene Natural products 0.000 description 1
- 150000003327 trichothecene derivatives Chemical class 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-O trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=[NH+]C(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-O 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- 229950000212 trioxifene Drugs 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- 229950010147 troxacitabine Drugs 0.000 description 1
- RXRGZNYSEHTMHC-BQBZGAKWSA-N troxacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)OC1 RXRGZNYSEHTMHC-BQBZGAKWSA-N 0.000 description 1
- HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 229950003364 tucotuzumab celmoleukin Drugs 0.000 description 1
- 108700008509 tucotuzumab celmoleukin Proteins 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- GFNNBHLJANVSQV-UHFFFAOYSA-N tyrphostin AG 1478 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1 GFNNBHLJANVSQV-UHFFFAOYSA-N 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- LLDWLPRYLVPDTG-UHFFFAOYSA-N vatalanib succinate Chemical compound OC(=O)CCC(O)=O.C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 LLDWLPRYLVPDTG-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229950004393 visilizumab Drugs 0.000 description 1
- 229960001771 vorozole Drugs 0.000 description 1
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
- 208000013013 vulvar carcinoma Diseases 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
It is bound to the antibody of PSMA and the conjugate of PBD dimer.
Description
Technical field
The present invention relates to have with the pyrrolo- benzo of the unstable C2 or N10 blocking group of the joint form with antibody
Diaza(Pyrrolobenzodiazepines are tall and erect, pyrrolobenzodiazepines) (PBD).
Background technique
Pyrrolobenzodiazepines
Some Pyrrolobenzodiazepines(PBD) it can identify and be incorporated into the particular sequence of DNA;Preferably sequence is
PuGPu.The first PBD antitumor antibiotics, Anthramycin (anthramycin) (Leimgruber, et are found in nineteen sixty-five
al.,J.Am.Chem.Soc.,87,5793-5795(1965);Leimgruber,et al.,J.Am.Chem.Soc.,87,
5791-5793(1965)).Thereafter, it has reported the PBD of many naturally occurrings, and has developed for various analogs more than 10
Kind route of synthesis (Thurston, et al., Chem.Rev.1994,433-465 (1994);Antonow,D.and
Thurston,D.E.,Chem.Rev.2011111(4),2815-2864).Family member includes abbeymycin
(Hochlowski, et al., J.Antibiotics, 40,145-148 (1987)), odd Ka-7038Ⅶ (chicamycin)
(Konishi, et al., J.Antibiotics, 37,200-206 (1984)), DC-81 (Japan Patent 58-180487;
Thurston,et al.,Chem.Brit.,26,767-772(1990);Bose,et al.,Tetrahedron,48,751-
758 (1992)), mazethramycin (mazethramycin) (Kuminoto, et al., J.Antibiotics, 33,665-
667 (1980)), neothramycin (neothramycin) A and B (Takeuchi, et al., J.Antibiotics, 29,93-
96(1976))、porothramycin(Tsunakawa,et al.,J.Antibiotics,41,1366-1373(1988))、
prothracarcin(Shimizu,et al,J.Antibiotics,29,2492-2503(1982);Langley and
Thurston, J.Org.Chem., 52,91-97 (1987)), sibanomicin (sibanomicin) (DC-102) (Hara, et
al.,J.Antibiotics,41,702-704(1988);Itoh,et al.,J.Antibiotics,41,1281-1284
(1988)), sibiromycin (sibiromycin) (Leber, et al., J.Am.Chem.Soc., 110,2992-2993
And tomamycin (tomamycin) (Arima, et al., J.Antibiotics, 25,437-444 (1972)) (1988)).PBD
For following general structure:
Their difference is the quantity, type and position of substituent group, is their aromatics A ring and pyrrolo- C ring two
Person, and it is C ring filling degree.In B ring, at the position N10-C11 (it is responsible for making the alkylated electrophilic center of DNA)
There are imines (N=C), carbinolamine (carbinolamine) (NH-CH (OH)) or carbinolamine methyl ethers (NH-CH (OMe)).It is all
Known natural products has (S)-configuration at the chiral position C11a, and when from from C ring to A ring, which mentions to them
(right-handed twist) is reversed for the right hand.This give they for the ditch of B-form DNA etc. helicities
(isohelicity) 3D shape appropriate obtains (Kohn, the In Antibiotics that is slidably matched at binding site
III.Springer-Verlag,New York,pp.3-11(1975);Hurley and Needham-VanDevanter,
Acc.Chem.Res.,19,230-237(1986)).The ability that they form adduct in ditch interferes them
DNA processing, therefore they can be used as antitumor agent.
By Gregson et al. as compound 1 (Chem.Commun.1999,797-798) and by Gregson et
Al. particularly advantageous Pyrrolobenzodiazepines are described as compound 4a (J.Med.Chem.2001,44,1161-1174)Compound.The compound, also referred to as SG2000, described below:
WO 2007/085930 is described with the dimerization for being connected to the linker group of cell binding agent (such as antibody)
The preparation of body PBD compound.Connector is present in the bridge of the monomer PBD unit of connection dimer.
The present inventor has been described in WO 2011/130613 and WO 2011/130616 to be had for being connected to carefully
The dimer PBD compound of the linker group of born of the same parents' bonding agent (such as antibody).Connector in these compounds is connected to by C2
PBD core, and usually cut by the effect of enzyme in linker group.In WO 2011/130598, connecing in these compounds
Head is connected to one in N10 obtainable on PBD core, and is usually cut by the effect of enzyme in linker group.
Antibody-drug conjugates
It has built up for the antibody therapy with cancer, immunological diseases and the targeted therapy of vascular disease
(Carter,P.(2006)Nature Reviews Immunology 6:343-357).It is thin for local delivery in treatment of cancer
Cellular toxicity agent or cytostatics (that is, drug) are to kill or inhibit the antibody-drug conjugates (ADC) of tumour cell (that is, exempting from
Epidemic disease conjugate) use target drug moiety be delivered to tumour, and intracellular accumulation wherein, and these non-binding drugs
The whole body of reagent, which is given, can cause to the unacceptable toxic level of normal cell (Xie et al (2006)
Expert.Opin.Biol.Ther.6(3):281-291;Kovtun et al(2006)Cancer Res.66(6):3214-
3121;Law et al(2006)Cancer Res.66(4):2328-2337;Wu et al(2005)Nature
Biotech.23(9):1137-1145;Lambert J.(2005)Current Opin.in Pharmacol.5:543-549;
Hamann P.(2005)Expert Opin.Ther.Patents 15(9):1087-1103;Payne,G.(2003)Cancer
Cell 3:207-212;Trail et al(2003)Cancer Immunol.Immunother.52:328-337;Syrigos
and Epenetos(1999)Anticancer Research 19:605-614)。
It hereby is observed that the greatest treatment efficacy with minimum toxicity.Design and the effort for improving ADC concentrate on monoclonal antibody
(mAb) in selectivity and mechanism of drug action, drug connection, drug/Antibody ratio (load) and drug release property
(Junutula,et al.,2008b Nature Biotech.,26(8):925-932;Dornan et al(2009)Blood
114(13):2721-2729;US 7521541;US 7723485;WO2009/052249;McDonagh(2006)Protein
Eng.Design&Sel.19(7):299-307;Doronina et al(2006)Bioconj.Chem.17:114-124;
Erickson et al(2006)Cancer Res.66(8):1-8;Sanderson et al(2005)Clin.Cancer
Res.11:843-852;Jeffrey et al(2005)J.Med.Chem.48:1344-1358;Hamblett et al
(2004)Clin.Cancer Res.10:7063-7070).Drug moiety can be by including that micro-pipe combines, DNA is combined, albumen
The mechanism that enzyme body and/or topoisomerase inhibit assigns their cytotoxicities and cyto-inhibition.Be bound to big antibody or
When protein receptor ligand, some cytotoxic drugs are intended to torpescence or compared with torpescence.
Present inventors have developed specific PBD homodimeric antibody conjugates.
Summary of the invention
The first aspect of the present invention includes formula L- (DL)pConjugate, wherein DLFor Formulas I or Formula II:
Wherein:
L is antibody as defined below (Ab);
As C2 ' and C3 ' between there are when double bond, R12Selected from the group being made up of:
(ia)C5-10Aryl group, the one or more substituent groups being optionally chosen in self-contained below group replace: halogen
Element, nitro, cyano, ether, carboxyl, ester, C1-7Alkyl, C3-7Heterocycle and double-oxygroup-C1-3Alkylidene;
(ib)C1-5Representative examples of saturated aliphatic alkyl;
(ic)C3-6Saturated cyclic alkyls;
(id)Wherein, R21、R22And R23Each of independently selected from H, C1-3Saturated alkyl, C2-3Alkene
Base, C2-3Alkynyl and cyclopropyl, wherein R12The sum of carbon atom is no more than 5 in group;
(ie)Wherein, R25aAnd R25bIn one be H and another be selected from: phenyl, the phenyl are optional
Ground is replaced by the group selected from halogen, methyl, methoxyl group;Pyridyl group;And thiophenyl;With
(if)Wherein, R24It is selected from: H;C1-3Saturated alkyl;C2-3Alkenyl;C2-3Alkynyl;Cyclopropyl;Phenyl,
The phenyl is optionally replaced by the group selected from halogen, methyl, methoxyl group;Pyridyl group;And thiophenyl;
As C2 ' and C3 ' between there are when singly-bound,
R12It isWherein, R26aAnd R26bIndependently selected from H, F, C1-4Saturated alkyl, C2-3Alkenyl, the alkyl and
Alkenyl group is optionally selected from C1-4Alkyl amino and C1-4The group of Arrcostab replaces;Alternatively, working as R26aAnd R26bIn one
When being H, another is selected from nitrile and C1-4Arrcostab;
R6And R9Independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR ', nitro, Me3Sn and halogen;
Wherein, R and R ' is independently selected from optionally substituted C1-12Alkyl, C3-20Heterocycle and C5-20Aryl group;
R7Selected from H, R, OH, OR, SH, SR, NH2, NHR, NHRR ', nitro, Me3Sn and halogen;
R " is C3-12Alkylidene group, the chain can be interrupted by item below one or more: hetero atom, such as O, S,
NRN2(wherein RN2It is H or C1-4Alkyl) and/or aromatic ring, such as benzene or pyridine;
Y and Y ' is selected from O, S or NH;
R6’、R7’、R9’It is respectively selected from and R6、R7And R9Identical group;
[Formulas I]
RL1’It is the connector for being connected to antibody (Ab);
R11aSelected from OH, ORA, wherein RAIt is C1-4Alkyl and SOzM, wherein z is that 2 or 3 and M is pharmaceutically may be used for unit price
The cation of receiving;
R20And R21Or it is formed together the double bond between the nitrogen and carbon atom that they are connected;Or
R20Selected from H and RC, wherein RCIt is end-capping group;
R21Selected from OH, ORAAnd SOzM;
When between C2 and C3 there are when double bond, R2Selected from the group being made up of:
(ia)C5-10Aryl group, the one or more substituent groups being optionally chosen in self-contained below group replace: halogen
Element, nitro, cyano, ether, carboxyl, ester, C1-7Alkyl, C3-7Heterocycle and double-oxygroup-C1-3Alkylidene;
(ib)C1-5Representative examples of saturated aliphatic alkyl;
(ic)C3-6Saturated cyclic alkyls;
(id)Wherein, R11、R12And R13Each of independently selected from H, C1-3Saturated alkyl, C2-3Alkene
Base, C2-3Alkynyl and cyclopropyl, wherein R2The sum of carbon atom is not more than 5 in group;
(ie)Wherein, R15aAnd R15bIn one be H, and another is selected from: phenyl, the benzene
Base is optionally replaced by the group selected from halogen, methyl, methoxyl group;Pyridyl group;And thiophenyl;With
(if)Wherein, R14It is selected from: H;C1-3Saturated alkyl;C2-3Alkenyl;C2-3Alkynyl;Cyclopropyl;Benzene
Base, the phenyl are optionally replaced by the group selected from halogen, methyl, methoxyl group;Pyridyl group;And thiophenyl;
When between C2 and C3 there are when singly-bound,
R2It isWherein, R16aAnd R16bIndependently selected from H, F, C1-4Saturated alkyl, C2-3Alkenyl, the alkyl
Optionally C is selected from alkenyl group1-4Alkyl amino and C1-4The group of Arrcostab replaces;Or work as R16aAnd R16bIn one be
When H, another is selected from nitrile and C1-4Arrcostab;
[Formula II]
R22It is formula III a, formula III b or formula III c:
(a)
Wherein, A is C5-7Aryl group, and
(i)Q1It is singly-bound, and Q2Selected from singly-bound and-Z- (CH2)n, wherein Z is selected from singly-bound, O, S and NH, and n is 1
To 3;Or
(ii)Q1It is-CH=CH-, and Q2It is singly-bound;
(b)
Wherein,
RC1、RC2And RC3Independently selected from H and unsubstituted C1-2Alkyl;
(C)
Wherein, Q is selected from O-RL2’、S-RL2’And NRN-RL2’, and RNSelected from H, methyl and ethyl;
It includes below group: O-R that X, which is selected from,L2’、S-RL2’、CO2-RL2’、CO-RL2’, NH-C (=O)-RL2’、NHNH-RL2’、
CONHNH-RL2’、 NRNRL2’, wherein RNSelected from including H and C1-4Alkyl
Group;
RL2’It is the connector for being connected to antibody (Ab);
R10And R11Or it is formed together the double bond between the nitrogen and carbon atom that they are connected;Or
R10It is H and R11Selected from OH, ORAAnd SOzM;
R30And R31Or it is formed together the double bond between the nitrogen and carbon atom that they are connected;Or
R30It is H and R31Selected from OH, ORAAnd SOzM。
In some embodiments, conjugate is not:
ConjA
ConjB
ConjC:
ConjD
ConjE:
In other embodiments, it may be preferred to conjugate be selected from formula ConjA, ConjB, ConjC, ConjD and
The conjugate of ConjE.
Subscript p in Formulas I is integer of 1 to 20.Therefore, conjugate includes to be covalently attached at least one by connector unit
The antibody (Ab) as defined below of a drug unit.It is the targeting agent for being bound to targeting moiety with body unit, hereafter carries out
A more complete description.Therefore, the present invention also provides the methods for treating for example various cancers and autoimmune disease.Drugloading rate
(drug loading) is indicated by p, is the number of every antibody drug molecule.Drugloading rate can be in 1 to 20 drug unit
(DLIn the range of)/antibody.For composition, p indicates the drug loading of conjugate in the composition, and p is 1 to 20
In range.
The second aspect of the present invention provides the method for preparation conjugate according to the first aspect of the invention, including by Formulas IL
Or Formula IILCompound:
It is bound to antibody as defined below (Ab), in which:
RL1It is the connector for being suitable for connection to antibody (Ab);
R22LIt is formula III aL, formula III bLOr formula III cL:
(a)
(b)
(c)
Wherein, QLSelected from O-RL2、S-RL2And NRN-RL2, and RNSelected from H, methyl and ethyl;
XLSelected from including below group: O-RL2、S-RL2、CO2-RL2、CO-RL2, N=C=O-RL2、NHNH-RL2、CONHNH-
RL2、NRNRL, wherein RNSelected from including H and C1-4The group of alkyl;
RL2It is the connector for being suitable for connection to antibody (Ab);
And what all residue group such as first aspects limited.
Therefore, in second aspect it may be preferred that the present invention provide preparation selected from by ConjA, ConjB, ConjC,
The method of the conjugate of the group of ConjD and ConjE composition, including A will be respectively selected from:
B:
C:
D:
And E:
Compound in conjunction with antibody as defined below.
WO 2011/130615 discloses compound 26:
It is the parent compound of A.Compound A includes the PBD and the connector for being connected to cell binding agent.Cell knot
Mixture provides multiple ethylene glycol moieties to provide dissolubility, is useful in the synthesis of conjugate.
WO 2010/043380 and WO 2011/130613 disclose compound 30:
WO 2011/130613 also discloses compound 51:
Compound B and 30 difference of compound are: only having (CH between the part PBD2)3Chain (tether), rather than
(CH2)5Chain, this reduces the lipophilicity of the PBD dimer of release.Linking group is in contraposition rather than meta position is connected to C2- phenyl base
Group.
WO 2011/130613 discloses compound 93:
Compound C is different from both ways.Cell binding agent provides the ethylene glycol moieties for increasing number to provide dissolution
Property, this is useful in the synthesis of conjugate, and phenyl substituent provides two rather than an oxygen atom, this is also contributed to
Dissolution.The structure of compound C can also mean that it is more strongly incorporated in ditch.
Compound A, B and C have on each C ring there are two sp2Center can permit than only having in each C ring
One sp2Stronger combination of the compound at center in DNA ditch.
WO 2011/130598 discloses compound 80:
Compound D is different from by the inclusion of the iodo-acetamide for being connected to cell binding agent.The group is being tied
In terms of stability when being bonded to cell binding agent, the advantage (see below) more than compound 80 can be provided.In compound 80
Maleimide base group reverse Michael can be undergone to react, become not in conjunction with cell binding agent, thus be easy to by comprising
The other biological molecule (such as albumin and glutathione) of mercaptan is removed.It cannot occur this not combine with compound A.In addition,
Iodoacetamido amine groups can avoid other undesirable side reactions.
Compound E by below with disclosed PBD dimer (the drug connector for having C2-3 cyclic olefinic bond) before no
It is same: to there is lesser, more alipotropic C2 substituent group, for example, 4F- phenyl, propylidene.In this way, conjugate (the ginseng of compound B
See following) less tend to assemble in synthesis.This poly- of conjugate can be measured by size exclusion chromatography (SEC)
Collection.
Compound D and E has in each C ring there are two sp2Center, this can permit than only having in each C ring
One sp2Stronger combination of the compound at center in DNA ditch.
It can will be in WO 2010/043880, WO 2011/130613, WO 2011/130598 and WO 2011/130616
Disclosed drug connector is used for this invention and incorporated herein by reference.It can the conjunction according to described in these disclosures
At drug connector described herein.
Specific embodiment
The present invention in terms of PBD compound to be provided to subject to preferred position suitable for using.Conjugate allows
Release does not retain any portion of activity PBD compound of connector.There is no the short of the reactivity that can influence PBD compound
Cut (residual, stub).Therefore, ConjA will discharge compound R elA:
ConjB will discharge compound R elB:
ConjC will discharge compound R elC:
ConjD will discharge compound R elD:
And ConjE will discharge compound R elE:
PBD dimer in the present invention and the given joint between antibody are preferably extracellularly stable.Conveying or
It is deliverrf into before cell, antibody-drug conjugates (ADC) are preferably stable and keep complete, that is, antibody keeps connecting
It is connected to drug moiety.Connector is stable outside target cell, and can be cut in the cell with effective speed.Effective connector
Will: the specific binding characteristics of (i) holding antibody;(ii) allow the Intracellular delivery of conjugate or drug;(iii) it keeps stablizing
With it is complete, that is, until conjugate be delivered or be delivered to it target site just cut;And (iv) keeps PBD drug portion
Cytotoxic effect, killing functions of immunocytes or the cyto-inhibition divided.Can by standard analytical techniques such as mass spectrum, HPLC and
Separation/analytical technology LC/MS measurement ADC stability.
Through enzyme (such as cathepsin) on linking group and especially on val-ala dipeptide moieties
Effect, formula ConjA, ConjB, ConjC, ConjD or ConjE conjugate expectation activation site at realize formula
The delivering of the compound of RelA, RelB, RelC, RelD or RelE.
Antibody
On the one hand, antibody is the antibody for being bound to PSMA, which includes to have according to SEQ ID NO.1,3,5,7,8,9
Or in 10 any sequence VH structural domain.
Antibody can further include VL structural domain.In some embodiments, antibody, which further includes, has according to SEQ
The VL structural domain of any sequence in ID NO.2,4,6,11,12,13,14,15,16,17 or 18.
In some embodiments, antibody includes the VH structural domain pairs of with VL structural domain, VH structural domain and VL structural domain
With the sequence selected from the group being made up of:
With pairs of SEQ ID NO.1 any in SEQ ID NO.2,4,6,11,12,13,14,15,16,17 or 18;
With pairs of SEQ ID NO.3 any in SEQ ID NO.2,4,6,11,12,13,14,15,16,17 or 18;
With pairs of SEQ ID NO.5 any in SEQ ID NO.2,4,6,11,12,13,14,15,16,17 or 18;
With pairs of SEQ ID NO.7 any in SEQ ID NO.2,4,6,11,12,13,14,15,16,17 or 18;
With pairs of SEQ ID NO.8 any in SEQ ID NO.2,4,6,11,12,13,14,15,16,17 or 18;
With pairs of SEQ ID NO.9 any in SEQ ID NO.2,4,6,11,12,13,14,15,16,17 or 18;
Or
With pairs of SEQ ID NO.10 any in SEQ ID NO.2,4,6,11,12,13,14,15,16,17 or 18.
For example, SEQ ID NO.1 pairs of with SEQ ID NO.2 and SEQ ID NO.4 pairs of SEQ ID NO.3 and SEQ ID
NO.6 pairs of SEQ ID NO.5 and SEQ ID NO.11 pairs of SEQ ID NO.7 and SEQ ID NO.12 pairs of SEQ
ID NO.7 and SEQ ID NO.13 pairs of SEQ ID NO.7 and SEQ ID NO.14 pairs of SEQ ID NO.7 and SEQ
It is ID NO.15 pairs of SEQ ID NO.7, SEQ ID NO.7 pairs of with SEQ ID NO.16, pairs of with SEQ ID NO.17
SEQ ID NO.7, with SEQ ID NO.18 pairs of SEQ ID NO.7, with SEQ ID NO.11 pairs of SEQ ID
NO.8 and SEQ ID NO.12 pairs of SEQ ID NO.8 and SEQ ID NO.13 pairs of SEQ ID NO.8 and SEQ ID
NO.14 pairs of SEQ ID NO.8, with SEQ ID NO.15 pairs of SEQ ID NO.8, it is pairs of with SEQ ID NO.16
SEQ ID NO.8 and SEQ ID NO.17 pairs of SEQ ID NO.8 and SEQ ID NO.18 pairs of SEQ ID NO.8,
Pairs of SEQ ID NO.9 and SEQ ID NO.12 pairs of SEQ ID NO.9 and SEQ ID with SEQ ID NO.11
NO.13 pairs of SEQ ID NO.9, with SEQ ID NO.14 pairs of SEQ ID NO.9, it is pairs of with SEQ ID NO.15
SEQ ID NO.9 and SEQ ID NO.16 pairs of SEQ ID NO.9 and SEQ ID NO.17 pairs of SEQ ID NO.9,
Pairs of SEQ ID NO.9 and SEQ ID NO.11 pairs of SEQ ID NO.10 and SEQ ID with SEQ ID NO.18
NO.12 pairs of SEQ ID NO.10, with SEQ ID NO.13 pairs of SEQ ID NO.10, it is pairs of with SEQ ID NO.14
SEQ ID NO.10 and SEQ ID NO.15 pairs of SEQ ID NO.10 and SEQ ID NO.16 pairs of SEQ ID
The NO.10 and SEQ ID NO.17 pairs of SEQ ID NO.10 or SEQ ID NO.10 pairs of with SEQ ID NO.18.
One or more VH structural domains and VL structural domain can be in pairs to form the antibody antigen-binding site for combining PSMA.
In some embodiments, antibody is the complete antibody comprising the VH structural domain pairs of with VL structural domain, VH structure
Domain and VL structural domain have the sequence selected from the group being made up of:
With pairs of SEQ ID NO.1 any in SEQ ID NO.2,4,6,11,12,13,14,15,16,17 or 18;
With pairs of SEQ ID NO.3 any in SEQ ID NO.2,4,6,11,12,13,14,15,16,17 or 18;
With pairs of SEQ ID NO.5 any in SEQ ID NO.2,4,6,11,12,13,14,15,16,17 or 18;
With pairs of SEQ ID NO.7 any in SEQ ID NO.2,4,6,11,12,13,14,15,16,17 or 18;
With pairs of SEQ ID NO.8 any in SEQ ID NO.2,4,6,11,12,13,14,15,16,17 or 18;
With pairs of SEQ ID NO.9 any in SEQ ID NO.2,4,6,11,12,13,14,15,16,17 or 18;
Or
With pairs of SEQ ID NO.10 any in SEQ ID NO.2,4,6,11,12,13,14,15,16,17 or 18.
For example, SEQ ID NO.1 pairs of with SEQ ID NO.2 and SEQ ID NO.4 pairs of SEQ ID NO.3 and SEQ ID
NO.6 pairs of SEQ ID NO.5 and SEQ ID NO.11 pairs of SEQ ID NO.7 and SEQ ID NO.12 pairs of SEQ
ID NO.7 and SEQ ID NO.13 pairs of SEQ ID NO.7 and SEQ ID NO.14 pairs of SEQ ID NO.7 and SEQ
It is ID NO.15 pairs of SEQ ID NO.7, SEQ ID NO.7 pairs of with SEQ ID NO.16, pairs of with SEQ ID NO.17
SEQ ID NO.7, with SEQ ID NO.18 pairs of SEQ ID NO.7, with SEQ ID NO.11 pairs of SEQ ID
NO.8 and SEQ ID NO.12 pairs of SEQ ID NO.8 and SEQ ID NO.13 pairs of SEQ ID NO.8 and SEQ ID
NO.14 pairs of SEQ ID NO.8, with SEQ ID NO.15 pairs of SEQ ID NO.8, it is pairs of with SEQ ID NO.16
SEQ ID NO.8 and SEQ ID NO.17 pairs of SEQ ID NO.8 and SEQ ID NO.18 pairs of SEQ ID NO.8,
Pairs of SEQ ID NO.9 and SEQ ID NO.12 pairs of SEQ ID NO.9 and SEQ ID with SEQ ID NO.11
NO.13 pairs of SEQ ID NO.9, with SEQ ID NO.14 pairs of SEQ ID NO.9, it is pairs of with SEQ ID NO.15
SEQ ID NO.9 and SEQ ID NO.16 pairs of SEQ ID NO.9 and SEQ ID NO.17 pairs of SEQ ID NO.9,
Pairs of SEQ ID NO.9 and SEQ ID NO.11 pairs of SEQ ID NO.10 and SEQ ID with SEQ ID NO.18
NO.12 pairs of SEQ ID NO.10, with SEQ ID NO.13 pairs of SEQ ID NO.10, it is pairs of with SEQ ID NO.14
SEQ ID NO.10 and SEQ ID NO.15 pairs of SEQ ID NO.10 and SEQ ID NO.16 pairs of SEQ ID
The NO.10 and SEQ ID NO.17 pairs of SEQ ID NO.10 or SEQ ID NO.10 pairs of with SEQ ID NO.18.
In some embodiments, the antibody with for be bound to PSMA by hybridoma ATCC accession number HB-12126 point
The antibody competition secreted.On the other hand, the antibody with for be bound to PSMA by hybridoma ATCC accession number HB-12109 secrete
Antibody competition.In one embodiment, antibody with 2,5 times or 10 times not less than the antibody secreted by hybridoma compared with
Low association constant (Ka) combine PSMA.
On the one hand, antibody is the antibody secreted by hybridoma.In one embodiment, hybridoma is ATCC accession number B-
12126.In another embodiment, hybridoma is ATCC accession number HB-12109.
In some embodiments, antibody is J415 antibody disclosed in WO02/098897.
In some embodiments, antibody is J519 antibody disclosed in WO02/098897.
On the one hand, antibody is antibody described herein, is modified (or further modification) as described below.?
In some embodiments, antibody is the humanization of antibody disclosed herein, deimmunizes (deimmunised) or resurfacing
(resurfaced) variant.For example, (i) comprising the VH structural domain SEQ ID NO.1 pairs of with VL structural domain SEQ ID NO.2
Antibody, J519 antibody disclosed in (ii) WO02/098897, (iii) are secreted anti-by hybridoma ATCC accession number HB-12109
Body, (iv) include the antibody of the VH structural domain SEQ ID NO.5 pairs of with VL structural domain SEQ ID NO.6, (v) WO02/
J415 antibody disclosed in 098897, (vi) by the hybridoma accession number HB-12126 antibody secreted humanization, go it is immune or
The variant of resurfacing.
Term
The term " antibody " of this paper be use and specifically cover in the broadest sense monoclonal antibody, polyclonal antibody,
Dimer, polymer, multi-specificity antibody (for example, bispecific antibody), complete antibody and antibody fragment, as long as they are showed
Desired bioactivity out, for example, in conjunction with ability (Miller et al (2003) Jour.of Immunology of PSMA
170:4854-4861).Antibody can be murine antibodies, human antibodies, humanized antibody, chimeric antibody or come from other
The antibody of species.Antibody is the protein generated by immune system that can identify and be bound to specific antigen.(Janeway,
C.,Travers,P.,Walport,M.,Shlomchik(2001)Immuno Biology,5th Ed.,Garland
Publishing,New York).Target antigen usually has many binding sites, also referred to as epitope, by Multiple Antibodies
CDR is identified.Every kind of antibody for being specifically bound to different epitopes has different structures.Therefore, a kind of antigen can have
More than one correspondence antibody.Antibody includes the immunocompetence portion of full-length immunoglobulin molecule or full-length immunoglobulin molecule
Point, that is, the molecule of the antigen binding site of antigen of interested target or part thereof, this target packet are combined comprising immunologic specificity
It includes but is not limited to cancer cell or generate the cell of autoimmune antibody relevant to autoimmunity disease.Immunoglobulin can be
Any form (for example, IgG, IgE, IgM, IgD and IgA), classification (such as IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2)
Or subclass or allograft (allotype) are (for example, mankind G1m1, G1m2, G1m3, non-G1m1 are [that is, in addition to G1m1
Any isoantigen immunoglobulin], G1m17, G2m23, G3m21, G3m28, G3m11, G3m5, G3m13, G3m14, G3m10,
G3m15, G3m16, G3m6, G3m24, G3m26, G3m27, A2m1, A2m2, Km1, Km2 and Km3) immunoglobulin molecules.Exempt from
Epidemic disease globulin can be originated from any species, including source of people, source of mouse or rabbit source.
As it is used herein, " in conjunction with PSMA " is higher than non-specific companion's such as bovine serum albumin(BSA) for referring to antibody
(BSA, Genbank accession number CAA76847, version number CAA76847.1GI:3336842 record update date: January 7 in 2011
Day, 02:30PM) affinity combination PSMA.In some embodiments, when measuring under the conditions of physiological solution, antibody is with height
In the antibody association constant at least 2 for BSA, 3,4,5,10,20,50,100,200,500,1000,2000,5000,104、105
Or 106Association constant (K againa) combine PSMA.Antibody of the invention can be with high-affinity combination PSMA.For example, in some realities
It applies in mode, antibody can be to be equal to or less than about 10-6M, such as 1 × 10-6、10-7、10-8、10-9,10-10、10-11、10-12、10
-13Or 10-14KDIn conjunction with PSMA.
As it is used herein, PSMA refers to prostate-specific membrane antigen.In one embodiment, PSMA polypeptide pair
Update date: June 23 in 2010 should be recorded in Genbank accession number AAA60209, version number AAA60209.1GI:190664
Day, 08:48AM.In one embodiment, the nucleic acid for encoding PSMA polypeptide corresponds to Genbank accession number M99487, version
Number M99487.1GI:190663 records update date: on June 23rd, 2010,08:48AM.
" antibody fragment " includes a part of full length antibody, usually its antigen binding domain or variable region.Antibody fragment
Example includes Fab, Fab', F (ab')2With scFv segment;Binary;Linear antibodies;The segment generated by Fab expression library resists only
Special type (anti-Id) antibody, CDR (complementary determining region) and any above immunologic specificity are bound to cancer cell antigen, viral antigen
Or the epitope binding fragments of microbial antigen, single-chain antibody molecules, and the multi-specificity antibody formed by antibody fragment.
As used in this article, term " monoclonal antibody " refers to obtained from the anti-of the substantially group of homogeneity antibody
Body, that is, in addition to the possible naturally occurring mutation that can be existed in a small amount, the single antibody including the group is identical
's.Monoclonal antibody is high degree of specificity for single antigen site.In addition, relative to polyclonal antibody preparations comprising
For the different antibodies of different determinants (epitope), each monoclonal antibody is for the single determinant on antigen.Except they
Other than specificity, monoclonal antibody is advantageous, because they can be synthesized without being polluted by other antibody.Modifier is " single
Clone " refers to the characteristic of the antibody of the substantially homogeneous population obtained from antibody, and is not construed as needing through any spy
Method is determined to produce antibody.For example, the hybridoma side described for the first time by Kohler et al (1975) Nature 256:495
Method can be prepared, or can be prepared monoclonal used according to the invention by DNA recombination method (referring to US 4816567) and be resisted
Body.Also Clackson et al (1991) Nature, 352:624-628 can be used;Marks et al(1991)
J.Mol.Biol., technology described in 222:581-597 is from phage antibody library or from carrying complete human immunoglobulin system
The transgenic mice (Lonberg (2008) Curr.Opinion 20 (4): 450-459) of system separates monoclonal antibody.
The monoclonal antibody of this paper definitely includes " chimeric " antibody, wherein the part of heavy chain and/or light chain be originated from spy
Corresponding sequence in the antibody of earnest kind is identical or homologous or belongs to specific specific antibodies classification or subclass, and the residue of chain
Part is identical or homologous as the corresponding sequence in the antibody for being originated from another species or belongs to another antibody isotype or subclass, with
And the segment of this antibody, as long as they show desired bioactivity (US 4816567;With Morrison et al
(1984)Proc.Natl.Acad.Sci.USA,81:6851-6855).Chimeric antibody includes comprising dynamic from non-human primates
The variable domains antigen-binding subsequences of object (for example, Old World Monkeys or ape and monkey) and human constant regions sequence it is " primatized
" antibody.
" complete antibody " of this paper is comprising VL structural domain and VH structural domain and light chain constant domain (CL) and heavy chain
The antibody of constant domain CH1, CH2 and CH3.Constant domain can be natural sequence constant domains (for example, the mankind day
Right sequence constant domains) or its amino acid sequence variation.Complete antibody can have one or more " effector functions ",
It refers to the bioactivity as caused by the region Fc (native sequence Fc region or the region amino acid sequence variation Fc) of antibody.Antibody
The example of effector function includes that C1q is combined;The cytotoxicity of Complement Dependent;Fc receptor combines;Antibody-dependant it is cell-mediated
Cytotoxicity (ADCC);Phagocytosis;With the downward of cell surface receptor (such as B-cell receptor and BCR).
Complete antibody can be divided into different " classes by the amino acid sequence of the constant domain depending on their heavy chain
Not ".There are 5 kinds of primary categories of complete antibody: IgA, IgD, IgE, IgG and IgM, and some in these can be further
It is divided into " subclass " (isotype), for example, IgG1, IgG2, IgG3, IgG4, IgA and IgA2.Corresponding to the different classes of of antibody
Heavy chain constant domain be referred to as α, δ, ε, γ and μ.The different classes of sub-unit structure of immunoglobulin and three kinds of rulers
Very little configuration is well known.
The modification of antibody
Antibody disclosed herein can be modified.For example, them is made to be less immunogenicity to human experimenter.This can be with
It is realized using any one of multinomial technology well known to those skilled in the art.It has been described more particularly below in these technologies
It is some.
Humanization
The technology for reducing the vivo immunogenicity of non-human antibody or antibody fragment includes being referred to as those of " humanization ".
" humanized antibody " refers to the polypeptide of the Variable Area at least partly modified comprising human antibodies, wherein part
Variable Area, be preferably significantly less than the part of complete human variable-domain, by pair from non-human species
Sequence substitutions are answered, and wherein, the Variable Area of modification is connected at least another part of another protein, and the preferably mankind are anti-
The constant region of body.Stating " humanized antibody " includes human antibodies, wherein one or more complementary determining region (" CDR ") amino
Sour residue and/or one or more framework region (" FW " or " FR ") amino acid residues are resisted from rodent or other non-humans
The same function site (analogous) displacement in body.State " humanized antibody " also comprising immunoglobulin amino acid sequence or it
Segment comprising the FR of the basic amino acid sequence with human immunoglobulin and basic with non-human immunoglobulin
Amino acid sequence CDR.
Non-human (for example, murine) antibody of " humanization " form is comprising being originated from non-human immunoglobulin most
The chimeric antibody of small sequence.Or see in another way, humanized antibody is also comprising replacing human sequence, coming in non-human
The human antibodies of the selected sequence of (for example, murine) antibody.Humanized antibody may include from identical or different species
Conservative amino acid displacement or non-natural residues, do not significantly change its combination and/or bioactivity.This antibody is to include
The chimeric antibody of minmal sequence from non-human immunoglobulin.
There are a large amount of humanization technologies, including ' CDR transplanting ', ' M8003 line ', ' going to be immunized ', ' resurfacing ' (also claim
For ' exterior trim (veneering) '), ' compound antibody ', ' mankind's chain content optimizes (Human String Content
Optimisation it) ' is mixed with frame.
CDR transplanting
In the art, humanized antibody is human immunoglobulin (receptor antibody), wherein from the mutual of receptor antibody
It mends and determines that the residue of area (CDR) is come from non-human species such as mouse, rat, camel, ox, goat or rabbit with desirable properties
CDR (donor antibody) replace (in fact, non-human CDR by ' transplanting " on human framework).In some embodiments, the mankind
Framework region (FR) residue of immunoglobulin is replaced by corresponding non-human residues (for example, this can occur as specific FR
When residue is to antigen is combined with remarkable effect).
In addition, humanized antibody may be embodied in and cannot all find in receptor antibody or the CDR or Frame sequence of implantation
Residue.These modifications are carried out further to improve and maximize antibody performance.Therefore, in general, humanized antibody will include
At least one and two kinds of whole variable domains in one aspect, wherein all the high of hypervariable region ring or whole become
Qu Huan corresponds to those of non-human immunoglobulin, and the area all or essentially all of FR is human immunoglobulin sequence
Those of.Humanized antibody optionally will also include at least part or human immunity ball egg of constant region for immunoglobulin (Fc)
White at least part.
M8003 line
This method is made up of: by the V of the given non-human antibody to defined epitope specificityHOr VLStructural domain and people
Class VHOr VLLibraries Combinatorial and special mankind's V structure domain is selected for the antigen of interest.Then by the selected mankind VH with
VL libraries Combinatorial is to generate complete mankind VHxVL combination.Nature Biotechnology(N.Y.)12,(1994)899-
This method is described in 903.
Compound antibody
In the method, two or more sections (segment) combination of the amino acid sequence from human antibodies is existed
In final antibody molecule.They are constructed and combining multiple mankind VH and VL section in assembly, which exists
Human T cell epitopes are limited or avoided in the final area compound antibody V.When needed, by with avoiding replacing for t cell epitope
Facilitate or encode the section in the area V of t cell epitope for segment exchange to limit or avoid t cell epitope.US2008/
This method is described in 0206239A1.
It goes to be immunized
This method is related to removing the mankind (or other second species) T cell from the area V of therapeutic antibodies (or other molecules)
Epitope.For example, by comparing with MHC binding motif (" motif " database e.g., being stored in www.wehi.edu.au), point
Analyse the presence of MHC class II binding motif in therapeutic antibodies V region sequence.Alternatively, it can be used such as Altuvia et al.
The computational threads method of (J.Mol.Biol.249244-250 (1995)) design identifies MHC class II binding motif;In these methods
In, the combination energy of they and MHC class II protein is tested for the continuous overlapping peptide from V region sequence.Then by the number
It is combined according to the information in other sequences feature, which is related to successfully presenting peptide, such as amphipathic, Rothbard motif and group
Knit the cleavage site of Cathepsin B He other processive enzymes.
When the t cell epitope of identified possible second species (for example, mankind), by changing one or more ammonia
Base acid eliminates them.The amino acid of modification can also close on the primary or two of protein usually in t cell epitope itself
The epitope (therefore, may be not close in primary structure) of level structure.Most commonly, change be by way of displacement,
But in some cases, it is more appropriate to add or delete meeting for amino acid.
All changes may be implemented by DNA recombinant technique, allow to by using the method well established (as oriented
Mutagenesis) final molecule prepared by the expression of recombinant host.It is also possible, however, to use protein chemistry or any other molecule change
Change mode.
Resurfacing
This method is related to:
(a) by the threedimensional model of building non-human antibody variable region, non-human (for example, rodent) antibody is determined
The conformational structure of (or its segment);
(b) it can reach distribution by the x- ray of enough non-humans and human antibody variable domains heavy chain and light chain using opposite
Crystal structure generates sequence alignment, to provide one group of heavy chain and light chain framework position, wherein aligned position is enough non-98%
It is identical in human antibody heavy chain and light chain;
(c) non-human antibody to humanization is determined using the frame position group generated in step (b), one group of heavy chain and light
The amino acid residue of chain surface exposure;
(d) amino acid residue of one group of heavy chain and light chain surface exposure, the amino are identified by human antibodies amino acid sequence
Sour residue and the amino acid residue of the one group of surface exposure limited in step (c) are the most similar, wherein the weight from human antibodies
Chain and light chain are naturally in pairs or cannot naturally in pairs;
(e) in the amino acid sequence to the non-human antibody of humanization, use in step (d) in identify one group of heavy chain and
The amino acid of the one group of heavy chain and light chain surface exposure that limit in the radical amino acid replacement step (c) of light chain surface exposure is residual
Base;
(f) threedimensional model of the variable region of the non-human antibody obtained by the specified displacement of step (e) is constructed;
(g) by comparing the threedimensional model constructed in step (a) and (f), identification step (c) or (d) in the group that identifies
Any amino acid residue, any original of the amino acid residue in any residue of the complementary determining region to humanizing non-human antibodies
In 5 angstroms of son;And
(h) any residue identified in step (g) is changed from human amino acid residues as original non-human amino acid
Residue, to limit non-human antibody's humanization group of the amino acid residue of surface exposure;Condition is not need to be walked first
Suddenly (a), but step (a) must be carried out before step (g).
Super humanized
This method is by non-human sequence and functional human reproduction's germ line genes pedigree (human germline gene
Repertoire) compare.Selection encodes typical case (canonical) structure those of identical or closely related with non-human sequence
Human gene.These selected genes in CDR with highest homology are elected to be FR donor.Finally, non-human CDR is moved
It plants on these mankind FR.This method is described in 2005/079479 A2 of patent WO.
The optimization of mankind's chain content
This method by non-human (for example, mouse) sequence compared with the pedigree of human reproduction's germ line genes, and by difference
Scoring is mankind's chain content (HSC) of the Quantitative Sequence in the level of possible MHC/T cell epitope.Then by making target sequence
HSC maximize rather than target sequence humanization is generated to a variety of different humanization variants using global identity measurement
(in Molecular Immunology, 44, describe in (2007) 1986-1998).
Frame mixing
It will be fused in the CDR frame of non-human antibody comprising all known heavy chains and light chain human reproduction's germ line genes frame
In the pond cDNA of frame.Then humanized antibody is selected for example, by the antibody library of elutriation (panning) phage display.This
Methods 36,43-60 is described in (2005).
Definition
Pharmaceutically acceptable cation
The example of pharmaceutically acceptable unit price and bivalent cation is discussed at Berge, et al., J.Pharm.Sci.,
66,1-19 (1977), it is incorporated herein by reference.
Pharmaceutically acceptable cation can be inorganic cation or organic cation.
The example of pharmaceutically acceptable monovalent inorganic cation includes but is not limited to alkali metal ion such as Na+And K+.Pharmacy
The example of upper acceptable divalent inorganic cations includes but is not limited to alkaline earth metal cation such as Ca2+And Mg2+.Pharmaceutically may be used
The example of the organic cation of receiving includes but is not limited to ammonium ion (i.e. NH4 +) and ammonium ion (such as the NH that replaces3R+、NH2R2 +、NHR3 +、NR4 +).The example of some suitable substituted ammonium ions is derived from the ammonium ion of those of following substitution: ethamine, two
Ethamine, dicyclohexyl amine, triethylamine, butylamine, ethylenediamine, ethanol amine, diethanol amine, piperazine, benzylamine, phenylbenzylamine, choline, Portugal's first
Amine and tromethamine and amino acid, such as lysine and arginine.The example of common quaternary ammonium ion is N (CH3)4 +。
Substituent group
As used in this article, phrase " optionally substituted " be related to its can be it is unsubstituted or its can be it is substituted
Female group.
Unless otherwise prescribed, as used in this article, term " substitution " is related to it with one or more substituent groups
Female group.Term " substituent group " be herein defined as in a conventional sense using and refer to such chemical part, covalently
It is connected to, or if applicable, condenses in female group.Various substituent groups are well-known, and are used for theirs
The method for forming and being introduced to various female groups is also well-known.
The example for being described in more detail below substituent group.
C1-12Alkyl: as used in this article, term " C1-12Alkyl " is related to by from 1 to 12 carbon atom
The carbon atom of hydrocarbon compound remove hydrogen atom monovalent moiety obtained, can be aliphatic series or alicyclic, and it can be with
It is saturated or unsaturated (such as part is unsaturated, completely unsaturated).As used in this article, term " C1-4Alkane
Base " is related to by removing hydrogen atom monovalent moiety obtained from the carbon atom of the hydrocarbon compound with 1 to 4 carbon atom,
It can be aliphatic series or alicyclic, and it can be saturated or unsaturated (such as part is unsaturated, completely unsaturated).
Therefore, term " alkyl " includes the subclass being discussed below: alkenyl, alkynyl, naphthenic base etc..
The example of saturated alkyl includes but is not limited to methyl (C1), ethyl (C2), propyl (C3), butyl (C4), amyl (C5)、
Hexyl (C6) and heptyl (C7)。
The example of saturated linear alkyl includes but is not limited to methyl (C1), ethyl (C2), n-propyl (C3), normal-butyl (C4)、
N-pentyl (amyl) (C5), n-hexyl (C6) and n-heptyl (C7)。
The example for being saturated branched alkyl includes isopropyl (C3), isobutyl group (C4), sec-butyl (C4), tert-butyl (C4), isoamyl
Base (C5) and neopentyl (C5)。
C2-12Alkenyl: as used in this article, term " C2-12Alkenyl " is related to having one or more carbon-to-carbon double bonds
Alkyl.
The example of unsaturated alkenyl includes but is not limited to vinyl (ethenyl) (vinyl, vinyl ,-CH=CH2)、1-
Acrylic (- CH=CH-CH3), 2- acrylic (allyl ,-CH-CH=CH2), isopropenyl (1- methyl ethylene ,-C (CH3)
=CH2), cyclobutenyl (C4), pentenyl (C5) and hexenyl (C6)。
C2-12Alkynyl: as used in this article, term " C2-12Alkynyl " is related to having one or more carbon-carbon triple bonds
Alkyl.
The example of unsaturated alkynyl includes but is not limited to acetenyl (- C ≡ CH) and 2-propynyl (2-propynyl) (alkynes third
Base (propargyl) ,-CH2-C≡CH)。
C3-12Naphthenic base: as used in this article, term " C3-12Naphthenic base " is related to and the alkyl of ring group;That is, logical
It crosses from the alicyclic ring atom of cyclic hydrocarbon (carbocyclic ring) compound and removes hydrogen atom monovalent moiety obtained, which has 3 to 7
Carbon atom, including 3 to 7 annular atoms.
The example of naphthenic base includes but is not limited to those naphthenic base, is originated from:
It is saturated monocycle hydrocarbon compound;
Cyclopropane (C3), cyclobutane (C4), pentamethylene (C5), hexamethylene (C6), cycloheptane (C7), methyl cyclopropane (C4)、
Dimethylcyclopropane (C5), methyl cyclobutane (C5), dimethylcyclobutane (C6), methyl cyclopentane (C6), dimethylcyclopentane
(C7) and hexahydrotoluene (C7);
Unsaturated monocyclic hydrocarbon compound;
Cyclopropylene (C3), cyclobutane (C4), cyclopentene (C5), cyclohexene (C6), methyl cyclopropene (C4), dimethylcyclopropene
(C5), methyl cyclobutane (C5), dimethyl cyclobutane (C6), methyl cyclopentene (C6), dimethylcyclopentene (C7) and methyl cyclohexane
Alkene (C7);And
It is saturated polycyclic hydrocarbon compounds:
Norcarane (norcarane) (C7), norpinane (norpinane) (C7), norcamphane (norbornane,
norbornane)(C7)。
C3-20Heterocycle: as used in this article, term " C3-20Heterocycle " is related to through the ring from heterocyclic compound
Atom removes hydrogen atom monovalent moiety obtained, which has 3 to 20 annular atoms, wherein 1 to 10 is ring hetero atom.
Preferably, each ring has 3 to 7 annular atoms, wherein 1 to 4 is ring hetero atom.
In this context, prefix (such as C3-20、C3-7、C5-6, etc.) indicate the number of annular atom or the number of annular atom
Range, but regardless of being carbon atom or hetero atom.For example, as used in this article, term " C5-6Heterocycle " is related to having
The heterocycle of 5 or 6 annular atoms.
The example of monocyclic heterocycles base includes but is not limited to be originated from those of following monocyclic heterocycles base:
N1: aziridine (C3), azetidine (C4), pyrrolidines (nafoxidine) (C5), pyrrolin is (for example, 3- pyrroles
Quinoline, 2,5- pyrrolin) (C5), 2H- pyrroles or 3H- pyrroles (different pyrroles, isoxazole) (C5), piperidines (C6), dihydropyridine
(C6), tetrahydropyridine (C6), azepine(C7);
O1: oxirane (oxirane) (C3), oxetanes (oxetane) (C4), tetrahydrofuran (tetrahydro furan
Mutter) (C5), oxole (divinylene oxide, oxole) (dihydrofuran) (C5), oxinane (exane) (oxinane)
(C6), dihydropyran (C6), pyrans (C6), oxa-(disliking heptan, oxepin) (C7);
S1: thiirane (C3), Thietane (C4), tiacyclopentane (thiophane) (C5), thia hexamethylene
(tetrahydric thiapyran) (C6), thia cycloheptane (thiepane) (C7);
O2: dioxolane (C5), dioxane (C6) and Dioxepane (dioxepane) (C7);
O3: trioxane (C6);
N2: imidazolidine (C5), pyrazolidine (two azo alkane) (C5), imidazoline (C5), pyrazoline (pyrazoline) (C5), piperazine
(C6);
N1O1: tetrahydro oxazole (C5), dihydro-oxazole (C5), tetrahydro isoxazole (C5), dihydro-isoxazole (C5), morpholine (C6)、
Tetrahydro oxazines (C6), dihydro oxazines (C6), oxazines (C6);
N1S1: thiazoline (C5), thiazolidine (C5), thiomorpholine (C6);
N2O1: oxadiazines (C6);
O1S1: oxygen dithiole (disliking thiophene, oxathiole) (C5) and thioxane (thiophene oxane) (C6);With
And
N1O1S1: dislike thiazine (C6)。
The example of substituted monocyclic heterocycles base includes the monocyclic heterocycles base that those replace, and is originated from the carbohydrate of loop type, example
Such as, furanose (C5), such as arabinofuranose, lysol furanose (lyxofuranose), ribofuranose and furyl xylose
(xylofuranse) and pyranose (C6), such as other pyranose (allopyranose), pyrans altrose, glucopyranose,
Mannopyranose, pyrans gulose (gulopyranose), pyrans idose (idopyranose), galactopyranose and pyrans
Talose (talopyranose).
C5-20Aryl: as used in this article, term " C5-20Aryl " is related to former by the aromatic ring from aromatic compounds
Son removal hydrogen atom monovalent moiety obtained, has 3 to 20 annular atoms.As used in this article, term " C5-7
Aryl " is related to having 5 to 7 rings by removing hydrogen atom monovalent moiety obtained from the aromatic ring atom of aromatic compounds
Atom, and as used in this article, term " C5-10Aryl " is related to by removing from the aromatic ring atom of aromatic compounds
Hydrogen atom monovalent moiety obtained has 5 to 10 annular atoms.Preferably, each ring has 5 to 7 annular atoms.
In this context, prefix (such as C3-20、C5-7、C5-6、C5-10Deng) indicate annular atom (carbon atom or hetero atom)
The range of number or the number of annular atom.For example, as used in this article, term " C5-6Aryl " is related to having 5 or 6
The aryl of annular atom.
Annular atom can all be carbon atom, such as in " carbon aryl ".
The example of carbon aryl includes but is not limited to be originated from those of following carbon aryl: benzene (i.e. phenyl) (C6), naphthalene (C10), Azulene
(azulenes) (C10), anthracene (C14), phenanthrene (C14), naphthonaphthalene (C18) and pyrene (C16)。
The example of aryl comprising condensed ring (at least one its is aromatic ring) includes but is not limited to be originated from group below: indane
(such as 2,3- dihydro -1H- indenes) (C9), indenes (C9), different indenes (C9), tetrahydronaphthalene (1,2,3,4- naphthane (C10), acenaphthene (C12)、
Fluorenes (C13), non-that alkene (C13), vinegar phenanthrene (C15) and aceanthrene (C16)。
Alternatively, annular atom may include one or more hetero atoms, such as in " heteroaryl ".The reality of bicyclic heteroaryl
Example includes but is not limited to from those of following:
N1: pyrroles (Pyrrole) (azoles, azole) (C5), pyridine (azine) (C6);
O1: furans (divinylene oxide, oxole) (C5);
S1: thiophene (thiophene) (thiophene, thiole) (C5);
N1O1: oxazole (C5), isoxazole (C5), isooxazine (C6);
N2O1: oxadiazoles (furazan) (C5);
N3O1: dislike triazole (C5);
N1S1: thiazole (C5), isothiazole (C5);
N2: imidazoles (1,3- diazole) (C5), pyrazoles (1,2- diazole) (C5), pyridazine (1,2- diazine) (C6), pyrimidine (1,3-
Diazine) (C6) (for example, cytimidine, thymidine, uracil), pyrazine (1,4-diazines) (C6);
N3: triazole (C5), triazine (C6);And
N4: tetrazolium (C5)。
The example of heteroaryl comprising condensed ring includes but is not limited to:
From C below9(there are 2 condensed ring): benzofuran (O1), isobenzofuran (O1), indoles (N1), iso-indoles
(N1), benzazole (N1), indoline (N1), isoindoline (N1), purine (N4) (for example, adenine, guanine), benzimidazole
(N2), indazole (N2), benzoxazoles (N1O1), benzo isoxazole (N1O1), benzo dioxolen (benzo two dislikes cyclopentadienyl)
(O2), benzofuraxan (N2O1), benzotriazole (N3), benzothiophene (S1), benzothiazole (N1S1), diazosulfide (N2S);
From C below10(there are 2 condensed ring): chromene (O1), heterochromatic alkene (O1), chroman (chroman) (O1), it is heterochromatic full
(O1), benzdioxan (O2), quinoline (N1), isoquinolin (N1), quinolizine (N1), benzoxazine (N1O1), benzodiazine (N2), pyrrole
Pyridine and pyridine (N2), quinoxaline (N2), quinazoline (N2), cinnolines (N2), phthalazines (phthalazine) (N2), naphthyridines (diaza
Naphthalene, naphthyridine) (N2), pteridine (N4);
From C below11(there are 2 condensed ring): benzodiazepine(N2);
From C below13(there are 3 condensed ring): carbazole (N1), dibenzofurans (O1), dibenzothiophenes (S1), carboline
(N2), pyridine (perimidine, perimidine) (N pah2), pyridine diindyl (N2);And
From C below14(there are 3 condensed ring): acridine (N1), xanthene (xanthene) (O1), thioxanthene (S1), dislike anthracene
(oxanthrene)(O2), phenoxazine thiophene (phenoxathiin) (O1S1), azophenlyene (N2), phenoxazine (N1O1), phenthazine (N1S1)、
Thianthrene (S2), phenanthridines (N1), phenanthroline (N2), azophenlyene (N2)。
Above-mentioned group, no matter individually or a part of another substituent group, can itself optionally by selected from them this
One or more groups of body and the other substituent group being listed below replace.
Halogen :-F ,-Cl ,-Br and-I.
Hydroxyl :-OH.
Ether :-OR, wherein R is ether substituent group, for example, C1-7Alkyl (is also known as C1-7Alkoxy is discussed below),
C3-20Heterocycle (is also known as C3-20Heterocyclic oxy group) or C5-20Aryl (is also known as C5-20Aryloxy group), preferably C1-7Alkyl.
Alkoxy :-OR, wherein R is alkyl, for example, C1-7Alkyl.C1-7The example of alkoxy includes but is not limited to-OMe
(methoxyl group) ,-OEt (ethyoxyl) ,-O (nPr) (positive propoxy) ,-O (iPr) (isopropoxy) ,-O (nBu) (n-butoxy) ,-
O (sBu) (sec-butoxy) ,-O (iBu) (isobutoxy) and-O (tBu) (tert-butoxy).
Acetal :-CH (OR1)(OR2), wherein R1And R2It is independently acetal substitutent group, for example, C1-7Alkyl, C3-20Heterocycle
Or C5-20Aryl, preferably C1-7Alkyl, alternatively, in the case where " ring-type " acetal groups, R1And R2Together with they connected two
A oxygen atom and the carbon atom that they are connected are formed together the heterocycle with 4 to 8 annular atoms.The example of acetal groups includes
But it is not limited to-CH (OMe)2、-CH(OEt)2With-CH (OMe) (OEt).
Hemiacetal :-CH (OH) (OR1), wherein R1It is hemiacetal substituent group, for example, C1-7Alkyl, C3-20Heterocycle or C5-20
Aryl, preferably C1-7Alkyl.The example of hemiacetal group includes but is not limited to-CH (OH) (OMe) and-CH (OH) (OEt).
Ketal :-CR (OR1)(OR2), wherein R1And R2It is as defined by acetal and R is contracting in addition to hydrogen
Ketone substituent group, for example, C1-7Alkyl, C3-20Heterocycle or C5-20Aryl, preferably C1-7Alkyl.The example of ketal group includes but not
It is limited to-C (Me) (OMe)2、-C(Me)(OEt)2、-C(Me)(OMe)(OEt)、-C(Et)(OMe)2、-C(Et)(OEt)2With-C
(Et)(OMe)(OEt)。
Hemiketal :-CR (OH) (OR1), wherein R1It is to be limited as being directed to hemiacetal, and R is hemiketal in addition to hydrogen
Substituent group, for example, C1-7Alkyl, C3-20Heterocycle or C5-20Aryl, preferably C1-7Alkyl.The example of hemiacetal group includes but not
It is limited to-C (Me) (OH) (OMe) ,-C (Et) (OH) (OMe) ,-C (Me) (OH) (OEt) and-C (Et) (OH) (OEt).
Oxo (ketone group, -one) :=O.
Thioketones (Thione) (thio ketone, thioketone) :=S.
Imino group (imines) :=NR, wherein R is imino group substituent group, for example, hydrogen, C1-7Alkyl, C3-20Heterocycle or C5-20
Aryl, preferably hydrogen or C1-7Alkyl.The example of ester group includes but is not limited to=NH ,=NMe ,=Net and=NPh.
Formoxyl (formaldehyde, carbaldehyde, carboxaldehyde) :-C (=O) H.
Acyl group (ketone group) :-C (=O) R, wherein R is acyl substituent, for example, C1-7Alkyl (is also known as C1-7Alkane acyl
Base), C3-20Heterocycle (is also known as C3-20Heterocyclic acyl) or C5-20Aryl (is also known as C5-20Aroyl), preferably C1-7Alkane
Base.The example of acyl group includes but is not limited to-C (=O) CH3(acetyl group) ,-C (=O) CH2CH3(propiono) ,-C (=O) C
(CH3)3(tertiary bytyry) and-C (=O) Ph (benzoyl, benzophenone).
Carboxyl (carboxylic acid) :-C (=O) OH.
Thiocarboxyl group (thiocarboxylic acid) :-C (=S) SH.
Sulfydryl for carboxyl (mercaptan carboxyl, Thiolocarboxy) (sulfydryl for carboxylic acid (thiol carboxylic acid),
Thiolocarboxylic acid) :-C (=O) SH.
Thion carboxyl (thiono carboxylic acid) :-C (=S) OH.
Imidic acid (Imidic acid) :-C (=NH) OH.
Hydroxamic acid :-C (=NOH) OH.
Ester (carboxylate (carboxylate, carboxylic acid ester), Epoxide carbonyl (oxycarbonyl)) :-
C (=O) OR, wherein R is ester substituent group, for example, C1-7Alkyl, C3-20Heterocycle or C5-20Aryl, preferably C1-7Alkyl.Ester group
Example includes but is not limited to-C (=O) OCH3,-C (=O) OCH2CH3,-C (=O) OC (CH3)3With-C (=O) Oph.
Acyloxy (reversed ester) :-OC (=O) R, wherein R is acyloxy substituent group, for example, C1-7Alkyl, C3-20Heterocycle
Or C5-20Aryl, preferably C1-7Alkyl.The example of acyloxy includes but is not limited to-OC (=O) CH3(acetoxyl group) ,-OC (=O)
CH2CH3,-OC (=O) C (CH3)3,-OC (=O) Ph and-OC (=O) CH2Ph。
Oxygroup carbonyloxy group (Oxycarboyloxy) :-OC (=O) OR, wherein R is ester substituent group, for example, C1-7Alkyl,
C3-20Heterocycle or C5-20Aryl, preferably C1-7Alkyl.The example of ester group includes but is not limited to-OC (=O) OCH3,-OC (=O)
OCH2CH3,-OC (=O) OC (CH3)3With-OC (=O) Oph.
Amino :-NR1R2, wherein R1And R2It is independently amino-substituent, for example, hydrogen, C1-7Alkyl (is also known as C1-7Alkane
Base amino or two C1-7Alkyl amino), C3-20Heterocycle or C5-20Aryl, preferably H or C1-7Alkyl, alternatively, in " ring-type " amino
In the case of, R1And R2The nitrogen-atoms connected together with them is formed together the heterocycle with 4 to 8 annular atoms.Amino can be primary
Amino (- NH2), secondary amino group (- NHR1) or tertiary amino (- NHR1R2), and in cationic form, can be quaternary ammonium (-+
NR1R2R3).The example of amino includes but is not limited to-NH2、-NHCH3、-NHC(CH3)2、-N(CH3)2、-N(CH2CH3)2With-
NHPh.The example of cyclic amino include but is not limited to '-aziridino, azetidinyl, pyrrolidines simultaneously, piperidino
(piperidino), Piperazino (piperazino), morpholino and thiomorpholine generation.
Acylamino- (carbamoyl, carbamyl, amino carbonyl, formamide) :-C (=O) NR1R2, wherein R1And R2Solely
It is on the spot amino-substituent, as defined by amino.The example of acylamino- includes but is not limited to-C (=O) NH2,-C (=
O)NHCH3,-C (=O) N (CH3)2,-C (=O) NHCH2CH3With-C (=O) N (CH2CH3)2And acylamino-, wherein R1And R2
The nitrogen-atoms connected together with them is formed together heterocycle structure, such as exists, for example, piperidino carbonyl, morpholino carbonyl, thio
In morpholino carbonyl and Piperazino carbonyl.
Thio acylamino (thiocarbamoyl) :-C (=S) NR1R2, wherein R1And R2It is independently amino-substituent,
As for defined by amino.The example of acylamino- includes but is not limited to-C (=S) NH2,-C (=S) NHCH3,-C (=S) N
(CH3)2With-C (=S) NHCH2CH3。
Acylamido (acylamino-) :-NR1C (=O) R2, wherein R1It is amide substituents, for example, hydrogen, C1-7Alkyl,
C3-20Heterocycle or C5-20Aryl, preferably hydrogen or C1-7Alkyl and R2It is acyl substituent, for example, C1-7Alkyl, C3-20Heterocycle
Base or C5-20Aryl, preferably hydrogen or C1-7Alkyl.The example of amide group includes but is not limited to-NHC (=O) CH3,-NHC (=O)
CH2CH3With-NHC (=O) Ph.R1And R2It can be formed together cyclic structure, such as existed, for example, succinimido, maleimide
In amido and phthalimidyl:
Amino carbonyloxy group :-OC (=O) NR1R2, wherein R1And R2It is independently amino-substituent, as limited for amino
's.The example of amino carbonyloxy group includes but is not limited to-OC (=O) NH2,-OC (=O) NHMe ,-OC (=O) NMe2With-OC (=O)
NEt2。
Urea groups :-N (R1)CONR2R3, wherein R2And R3It is independently amino-substituent, as defined by amino, and
R1It is Carbamido substituted base, for example, hydrogen, C1-7Alkyl, C3-20Heterocycle or C5-20Aryl, preferably hydrogen or C1-7Alkyl.The example of urea groups
Including but not limited to-NHCONH2、-NHCONHMe、-NHCONHEt、-NHCONMe2、-NHCONEt2、-NMeCONH2、-
NMeCONHMe、-NMeCONHEt、-NMeCONMe2With-NMeCONEt2。
Guanidine radicals :-NH-C (=NH) NH2。
Tetrazole radical: five yuan of aromatic rings with 4 nitrogen-atoms and a carbon atom,
Imino group :=NR, wherein R is imino group substituent group, for example, hydrogen, C1-7Alkyl, C3-20Heterocycle or C5-20Aryl,
It is preferred that H or C1-7Alkyl.The example of imino group includes but is not limited to=NH ,=NMe and=NEt.
Amidine (amidino groups) :-C (=NR) NR2, wherein each R is amidine substituent group, for example, hydrogen, C1-7Alkyl, C3-20Heterocycle or
C5-20Aryl, preferably H or C1-7Alkyl.The example of amidine group includes but is not limited to-C (=NH) NH2,-C (=NH) NMe2With-C
(=NMe) NMe2。
Nitro :-NO2。
Nitroso :-NO.
Azido :-N3。
Cyano (nitrile, nitrile, carbonitrile) :-CN.
Isocyano group :-NC.
Cyanato (Cyanato) :-OCN.
Isocyanato :-NCO.
Thiocyanogen (Thiocyano) (thiocyanogen) :-SCN.
Isothiocyano (isothiocyano) (isothiocyano, isothiocyanato) :-NCS.
Sulfydryl (Sulfhydryl) (mercaptan, thiol;Sulfydryl, mercapto) :-SH.
Thioether (sulfide) :-SR, wherein R is thioether substituent, for example, C1-7Alkyl (is also known as C1-7Alkylthio group),
C3-20Heterocycle or C5-20Aryl, preferably C1-7Alkyl.C1-7The example of alkylthio group includes but is not limited to-SCH3With-SCH2CH3。
Disulphide :-SS-R, wherein R is disulphide substituent group, for example, C1-7Alkyl, C3-20Heterocycle or C5-20Virtue
Base, preferably C1-7Alkyl (also referred to as C1-7Alkyl disulfide).C1-7The example of alkyl disulfide group include but
It is not limited to-SSCH3With-SSCH2CH3。
Sulfime base (sulfonium compound, sulfine) (sulfinyl, sulfoxide) :-S (=O) R, wherein R is sulfime base substituent group, example
Such as, C1-7Alkyl, C3-20Heterocycle or C5-20Aryl, preferably C1-7Alkyl.The example of sulfime base group including but not limited to-S (=
O)CH3With-S (=O) CH2CH3。
Sulfone (sulfonyl) :-S (=O)2R, wherein R is sulfone substituent group, for example, C1-7Alkyl, C3-20Heterocycle or C5-20Virtue
Base, preferably C1-7Alkyl, including, for example, fluorination or perfluorinated C1-7Alkyl.The example of sulfone group includes but is not limited to-S (=O)2CH3(mesyl) ,-S (=O)2CF3(trifyl, triflyl) ,-S (=O)2CH2CH3(ethylsulfonyl,
Esyl) ,-S (=O)2C4F9(nine fluorine fourth sulfonyls, nonaflyl) ,-S (=O)2CH2CF3(trifluoro ethylsulfonyl, tresyl) ,-
S (=O)2CH2CH2NH2(tauryl-, tauryl) ,-S (=O)2Ph (benzene sulfonyl, benzenesulfonyl (besyl)), 4- methylbenzene sulphur
Acyl (tosyl (tosyl)), 4- chlorobenzenesulfonyl (chlorobenzenesulfonyl (closyl)), 4- bromophenylsulfonyl (bromobenzenesulfonyl
(brosyl)), 4- nitrobenzophenone (nitrobenzenesulfonyl (nosyl)), 2- napsylate (naphthalene sulfonyl base, napsyl) and 5- diformazan
Base amino-naphthalene -1- base sulphonic acid ester (dansyl (dansyl)).
Sulfinic acid (sulfino) :-S (=O) OH ,-SO2H。
Sulfonic acid (sulfo group) :-S (=O)2OH、-SO3H。
Sulfinic acid ester (sulfinate) (sulfinic acid ester, sulfinic acid ester) :-S (=O) OR;Wherein R is sub-
Sulfonate substituent, for example, C1-7Alkyl, C3-20Heterocycle or C5-20Aryl, preferably C1-7Alkyl.The example of sulfinate groups
Including but not limited to-S (=O) OCH3(methoxyl group sulfinyl;Sulfinic acid methyl esters) and-S (=O) OCH2CH3(ethyoxyl sulfurous
Acyl group;Sulfinic acid ethyl ester).
Sulphonic acid ester (sulfonate) (sulphonic acid ester, sulfonic acid ester) :-S (=O)2OR, wherein R is sulfonic acid
Ester substituent group, for example, C1-7Alkyl, C3-20Heterocycle or C5-20Aryl, preferably C1-7Alkyl.The example of sulfonate ester group include but
It is not limited to-S (=O)2OCH3(methoxysulfonyl;Methylmesylate) and-S (=O)2OCH2CH3(ethoxysulfonyl;Sulfonic acid second
Ester).
Sulfenyl oxygroup :-OS (=O) R, wherein R is thionyl oxy substituents, for example, C1-7Alkyl, C3-20Heterocycle
Or C5-20Aryl, preferably C1-7Alkyl.The example of sulfurous acyloxy includes but is not limited to-OS (=O) CH3With-OS (=O)
CH2CH3。
Sulfonyloxy :-OS (=O)2R, wherein R is sulfonyloxy substituent, for example, C1-7Alkyl, C3-20Heterocycle or
C5-20Aryl, preferably C1-7Alkyl.The example of sulfonyloxy includes but is not limited to-OS (=O)2CH3(methanesulfonates) and-OS (=
O)2CH2CH3(esilate).
Sulfuric ester :-OS (=O)2OR;Wherein R is sulfuric ester substituent group, for example, C1-7Alkyl, C3-20Heterocycle or C5-20Virtue
Base, preferably C1-7Alkyl.The example of sulfate group includes but is not limited to-OS (=O)2OCH3With-SO (=O)2OCH2CH3。
Sulfonamides (sulfamyl) (sulfonamides (sulfamoyl);Sulfinic acid amide;Sulfenamide) :-S (=O) NR1R2,
Wherein R1And R2It is independently amino-substituent, as defined by amino.The example of sulfonamides including but not limited to-S (=
O)NH2,-S (=O) NH (CH3) ,-S (=O) N (CH3)2,-S (=O) NH (CH2CH3) ,-S (=O) N (CH2CH3)2With-S (=O)
NHPh。
Sulfonamido (sulfonimide groups;Sulfonic acid amides;Sulfonamides) :-S (=O)2NR1R2, wherein R1And R2It is independently
Amino-substituent, as defined by amino.The example of sulfonamido includes but is not limited to-S (=O)2NH2,-S (=O)2NH(CH3) ,-S (=O)2N(CH3)2,-S (=O)2NH(CH2CH3) ,-S (=O)2N(CH2CH3)2With-S (=O)2NHPh。
Sulfoamino-group :-NR1S (=O)2OH, wherein R1It is amino-substituent, as defined by amino.The reality of sulfoamino-group
Example includes but is not limited to-NHS (=O)2OH and-N (CH3) S (=O)2OH。
Sulfonamido (Sulfonamino) :-NR1S (=O)2R, wherein R1It is amino-substituent, as limited for amino
And R be sulfonamide substituent, for example, C1-7Alkyl, C3-20Heterocycle or C5-20Aryl, preferably C1-7Alkyl.Sulphonyl ammonia
The example of base includes but is not limited to-NHS (=O)2CH3With-N (CH3) S (=O)2C6H5。
Sulfonamido (Sulfinamino) :-NR1S (=O) R, wherein R1It is amino-substituent, as limited for amino
Fixed, and R is sulfinamino substituent, for example, C1-7Alkyl, C3-20Heterocycle or C5-20Aryl, preferably C1-7Alkyl.It is sub-
The example of sulfonamido includes but is not limited to-NHS (=O) CH3With-N (CH3) S (=O) C6H5。
Phosphino- (phosphine) :-PR2, wherein R is phosphino- substituent group, for example,-H, C1-7Alkyl, C3-20Heterocycle or C5-20Aryl,
It is preferred that-H, C1-7Alkyl or C5-20Aryl.The example of phosphino- includes but is not limited to-PH2、-P(CH3)2、-P(CH2CH3)2、-P(t-
Bu)2With-P (Ph)2。
Phospho :-P (=O)2。
Phosphoryl (phosphine oxide) :-P (=O) R2, wherein R is phosphinyl substituent group, for example, C1-7Alkyl, C3-20Heterocycle or
C5-20Aryl, preferably C1-7Alkyl or C5-20Aryl.The example of phosphoryl includes but is not limited to-P (=O) (CH3)2,-P (=O)
(CH2CH3)2,-P (=O) (t-Bu)2With-P (=O) (Ph)2。
Phosphonic acids (phosphono) :-P (=O) (OH)2。
Phosphonate ester (phosphono base ester) :-P (=O) (OR)2, wherein R is phosphonate substituted base, for example,-H, C1-7Alkyl, C3-20
Heterocycle or C5-20Aryl, preferably-H, C1-7Alkyl or C5-20Aryl.The example of phosphonate groups includes but is not limited to-P (=O)
(OCH3)2,-P (=O) (OCH2CH3)2,-P (=O) (O-t-Bu)2With-P (=O) (OPh)2。
Phosphoric acid (phosphonato) :-OP (=O) (OH)2。
Phosphate (phosphonato ester) :-OP (=O) (OR)2, wherein R is phosphate ester substituents, for example,-H, C1-7Alkyl,
C3-20Heterocycle or C5-20Aryl, preferably-H, C1-7Alkyl or C5-20Aryl.The example of bound phosphate groups includes but is not limited to-OP
(=O) (OCH3)2,-OP (=O) (OCH2CH3)2,-OP (=O) (O-t-Bu)2With-OP (=O) (OPh)2。
Phosphorous acid :-OP (OH)2。
Phosphite ester :-OP (OR)2, wherein R is phosphite ester substituent group, for example,-H, C1-7Alkyl, C3-20Heterocycle or
C5-20Aryl, preferably-H, C1-7Alkyl or C5-20Aryl.The example of phosphite group includes but is not limited to-OP (OCH3)2、-OP
(OCH2CH3)2、-OP(O-t-Bu)2With-OP (OPh)2。
Phosphoramidite :-OP (OR1)-NR2 2, wherein R1And R2It is phosphoramidite substituent group, for example,-H, (optionally substituted)
C1-7Alkyl, C3-20Heterocycle or C5-20Aryl, preferably-H, C1-7Alkyl or C5-20Aryl.The example of phosphoramidite group include but
It is not limited to-OP (OCH2CH3)-N(CH3)2、-OP(OCH2CH3)-N(i-Pr)2With-OP (OCH2CH2CN)-N(i-Pr)2。
Phosphoramidate :-OP (=O) (OR1)-NR2 2, wherein R1And R2Phosphoramidate substituent group, for example,-H, (can
Choose generation) C1-7Alkyl, C3-20Heterocycle or C5-20Aryl, preferably-H, C1-7Alkyl or C5-20Aryl.Phosphoramidic acid ester group
Example include but is not limited to-OP (=O) (OCH2CH3)-N(CH3)2,-OP (=O) (OCH2CH3)-N(i-Pr)2With-OP (=
O)(OCH2CH2CN)-N(i-Pr)2。
Alkylidene
C3-12Alkylidene: as used in this article, term " C3-12Alkylidene " is related to by from 3 to 12 carbon
The identical carbon atoms of the hydrocarbon compound of atom (unless otherwise prescribed) remove two hydrogen atoms or each from two different carbon atoms
A hydrogen atom two toothed portion obtained is removed, can be aliphatic series or alicyclic, and it can be saturation, part not
It is saturation or complete unsaturated.Therefore, term " alkylidene " includes the following subclass being discussed below: alkenylene, alkynylene, ring
Alkylidene etc..
Linear saturation C3-12The example of alkylidene includes but is not limited to-(CH2)n, wherein n is 3 to 12 integer, for example,-
CH2CH2CH2(propylidene) ,-CH2CH2CH2CH2(butylidene) ,-CH2CH2CH2CH2CH2(pentylidene) and-
CH2CH2CH2CH-2CH2CH2CH2(heptamethylene).
Branch is saturated C3-12The example of alkylidene includes but is not limited to-CH (CH3)CH2-、-CH(CH3)CH2CH2-、-CH
(CH3)CH2CH2CH2-、-CH2CH(CH3)CH2-、-CH2CH(CH3)CH2CH2-、-CH(CH2CH3)-、-CH(CH2CH3)CH2And-
CH2CH(CH2CH3)CH2-。
The unsaturated C of linear fraction3-12Alkylidene (C3-12Alkenylene and alkynylene) example include but is not limited to-CH=
CH-CH2-、-CH2- CH=CH2,-CH=CH-CH2-CH2,-CH=CH-CH2-CH2-CH2,-CH=CH-CH=CH- ,-CH
=CH-CH=CH-CH2,-CH=CH-CH=CH-CH2-CH2,-CH=CH-CH2- CH=CH- ,-CH=CH-CH2-CH2-CH
=CH- and-CH2-C≡C-CH2-。
The unsaturated C of branched fraction3-12Alkylidene (C3-12Alkenylene and alkynylene) example include but is not limited to-C
(CH3)=CH-.-C(CH3)=CH-CH2,-CH=CH-CH (CH3)-and-C ≡ C-CH (CH3)-。
Alicyclic saturation C3-12Alkylidene (C3-12Ring alkylidene) example include but is not limited to that (such as ring is amyl- for cyclopentylene
1,3- subunit) and cyclohexylidene (such as hexamethylene -1,4- subunit).
The unsaturated C of cycloaliphatic moiety3-12Alkylidene (C3-12Ring alkylidene) example include but is not limited to cyclopentenylidene
(such as 4- cyclopentene -1,3- subunit), cyclohexadienylidene (such as 2- cyclohexene -1,4- subunit;3- cyclohexene -1,2- subunit;2,
5- cyclohexadiene -1,4- subunit).
Carbamate nitrogen-protecting group group: term " carbamate nitrogen-protecting group group " is related to such part, masking
Nitrogen in imine linkage, and be well known in the art.These groups have a structure that
Wherein R '10It is R as defined above.Largely suitable group is described in Greene, T.W.and Wuts,
G.M.,Protective Groups in Organic Synthesis,3rd Edition,John Wiley&Sons,Inc.,
1999 page 503 to 549, it is incorporated herein by reference.
Hemiacetal amine nitrogen-protecting group group: term " hemiacetal amine nitrogen-protecting group group " is related to the group having following structure:
Wherein R '10It is R as defined above.The a large amount of suitable group as amide blocking group is described in
Greene,T.W.and Wuts,G.M.,Protective Groups in Organic Synthesis,3rd Edition,
Page 633 to 647 of John Wiley&Sons, Inc., 1999, it is incorporated herein by reference.
Group carbamate nitrogen-protecting group group and hemiacetal nitrogen-protecting group group can be commonly referred to as " the nitrogen for synthesis
Blocking group ".
Conjugate
The present invention provides the conjugate of the PBD compound comprising being connected to antibody via connector unit.
In one embodiment, conjugate includes the antibody for being connected to introns linking group, is connected to initiator
(trigger) introns, the initiator for being connected to selfdecomposition (from eliminating, self-destruction, self-immolative) connector and connection
To the selfdecomposition connector of the position N10 of PBD compound.Following illustrate this conjugates:
Wherein, Ab is antibody defined above and PBD is Pyrrolobenzodiazepines described hereinCompound
(D).Illustrate to show the R corresponding in certain embodiments of the inventionL’、A、L1And L2Part.RL’It can be RL1’Or
RL2’.D is wherein to remove RL1’Or RL2’DL。
Purposes of the present invention suitable for PBD compound to be provided to preferred position subject.In preferred embodiment party
In formula, conjugate allows to discharge the active PBD compound for not retaining any junction portion.There is no can influence PBD compound
Reactivity residual.
Antibody is connected to PBD drug moiety D by one or more covalent bonds by connector.Connector is difunctionality or more officials
The part of energy, can be used for connecting one or more drug moieties (D) and antibody units (Ab) to form antibody-drug conjugates
(ADC).Connector (RL’) except cell (that is, extracellular) can be stable or it is by enzymatic activity, hydrolysis or other are new
Old metabolic conditions are cleavable.It can be convenient using having for being bound to the connector of the reactive functional group degree of drug moiety and antibody
Ground prepares antibody-drug conjugates (ADC).The cysteine mercaptan or amine of antibody (Ab), such as N-terminal or amino acid side chain are (such as
Lysine), it can be with connector or introns reagent, PBD drug moiety (D) or agent-linker reagent (DL, D-RL) functional group
Form key, wherein RLIt can be RL1Or RL2。
The connector of ADC is preferably prevented from the aggregation of ADC molecule, and ADC is kept to be soluble in aqueous medium and protected
It holds in free state.
The connector of ADC is preferably extracellularly being stablized.Before conveying or being delivered to cell, antibody-drug conjugates
(ADC) it is preferably stable and keeps complete, that is, antibody remains attached to drug moiety.Connector is steady outside target cell
Fixed, and can be cut in the cell with effective speed.Effective connector is incited somebody to action: the specific binding characteristics of (i) holding antibody;
(ii) allow the Intracellular delivery of conjugate or drug moiety;(iii) keep stable and complete, that is, until conjugate is delivered
Or it is delivered to its target site and just cuts;And (iv) keeps cytotoxic effect, the killing functions of immunocytes of PBD drug moiety
Or cyto-inhibition.The steady of ADC can be measured by standard analytical techniques such as mass spectrum, HPLC and separation/analytical technology LC/MS
It is qualitative.
The covalent linkage of antibody and drug moiety needs connector tool, and there are two reactive functional groups, that is, in reaction meaning
Divalent.It can be used for connecting two or more funtion parts or biologically-active moiety such as peptide, nucleic acid, drug, toxin, antibody, half to resist
Former and reporter group bivalent linker is known, and has had method to describe the conjugate that they are obtained
(Hermanson,G.T.(1996)Bioconjugate Techniques;Academic Press:New York,p 234-
242)。
In another embodiment, connector can be replaced by adjusting aggregation, solubility or reactive group.For example,
Sulfonate substituent can increase the water solubility of reagent and promote the coupling reaction of linker reagents and antibody or drug moiety,
Or promote Ab-L and DLOr DLThe coupling reaction of-L and Ab, this depends on preparing the synthesis path that ADC is used.
In one embodiment, L-RL’It is following group:
Wherein, asterisk indicates the point for being connected to drug unit (D), and Ab is antibody (L), L1It is connector, A is by L1It is connected to
The linking group of antibody, L2Be covalent bond or with-OC (=O)-be formed together selfdecomposition connector and L1Or L2It is cleavable
Connector.
L1Preferably cleavable connector, and can be by being known as the initiator for activating joint cutting.
When it is present, L1And L2Property can change extensively.Based on their Cutting feature come these groups of selection,
It can be determined by the condition in the site that conjugate is delivered.Although also can be used through pH variation (for example, acid or alkali are not
Stability), temperature or be cleavable connector by radiation (for example, to unstability of light), but cut by the effect of enzyme
It is preferred for those of cutting connector.Cleavable connector under reduction or oxidizing condition can also be used in the present invention.
L1It may include the continuous sequence of amino acid.Amino acid sequence can be the target substrate cut for digestion, to permit
Perhaps L-R is discharged from the position N10L’。
In one embodiment, L can be cut by the effect of enzyme1.In one embodiment, enzyme is esterase or peptide
Enzyme.
In one embodiment, there are L2And selfdecomposition connector is formed together with-C (=O) O-.In an embodiment party
In formula, L2It is the substrate for enzymatic activity, to allow to discharge L-R from the position N10L’。
In one embodiment, work as L1In the effect of enzyme be cleavable and there are L2When, L is cut in digestion1And L2Between
Key.
L1And L2(when it is present) key connection selected from the following can be passed through:
- C (=O) NH-,
- C (=O) O-,
- NHC (=O)-,
- OC (=O)-,
- OC (=O) O-,
- NHC (=O) O-,
- OC (=O) NH- and
- NHC (=O) NH-.
It is connected to L2L1Amino group can be the end N- of amino acid, or amino acid side chain can be originated from and (such as rely ammonia
Sour amino acid side chain) amino group.
It is connected to L2L1Carboxylic group can be the end C- of amino acid, or amino acid side chain (such as paddy ammonia can be originated from
Sour amino acid side chain) carboxylic group.
It is connected to L2L1Hydroxyl group can be originated from amino acid side chain (such as serine amino acids side chain) hydroxyl base
Group.
Term " amino acid side chain " includes those of discovery group in the following: (i) naturally occurring amino acid, such as the third ammonia
Acid, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine,
Leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine;
(ii) micro-amino acid (minor amino acids), such as ornithine and citrulling;(iii) unnatural amino acid, beta-amino
The synthetic analogues and derivative of sour, naturally occurring amino acid;And (iv) all enantiomters, diastereoisomer,
The isomer that is rich in, isotope labelling (for example,2H、3H、14C、15N), protected form and their racemic mixing
Object.
In one embodiment ,-C (=O) O- and L2It is formed together following group:
Wherein, asterisk indicates the point for being connected to the position N10, and wave expression is connected to connector L1Point, Y be-N (H)-,-
O- ,-C (=O) N (H)-or-C (=O) O-, and n is 0 to 3.Phenylene ring is optionally by one described herein, two
Or three substituent groups replace.In one embodiment, subphenyl group is optionally by halogen, NO2, R or OR replace.
In one embodiment, Y is NH.
In one embodiment, n is 0 or 1.Preferably, n is 0.
When Y is NH and n is 0, selfdecomposition connector can be referred to as aminobenzyl carbonyl linker (PABC).
When distal site is activated, selfdecomposition connector is allowed to discharge shielded compound, along road as shown below
Line carries out (n=0):
Wherein, L*It is the activated form of the remainder of connector.These groups have and make to activate site and shieldedization
Close the advantage of object separation.As described above, subphenyl group can be optionally substituted.
In an embodiment as described herein, group L*It is connector L as described herein1, may include dipeptides
Group.
In another embodiment ,-C (=O) O- and L2It is formed together group selected from the following:
Wherein, asterisk, wave, Y and n be as defined above.Each phenylene ring is optionally described herein
One, two or three substituent group replaces.In one embodiment, the phenylene ring with Y substituent group is optionally substituted
And the phenylene ring for not having Y substituent group is unsubstituted.In one embodiment, with the phenylene ring of Y substituent group
Be it is unsubstituted and do not have Y substituent group phenylene ring be optionally substituted.
In another embodiment ,-C (=O) O- and L2It is formed together group selected from the following:
Wherein, asterisk, wave, Y and n are that as defined above, E is O, S or NR, and D is N, CH or CR, and F is
N, CH or CR.
In one embodiment, D is N.
In one embodiment, D is CH.
In one embodiment, E is O or S.
In one embodiment, F is CH.
In a preferred embodiment, connector is cathepsin unstability connector.
In one embodiment, L1Including dipeptides.The dipeptides can be expressed as-NH-X1-X2- CO-, wherein-NH- and-
CO- respectively indicates amino acid group X1And X2N and C-terminal.Amino acid in the dipeptides can be any group of natural amino acid
It closes.When connector is cathepsin unstability connector, dipeptides can be the action site of the cutting of cathepsin mediation.
In addition, distinguishing such as Glu and Lys, CO for those of carboxyl or amino side chain degree of functionality amino acid group
The side chain functionalities can be indicated with NH.
In one embodiment, dipeptides-NH-X1-X2Group-X in-CO-1-X2, it is selected from:
-Phe-Lys-、
-Val-Ala-、
-Val-Lys-、
-Ala-Lys-、
-Val-Cit-、
-Phe-Cit-、
-Leu-Cit-、
-Ile-Cit-、
-Phe-Arg-、
- Trp-Cit-,
Wherein, Cit is citrulling.
Preferably, dipeptides-NH-X1-X2Group-X in-CO-1-X2, it is selected from:
-Phe-Lys-、
-Val-Ala-、
-Val-Lys-、
-Ala-Lys-、
-Val-Cit-。
It is highly preferred that dipeptides-NH-X1-X2Group-X in-CO-1-X2, it is-Phe-Lys- or-Val-Ala-.
The combination of other dipeptides can be used comprising Dubowchik et al., Bioconjugate Chemistry,
Those of 2002,13,855-869 descriptions, are incorporated by reference herein.
In one embodiment, in the appropriate case, amino acid side chain is derivative.For example, the ammonia of amino acid side chain
Base group or carboxylic group can be derivative.In one embodiment, the amino group of side chain amino acid (such as lysine)
NH2It is selected from by NHR and NRR ' derivative form of group that forms.In one embodiment, side chain amino acid (such as asparagus fern ammonia
Acid) carboxylic group COOH be selected from by COOR, CONH2, CONHR and CONRR ' composition group derivative form.
In one embodiment, in the appropriate case, amino acid side chain is chemoproection.Side chain protecting group can be with
It is below in relation to group RLThe group of discussion.Present inventor have determined that shielded amino acid sequence is by enzyme cleavable.Example
Such as, it has been determined that the dipeptide sequence of the Lys residue comprising Boc side chain protection is histone enzyme cleavable.
Blocking group for amino acid side chain is well known in the art and retouches in Novabiochem catalogue
It states.Other protecting groups are described in Protective Groups in Organic Synthesis, Greene and Wuts
Group's strategy.
For shown below possible side chain protecting group with those of reactive side chain degree of functionality amino acid:
Arg:Z, Mtr, Tos;
Asn:Trt, Xan;
Asp:Bzl, t-Bu;
Cys:Acm, Bzl, Bzl-OMe, Bzl-Me, Trt;
Glu:Bzl, t-Bu;
Gln:Trt, Xan;
His:Boc, Dnp, Tos, Trt;
Lys:Boc, Z-Cl, Fmoc, Z, Alloc;
Ser:Bzl, TBDMS, TBDPS;
Thr:Bz;
Trp:Boc;
Tyr:Bzl, Z, Z-Br.
In one embodiment, when it is present, it selects Side chain protective group and is provided as end-capping group or partially end-blocked base
The group of group is orthogonal.Therefore, remove side chain protecting group do not remove end-capping group or it is any be end-capping group a part guarantor
Protect group functionalities.
In other embodiments of the invention, selected amino acid is that do not have those of reactive side chain degree of functionality.
For example, amino acid can be selected from: Ala, Gly, Ile, Leu, Met, Phe, Pro and Val.
In one embodiment, dipeptides is used with selfdecomposition splice combinations.Selfdecomposition connector can connect to-X2-。
When there are selfdecomposition connector ,-X2It is connected directly to selfdecomposition connector.Preferably, group-X2- CO- is connected to Y,
Wherein, Y is NH, to form group-X2-CO-NH-。
-NH-X1It is connected directly to A.A may include functional group-CO-, to be formed and-X1The amide of connection.
In one embodiment, L1And L2It together include group NH-X with-OC (=O)-1-X2-CO-PABC-.PABC base
Group is connected directly to the position N10.Preferably, selfdecomposition connector and dipeptides are formed together group-NH-Phe-Lys-CO-NH-
PABC-, described below:
Wherein, asterisk indicates that the point for being connected to the position N10 and wave expression are connected to connector L1Remainder
Point or the point for being connected to A.Preferably, wave indicates the point for being connected to A.The side chain of Lys amino acid can be shielded, example
Such as, it is protected with Boc, Fmoc or Alloc described above.
Alternatively, selfdecomposition connector and dipeptides are formed together group-NH-Val-Ala-CO-NH-PABC-, following
It shows:
Wherein, asterisk and wave be as defined above.
Alternatively, selfdecomposition connector and dipeptides are formed together group-NH-Val-Cit-CO-NH-PABC-, following
It shows:
Wherein, asterisk and wave be as defined above.
In one embodiment, A is covalent bond.Therefore, L1It is directly connected to antibody.For example, working as L1Comprising continuous
Amino acid sequence when, the N-terminal of sequence can be directly connected to antibody.
Therefore, when A is covalent bond, antibody and L1Between connection can be selected from:
- C (=O) NH-,
- C (=O) O-,
- NHC (=O)-,
- OC (=O)-,
- OC (=O) O-,
- NHC (=O) O-,
- OC (=O) NH-,
- NHC (=O) NH-,
- C (=O) NHC (=O)-,
-S-、
-S-S-、
-CH2C (=O)-and
=N-NH-.
It is connected to the L of antibody1Amino group can be the N-terminal of amino acid, or amino acid side chain can be originated from and (such as relied
Valine amino acid side chain) amino group.
It is connected to the L of antibody1Carboxylic group can be the C-terminal of amino acid, or amino acid side chain (such as paddy can be originated from
Valine amino acid side chain) carboxylic group.
It is connected to the L of antibody1Hydroxyl group can be originated from amino acid side chain (such as serine amino acids side chain) hydroxyl
Base group.
It is connected to the L of antibody1Thiol group can be originated from amino acid side chain (such as serine amino acids side chain) sulphur
Alcohol groups.
Above with respect to L1Amino, carboxyl, hydroxyl and thiol group annotation also apply to antibody.
In one embodiment, L2It is indicated together with-OC (=O)-:
Wherein, asterisk indicates the point for being connected to the position N10, and wave expression is connected to L1Point, n is that 0 to 3, Y is covalent
Key or functional group and E are can to activate group, such as by enzyme effect or light, to generate the unit of selfdecomposition.Phenylene ring
Optionally it is further substituted with by one, two or three substituent group described herein.In one embodiment, phenylene base
Group is optionally by halogen, NO2, R or OR be further substituted with.Preferably, n is 0 or 1, most preferably 0.
Selection E makes group be easy to activate, for example, activating by light or by the effect of enzyme.E can be-NO2Or grape
Uronic acid.The former may may be vulnerable to the effect of GRD beta-glucuronidase vulnerable to the effect of nitroreductase, the latter.
In this embodiment, when E is activated, selfdecomposition connector will allow to discharge shielded compound, along with
Route shown in lower carries out (n=0):
Wherein, asterisk indicates the point for being connected to the position N10, and E* is the activated form of E, and Y is as described above.These
Group has the advantage for separating activation site with shielded compound.As described above, subphenyl group can be
Optionally it is further substituted with.
Group Y can be down to L1Covalent bond.
Group Y can be functional group selected from the following:
- C (=O)-,
-NH-、
-O-、
- C (=O) NH-,
- C (=O) O-,
- NHC (=O)-,
- OC (=O)-,
- OC (=O) O-,
- NHC (=O) O-,
- OC (=O) NH-,
- NHC (=O) NH-,
- NHC (=O) NH,
- C (=O) NHC (=O)-and
-S-。
Work as L1When being dipeptides, preferably Y is-NH- or-C (=O)-, to form L1Amido bond between Y.At this
In embodiment, dipeptide sequence needs not be the substrate of enzymatic activity.
In another embodiment, A is spacer groups.Therefore, L1It is indirectly connected with antibody.
L1Key connection selected from the following can be passed through with A:
- C (=O) NH-,
- C (=O) O-,
- NHC (=O)-,
- OC (=O)-,
- OC (=O) O-,
- NHC (=O) O-,
- OC (=O) NH- and
- NHC (=O) NH-.
In one embodiment, group A is:
Wherein, asterisk expression is connected to L1Point, wave indicates to be connected to the point of antibody, and n is 0 to 6.At one
In embodiment, n is 5.
In one embodiment, group A is:
Wherein, asterisk expression is connected to L1Point, wave indicates to be connected to the point of antibody, and n is 0 to 6.At one
In embodiment, n is 5.
In one embodiment, group A is:
Wherein, asterisk expression is connected to L1Point, wave indicates to be connected to the point of antibody, and n is 0 or 1, and m be 0 to
30.In one preferred embodiment, it is 0 to 10,1 to 8, preferably 4 to 8 and most preferably 4 or 8 that n, which is 1 and m,.?
In another embodiment, m is 10 to 30, and preferably 20 to 30.Alternatively, m is 0 to 50.Preferably
In, m is preferably 10-40, and n is 1.
In one embodiment, group A is:
Wherein, asterisk expression is connected to L1Point, wave indicates to be connected to the point of antibody, and n is 0 or 1, and m be 0 to
30.In one preferred embodiment, it is 0 to 10,1 to 8, preferably 4 to 8 and most preferably 4 or 8 that n, which is 1 and m,.?
In another embodiment, m is 10 to 30, and preferably 20 to 30.Alternatively, m is 0 to 50.Preferably
In, m is preferably 10-40, and n is 1.
In one embodiment, the connection between antibody and A passes through the thiol residue of antibody and the dimaleoyl imino of A
Group.
In one embodiment, the connection between antibody and A is:
Wherein, asterisk indicates the point for being connected to the remainder of A, and wave indicates the remainder for being connected to antibody
Point.In this embodiment, S atom generally originates from antibody.
In each of embodiment of above, alternative degree of functionality can be used instead of described below and be originated from Malaysia
Imido group:
Wherein, wave indicates the point for being connected to antibody as before, and asterisk is indicated to the remainder of A group
Key.
In one embodiment, the group from maleimide is replaced with following group:
Wherein, wave indicates the point for being connected to antibody, and asterisk indicates the key of the remainder to A group.
In one embodiment, the group from maleimide is replaced by group, the group optionally with antibody one
It rises, is selected from:
- C (=O) NH-,
- C (=O) O-,
- NHC (=O)-,
- OC (=O)-,
- OC (=O) O-,
- NHC (=O) O-,
- OC (=O) NH-,
- NHC (=O) NH-,
- NHC (=O) NH,
- C (=O) NHC (=O)-,
-S-、
-S-S-、
-CH2C (=O)-,
- C (=O) CH2-、
=N-NH- and
- NH-N=.
In one embodiment, the group from maleimide is replaced by group, the group optionally with antibody one
It rises, is selected from:
Wherein, wave indicates to be connected to the point of antibody or the key of the remainder to A group, and asterisk indicates connection
To the key of the other point or the remainder to A group of antibody.
It describes and is suitable for L in WO 2005/0820231It is connected to the other groups of antibody.
In one embodiment, there are linking group A, and there are initiator L1And selfdecomposition connector L is not present2.Cause
This, L1It is directly connected to drug unit via key.It is equal in this embodiment, L2It is key.Work as DLWhen being Formula II, this can be with
It is especially interesting.
L1Key connection selected from the following can be passed through with D:
- C (=O) N <,
- C (=O) O-,
- NHC (=O)-,
- OC (=O)-,
- OC (=O) O-,
- NHC (=O) O-,
- OC (=O) N <, and
- NHC (=O) N <,
Wherein, N < or O- is a part of D.
In one embodiment, L1With D by key connection selected from the following:
- C (=O) N <, and
- NHC (=O)-.
In one embodiment, L1One end comprising dipeptides and dipeptides is connected to D.As described above, dipeptides
In amino acid can be any combination of natural amino acid and unnatural amino acid.In some embodiments, dipeptides includes
Natural amino acid.When connector is the unstable connector of cathepsin, dipeptides is the effect for the cutting that cathepsin mediates
Site.Then dipeptides is the recognition site of cathepsin.
In one embodiment, dipeptides-NH-X1-X2Group-X in-CO-1-X2, it is selected from:
-Phe-Lys-、
-Val-Ala-、
-Val-Lys-、
-Ala-Lys-、
-Val-Cit-、
-Phe-Cit-、
-Leu-Cit-、
-Ile-Cit-、
- Phe-Arg- and
-Trp-Cit-;
Wherein, Cit is citrulling.In this dipeptides ,-NH- is X1Amino group, and CO is X2Carbonyl group.
Preferably, dipeptides-NH-X1-X2Group-X in-CO-1-X2, it is selected from:
-Phe-Lys-、
-Val-Ala-、
-Val-Lys-、
- Ala-Lys- and
-Val-Cit-。
It is highly preferred that dipeptides-NH-X1-X2Group-X in-CO-1-X2, it is-Phe-Lys- or-Val-Ala-.
Other interested dipeptides, which combine, includes:
-Gly-Gly-、
- Pro-Pro- and
-Val-Glu-。
The combination of other dipeptides, including those described above can be used.
In one embodiment, L1- D is:
Wherein ,-NH-X1-X2- CO is dipeptides, and a part of-N <be drug unit, asterisk expression is connected to drug unit
The point of remainder, and wave expression is connected to L1Remainder point or be connected to the point of A.Preferably, wave
Indicate the point for being connected to A.
In one embodiment, dipeptides is val-ala and L1- D is:
Wherein asterisk ,-N < and wave be as defined above.
In one embodiment, dipeptides is Phe-Lys and L1- D is:
Wherein asterisk ,-N < and wave be as defined above.
In one embodiment, dipeptides is valine-citrulline.
In one embodiment, group A-L1It is:
Wherein, asterisk expression is connected to L2Or the point of D, wave expression are connected to the point with body unit, and n be 0 to
6.In one embodiment, n is 5.
In one embodiment, group A-L1It is:
Wherein, asterisk expression is connected to L2Or the point of D, wave expression are connected to the point with body unit, and n be 0 to
6.In one embodiment, n is 5.
In one embodiment, group A-L1It is:
Wherein, asterisk expression is connected to L2Or the point of D, wave expression are connected to the point with body unit, n is 0 or 1, and
And m is 0 to 30.In one preferred embodiment, n be 1 and m be 0 to 10,1 to 8, preferably 4 to 8, most preferably 4 or
8。
In one embodiment, group A-L1It is:
Wherein, asterisk expression is connected to L2Or the point of D, wave expression are connected to the point with body unit, n is 0 or 1, and
And m is 0 to 30.In one preferred embodiment, n be 1 and m be 0 to 10,1 to 7, preferably 3 to 7, most preferably 3 or
7。
In one embodiment, group A-L1It is:
Wherein, asterisk expression is connected to L2Or the point of D, wave expression are connected to the point with body unit, and n be 0 to
6.In one embodiment, n is 5.
In one embodiment, group A-L1It is:
Wherein, asterisk expression is connected to L2Or the point of D, wave expression are connected to the point with body unit, and n be 0 to
6.In one embodiment, n is 5.
In one embodiment, group A-L1It is:
Wherein, asterisk expression is connected to L2Or the point of D, wave expression are connected to the point with body unit, n is 0 or 1, and
And m is 0 to 30.In one preferred embodiment, n be 1 and m be 0 to 10,1 to 8, preferably 4 to 8, most preferably 4 or
8。
In one embodiment, group A-L1It is:
Wherein, asterisk expression is connected to L2Or the point of D, wave expression are connected to the point with body unit, n is 0 or 1, and
And m is 0 to 30.In one preferred embodiment, n be 1 and m be 0 to 10,1 to 8, preferably 4 to 8, most preferably 4 or
8。
In one embodiment, group A-L1It is:
Wherein, asterisk expression is connected to L2Or the point of D, S are the methylthio groups with body unit, wave expression is connected to ligand
The point of the rest part of unit, and n is 0 to 6.In one embodiment, n is 5.
In one embodiment, group A-L1It is:
Wherein, asterisk expression is connected to L2Or the point of D, S are the methylthio groups with body unit, wave expression is connected to ligand
The point of the remainder of unit, and n is 0 to 6.In one embodiment, n is 5.
In one embodiment, group A1-L1It is:
Wherein, asterisk expression is connected to L2Or the point of D, S are the methylthio groups with body unit, wave expression is connected to ligand
The point of the remainder of unit, n is 0 or 1, and m is 0 to 30.In one preferred embodiment, n be 1 and m be 0 to
10,1 to 8, preferably 4 to 8, most preferably 4 or 8.
In one embodiment, group A1-L1It is:
Wherein, asterisk expression is connected to L2Or the point of D, wave expression are connected to the point with body unit, n is 0 or 1, and
And m is 0 to 30.In one preferred embodiment, n be 1 and m be 0 to 10,1 to 7, preferably 4 to 8, most preferably 4 or
8。
In one embodiment, group A1-L1It is:
Wherein, asterisk expression is connected to L2Or the point of D, wave indicate the point for being connected to the remainder with body unit,
And n is 0 to 6.In one embodiment, n is 5.
In one embodiment, group A1-L1It is:
Wherein, asterisk expression is connected to L2Or the point of D, wave indicate the point for being connected to the remainder with body unit,
And n is 0 to 6.In one embodiment, n is 5.
In one embodiment, group A1-L1It is:
Wherein, asterisk expression is connected to L2Or the point of D, wave indicate the point for being connected to the remainder with body unit, n
It is 0 or 1, and m is 0 to 30.In one preferred embodiment, n be 1 and m be 0 to 10,1 to 8, preferably 4 to 8,
Most preferably 4 or 8.
In one embodiment, group A1-L1It is:
Wherein, asterisk expression is connected to L2Or the point of D, wave indicate the point for being connected to the remainder with body unit, n
It is 0 or 1, and m is 0 to 30.In one preferred embodiment, n be 1 and m be 0 to 10,1 to 8, preferably 4 to 8,
Most preferably 4 or 8.
Group RL’It may originate from group RL.By the way that antibody is connected to RLFunctional group can be by group RLIt is converted into group
RL’.Other steps can be taken RLIt is converted into RL’.These steps may include removing existing blocking group or introducing suitably
Functional group.
RL
Connector may include the peptide moiety of the albumen enzyme cleavable comprising one or more Amino Acid Units.Peptide can be passed through
Solid phase known to chemical field or liquid-phase synthesis process (E. and K.Lübke,The Peptides,volume
1, pp 76-136 (1965) Academic Press), including t-BOC chemistry (Geiser et al " Automation of
solid-phase peptide synthesis"in Macromolecular Sequencing and Synthesis,Alan
R.Liss, Inc., 1988, pp.199-218) and Fmoc/HBTU chemistry (Fields, G.and Noble, R. (1990) " Solid
phase peptide synthesis utilizing 9-fluoroenylmethoxycarbonyl amino acids",
Int.J.Peptide Protein Res.35:161-214), in Fully automated synthesis instrument such as Rainin Symphony peptide synthesizer
(Protein Technologies, Inc., Tucson, AZ) or Model 433 (Applied Biosystems, Foster
City, CA) on prepare peptide linker reagent.
Illustrative Amino acid linker includes dipeptides, tripeptides, tetrapeptide or pentapeptide.Illustrative dipeptides includes: valine-melon
The illustrative tripeptides of propylhomoserin (vc or val-cit), alanine-phenylalanine (af or ala-phe) includes: glycine-valine-
Citrulling (gly-val-cit) and Gly-Gly-Gly (gly-gly-gly).Ammonia comprising Amino acid linker component
Base acid residue includes those of naturally occurring and micro-amino acid and non-naturally occurring amino acid analogue, such as citrulling.
The digestion by the relevant protease of certain enzyme such as tumour, cathepsin B, C and D or plasmase is cut at them
Selectivity aspect, can design and optimize Amino acid linker.
Amino acid side chain includes those of naturally occurring and micro-amino acid and non-naturally occurring amino acid analogue,
Such as citrulling.Amino acid side chain include hydrogen, methyl, isopropyl, isobutyl group, sec-butyl, benzyl, to hydroxybenzyl ,-CH2OH、-
CH(OH)CH3、-CH2CH2SCH3、-CH2CONH2、-CH2COOH、-CH2CH2CONH2、-CH2CH2COOH、-(CH2)3NHC (=NH)
NH2、-(CH2)3NH2、-(CH2)3NHCOCH3、-(CH2)3NHCHO、-(CH2)4NHC (=NH) NH2、-(CH2)4NH2、-(CH2)4NHCOCH3、-(CH2)4NHCHO、-(CH2)3NHCONH2、-(CH2)4NHCONH2、-CH2CH2CH(OH)CH2NH2, 2- pyridine first
Base, 3- pyridylmethyl, 4- pyridylmethyl, phenyl, cyclohexyl and with flowering structure:
When amino acid side chain includes other than hydrogen (glycine), the carbon atom of amino acid side chain connection is chiral.
Each carbon atom of amino acid side chain connection is independently (S) or (R) configuration or racemic mixture.Therefore, agent-linker
Reagent can be enantiomer-pure, racemic or diastereomer.
In an exemplary embodiment, amino acid side chain is selected from those of natural and unnatural amino acid, including the third ammonia
Acid, 2- amino -2- cyclohexyl-acetic acid, 2- amino -2- phenylacetic acid, arginine, asparagine, aspartic acid, cysteine, paddy
Glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, nor-leucine, phenylpropyl alcohol ammonia
Acid, proline, serine, threonine, tryptophan, tyrosine, valine, γ-aminobutyric acid, alpha, alpha-dimethyl gamma-amino fourth
Acid, beta, beta-dimethyl γ-aminobutyric acid, ornithine and citrulling (Cit).
Introns with aminobenzyl carbamyl (PAB) selfdecomposition, suitable for constitute for being bound to antibody
Connector-PBD drug moiety intermediate exemplary valine-citrulline (val-cit or vc) dipeptides linker reagents have with
Flowering structure:
Wherein, Q is C1-C8Alkyl ,-O- (C1-C8Alkyl) ,-halogen ,-NO2Or-CN;And m is the integer of 0-4.
Can be had according to Dubowchik, et al. (1997) Tetrahedron Letters, 38:5257-60 preparation
Exemplary phe-lys (Mtr) dipeptides linker reagents of aminobenzyl group, and have a structure that
Wherein, Mtr is mono- 4- Methoxytrityl, and Q is C1-C8Alkyl ,-O- (C1-C8Alkyl) ,-halogen ,-NO2Or-
CN;And m is the integer of 0-4 range.
" selfdecomposition connector " PAB (to amino benzyloxy carbamyl) connects drug moiety in antibody drug conjugate
To antibody (Carl et al (1981) J.Med.Chem.24:479-480;Chakravarty et al(1983)
J.Med.Chem.26:638-644;US 6214345;US20030130189;US20030096743;US6759509;
US20040052793;US6218519;US6835807;US6268488;US20040018194;WO98/13059;
US20040052793;US6677435;US5621002;US20040121940;WO2004/032828).In addition to PAB, divide certainly
Other examples of the introns of solution include but is not limited to: (i) charge is similar to the aromatic compound such as 2- amino miaow of PAB group
Azoles -5- carbinol derivatives (Hay et al. (1999) Bioorg.Med.Chem.Lett.9:2237), thiazole (US
7375078) PAB unit (de Groot et al (2001) J.Org.Chem.66:8815-8830) that is, more, extending;With it is o-
Aminobenzene acetal or p-aminophenyl acetal;The styryl PAB analog (US 7223837) of (ii) confirmation.It can be used logical
The introns of superamide key hydrolysis experience cyclisation, 4-Aminobutanoicacid amide (Rodrigues et al such as replace and unsubstituted
(1995) Chemistry Biology 2:223), bicyclic [2.2.1] ring system and bicyclic [2.2.2] ring system that suitably replace
(Storm et al (1972) J.Amer.Chem.Soc.94:5815) and 2- aminophenyl propionic acid (Amsberry, et al
(1990)J.Org.Chem.55:5867).Eliminate (the Kingsbury et al (1984) containing drug amine replaced at glycine
J.Med.Chem.27:1447 the example of useful selfdecomposition introns) and in the adc.
In one embodiment, valine-citrulline dipeptides PAB analog reagent has 2,6- 3,5-dimethylphenyl group
And it has a structure that
There are the linker reagents for antibody drug conjugate of the invention to include but is not limited to: BMPEO, BMPS, EMCS,
GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfo group-EMCS, sulfo group-GMBS,
Sulfo group-KMUS, sulfo group-MBS, sulfo group-SIAB, sulfo group-SMCC and sulfo group-SMPB and SVSB (succinimido-(4- ethylene
Base sulfone) benzoic ether) and double-maleimide reagent: DTME, BMB, BMDB, BMH, BMOE, 1,8- be bis--maleimide
Diethylene glycol (DEG) (BM (PEO)2) and 1,11- it is bis--maleimide triethylene glycol (BM (PEO)3), by Pierce Biotechnology,
Inc., ThermoScientific, Rockford, IL and other reagent suppliers business can get.Double-maleimide reagent
Allow that the free thiol group of the cysteine of antibody is connected to drug moiety, mark containing mercaptan in a manner of serially or simultaneously
Note or connector intermediate.In addition to maleimide, reacted with the thiol group of antibody, PBD drug moiety or connector intermediate
Other functional groups include iodo-acetamide, acetbromamide, vinylpyridine, disulphide, pyridyl disulfide, isocyanic acid
Ester and isothiocyanates.
The other embodiments of linker reagents are: N- succinimido -4- (2- pyridylthio) valerate (SPP),
N- succinimido -3- (2- pyridyl group two is thio) propionic ester (SPDP, Carlsson et al (1978)
Biochem.J.173:723-737), succinimido -4- (N- Maleimidomethyl) hexamethylene -1- carboxylate
(SMCC), iminothiolane (IT), the bifunctional derivative of polyurethane (such as dimethyl adipimide ester HCl), active ester be (such as
Two succinimidyl suberates), aldehyde (such as glutaraldehyde), double azido compound (as bis- (to azidobenzoyls) oneself two
Amine), double-diazo compound derivative (as bis- (to diazoniumbenzoyl)-ethylenediamines), diisocyanate (such as toluene 2,6- diisocyanate
Ester) and double activated fluorine compounds (such as fluoro- 2,4- dinitrobenzene of 1,5- bis-).Pass through other commercial sources, such as Molecular
Biosciences Inc. (Boulder, CO) also available useful linker reagents, or according to Toki et al (2002)
J.Org.Chem.67:1866-1872;US 6214345;WO 02/088172;US 2003130189;US2003096743;WO
03/026577;WO 03/043583;Useful linker reagents can also be synthesized with step described in WO 04/032828.
Connector can be for being covalently attached to more than one drug moiety by branching, polyfunctional junction portion
Dendritic type fittings (the US 2006/116422 of antibody;US2005/271615;de Groot et al(2003)
Angew.Chem.Int.Ed.42:4490-4494;Amir et al(2003)Angew.Chem.Int.Ed.42:4494-
4499;Shamis et al(2004)J.Am.Chem.Soc.126:1726-1731;Sun et al(2002)Bioorganic&
Medicinal Chemistry Letters 12:2213-2215;Sun et al(2003)Bioorganic&Medicinal
Chemistry 11:1761-1768;King et al(2002)Tetrahedron Letters43:1987-1990).Branch
Shaped polymer connector can increase the molar ratio of drug and antibody, that is, and drugloading rate is related to the effect of ADC.Therefore, when anti-
When body only has a reactive cysteine thiol group, high amount of drug part can be linked by dendritic or branch
Head connection.
One illustrative embodiments of dendritic type fittings have a structure that
Wherein, asterisk indicates the point for being connected to the position N10 of the part PBD.
Rc, end-capping group
The conjugate of the first aspect of the present invention can have end-capping group R at the position N10C.Compound E can have
End-capping group RC。
In one embodiment, when conjugate is that wherein each monomer is the dimer of formula (A), a monomeric unit
In group R10It is end-capping group RCOr group R10。
In one embodiment, when conjugate is that wherein each monomer is the dimer of formula (A), a monomeric unit
In group R10It is end-capping group RC。
In one embodiment, when compound E is that wherein each monomer is the dimer of formula (E), a monomer list
Group R in memberLIt is end-capping group RCOr the connector for being connected to antibody.
In one embodiment, when conjugate is that wherein each monomer is the dimer of formula (E), a monomeric unit
In group RLIt is end-capping group RC。
Group R can be removed from the position N10 of the part PBDCTo residue N10-C11 imine linkage, carbinolamine, substituted methanol
Amine, wherein QR11It is OSO3M, disulfide adducts, thiomethoxide amine, substituted thiomethoxide amine or substituted carbinolamine.
In one embodiment, RCRemovable blocking group be can be to residue N10-C11 imine linkage, methanol
Amine, substituted carbinolamine or disulfide adducts, wherein QR11It is OSO3M.In one embodiment, RCIt is that can remove
To the blocking group of residue N10-C11 imine linkage.
It is directed at and is used to remove group R10Required condition for example generates N10-C11 imine linkage, methanol under the same conditions
Under conditions of amine etc., group R can be removedc.End-capping group plays the blocking group of the expection functional group at the position N10.Purport
End-capping group not with antibody response.For example, RCWith RLIt is different.
In the synthesis of the dimer with imide monomers, the compound with end-capping group can be used as intermediate.
Alternatively, the compound with end-capping group can be used as conjugate, wherein remove end-capping group from target location to produce
Raw imines, carbinolamine, substituted carbinolamine etc..Therefore, in this embodiment, end-capping group is referred to alternatively as to remove in treatment
Nitrogen-protecting group group, as defined in the earlier application WO 00/12507 of inventor.
In one embodiment, in cutting group R10Connector RLUnder conditions of, group R can be removedC.Therefore, one
In a embodiment, end-capping group is cleavable under enzyme effect.
In an alternative embodiment, by connector RLIt is connected to before antibody, end-capping group can be removed.At this
In embodiment, connector R is not being cutLUnder conditions of can remove end-capping group.
When compound includes functional group G1When forming the connection with antibody, in addition or unmasked G1Before, sealing end can be removed
Group.
End-capping group can be used as to a part of blocking group strategy to ensure the only one monomeric unit in dimer
It is connected to antibody.
End-capping group can be used as to the shelter (mask) of N10-C11 imine linkage.Imines can be needed in compound
The time of functional group removes end-capping group.Carbinolamine, substituted carbinolamine and the curing that end-capping group is also described above
The shelter of object adduct.
RCIt can be N10 blocking group, those groups as described in the earlier application WO 00/12507 in inventor.
In one embodiment, RCIt is to treat upper removable nitrogen-protecting group group, such as in the earlier application WO 00/12507 of inventor
Defined in.
In one embodiment, RCIt is carbamate protecting group.
In one embodiment, carbamate protecting group is selected from:
Alloc, Fmoc, Boc, Troc, Teoc, Psec, Cbz and PNZ.
Optionally, carbamate protecting group is further selected from Moc.
In one embodiment, RCIt is the absence of the linker group R of the functional group for being connected to antibodyL。
Special consideration should be given to the R that those are carbamate by the applicationCGroup.
In one embodiment, RCIt is following group:
Wherein, asterisk indicates the point for being connected to the position N10, G2It is end-capping group, L3It is covalent bond or cleavable connector
L1, L2It is covalent bond or is formed together selfdecomposition connector with OC (=O).
Work as L3And L2When being all covalent bond, G2Carbamate groups defined above are formed together with OC (=O).
As defined above, L1With R10It is related.
As defined above, L2With R10It is related.
A variety of end-capping groups are described below, including based on those of well known blocking group.
In one embodiment, L3It is cleavable connector L1, and L2Selfdecomposition connector is formed together with OC (=O).
In this embodiment, G2It is Ac (acetyl group) or Moc or carbamate protecting group selected from the following:
Alloc, Fmoc, Boc, Troc, Teoc, Psec, Cbz and PNZ.
Optionally, carbamate protecting group is further selected from Moc.
In another embodiment, G2It is carboxyl groups-C (=O) G3, wherein G3Selected from alkyl (including naphthenic base, alkene
Base and alkynyl), miscellaneous alkyl, heterocycle and aryl (including heteroaryl and carbon aryl (carboaryl)).These groups can be can
Choose generation.When suitable, aryl group and L3Or L2Amino group can form amido bond together.When suitable, aryl group with
L3Or L2Hydroxyl group can form ester bond together.
In one embodiment, G3It is miscellaneous alkyl.Miscellaneous alkyl group may include polyethylene glycol.Miscellaneous alkyl group can be with
With the hetero atom for closing on aryl group, such as O or N, thus when suitable, and it is present in group L3Or L2In hetero atom formed
Carbamate or carbonate group.
In one embodiment, G3Selected from NH2, NHR and NRR '.Preferably, G3It is NRR '.
In one embodiment, G2It is following group:
Wherein, asterisk expression is connected to L3Point, n is 0 to 6, and G4Selected from OH, OR, SH, SR, COOR, CONH2、
CONHR、CONRR’、NH2、NHR、NRR’、NO2And halogen.Group OH, SH, NH2It is shielded with NHR.In an embodiment party
In formula, n is 1 to 6, and preferably n is 5.In one embodiment, G4It is OR, SR, COOR, CONH2、CONHR、CONRR’
And NRR '.In one embodiment, G4It is OR, SR and NRR '.Preferably, G4Selected from OR and NRR ', most preferably, G4It is OR.
Most preferably, G4It is OMe.
In one embodiment, group G2It is:
Wherein, asterisk expression is connected to L3Point, and n and G4It is such as defined above.
In one embodiment, group G2It is:
Wherein, asterisk expression is connected to L3Point, n is 0 or 1, and m is 0 to 50, and G4Selected from OH, OR, SH, SR, COOR,
CONH2、CONHR、CONRR’、NH2、NHR、NRR’、NO2And halogen.In one preferred embodiment, it is 0 that n, which is 1 and m,
To 10,1 to 2, preferably 4 to 8 and most preferably 4 or 8.In another embodiment, it is 10 to 50 that n, which is 1 and m, excellent
Selection of land is 20 to 40.Group OH, SH, NH2It is shielded with NHR.In one embodiment, G4Be OR, SR, COOR,
CONH2, CONHR, CONRR ' and NRR '.In one embodiment, G4It is OR, SR and NRR '.Preferably, G4Selected from OR and
NRR ', most preferably, G4It is OR.Preferably, G4It is OMe.
In one embodiment, group G2It is:
Wherein, asterisk expression is connected to L3Point and n, m and G4As defined above.
In one embodiment, group G2It is:
Wherein, n is 1-20, and m is 0-6, and G4Selected from OH, OR, SH, SR, COOR, CONH2、CONHR、CONRR’、NH2、
NHR、NRR’、NO2And halogen.In one embodiment, n is 1-10.In another embodiment, n is 10 to 50, preferably
Ground is 20 to 40.In one embodiment, n is 1.In one embodiment, m is 1.Group OH, SH, NH2With NHR be by
Protection.In one embodiment, G4It is OR, SR, COOR, CONH2, CONHR, CONRR ' and NRR '.In an embodiment
In, G4It is OR, SR and NRR '.Preferably, G4Selected from OR and NRR ', most preferably, G4It is OR.Preferably, G4It is OMe.
In one embodiment, group G2It is:
Wherein, asterisk expression is connected to L3Point and n, m and G4As defined above.
In each of embodiment of above, G4It can be OH, SH, NH2And NHR.These groups are preferably protected
's.
In one embodiment, OH is protected with Bzl, TBDMS or TBDPS.
In one embodiment, SH is protected with Acm, Bzl, Bzl-OMe, Bzl-Me or Trt.
In one embodiment, NH is protected with Boc, Moc, Z-Cl, Fmoc, Z or Alloc2Or NHR.
In one embodiment, group G2With group L3Combination exists, group L3It is dipeptides.
End-capping group, which is intended to be not used in, is connected to antibody.Accordingly, there exist the other monomers in dimer to be used as via connecing
Head is connected to the point of antibody.It is therefore preferable that the functional group being present in end-capping group is not useable for and antibody response.Cause
This, is preferably avoided reactive functional groups, such as OH, SH, NH2,COOH.However, if protected, as described above, this
Kind functional group can reside in end-capping group.
Embodiment
Embodiments of the present invention include ConjA, wherein antibody is as defined above.
Embodiments of the present invention include ConjB, wherein antibody is as defined above.
Embodiments of the present invention include ConjC, wherein antibody is as defined above.
Embodiments of the present invention include ConjD, wherein antibody is as defined above.
Embodiments of the present invention include ConjE, wherein antibody is as defined above.
As described above, some embodiments of the present invention do not include ConjA, ConjB, ConjC, ConjD and ConjE.
Drugloading rate
Drugloading rate is the average number of every antibody (for example, antibody) PBD drug.When the compound of the present invention is bonded to half Guang
When propylhomoserin, drugloading rate can be in 1 to 8 drug (D of every antibodyL) in the range of, that is, wherein 1,2,3,4,5,6,7 and 8 drug
Some covalent is connected to antibody.The composition of conjugate includes the set for being combined with the antibody of drug within the scope of 1 to 8.When this
When the compound of invention is bonded to lysine, drugloading rate can be in 1 to 80 drug (D of every antibodyL) in the range of, although 40,
20,10 or 8 upper limits may be preferred.The composition of conjugate includes being combined with 1 to 80,1 to 40,1 to 20,1 to 10
Or within the scope of 1 to 8 the antibody of drug set.
Prepared in product in the ADC from association reaction, the average number of every antibody drug can by usual manner, as UV,
Reverse hplc, HIC, mass spectrum, ELISA measurement and electrophoresis characterization.It can also determine with the quantitative distribution of the p ADC indicated.Pass through
ELISA can determine average value (Hamblett et al (2004) Clin.Cancer for preparing p in product in specific ADC
Res.10:7063-7070;Sanderson et al(2005)Clin.Cancer Res.11:843-852).However, by anti-
Body-antigen binding and the detection of ELISA limit, the distribution of p (drug) value is unrecognizable.In addition, for detecting antibody-drug
The ELISA measurement of conjugate not can determine where drug moiety is being connected to antibody, such as heavy chain or light chain segments or specific
Amino acid residue.In some cases, it can realize that (wherein p is homogeneous ADC by way of such as reversed-phase HPLC or electrophoresis
Specific value) separation, purifying and characterization with the ADC with other drugloading rates.This technology is also applied for other kinds of knot
Close object.
For certain antibody-drug conjugates, p can be limited by the number of connection site on antibody.For example, antibody can be with
With only one or there are multiple cysteine thiol groups, or can have only one or there are multiple sufficiently reactive sulphur
Alcohol groups can connect connector by the thiol group.Higher drugloading rate, such as p > 5 can cause certain antibody-drugs
The aggregation of conjugate, insoluble, toxicity or cell permeability are lost.
In general, the drug moiety less than theoretical maximum amount is bound to antibody by association reaction.For example, antibody can wrap
The lysine residue not reacted with agent-linker intermediate (D-L) or linker reagents containing many.Only most reactive lysine
Group can be reacted with amine reactivity linker reagents.In addition, only most reactive cysteine residues can be with thiol reaction
Property linker reagents reaction.In general, antibody does not include cysteine thiol that many (if any) is dissociated and reactive
Group, can connect to drug moiety.Most of cysteine mercaptan residues in the antibody of compound exist as disulphide bridges,
And it must be restored under part or all of reducing condition with reducing agent such as dithiothreitol (DTT) (DTT) or TCEP.It can be with
The drugloading rate (drug/antibody ratio) of various ways control ADC, comprising: (i) limits agent-linker intermediate (D-L) or connector examination
Molar excess of the agent relative to antibody, (ii) limit association reaction time or temperature, and (iii) is repaired for cysteine mercaptan
The part of decorations or restricted reducing condition.
Certain antibody have disulphide in reducible chain, that is, cysteine bridge.For and linker reagents combination,
Antibody can be made to become that there is reactivity by being handled with reducing agent such as DTT (dithiothreitol (DTT)).Therefore, theoretically each half Guang
Propylhomoserin bridge will form two reactive nucleophilic thiol bodies.By obtaining the lysine and 2- imino group thiophene of conversion of the amine as mercaptan
The reaction of pheno (Traut ' s reagent), other nucleophilic group can be introduced in antibody.Pass through design 1,2,3,4 or more
Cysteine residues (for example, the mutant antibodies of preparation comprising one or more non-natural cysteine residues) can be by mercapto
Group is introduced to antibody (or their segment).The introduction of US 7521541 is anti-by introducing reactive cysteine amino acids design
Body.
Cysteine residues can be designed at the reaction site in antibody and it is not formed in chain or intramolecular disulfide
Key (Junutula, et al., 2008b Nature Biotech., 26 (8): 925-932;Dornan et al(2009)
Blood 114(13):2721-2729;US 7521541;US 7723485;WO2009/052249).The hcy thiolactone of design
Alcohol can be with linker reagents with thiol reactivity, electrophilic group (such as maleimide or alpha-halogenate amide) or of the invention
The reaction of agent-linker reagent is to form the antibody of the cysteine with design and the ADC of PBD drug moiety.Therefore, Ke Yishe
The position of meter, control and known drug part.Due to design cysteine thiol group usually with high yield it is anti-with mercaptan
Answering property linker reagents or the reaction of agent-linker reagent, it is all to can control drugloading rate.Pass through the single site in heavy chain or light chain
Displacement is to design IgG antibody to introduce cysteine amino acids and generate two new cysteines on symmetrical antibody.Pass through knot
Close product ADC close to homogeney, the drugloading rate close to 2 may be implemented.
Alternatively, as Axup et al. ((2012), Proc Natl Acad Sci U S A.109 (40): 16101-
16116) described, by the way that antibody design to include unnatural amino acid in their heavy chain and/or light chain, may be implemented
Locus specificity combines.Unnatural amino acid provides other advantage, it can designs orthogonal chemistry and carrys out jointing reagent
And drug.
When the more than one nucleophilic or electrophilic group of antibody and connecing before agent-linker intermediate or drug moiety reagent
When head reagent reaction, then obtained product is the distribution with the drug moiety (for example, 1,2,3 etc.) for being connected to antibody
The mixture of ADC compound.Liquid chromatography, as polymer reverse phase (PLRP) and hydrophobic interaction can pass through drugloading rate value
Compound in separating mixture.The ADC with single drugloading rate value (p) can be separated prepares product, however, these single loads
Dose value ADC still can be a variety of mixtures, because drug moiety can be connected to the different loci of antibody via connector
On.
Therefore, antibody-drug combining compositions of the invention include the mixture of antibody-drug binding compounds, wherein
Antibody has one or more PBD drug moiety, and wherein, drug moiety can be connected to anti-at different aminoacids residue
Body.
In one embodiment, the dimer Pyrrolobenzodiazepines of every antibodyThe average number of group 1 to
In the range of 20.In some embodiments, range is selected from 1 to 8,2 to 8,2 to 6,2 to 4 and 4 to 8.
In some embodiments, there are a dimer Pyrrolobenzodiazepines in every antibodyIncluding other shapes
Formula
It unless otherwise prescribed, hereinbefore include well-known ion, salt, solvate and the protection of these substituent groups
Form.For example, referring to that carboxylic acid (- COOH) further includes its anion (carboxylate radical) form (- COO-), salt or solvate, and
Conventional protected forms.Similarly, refer to that amino includes the protonated form (- N of amino+HR1R2), salt or solvate, for example,
The conventional protected forms of hydrochloride and amino.Similarly, refer to that hydroxyl further includes its anionic form (- O-), salt or solvent
Compound and conventional protected forms.
Salt
It is can be convenient or it is expected that preparation, purifying and/or processing reactive compound corresponding salt, for example, pharmacy
Upper acceptable salt.The example of pharmaceutically acceptable salt is discussed at Berge, et al., J.Pharm.Sci., 66,1-19
(1977)。
For example, if compound is anionic compound, or can be the functional group of anion (for example,-COOH with it
It can be-COO-), then can be with suitable salt forming cation.The example of suitable inorganic cation includes but is not limited to
Alkali metal ion such as Na+And K+, alkaline earth metal cation such as Ca2+And Mg2+And other cations such as Al+3.Suitable organic sun
The example of ion includes but is not limited to ammonium ion (i.e. NH4 +) and ammonium ion (such as the NH that replaces3R+、NH2R2 +、NHR3 +、NR4 +)。
The example of some suitable substituted ammonium ions is the ammonium ion that those replace, and is originated from: ethamine, diethylamine, dicyclohexyl amine, three
Ethamine, butylamine, ethylenediamine, ethanol amine, diethanol amine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine and tromethamine
(tromethamine) and amino acid, such as lysine and arginine.The example of common quaternary ammonium ion is N (CH3)4 +。
If compound is cationic compound, or can be the functional group (such as-NH of cation with it2Can be-
NH3 +), then can be with suitable anion forming salt.The example of suitable inorganic anion include but is not limited to be originated from it is following
Those of inorganic acid: hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfurous acid, nitric acid, nitrous acid, phosphoric acid and phosphorous acid.
The example of suitable organic anion includes but is not limited to be originated from those of following organic acid: 2- acetyloxy phenyl first
Acid, acetic acid, ascorbic acid, aspartic acid, benzoic acid, camphorsulfonic acid, cinnamic acid, citric acid, ethylenediamine tetra-acetic acid, two sulphur of ethane
Acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic, hydroxymaleic acid, hydroxynaphthoic acid, hydroxyl second sulphur
Acid, lactobionic acid, lauric acid, maleic acid, malic acid, methanesulfonic acid, glactaric acid, oleic acid, oxalic acid, palmitinic acid, flutters acid, pantothenic acid, benzene at lactic acid
Acetic acid, benzene sulfonic acid, propionic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, p-aminobenzene sulfonic acid, tartaric acid, toluenesulfonic acid, three
Fluoroacetic acid and valeric acid.The example of suitable macromolecule organic anion includes but is not limited to those macromolecule organic anions,
From following polymeric acid: tannic acid, carboxymethyl cellulose.
Solvate
Coordinative solvent compound that is can be convenient or desirably preparing, purify and/or handle reactive compound.Term
" solvate " is come with conventional sense using being used to refer to solute (such as salt of reactive compound, reactive compound) herein
With the compound of solvent.If solvent is water, solvate is referred to as hydrate with can be convenient, for example, monohydrate, two hydrations
Object, trihydrate etc..
The present invention includes that the compound of solvent is wherein added across the imine linkage of the part (across) PBD, is shown hereafter,
Wherein solvent is water or alcohol (RAOH, wherein RAIt is C1-4Alkyl):
The carbinolamine and methanol amidogen ether form that these forms can be referred to as PBD are (such as above with respect to R10Part in institute
Description).The balance of these equatioies depends on the condition of discovery compound and the characteristic of part itself.
For example, these specific compounds can be separated in solid form by freeze-drying.
Isomers
Certain compounds of the invention can with one or more specific geometric formats, optical form, enantiomeric form,
Diastereomer form, epimeric form, dystopy isomers (atropic) form, stereoisomer form, tautomer
Form, conformational forms or different head isomers (anomeric) form, including but not limited to cis and trans;E type and Z-type;C formula, t
Formula and r formula;Interior form and outer form;R type, S type and meso-form;D type and L-type;D type and l type;(+) and (-) form;Keto-acid,
Enol form and enolate-forms;Cis and trans;To oblique formula and anticline form;Alpha form and beta form;Axial form peace
Volt form;Boat form, turns round formula, envelope type and half-chair at chair form;And their combination, hereinafter collectively referred to as " isomers " (or
" isomeric forms ").
Term " chirality " refers to non-overlap (non-overlapping, non-superimposability) property with mirror image companion
The molecule of matter, and term " achirality " refers to it is the molecule being overlapped on their mirror image companion.
Term " stereoisomer " refer to identical chemical component, but spatially atom or group arrange it is different
Compound.
" diastereoisomer " refers to two or more chiral centres and its molecule is not mutually another mirror
The stereoisomer of picture.Diastereoisomer has different physical properties, for example, fusing point, boiling point, spectral property and reaction
Property.It can be under high redissolution analytical procedure such as the mixture of electrophoresis and chromatographic isolation diastereoisomer.
" enantiomter " refers to two kinds of stereoisomers of compound, is mutual non-superimposable mirror images.
Spatial chemistry used herein limits and regulation usually follows S.P.Parker, Ed., McGraw-Hill
Dictionary of Chemical Terms(1984)McGraw-Hill Book Company,New York;and
Eliel, E.and Wilen, S., " Stereochemistry of Organic Compounds ", John Wiley&Sons,
Inc.,New York,1994.The compound of the present invention may include asymmetric or chiral centre, therefore different with different solids
Structure body form exists.Be intended to the compound of the present invention all stereoisomer forms include but is not limited to diastereoisomer,
Enantiomter and atropisomer (atropisomer) and their mixture (such as racemic mixture), form this hair
Bright a part.Many organic compounds exist with optical active forms, that is, they have the Plane Rotation for making linearly polarized light
Ability.In description optically active compound, prefix D and L or R and S be used to indicate molecule about it chiral centre it is exhausted
To configuration.The symbol rotated using the linearly polarized light of prefix d and l or (+) and (-) Lai Zhiding chemicals, wherein (-) or l are
Refer to that compound is left-handed.Prefix is (+) or the compound of d is dextrorotation.For given chemical structure, these alloisomerisms
Body is identical other than they are mutual mirror images.Specific stereoisomer can be by referred to as enantiomter, and passes through
The mixture of this isomers is often known as enantiomeric mixture.The 50:50 mixture of enantiomter is known as racemic
Mixture or racemic modification, this can occur in the chemical reaction for not having stereoselectivity or stereospecificity or in the process.
Term " racemic mixture " and " racemic modification " refer to that two kinds of equimolars without optically active enantiomter substance are mixed
Close object.
It should be noted that unless as follows be directed to what tautomeric forms were discussed, from term " isomers " (such as at this
It is as used herein) structure (or construction) isomers is clearly excluded (that is, its difference is connection from atom to atom and not only exists
Isomers in the position of atom in space).For example, referring to methoxyl group (- OCH3) be not interpreted to refer to its structure
Isomers (methylol ,-CH2OH).Similarly, refer to that Chloro-O-Phenyl is not interpreted to refer to its constitutional isomer (m-chloro
Phenyl).However, referring to that a class formation may include structural isomer forms (such as the C within the scope of falling in the above-mentioned type1-7
Alkyl includes n-propyl and isopropyl;Butyl includes normal-butyl, isobutyl group, sec-butyl and tert-butyl;Methoxyphenyl includes neighbour
Methoxyphenyl, m-methoxyphenyl and p-methoxyphenyl).
Above-mentioned exclusion is not related to tautomeric forms, such as exists, for example, following tautomer centering: ketone/enol
(as shown below), imines/enamine, amide/imino group alcohol, amidine/amidine, nitroso/oxime, thioketones/alkene mercaptan, N- nitroso/hydroxyl
It is in base azo and nitro/isonitro for example, keto-acid, enol form and enolate-forms.
Term " tautomer " or " tautomeric forms " refer to the constitutional isomer of different-energy, pass through low energy
It is interconvertible for measuring potential barrier.For example, proton tautomer (also referred to as protic tautomer) includes moving by proton
The enantiotropy of shifting, such as keto-enol and imine-enamine isomerizations.Valence tautomers include passing through some bonding electrons
Recombination (reorganization) enantiotropy.
It should be noted that term " isomers " particularly including the compound that there are one or more isotopes to replace.For example,
H can be any isotope form, including1H、2H (D) and3H(T);C can be any isotope form, including12C、13C and14C;O can be any isotope form, including16O and18O;Etc..
The example for the isotope that can be bound in the compound of the present invention includes the same of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine
Position element, such as, but not limited to,2H (deuterium, D),3H (tritium),11C、13C、14C、15N、18F、31P、32P、35S、36Cl and125I.Of the invention is each
The compound of kind isotope labelling, such as radioactive isotope such as 3H, 13C, 14C are incorporated into these compounds.It is such same
The compound of position element label can be used for being metabolized research, Reaction kinetics research, detection or imaging technique, as positive electron tomography is swept
Imaging (PET) or single photon emission computed tomography (SPECT), including drug or substrate tissue distributional analysis are retouched, or
In the radiation treatment of patient.Deuterium-labeled or substituted therapeutic compound of the invention can have improved DMPK
(drug metabolism and pharmacokinetics) property is related to distribution, metabolism and excretion (ADME).It is taken with heavier isotope (such as deuterium)
In generation, can provide certain treatment advantages generated by higher metabolic stability, for example, Half-life in vivo increase or required
Dosage is reduced.The compound of 18F label is useful to PET or SPECT research.The compound of isotope labelling of the invention is logical
Following preparation can often be passed through: implementing the step of disclosing in reaction scheme or embodiment as described below and preparation example (journey
Sequence), isotope-labeled reagent is replaced with the reagent for the isotope labelling being easy to get.In addition, with heavier isotope, especially
It is deuterium (that is, 2H or D) substitution, certain treatment advantages generated by higher metabolic stability can be provided, for example, in vivo
Half-life period increases or required dosage reduces or therapeutic index increases.It should be understood that the deuterium in context is regarded as replacing
Base.The concentration of this higher isotope (especially deuterium) can be limited by isotope enrichment factor.In chemical combination of the invention
It is any not clearly indicate any stable isotope for referring to the atom for the atom of specific isotope in object.
Unless otherwise stated, the particular compound otherwise mentioned include all these isomeric forms, including its (all or
Partly) racemic and other mixtures.Preparation (for example, asymmetric syntheses) and separation (example for this isomeric forms
Such as, fractional crystallization and chromatography) method be known in the art, or adjust side teaching herein by known methods
Method or known method are readily available.
Bioactivity
In vitro cell proliferation assay
In general, passing through the cytotoxicity or cell inhibitory activity of following measurement antibody-drug conjugates (ADC): will have
The mammalian cell of receptor protein is exposed to the antibody of ADC in cell culture medium;It cultivates one section of cell about 6 hours to about 5 days
Period;And measurement cell viability.External test based on cell is used to measure the survival ability of ADC of the invention
The induction (caspase activation) of (proliferation), cytotoxicity and cell death.
The vitro efficacy of antibody-drug conjugates can be measured by cell proliferating determining.
Luminescent cell viability analyzer is commercially available (Promega Corp., Madison, WI), is based on
Homogeneity measuring method (the US patent No. 5583024 of the recombinant expression of Coleoptera luciferase;5674713 Hes
5700670).For the cell proliferating determining based on there are the number for quantitatively determining Survival Cells in culture medium of ATP, which is generation
Thank to instruction (Crouch et al (1993) J.Immunol.Meth.160:81-88 of competent cell;US 6602677).96
It is carried out in orifice plateMeasurement makes it that can be subjected to inspection (the Cree et al of high throughput screening (HTS)
(1995)AntiCancer Drugs 6:398-404).Determination step of the same race be related to directly adding single agents (Reagent) to culture supplement serum culture medium cell.Cell washing removes culture medium and repeatedly moves
Liquid step is unwanted.Add reagent and mixing after, in 10 minutes system detect in 384 orifice plates down to 15 cells/
Hole.ADC continuous processing cell can be used, or can handle cell and separate it with ADC.In general, simple process is (that is, 3 is small
When) cell effect identical as the cell of continuous processing is shown.
" addition-mixing-measurement " mode of homogeneity causes cell lysis to act on and proportional to the amount there are ATP shine
(luminescent) generation of signal.The amount of ATP and the number for the cell being present in culture medium are directly proportional.Measurement generates " growth type " luminous signal generated by luciferase reaction, depending on the cell class used
Type and culture medium have the half-life period for being typically larger than 5 hours.Survival Cells react on relative luminescent units (RLU).Pass through
Recombinate the adjoint conversion of firefly luciferase and ATP to AMP and the generation of photon, substrate B eetle Luciferin (beetle
Fluorescein) it is oxidized decarboxylation.
The vitro efficacy of antibody-drug conjugates can also be measured by cytotoxicity assay.It is washed with PBS, with pancreas egg
The adherent cell that white enzyme is separately cultured is diluted in the complete medium comprising 10%FCS, be centrifuged, be resuspended in it is fresh
In culture medium, and counted with hemacytometer (haemocytometer).Directly count suspension culture.Suitable for counting
Monodisperse cell suspension may be needed by repeating to supply gas to stir suspended matter to break up cell mass.
Cell suspension is diluted to desired inoculum density and is dispersed in 96 orifice plates of black (100 hole μ l/).
The plate of adherent cell system is incubated for overnight to allow to adhere to.The suspension cell of culture can be used on the day of inoculation.
The stock solution (1ml) of ADC (20 μ g/ml) is prepared in cell culture medium appropriate.By the way that sequentially 100 μ l are turned
The cell culture medium for moving to 900 μ l, a series of 10 times of dilutions of preparation deposit ADC in 15ml centrifuge tube.
Before with cell suspending liquid (100 μ l) bed board, four repeating holes of each ADC dilution (100 μ l) are dispersed
In 96 hole blackboards, 200 μ l of final volume is obtained.Control wells receive cell culture medium (100 μ l).
If the doubling time of cell line is greater than 30 hours, ADC is incubated for 5 days, otherwise completes to be incubated in four days.
In incubation time section finally, with the blue measurement assessment cell viability of alma (Alamar).By alma indigo plant
(Invitrogen) it is dispersed on entire plate (20 hole μ l/) and is incubated for 4 hours.In the quick plate reader of Varioskan with
570nm excitation, 585nm emission measurement alma indigo plant fluorescence.Compared with the mean fluorecence in control wells, in the hole by ADC processing
Mean fluorecence calculate percentage cell survival rate.
Purposes
Conjugate of the invention can be used for providing PBD compound in target location.
Target location is preferably the cell colony being proliferated.Antibody is the antigen for being present on proliferating cell population
Antibody.
In one embodiment, with the amount for the antigen being present in proliferating cell population (for example, tumor cell colonies)
It compares, antigen is not present or is present in non-proliferative cell colony with reduction level.
In target location, connector can be cut, to discharge compound R elA, RelB, RelC, RelD or RelE.Therefore,
Conjugate can be used to compound R elA, RelB, RelC, RelD or RelE being selectively provided to target location.
Connector can be cut by the digestion for being present in target location.
Target location can be external, internal or external.
Antibody-drug conjugates (ADC) compound of the invention includes having for those of anticancer activity effectiveness.Specifically
Ground, compound include combining, that is, the antibody of PBD drug moiety (that is, toxin) is covalently attached to by connector.When drug does not have
When being bound to antibody, PBD drug has cytotoxic effect.Therefore, by and the combination of antibody adjust PBD drug moiety
Bioactivity.The cytotoxic reagent of effective dose is selectively delivered to tumour by antibody-drug conjugates (ADC) of the invention
Tissue, so as to realize higher selectivity, that is, less effective dose.
Therefore, on the one hand, the present invention provides the combination compounds for being described herein for using in the treatment.
Further, it also provides and is described herein for the conjugate used in the treatment of proliferative disease
Compound.The second aspect of the present invention, which provides, combines compounds preparing the use in the drug for treating proliferative disease
On the way.
Those of ordinary skill in the art can be readily determined whether candidate conjugate treats any particular cell types
Proliferative disorders.For example, describing such measuring method in the following examples, they may be conveniently used assessment by specific
Activity provided by compound.
Term " proliferative disease " is related to the unwanted or uncontrolled cell of undesirable over or abnormal cell
Hyperplasia, e.g., angiogenic or Hyperplastic growth (either in vitro or in vivo).
The example of proliferative disorders is including but not limited to benign, deteriorates preceding and malignant cell proliferation, including but not limited to newly
Biology and tumour (for example, histocytoma, glioma, astrocytoma, osteoma), cancer (such as lung cancer, Small Cell Lung Cancer,
Human primary gastrointestinal cancers, intestinal cancer, colon cancer, breast cancer, oophoroma, prostate cancer, carcinoma of testis, liver cancer, kidney, bladder cancer, cancer of pancreas, the cancer of the brain,
Sarcoma, osteosarcoma, Kaposi sarcoma, melanoma), lymthoma, leukaemia, psoriasis, osteopathy, fibroproliferative disease (such as
The fibroproliferative disease of connective tissue) and atherosclerosis.Cancer of special interest include but is not limited to leukaemia and
Oophoroma.
It can treat any kind of cell, including but not limited to lung, gastrointestinal tract (including for example, intestines, colon), cream (cream
Room), ovary, prostate, liver (liver), kidney (kidney), bladder, pancreas, brain and skin.
Cancer of special interest includes but is not limited to prostate cancer.
And have been shown that PSMA is significantly expressed in the new vessels of non-prostate solid tumor, the non-prostate entity
Tumor includes colon tumor, lacteal tumor, bladder tumor, Vipoma, nephroncus and melanoma, but does not include normal hemangioma.Therefore, PSMA
Specific ADC can be used for the non-tumor of prostate that treatment has PSMA positive new vessels.
It is expected that antibody-drug conjugates (ADC) of the invention can be used for treating a variety of diseases or disorder, for example, by swelling
The overexpression of tumor antigen characterizes.Exemplary conditions or hyperplasia sexual disorder include benign or malignant tumour;Leukaemia, blood and
Lymphoid malignancies.Other include disorder below: neuron, Deiter's cells, astrocyte, hypothalamus
, body of gland, macrophage, epithelium, matrix, blastocoele, inflammatory, blood vessel generates and immunologic, packet
Include autoimmune disorders.
In general, disease to be treated or disorder are hyperproliferative diseases, such as cancer.The reality of cancer to be treated herein
Example includes but is not limited to cancer, lymthoma, blastoma, sarcoma and leukaemia or lymphoid malignancy.This cancer it is more specific
Ground example include squamous cell carcinoma (for example, epithelial squamous cell cancer), lung cancer (including Small Cell Lung Cancer, non-small cell lung cancer),
The gland cancer of the squamous cell carcinoma of lung and lung, peritoneal cancer, hepatocellular carcinoma, gastric cancer or stomach cancer (including human primary gastrointestinal cancers), cancer of pancreas, plastic
Cell plastid tumor, cervical carcinoma, oophoroma, liver cancer, bladder cancer, hepatoma, breast cancer, colon and rectum carcinoma, colorectal cancer, son
Endometrial carcinoma or uterine cancer, salivary-gland carcinoma, kidney or renal cancer, prostate cancer, carcinoma of vulva, thyroid cancer, liver tumour, anus
Cancer, carcinoma of penis and head and neck cancer.
Can be used in the treatment ADC autoimmune disease include rheumatic disease (as example, rheumatoid arthritis,
Sjogren syndrome, chorionitis, lupus such as SLE and lupus nephritis, polymyositis/dermatomyositis, cryoglobulinemia, anti-phospholipid antibody
Syndrome and psoriatic arthritis), osteoarthritis, autoimmune gastrointestinal and liver disorder are (as example, inflammatory bowel disease (example
Such as, ulcerative colitis and Crohn disease), autoimmune gastritis and pernicious anaemia, oneself immunity hepatitis, primary biliary
Property cirrhosis, primary sclerotic cholangitis and chylous diarrhea, vasculitis is (as example, the relevant vasculitis of ANCA, including Qiu-are applied
Vasculitis, Wegner's granulomatosis and panarteritis), Autoimmune neuropathies disorder is (e.g., for example, multiple sclerosis, slanting eye
Myoclonic syndrome, myasthenia gravis, neuromyelitis optica, Parkinson's disease, Alzheimer's disease and autoimmune are more
Send out nerve lesion), kidney trouble (as example, glomerulonephritis, Goodpasture's syndrome and Bei Geershi disease), itself
Immune dermatosis disorder is (as example, psoriasis, nettle rash, morbilli, pemphigus vulgaris, bullous pemphigoid and skin are red
Yabbi sore), hematology disorder is (as example, thrombocytopenic purpura, thrombotic thrombocytopenic purpura, post-transfusion purpura
And autoimmune hemolytic anemia), atherosclerosis, uveitis, autoimmune auditory disorder is (as example, inner ear
Disease and hearing loss), Behcet's disease, Raynaud's syndrome, organ transplant and autoimmune endocrine disturbance (as example,
Diabetes associated autoimmune disease such as insulin-dependent diabetes mellitus (IDDM), Addison's disease and Autoimmune Thyroid
Sick (for example, Graves disease and thyroiditis)).Preferred this disease includes, for example, rheumatic arthritis, exedens
It is the relevant vasculitis of colitis, ANCA, lupus, multiple sclerosis, Sjogren syndrome, Graves disease, IDDM, pernicious poor
Blood, thyroiditis and glomerulonephritis.
Treatment method
Conjugate of the invention can use in treatment method.There is also provided a kind of method for the treatment of, including to needing
The subject wanted gives the combination compounds of the invention of therapeutically effective amount.Term " therapeutically effective amount " is to be enough to show to trouble
The amount that person benefits.Above-mentioned benefit, which can be, at least improves a kind of symptom.The actual amount given and the velocity and time given
Process will depend on property to be treated and seriousness.Treatment prescription, such as dosage determine, are in omni-doctor and other doctors
The Limitation on Liability in.
It can individually give or be combined with other treatment and give the compound of the present invention, while give or sequence is to prefetching
Certainly in illness to be treated.The example for the treatment of and therapy includes but is not limited to that chemotherapy (gives activating agent, including such as medicine
Object, such as chemotherapy);Operation;And radiotherapy.
Do not consider mechanism of action, " chemotherapeutics " is chemical compound useful in cancer treatment.The classification packet of chemotherapeutics
Include but be not limited to Alkylators, antimetabolite, spindle poisonous plant alkaloid, cytotoxicity/antitumor antibiotics, topoisomerase
Enzyme inhibitor, antibody, photosensitizer and kinase inhibitor.Chemotherapeutics is included in chemical combination used in " targeted therapies " and conventional chemotherapy
Object.
The example of chemotherapeutics include: Tarceva (Genentech/OSI Pharm.), more west he
Match (Sanofi-Aventis), 5-FU (fluorouracil, 5 FU 5 fluorouracil, CAS No.51-21-8), Ji
His shore of west (Lilly), PD-0325901 (CAS No.391210-10-9, Pfizer), cis-platinum (cis- two
Amine, dichloro platinum (II), CAS No.15663-27-1), carboplatin (CAS No.41575-94-4), taxol (
Bristol-Myers Squibb Oncology, Princeton, N.J.), Herceptin (
Genentech), Temozolomide (bicyclic [4.3.0] the nonyl- 2,7,9- triolefin -9- of 4- methyl -5- oxo -2,3,4,6,8- pentaaza
Formamide, CAS No.85622-93-1,Schering Plough), he not
Former times sweet smell ((Z) -2- [4- (1,2- diphenyl but-1-ene base) phenoxy group]-N, N- dimethyl amine,) and Doxorubicin
Akti-1/2, HPPD and rapamycin.
More examples of chemotherapeutics include: oxaliplatinSanofi), bortezomib (Millennium Pharm.), sotan (SU11248, Pfizer), Letrozole (Novartis), imatinib mesylate (Novartis), (Mek inhibits XL-518
Agent, Exelixis, WO 2007/044515), ARRY-886 (Mek inhibitor, AZD6244, Array BioPharma, Astra
Zeneca), SF-1126 (PI3K inhibitor, Semafore Pharmaceuticals), BEZ-235 (PI3K inhibitor,
Novartis), XL-147 (PI3K inhibitor, Exelixis), PTK787/ZK 222584 (Novartis), fulvestrant (AstraZeneca), Calciumlevofolinate (folinic acid), rapamycin (sirolimus,Wyeth), Lapatinib (GSK572016, Glaxo Smith Kline), Lip river that
Method Buddhist nun (SARASARTM, SCH 66336, Schering Plough), Sorafenib (BAY43-9006,
Bayer Labs), Gefitinib (AstraZeneca), Irinotecan (CPT-
11, Pfizer) pyrrole method Buddhist nun (ZARNESTRA, is replacedTM, Johnson&Johnson), ABRAXANETM(be free of polyoxyethylene caster
Oil), the albumin nano of taxol design preparation (American Pharmaceutical Partners, Schaumberg,
Il), Vande Thani (rINN, ZD6474,AstraZeneca), Chlorambucil, AG1478, AG1571
(SU5271;Sugen), sirolimus (Wyeth), pazopanib (GlaxoSmithKline), camphane Buddhist (Telik), phosphinothioylidynetrisaziridine and cyclophosphamideAlkyl sulfonic ester is such as
Busulfan, Improsulfan and piposulfan;Aziridines such as Benzodepa (benzodopa), carboquone, Meturedepa
(meturedopa) and urethimine (uredopa);Ethylenimines and methylmelamines (methylamelamines
Including hemel, triethylenemelamine, triethylphosphoramide, triethylene thiophosphamide and three (methylamelamines),
Methylol melamine (trimethylolomelamine);Lactone (especially its pungent and its octanone of Bradley of Bradley);Camptothecine (including
The class topotecan of synthesis);Bryostatin;callystatin;CC-1065 (including it] Adozelesin, Carzelesin and ratio
It rolls over and carrys out new synthetic analogues);Cryptophycin (the especially cryptophycin 8 of 1 sum of cryptophycin);Dolastatin;Times carcinomycin (including close
At analog, KW-2189 and CB1-TM1);Eleutherobin (soft coral alcohol);Water ghost any of several broadleaf plants alkali;Sarcodictyin (branch of crawling
Coral alcohol);spongistatin;Mustargen for example Chlorambucil, Chlornaphazine, chlorine phosphamide (chlorophosphamide), it is female not
Take charge of spit of fland, ifosfamide, mechlorethamine, mechlorethamine oxide salt acidulants, melphalan, novembichin,
Phenesterin, pennisetum mustard, trofosfamide, uracil mastard;Nitroso ureas such as Carmustine, chloramphenicol, good fortune are not
Take charge of spit of fland, lomustine, Nimustine and ranimnustine;Antibiotic such as enediyne antibiotic (such as in Calicheamicin, card
Miramycin γ 1I, Calicheamicin Ω I1 (Angew Chem.Intl.Ed.Engl. (1994) 33:183-186);Up to endomycin
(dynemicin), endomycin A is reached;Diphosphonate, such as clodronate;Ai Sipeila mycin;And neoearcinostain chromophore and
Related chromoprotein enediyne antibiotic chromophore), aclacinomycin, D actinomycin D, authramycin, azaserine, it is rich come
It is mycin, D actinomycin D, carabicin, carminomycin, carzinophillin, chromomycin (chromomycinis), dactinomycin D, soft red
Mycin, Detorubicin, 6- diazonium -5- oxn-l-norieucin, morpholino-adriamycin, cyanomorpholino-doxorubicin, 2- pyrroles
Quinoline base-adriamycin and deoxy doxorubicin, epirubicin, esorubicin, idarubicin, Nemorubicin, marcellomycin, mitogen
Mycin for example mitomycin C, mycophenolic acid, nogalamycin, olivomycin class, Peplomycin, porfiromycin, puromycin, three-iron Ah
Mycin, rodorubicin, streptonigrin, streptozotocin, tuberculin (tubercidin), ubenimex, Zinostatin, the soft ratio of assistant
Star;Antimetabolite such as methotrexate (MTX) and 5 FU 5 fluorouracil (5-FU);Folacin for example denopterin, methotrexate (MTX), pteropterin,
Trimetrexate;Purine analogue such as fludarabine, Ismipur, thiapurine, thioguanine;Pyrimidine analogue such as Anxi he
Shore, azacitidine, 6- azauridine, Carmofur, cytarabine, di-deoxyuridine, doxifluridine, enocitabine, floxuridine;It is male
Hormone such as Calusterone, Masterone, epithioandrostanol, Mepitiostane, Testolactone;Anti- adrenal gland such as aminoglutethimide
(aminoglutethimide), mitotane, Trilostane;Folic acid supplement such as folinic acid;Aceglatone
(aceglatone);Aldophosphamideglycoside;Amino-laevulic acid;Eniluracil;Amsacrine;bestrabucil;Bisantrene;According to
Up to Qu Sha (edatraxate);Defosfamide (defosfamide);Demecolcine (Demecolcine);Diaziquone;
elfornithine;Elliptinium Acetate;Epothilones;Ethoglucid;Gallium nitrate;Hydroxycarbamide;Lentinan;Lonidamine
(lonidainine);Maytansinol (maytansinoid) such as maytansine (maytansine) and ansamitocin
(ansamitocin);Mitoguazone;Mitoxantrone;mopidanmol;Nitrazine (nitragin (nitraerine));Spray department he
Fourth;Benzene carrys out beautiful spy;Pirarubicin;Losoxantrone;Podophyllic acid (podophyllinic acid);2- ethyl hydrazine;Procarbazine;Polysaccharide compound (JHS Natural Products, Eugene, OR);Razoxane;Rhizomycin;Sizofiran;Spirogermanium
(spirogermanium);Tenuazonic acid;Triethyleneiminobenzoquinone;2,2 ', 2 "-trichlorotriethylamines;Trichothecenes toxin
Class (especially T-2 toxin, myconomycin A (verracurin A), Roridine A and anguidin);Urethane;Long fields for spring sowing
It is pungent;Dacarbazine;Mannomustin;Dibromannitol;Mitolactol;Pipobroman;gacytosine;Cytarabine
("Ara-C");Cyclophosphamide;Phosphinothioylidynetrisaziridine;6- thioguanine;Purinethol;Methotrexate (MTX);Platinum analogs such as cis-platinum and carboplatin;
Vinblastine;Etoposide (VP-16);Ifosfamide;Mitoxantrone;Vincristine;VinorelbineNovantrone (novantrone);Teniposide;Edatrexate;Daunorubicin;Aminopterin;Card training
His shoreRoche);Ibandronate;CPT-11;Topoisomerase enzyme inhibitor RFS2000;Difluoromethyl bird ammonia
Sour (DFMO);Retinoids class (biostearin) such as retinoic acid;Pharmaceutically acceptable salt, acid and the derivative of any of the above
Object.
Further include in the restriction of " chemotherapeutics ": (i) effect is anti-for the hormonal action in adjusting or inhibition tumour
Hormone agents such as antiestrogenic and selective estrogen receptor modulators (SERM), for example including tamosifen (includingCitric acid tamosifen), Raloxifene, Droloxifene, 4- hydroxy tamoxifen, Trioxifene, that Lip river
Former times sweet smell (keoxifene), LY117018, Onapristone and(citric acid toremifene);(ii) inhibit enzyme
The aromatase inhibitor of aromatase enzyme, adjusting result from adrenal estrogen such as such as 4 (5)-imidazoles, aminoglutethimide,(megestrol acetate),(Exemestane;Pfizer), Formestane
(formestanie), Fadrozole,(Vorozole),(Letrozole;Novartis) and(Anastrozole;AstraZeneca);(iii) antiandrogen such as Drogenil, Nilutamide, than card Shandong
Amine, Leuprorelin and Goserelin;And troxacitabine (1,3- dioxolane nucleoside analogue of cytosine);(iv) protein swashs
Enzyme inhibitor such as mek inhibitor (WO 2007/044515);(v) lipid kinase inhibitors;(vi) antisense oligonucleotides, especially
Inhibit those of gene such as PKC- α, Raf and the H-Ras expression of signal path impacted in abnormal cell proliferation, benefit such as difficult to understand
Write from memory gloomy (oblimersen) (Genta Inc.);(vii) ribozyme such as vegf expression inhibitor (example
Such as,) and HER2 expression inhibiting agent;(viii) vaccine such as gene therapy vaccine, such asWithrIL-2;Topology is different
1 inhibitor of structure enzyme is such asrmRH;(ix) anti-angiogenic producing agent such as shellfish cuts down pearl
Monoclonal antibody () and the pharmaceutically acceptable salt of any of the above, acid and derivative Genentech.
Further include " chemotherapeutics " restriction in be therapeutic antibodies such as alemtuzumab (Campath), Avastin (Genentech);Cetuximab (Imclone);Victibix (Amgen), Rituximab (Genentech/Biogen Idec), method difficult to understand wood
Monoclonal antibody (GSK), handkerchief trastuzumab (PERJETATM, OMNITARGTW, 2C4, Genentech), toltrazuril
Monoclonal antibody (Genentech), tositumomab (Bexxar, Corixia) and antibody drug conjugate, Ji
Trastuzumab (gemtuzumab ozogamicin) (Wyeth)。
With the Humanized monoclonal antibodies that the treatment potentiality as chemotherapeutics is combined with conjugate of the invention include: Ah
Logical sequence monoclonal antibody, A Bozhu monoclonal antibody, A Saizhu monoclonal antibody, atlizumab, Ba Pinzhu monoclonal antibody (bapineuzumab), Avastin, not
Than cutting down pearl monoclonal antibody (bivatuzumab mertansine), not bank trastuzumab (cantuzumab mertansine), Seeley pearl
Monoclonal antibody, match trastuzumab (certolizumab pegol), cidfusituzumab, cidtuzumab, daclizumab, Yi Ku
The sharp pearl monoclonal antibody of beautiful monoclonal antibody, efalizumab, epratuzumab, strategic point, felvizumab, fragrant trastuzumab
(Fontolizumab), lucky trastuzumab, English trastuzumab (Inotuzumab Ozogamicin), her monoclonal antibody, draw Bei Zhudan
Anti-, lintuzumab, matuzumab, mepolizumab, Mo Weizhu monoclonal antibody, motovizumab, natalizumab, the appropriate pearl of Buddhist nun
Monoclonal antibody, nolovizumab, numavizumab, auspicious pearl monoclonal antibody (ocrelizumab) difficult to understand, omalizumab, palivizumab, pa
Examine pearl monoclonal antibody, pecfusituzumab, pectuzumab, handkerchief trastuzumab, training gram pearl monoclonal antibody, ralivizumab, Lei Zhudan
Anti-, reslivizumab, Rayleigh pearl monoclonal antibody, resyvizumab, rovelizumab, ruplizumab, sibrotuzumab, Seeley pearl
Monoclonal antibody (Siplizumab), Suo Tuzhu monoclonal antibody, his pearl monoclonal antibody (tacatuzumab tetraxetan), he spend pearl monoclonal antibody, his benefit
Pearl monoclonal antibody, special non-pearl monoclonal antibody, tower Xidan is anti-, holds in the palm sharp pearl monoclonal antibody (toralizumab), trastuzumab, tucotuzumab
Celmoleukin, tucusituzumab, umavizumab, black pearl monoclonal antibody and Wei Xi pearl monoclonal antibody (visilizumab).
According to the invention and pharmaceutical composition used according to the present invention is removed active constituent (that is, in conjunction with compounds)
It in addition, can also include pharmaceutical excipient, carrier, buffer, stabilizer or other substances well known to those skilled in the art.This
The substance of sample should be effect that is nontoxic, and should not interfere with active constituent.The definite property of carrier or other substances will depend on
In giving approach, this is given approach and can be orally or through injection (such as skin, subcutaneous or intravenous).
It can be tablet, capsule, powder or liquid form for the oral pharmaceutical composition given.Tablet may include
Solid carrier or adjuvant.Composition of liquid medicine generally comprises liquid-carrier such as water, petroleum (petroleum), animal or plant
Oil, mineral oil or synthetic oil.It may include normal saline solution, dextrose or other sugar juices or glycols such as ethylene glycol, third
Glycol or polyethylene glycol.Capsule may include solid carrier such as gelatin.
For intravenous, skin or subcutaneous injection, or the injection at painful position, active component will have parenteral
The form of acceptable aqueous solution is pyrogen-free and has suitable pH, isotonicity and stability.Those skilled in the art
It is able to use for example, isotonic vehicle such as sodium chloride injection, ringer's injection, lactated ringer's injection are prepared well
Suitable solution.It as needed, may include preservative, stabilizer, buffer, antioxidant and/or other additives.
Preparation
Although can be used alone (for example, giving) in conjunction with compounds, often preferably make it as composition
Or preparation exists.
In one embodiment, composition is comprising combination compounds described herein and pharmaceutically acceptable
The pharmaceutical composition (for example, preparation, preparation, drug) of carrier, diluent or excipient.
In one embodiment, composition be comprising at least one combination compounds described herein and it is a kind of or
The pharmaceutical composition of a variety of pharmaceutically acceptable ingredients well known to those skilled in the art, which includes but is not limited to pharmacy
Upper acceptable carrier, diluent, excipient, adjuvant, filler, buffer, preservative, antioxidant, lubricant, stabilizer,
Solubilizer, surfactant (for example, wetting agent), screening agent, colorant, flavoring agent and sweetener.
In one embodiment, composition further includes other activating agents, for example, other therapeutic agents or prophylactic.
Suitable carrier, diluent, excipient etc. can be found in standard pharmaceutical text.See, e.g.,Handbook of Pharmaceutical Additives,2nd Edition(eds.M.Ash and I.Ash),2001(Synapse
Information Resources,Inc.,Endicott,New York,USA),Remington's Pharmaceutical Sciences,20th edition,pub.Lippincott,Williams&Wilkins,2000;WithHandbook of Pharmaceutical Excipients,2nd edition,1994。
Another aspect of the present invention relates to the methods of preparation pharmaceutical composition, including at least one that will be limited herein
[11C]-labelled with radioisotope conjugate or combine class compound and it is one or more it is well known to those skilled in the art its
He mixes pharmaceutically acceptable ingredient, for example, carrier, diluent, excipient etc..If being formulated as discrete unit
(for example, tablet etc.), then each unit includes the reactive compound of predetermined amount (dosage).
The term as used herein " pharmaceutically acceptable " is related to compound, ingredient, material, composition, dosage form etc.,
Reasonable medical judgment scope is interior, excessive suitable for contacting without with the tissue of the subject (for example, mankind) discussed
Toxicity, stimulation, allergic reaction or other problems or complication, and match with reasonable interests/Hazard ratio.Every kind of carrier, dilution
Agent, excipient etc. also must be " acceptable " in the sense that compatible with the other compositions of preparation.
Preparation can be prepared by any method known to pharmaceutical field.Such method includes making reactive compound and structure
At the carrier-bound step of one or more auxiliary elements.In general, preparation is by making reactive compound and carrier (example
Such as, liquid-carrier, fine solid carrier etc.) it is uniform closely combine, make product shaping if necessary then to prepare.
Preparation can be prepared as discharging quickly or at a slow speed;Immediately, delay, instant or slow release;Or their combination.
Preparation suitable for parenterally giving (for example, passing through injection) includes aqueous or non-aqueous, isotonic, apyrogeneity
, sterile liquid (such as solution, suspension), wherein active constituent be dissolved, suspend or otherwise provide (for example,
In liposome or other particles).In addition this liquid can contain other pharmaceutically acceptable ingredient such as antioxidants, buffering
Agent, preservative, stabilizer, bacteriostatic agent, suspending agent, thickener and blood (or other dependent bodies for making preparation and intended recipient
Liquid) isotonic solute.The example of excipient includes, for example, water, alcohol, polyalcohol, glycerol, vegetable oil etc..For such preparation
The example of suitable isotonic vehicle includes sodium chloride injection, ringer's solution (Ringer's Solution) or lactated Ringer note
Penetrate liquid.In general, the concentration of active constituent is about 1ng/ml to about 10 μ g/mL, for example, about 10ng/mL to about 1 μ g/mL in liquid.
Said preparation may be present in unit dose or multi-dose sealing container, such as in ampoule and phial, and (can freeze in freeze-drying
It is dry) under the conditions of store, it is only necessary to sterile liquid carrier such as water for injection is being added before use.Can by aseptic powdery, particle and
Tablet prepares injection solution and suspension on the spot.
Dosage
It will be apparent to a skilled person that in conjunction with compounds and including the composition for combining compounds
Suitable dosage can be different because of patient.The level for making treatment benefit and any risk or harmful secondary will be involved by determining optimal dose generally
Effect balance.The dosage level of selection will depend on Multiple factors, including but not limited to the activity of specific compound, give way
Diameter, excretion time, the duration for the treatment of, other drugs, compound and/or the object being applied in combination for giving time, compound
Matter, the seriousness of the patient's condition and species, gender, age, weight, the patient's condition, general health and the medical history of patient.The amount of compound
It finally will cautiously be determined by doctor, animal doctor or clinician with approach of giving, but in general, by selection dosage to act on
Position, which reaches, realizes the desired local concentration acted on without will cause material injury or harmful side effect.
During the entire course for the treatment of, can with single dose, it is continuously or intermittently (for example, with appropriate time interval divided dose) real
Now give.Determine that the most effective means and the method for dosage given are well known to those skilled in the art, and will be with being used to treat
The preparation of method, therapy purpose, (a variety of) target cell treated and the difference of the subject treated and change.Treatment can be used
Doctor, the dosage level of animal doctor or clinician's selection and mode carry out single or multiple give.
In general, the suitable dose of reactive compound is that (more generally about 1 μ g is to about in about 100 μ g to about 25mg
In the range of 10mg)/kg of body's body weight/day.In the case where the compound is salt, ester, amide, prodrug etc., based on mother
Body compound calculates administered dose, so the proportional increase of actual weight used.
In one embodiment, reactive compound is given to human patients according to following dosage: about 100mg,
3 times a day.
In one embodiment, reactive compound is given to human patients according to following dosage: about 150mg,
2 times a day.
In one embodiment, reactive compound is given to human patients according to following dosage: about 200mg,
2 times a day.
However, in one embodiment, will be given in conjunction with compounds to human patients according to following dosage: about
50 or about 75mg, daily 3 or 4 times.
In one embodiment, will be given to human patients in conjunction with compounds according to following dosage: about 100 or
About 125mg, 2 times a day.
Dosage described above can be adapted for conjugate (comprising PBD part and to antibody connector) or be suitable for provide
PBD compound effective quantity, for example, the amount of the compound discharged after joint cutting.
For preventing or treating disease, the suitable dosage of ADC of the invention will depend on disease defined above to be treated
Sick type, the severity of disease and situation (no matter giving molecule for prevention or therapeutic purposes), prior treatment, patient
Clinical medical history and to the reaction of antibody and the judgement of attending physician.Once or by a series of treatments by molecule suitably give
It gives to patient.Depending on the type and severity of disease, no matter, such as individually given or by one or many by continuous
Infusion, the molecule of about 1 μ g/kg to 15mg/kg (for example, 0.1-20mg/kg) is for giving to the initial candidate dosage of patient.
Common daily dosage can be in about 1 μ g/kg to 100mg/kg or more, this depends on above-mentioned factor.It gives
To patient ADC exemplary dose in the range of about 0.1 to about 10mg/kg patient weight.For several days or longer heavy
It gives again, depends on illness, treatment, which continues to, realizes that the expectation of disease symptoms inhibits.Exemplary dose scheme includes giving about
The case where 4mg/kg initial drugloading rate, then weekly, every two weeks or the ADC of the every three weeks other dosage of addition.Other dosages
It can be useful.The progress of the therapy is easy to monitor by routine techniques and measuring method.
Treatment
In the case where treating illness term as used herein " treatment " be usually directed to no matter mankind or animal (for example,
Veterinary application) treatment and therapy, wherein wherein realize some desired curative effects, for example, the inhibition to ongoing disease, and
And including development speed reduce, development speed halves, illness is restored, illness improves and illness rehabilitation.It further include as preventative
The treatment of measure (that is, prevent, prevent).
Term as used herein " therapeutically effective amount " is related to reactive compound or the substance comprising reactive compound, combination
The amount of object or dosage form is effective and closes when being given according to desired therapeutic scheme for generating some desired curative effects
Interests/Hazard ratio of reason is suitable.
Similarly, term as used herein " prevention effective dose " is related to reactive compound or the object comprising reactive compound
The amount of matter, composition or dosage form, when being given according to desired therapeutic scheme, desired preventive effects some for generation are
Effectively, suitable with reasonable interests/Hazard ratio.
The preparation of drug conjugates
Can by number of ways well known by persons skilled in the art, using organic chemical reactions, condition and reagent, including
The nucleophilic group of antibody is reacted with agent-linker reagent, prepares antibody drug conjugate.This method can be used to prepare this
The antibody-drug conjugates of invention.
Nucleophilic group on antibody includes but is not limited to side chain thiol moiety, for example, cysteine.Thiol group is nucleophilic
And can react to form covalent bond with the electrophilic group (such as those of present invention) on junction portion.Certain antibody have can
Disulphide in the chain of reduction, that is, cysteine bridge.By with reducing agent such as DTT (Ke Lailanshi reagent (Cleland's), two
Thio threitol) or TCEP (three (2- carboxyethyl) hydrogen phosphide hydrochlorides;Getz et al(1999)Anal.Biochem.Vol
273:73-80;Soltec Ventures, Beverly, MA) processing can make the combination of antibody and linker reagents become easily anti-
It answers.Therefore, the last cysteine disulphide bridges of every theory will form two reactive nucleophilic thiol bodies.By generating amine to mercaptan
The lysine of conversion is reacted with 2- imino group thiophene (Te Laoteshi (Traut ' s) reagent), other nucleophilic groups can be drawn
Enter into antibody.
Subject/patient
Subject/patient can be animal, mammal, placental mammals, marsupial (for example, kangaroo, wombat),
Monotreme (for example, platypus), rodent (for example, cavy, hamster, rat, mouse), murine are (for example, small
Mouse), lagomorph (for example, rabbit), birds (for example, bird), canid (for example, domesticated dog), felid is (for example, family
Cat), equid (for example, horse), porcine animals (for example, domestic pig), sheep class (for example, sheep), bovid is (for example, milk
Ox), primate, apes (for example, monkey or anthropoid), monkey (for example, marmoset, baboon), anthropoid (for example, gorilla,
Chimpanzee, orangutan, gibbon) or the mankind.
In addition, subject/patient can be any form of its development, such as fetus.In a preferred embodiment, by
Examination person/patient is the mankind.
Further preference
It preferably can be adapted for all aspects of invention described above below or can be related to single aspect.This preferably can be with
It is combined with any combination.
In some embodiments, R6’、R7’、R9’And Y ' preferably respectively with R6、R7、R9It is identical with Y.
Dimer connection
Y and Y ' are preferably O.
R " is suitably without the C of substituent group3-7Alkylidene.It is highly preferred that R " is C3、C5Or C7Alkylidene.Most preferably, R "
It is C3Or C5Alkylidene.
R6To R9
R9Preferably H.
R6It is preferably selected from H, OH, OR, SH, NH2, nitro and halogen, and more preferably H or halogen, and most preferably H.
R7It is preferably selected from H, OH, OR, SH, SR, NH2, NHR, NRR ' and halogen, and be more preferably independently selected from H, OH and
OR, wherein R is preferably selected from optionally substituted C1-7Alkyl, C3-10Heterocycle and C5-10Aryl.R can more preferably can with or not
It can be with substituted C1-4Alkyl.Interested substituent group is C5-6Aryl (such as phenyl).Particularly preferred at 7 positions takes
Dai Ji is OMe and OCH2Ph.Other particularly interesting substituent groups are dimethylamino (i.e.-NMe2);-(OC2H4)qOMe,
Wherein q is 0 to 2;Nitrogenous C6Heterocycle, including morpholino, piperidyl and N- methyl-piperazinyl group.
These preferences are respectively suitable for R9’、R6’And R7’。
R12
As C2 ' and C3 ' between there are when double bond, R12It is selected from:
(a)C5-10Aryl, optionally by selected from including below group one or more substituent groups replace: halogen, nitro,
Cyano, ether, C1-7Alkyl, C3-7Heterocycle and double-oxygroup-C1-3Alkylidene;
(b)C1-5Radical of saturated aliphatic alkyl;
(c)C3-6Saturated cyclic alkyls;
(d)Wherein R21、R22And R23It is each independently selected from H, C1-3Saturated alkyl, C2-3Alkenyl, C2-3Alkynes
Base and cyclopropyl, wherein in R12The sum of carbon atom is not more than 5 in group;
(e)Wherein R25aAnd R25bIn one be H and another is selected from: (it is by selected from halogenated to phenyl
Methyl, the group of methoxyl group are optionally substituted);Pyridyl group;And thiophenyl;And
(f)Wherein R24It is selected from: H;C1-3Saturated alkyl;C2-3Alkenyl;C2-3Alkynyl;Cyclopropyl;Phenyl (its
It is by optionally substituted selected from halogenated methyl, the group of methoxyl group);Pyridyl group;And thiophenyl.
Work as R12It is C5-10When aryl, it can be C5-7Aryl.C5-7Aryl can be phenyl or C5-7Heteroaryl, such as furan
It mutters base, thiophenyl and pyridyl group.In some embodiments, R12Preferably phenyl.In other embodiments, R12Preferably
Thiophenyl, for example, thiophene -2- base and thiene-3-yl.
Work as R12It is C5-10When aryl, it can be C8-10Aryl, such as quinolyl or isoquinolyl.Quinolyl or isoquinolin
Base can be incorporated into PBD core by any available ring position.For example, quinolyl can be quinoline -2- base, quinoline -3- base,
Quinolyl-4, quinoline -5- base, quinoline -6- base, quinoline -7- base and quinoline-8-yl.Wherein, quinoline -3- base and quinoline -6- base
It can be preferred.Isoquinolyl can be isoquinolyl-1, isoquinolin -3- base, isoquinolin -4- base, isoquinolin -5- base, different
Quinoline -6- base, isoquinolin -7- base and isoquinolin -8- base.Wherein, isoquinolin -3- base and isoquinolin -6- base can be preferably.
Work as R12It is C5-10When aryl, it can have any amount of substituent group.It preferably has 1 to 3 substituent group,
In 1 and 2 substituent group be more preferred, and mono-substituted group is most preferred.Substituent group can be in any position.
In R12It is C5-7In the case where aryl, monosubstituted base preferably on annular atom, not adjacent to compound
The key of remainder, that is, it is preferably β or γ with the key of the remainder of compound.Therefore, in C5-7Aryl is phenyl
In the case where, substituent group is more preferably aligning preferably in meta or para position.
In R12It is C8-10In the case where aryl, such as quinolyl or isoquinolyl, it can be in quinoline or isoquinolin ring
Any amount of substituent group is had at any position.In some embodiments, it has one, two or three substituent group,
And these substituent groups can be upper (if more than one substituent group) in nearside or distal loop or both.
R12Substituent group works as R12It is C5-10When aryl group
Work as R12It is C5-10When aryl, if in R12On substituent group be halogen, then it is preferably F or Cl, more preferable Cl.
Work as R12It is C5-10When aryl, if in R12On substituent group be ether, then it can be alkane in some embodiments
Oxygroup, for example, C1-7Alkoxy (such as methoxyl group, ethyoxyl), or it can be C in some embodiments5-7Aryloxy group (example
Such as phenoxy group, pyridine oxygroup, furans oxygroup).Alkoxy itself can be further substituted, such as by amino (such as dimethyl
Amino).
Work as R12It is C5-10When aryl, if in R12On substituent group be C1-7Alkyl, it can be preferably C1-4Alkyl (such as
Methyl, ethyl, propyl, butyl).
Work as R12It is C5-10When aryl, if in R12On substituent group be C3-7Heterocycle, then it can in some embodiments
To be C6Nitrogen heterocycle, such as morpholino, thiomorpholine generation, piperidyl, piperazinyl.These groups can be via nitrogen-atoms knot
Together in the remainder of the part PBD.These groups can be further substituted, for example, by C1-4Alkyl.If C6Nitrogen-containing heterocycle
Base is piperazinyl, then the further substituent group can be on the second nitrogen ring atom.
Work as R12It is C5-10When aryl, if in R12On substituent group be double-oxygroup-C1-3Alkylidene, this is preferably double-oxygen
Base-methylene or double-oxygroup-ethylidene.
Work as R12It is C5-10When aryl, if R12On substituent group be ester, then it is preferably methyl ester or ethyl ester.
Work as R12It is C5-10When aryl, particularly preferred substituent group include methoxyl group, ethyoxyl, fluorine-based, chloro, cyano, it is double-
Oxygroup-methylene, methyl-piperazinyl group, morpholino and methyl-phenylsulfanyl.For R12Other particularly preferred substituent groups be two
Methylamino propoxyl group and carboxyl.
Work as R12It is C5-10When aryl, particularly preferred substituted R12Group includes but is not limited to: 4- methoxyl group-phenyl, 3-
Methoxyphenyl, 4- ethyoxyl-phenyl, 3- ethyoxyl-phenyl, 4- fluoro-phenyl, the chloro- phenyl of 4-, 3,4- dioxymethylene-benzene
Base, 4- methylphenyl-sulfanyl, 4- cyano-phenyl, 4- Phenoxyphenyl, quinoline -3- base and quinoline -6- base, isoquinolin -3- base and different
Quinoline -6- base, 2- thienyl, 2- furyl, methoxyl group naphthalene and naphthalene.Alternatively possible substituted R12Group is 4- nitro
Phenyl.R of special interest12Group includes 4- (4- methylpiperazine-1-yl) phenyl and 3,4- dioxygen methylene-phenyl.
Work as R12It is C1-5When radical of saturated aliphatic alkyl, it can be methyl, ethyl, propyl, butyl or amyl.In some implementations
In mode, it can be methyl, ethyl or propyl (n-pentyl or isopropyl).These embodiments it is some in, it can be with
It is methyl.In other embodiments, it can be butyl or amyl, can be linear chain or branched chain.
Work as R12It is C3-6When saturated cyclic alkyls, it can be cyclopropyl, cyclobutyl, cyclopenta or cyclohexyl.In some implementations
In mode, it can be cyclopropyl.
Work as R12It isWhen, R21、R22And R23It is each independently selected from H, C1-3Saturated alkyl, C2-3Alkenyl, C2-3
Alkynyl and cyclopropyl, wherein in R12The sum of carbon atom in group is not more than 5.In some embodiments, in R12In group
Carbon atom sum no more than 4 or be not more than 3.
In some embodiments, R21、R22And R23One of be H, and other two kinds of groups be selected from H, C1-3It is saturated alkane
Base, C2-3Alkenyl, C2-3Alkynyl and cyclopropyl.
In other embodiments, R21、R22And R23In two kinds be H, and a kind of other groups are selected from H, C1-3It is saturated alkane
Base, C2-3Alkenyl, C2-3Alkynyl and cyclopropyl.
It in some embodiments, is not the group of H selected from methyl and ethyl.These embodiments it is some in, no
The group for being H is methyl.
In some embodiments, R21It is hydrogen.
In some embodiments, R22It is hydrogen.
In some embodiments, R23It is hydrogen.
In some embodiments, R21And R22It is H.
In some embodiments, R21And R23It is H.
In some embodiments, R22And R23It is H.
Particularly interesting R12Group is:
Work as R12It isWhen, R25aAnd R25bIn one be hydrogen, and another is selected from: (it is by being selected to phenyl
Halogen, methyl, the group of methoxyl group are optionally substituted);Pyridyl group;And thiophenyl.It in some embodiments, is not the base of H
Group is optionally substituted phenyl.If the optional substituent group of phenyl is halogen, it is preferably fluorine.In some embodiments,
Phenyl is unsubstituted.
Work as R12It isWhen, R24It is selected from: H;C1-3Saturated alkyl;C2-3Alkenyl;C2-3Alkynyl;Cyclopropyl;Phenyl
(it is by optionally substituted selected from halogenated methyl, the group of methoxyl group);Pyridyl group;And thiophenyl.If phenyl is optional
Substituent group is halogen, then it is preferably fluorine.In some embodiments, phenyl is unsubstituted.
In some embodiments, R24Selected from H, methyl, ethyl, vinyl and acetenyl.The one of these embodiments
In a little, R24Selected from H and methyl.
As C2 ' and C3 ' between there are when singly-bound,
R12It isWherein, R26aAnd R26bIndependently selected from H, F, C1-4Saturated alkyl, C2-3Alkenyl, the alkyl and
Alkenyl group is optionally selected from C1-4Alkyl amino and C1-4The group of Arrcostab replaces;Alternatively, working as R26aAnd R26bIn one
When being H, another is selected from nitrile and C1-4Arrcostab;
In some embodiments, it may be preferable that R26aAnd R26bIt is all H.
In other embodiments, preferably R26aAnd R26bIt is all methyl.
In further embodiment, preferably R26aAnd R26bIn one be H and another is selected from C1-4It is saturated alkane
Base, C2-3Alkenyl, wherein alkyl and alkenyl group are optionally substituted.It, can be further in these further embodiments
It is preferred that whether the group of H is selected from methyl and ethyl.
R2
Above for R12Preference be equally applicable to R2。
R22
In some embodiments, R22It is Formula II a.
When it is Formula II a, R22In A can be phenyl group or C5-7Heteroaryl groups, such as furyl, thiophenyl
And pyridyl group.In some embodiments, A is preferably phenyl.
Q2- X can be in C5-7On any available annular atom of aryl group, but preferably in the remainder with compound
On the non-conterminous annular atom of key divided, that is, preferably at β or γ of the key of the remainder of compound.Therefore, work as C5-7
When aryl group (A) is phenyl, substituent group (Q2- X) preferably in meta or para position, and more preferably aligning.
In some embodiments, Q1It is singly-bound.In these embodiments, Q2Selected from singly-bound and-Z- (CH2)n,
In, Z is selected from singly-bound, O, S and NH, and n is 1 to 3.These embodiments it is some in, Q2It is singly-bound.In other embodiment party
In formula, Q2It is-Z- (CH2)n-.In these embodiments, Z can be O or S, and n can be 1 or n can be 2.At these
In the others of embodiment, Z can be singly-bound, and n can be 1.
In other embodiments, Q1It is-CH=CH-.
In other embodiments, R22It is Formula II b.In these embodiments, RC1、RC2And RC3Independently selected from H and not
Substituted C1-2Alkyl.In some preferred embodiments, RC1、RC2And RC3It is all H.In other embodiments, RC1、RC2
And RC3It is all methyl.In some embodiments, RC1、RC2And RC3Independently selected from H and methyl.
X is selected from the group comprising list below: O-RL2’、S-RL2’、CO2-RL2’、CO-RL2’, NH-C (=O)-RL2’、
NHNH-RL2’、CONHNH-RL2’、 NRNRL2’, wherein RNSelected from including H and C1-4
The group of alkyl.X can be preferred that: OH, SH, CO2H ,-N=C=O or NHRN, and can be more preferably: O-RL2’、S-
RL2’、CO2-RL2’,-NH-C (=O)-RL2’Or NH-RL2’.Particularly preferred group includes: O-RL2’、S-RL2’And NH-RL2’, NH-
RL2’It is most preferred group.
In some embodiments, R22It is Formula II c.In these embodiments, preferably Q is NRN-RL2’.At other
In embodiment, Q is O-RL2’.In further embodiment, Q is S-RL2’。RNIt is preferably chosen from H and methyl.Some
In embodiment, RNIt is H.In other embodiments, RNIt is methyl.
In some embodiments, R22It can be-A-CH2- X and-A-X.In these embodiments, X can be O-
RL2’、S-RL2’、CO2-RL2’、CO-RL2’And NH-RL2’.In particularly preferred embodiments, X can be NH-RL2’。
R10、R11
In some embodiments, R10And R11The double bond being formed together between the nitrogen and carbon atom that they are connected.
In some embodiments, R11It is OH.
In some embodiments, R11It is OMe.
In some embodiments, R11It is SOzM, wherein z be 2 or 3 and M be unit price it is pharmaceutically acceptable sun from
Son.
R11a
In some embodiments, R11aIt is OH.
In some embodiments, R11aIt is OMe.
In some embodiments, R11aIt is SOzM, wherein z is the pharmaceutically acceptable sun that 2 or 3 and M is unit price
Ion.
R20、R21
In some embodiments, R20And R21The double bond being formed together between the nitrogen and carbon atom that they are connected.
In some embodiments, R20It is H.
In some embodiments, R20It is RC。
In some embodiments, R21It is OH.
In some embodiments, R21It is OMe.
In some embodiments, R21It is SOzM, wherein z be 2 or 3 and M be unit price it is pharmaceutically acceptable sun from
Son.
R30、R31
In some embodiments, R30And R31The double bond being formed together between the nitrogen and carbon atom that they are connected.
In some embodiments, R31It is OH.
In some embodiments, R31It is OMe.
In some embodiments, R31It is SOzM, wherein z be 2 or 3 and M be unit price it is pharmaceutically acceptable sun from
Son.
M and z
Preferably, M is the cation of the pharmaceutical acceptable of unit price, and more preferably Na+。
Z is preferably 3.
The D that can have Formulas I a preferably in combination with object of the first aspect of the present inventionL:
Wherein,
RL1’、R20And R21It is as defined above;
N is 1 or 3;
R1aIt is methyl or phenyl;And
R2aIt is selected from:
(a)
(b)
(c)
(d)
(e)
(f)
(g)With
(h)
The D that can have Formulas I b preferably in combination with object of the first aspect of the present inventionL:
Wherein,
RL1’、R20And R21As defined above;
N is 1 or 3;And
R1aIt is methyl or phenyl.
The D that can have Formulas I c preferably in combination with object of the first aspect of the present inventionL:
Wherein, RL2’、R10、R11、R30And R31As defined above,
N is 1 or 3;
R12aIt is selected from:
(a)
(b)
(c)
(d)
(e)
(f)
(g)With
(h)
Meta or para position of the amino group in phenyl group.
The D that can have Formulas I d preferably in combination with object of the first aspect of the present inventionL:
Wherein, RL2’、R10、R11、R30And R31As defined above,
N is 1 or 3;
R1aIt is methyl or phenyl;
R12aIt is selected from:
(a)
(b)
(c)
(d)
(e)
(f)
(g)With
(h)
The D that can have Formulas I e preferably in combination with object of the first aspect of the present inventionL:
Wherein, RL2’、R10、R11、R30And R31As defined above,
N is 1 or 3;
R1aIt is methyl or phenyl;
R12aIt is selected from:
(a)
(b)
(c)
(d)
(e)
(f)
(g)With
(h)
Embodiment
General Experimental Procedures
As unit of measuring optical activity on 220 polarimeter of ADP (Bellingham Stanley Ltd.) and by g/100mL
To provide concentration (c).Fusing point is measured using numeral melting point instrument (Electrothermal).Use Perkin-Elmer
Spectrum 1000FT IR spectrometer is composed to record IR.At 300k, using Bruker Avance NMR spectrometer, respectively
It is obtained at 400 and 100MHz1H and13C H NMR spectroscopy.Chemical shift is reported relative to TMS (δ=0.0ppm), and by signal designation
For s (unimodal), d (bimodal), t (triplet), dt (double triplets), dd (bimodal is bimodal), ddd (bimodal double doublet) or m
(multiplet), wherein providing coupling constant so that hertz (Hz) is unit.Using being connected to Waters 2996PDA's
Waters Micromass ZQ instrument on Waters 2695HPLC collects mass spectrum (MS) data.The Waters used
Micromass ZQ parameter is: capillary (kV), 3.38;It bores voltage (V), 35;Extractor (V), 3.0;Source temperature (DEG C), 100;
Desolvation temperature (DEG C), 200;Coning tower tray speed (L/h), 50;Desolvation flow velocity (L/h), 250.The borosilicate coated using metal
Glass tip introduces the sample into instrument, with positive W mode records high-resolution on Waters Micromass QTOF Global
Rate mass spectrum (HRMS) data.In silica gel aluminium sheet (Merck 60, F254) on carry out thin-layer chromatography (TLC), and utilize silica gel (Merck
60,230-400 mesh ASTM) Lai Jinhang flash chromatography.Except HOBt (NovaBiochem) and supported reagents (Argonaut) it
Outside, every other chemicals and solvent are purchased from Sigma-Aldrich and as that supplies is used without further purifying.Having
Under the conditions of appropriate desiccant is existing, under a dry nitrogen atmosphere, anhydrous solvent is prepared by distilling, and be stored inPoint
On son sieve or sodium wire.Petroleum ether refers to the fraction to boil at 40-60 DEG C.
Common LC/MS condition:
Method 1 (otherwise default method uses unless otherwise noted)
HPLC (Waters is run using the mobile phase of water (A) (formic acid 0.1%) and acetonitrile (B) (formic acid 0.1%)
Alliance 2695).Gradient: initial composition 5%B continues 1.0 minutes, then, in 3 minutes, is increased to 95% from 5%B
B.Above-mentioned composition is maintained at 95%B lower 0.1 minute, 5%B is then returned in 0.03 minute and keeps 0.87min.Total gradient
Runing time is equal to 5 minutes.
Method 2
HPLC (Waters is carried out using the mobile phase of water (A) (formic acid 0.1%) and acetonitrile (B) (formic acid 0.1%)
Alliance 2695).Gradient: initial composition 5%B continues 1.0 minutes, then, in 2.5 minutes, is increased to from 5%B
95%B.Above-mentioned composition is maintained at 95%B lower 0.5 minute, 5%B is then returned in 0.1 minute and keeps 0.9min.Total ladder
Runing time is spent to be equal to 5 minutes.
For each method
Flow velocity 3.0mL/min separates 400 μ L via zero dead volume T shape pipe (it is passed through mass spectrograph).Wavelength detecting model
It encloses: 220 to 400nm.Function type: diode array (535 scanning).Column: Onyx Monolithic
C1850×4.60mm。
It is as follows that reverse phase rapidly purifies condition: carrying out flash purification system using the mobile phase of water (A) and acetonitrile (B)
(Varian 971-Fp).Gradient: under 20C.V (column volume), initial composition 5%B, then from 5%B to 70% in 60C.V
B.The composition of 95%B is kept into 15C.V., 5%B is then returned in 5C.V., and be maintained at 5%B and continue 10C.V..Total gradient
Runing time is equal to 120C.V.Flow velocity: 6.0mL/min.Wavelength detection range: 254nm.Column: Agilent AX1372-1SF10-
5.5gC8。
Preparative HPLC: reverse phase ultra high efficiency is carried out on the 5 μ C-18 column of Phenomenex Gemini NX of following size
Liquid chromatography (UPLC).150 × 4.6mm is used to analyze and 150 × 21.20mm is used to prepare work.Pass through gradient condition
Execute all UPLC experiments.Eluent is the solvent A (H with 0.1% fumaric acid2O) and solvent B (has 0.1% fumaric acid
CH3CN).The flow velocity used is that 1.0ml/min is used to analyze and 20.0ml/min is used to prepare type HPLC.In 254nm and
It is detected at 280nm.
The synthesis of intermediate 12
(a) 1 ', 3 '-bis- [2- methoxyl group -4- (methoxycarbonyl) phenoxy group] propane (3)
Under 0-5 DEG C (ice/acetone), in a nitrogen atmosphere, by azo-2-carboxylic acid's diisopropyl ester within the 60min period
(71.3mL, 73.2g, 362mmol) is added dropwise to vanillic acid methyl esters 2 (60.0g, 329mmol) and Ph3P (129.4g,
494mmol) in the solution of the upper belt stirring in anhydrous THF (800mL).Permission is stirred to react mixture other 1 at 0-5 DEG C
Hour, after which time, 1,3-PD (11.4mL, 12.0g, 158mmol) is added dropwise within the 20min period in THF
Solution in (12mL).Allow for reaction mixture to be warming up to room temperature, and stirs 5 days.It is collected by vacuum filtration
White depositions 3 are washed with THF and are dried in vacuum desiccator to constant weight.Yield=54.7g (it is based on 1,3-PD,
84%).Purity satisfaction, LC/MS (3.20min (ES+) m/z (relative intensity) 427 ([M+Na]+., 10);1H NMR
(400MHz, CDCl3) δ 7.64 (dd, 2H, J=1.8,8.3Hz), 7.54 (d, 2H, J=1.8Hz), 6.93 (d, 2H, J=
8.5Hz), 4.30 (t, 4H, J=6.1Hz), 3.90 (s, 6H), 3.89 (s, 6H), 2.40 (p, 2H, J=6.0Hz).
(b) 1 ', 3 '-bis- [2- methoxyl group -4- (methoxycarbonyl) -5- nitro-phenoxy] propane (4)
Under 0-5 DEG C (ice/acetone), by solid Cu (NO3)2·3H2O (81.5g, 337.5mmol) be added slowly to it is double-
Ester 3 (54.7g, 135mmol) is in the slurry of the top band stirring in acetic anhydride (650mL).Permission is stirred to react mixed at 0-5 DEG C
It closes object 1 hour, then it is allowed to be warming up to room temperature.At this stage, slight exotherm (about 40-50 DEG C) is observed, along with mixing
Object retrogradation and NO2Release.Other acetic anhydride (300mL) is added, and it is small to allow to be stirred at room temperature reaction mixture 16
When.Reaction mixture is poured on ice (~1.5L), and stirs and it is allowed to be back to room temperature.It is collected by vacuum filtration
Obtained yellow mercury oxide, and dry in drier to provide desired double -4 yellow solid of nitro compound.Yield=
66.7g (100%).Purity satisfaction, LC/MS (3.25min (ES+) m/z (relative intensity) 517 ([M+Na]+., 40);1H NMR
(400MHz, CDCl3) δ 7.49 (s, 2H), 7.06 (s, 2H), 4.32 (t, 4H, J=6.0Hz), 3.95 (s, 6H), 3.90 (s,
6H), 2.45-2.40 (m, 2H).
(c) 1 ', 3 '-bis- (4- carboxyl -2- methoxyl group -5- nitro-phenoxy) propane (5)
The slurry of methyl esters 4 (66.7g, 135mmol) in THF (700mL) is handled with 1N NaOH (700mL), and is allowed
It is vigorously mixed at room temperature for reaction mixture.After stirring 4 days, which becomes dark solution, undergoes the solution under reduced pressure
Rotary evaporation is to remove THF.With dense HCl be acidified it is aqueous remain to pH 1, and collect colorless precipitation 5, Yi Ji
It is thoroughly dried in vacuum drying oven (50 DEG C).Yield=54.5g (87%).Purity satisfaction, LC/MS (2.65min (ES+) m/z
(relative intensity) 489 ([M+Na]+.,30);1H NMR (400MHz, DMSO-d6) δ 7.62 (s, 2H), 7.30 (s, 2H), 4.29
(t, 4H, J=6.0Hz), 3.85 (s, 6H), 2.30-2.26 (m, 2H).
(d) 1,1 '-[[(propane -1,3- diyl) dioxy] is bis- [(5- methoxyl group -2- nitro -1,4- phenylene) carbonyl]] are double
[(2S, 4R)-methyl -4- hydroxyl pyrrolidine -2- carboxylate] (6)
Oxalyl chloride (24.5mL, 35.6g, 281mmol) is added to paranitrobenzoic acid 5 (43g, 92.3mmol) and MDF
(6mL) is in the stirred suspension of anhydrous DCM (600mL).After initial effervescence, reaction suspension becomes solution, and allows
It stirs mixture 16 hours at room temperature.By determining the conversion ratio of acid chloride with the sample of MeOH reaction mixture, and
And double-the methyl ester observed by LC/MS.Most of solvent is removed by evaporating under reduced pressure;Obtained concentration is molten
Liquid is re-dissolved in the anhydrous DCM of minimum, and is beaten with diethyl ether.The yellow mercury oxide being collected by filtration is used
Cold diethyl ether washing, and it is 1 hour dry in 40 DEG C of vacuum drying ovens.Within the 25min period, -40 DEG C (dry ice/
CH3CN solid acid chloride is added batch-wise to (2S, 4R)-methyl -4- hydroxyl pyrrolidine -2- carboxylate salts acidulants under)
(38.1g, 210mmol) and TEA (64.5mL, g, 463mmol) are in the stirred suspension in DCM (400mL).At once, pass through
LC/MS (2.47min (ES+) m/z (relative intensity 721 ([M+H]+., 100) and determine that reaction is completed.Simultaneously with DCM (200mL) dilution
And with 1N HCl (300mL), saturation NaHCO3(300mL), salt water (400mL), dry (MgSO4) washing mixture, filtering is simultaneously
Solvent is evaporated, in vacuo to obtain the pure products 6 (66.7g, 100%) for orange solids.[α]22 D=-46.1 ° of (c=
0.47, CHCl3);1H NMR (400MHz, CDCl3) (rotational isomer) δ 7.63 (s, 2H), 6.82 (s, 2H), 4.79-4.72
(m, 2H), 4.49-4.28 (m, 6H), 3.96 (s, 6H), 3.79 (s, 6H), 3.46-3.38 (m, 2H), 3.02 (d, 2H, J=
11.1Hz), 2.48-2.30 (m, 4H), 2.29-2.04 (m, 4H);13C NMR (100MHz, CDCl3) (rotational isomer) δ
172.4,166.7,154.6,148.4,137.2,127.0,109.7,108.2,69.7,65.1,57.4,57.0,56.7,
52.4,37.8,29.0;IR (ATR, CHCl3) 3410 (br), 3010,2953,1741,1622,1577,1519,1455,1429,
1334,1274,1211,1177,1072,1050,1008,871cm-1;MS(ES+) m/z (relative intensity) 721 ([M+H]+., 47),
388(80);HRMS[M+H]+.Theoretical C31H36N4O16M/z721.2199 has found (ES+)m/z 721.2227。
(e) 1,1 '-[[(propane -1,3- diyl) two oxygroups] bis- methoxyl group -1,2,3 (11aS, 2R) -2- (hydroxyl) -7-,
10,11,11a- hexahydro -5H- pyrrolo- [2,1-c] [1,4]-benzodiazepine5,11- diketone] (7)
Method A: solution of the nitro ester 6 (44g, 61.1mmol) in MeOH (2.8L) is added to 3 neck round-bottom flask of 5L
In newly buyNickel (~50g, in water~50% slurry) and uprising boiling particle in.Heating mixing under reflux
Then object is handled dropwise with the solution of hydrazine hydrate (21.6mL, 22.2g, 693mmol) in MeOH (200mL), at this point, observation
To sufficient effervesce.It is careful to add in addition when completing to add (~45min)Nickel stops until effervesce, and arranges
Initial yellow reaction mixture out.Mixture 5min is in addition heated under reflux, at this point, by TLC (90:10v/v CHCl3/
) and LC/MS (2.12min (ES+) m/z (relative intensity) 597 ([M+H] MeOH+., 100) reaction be considered as completion.Pass through packet immediately
The sinter funnel heat filtering reaction mixture of containing diatomite (celite) and vaccum suction pipe.Reduce filtrate body by being evaporated in vacuo
Product, at this point, forming colourless precipitate, precipitating is collected by filtration and drying in vacuum desiccator to provide 7 (31g, 85%).
[α]27 D=+404 ° (c=0.10, DMF);1H NMR (400MHz, DMSO-d6) δ 10.2 (s, 2H, NH), 7.26 (s, 2H), 6.73
(s, 2H), 5.11 (d, 2H, J=3.98Hz, OH), 4.32-4.27 (m, 2H), 4.19-4.07 (m, 6H), 3.78 (s, 6H),
3.62 (dd, 2H, J=12.1,3.60Hz), 3.43 (dd, 2H, J=12.0,4.72Hz), 2.67-2.57 (m, 2H), 2.26 (p,
2H, J=5.90Hz), 1.99-1.89 (m, 2H);13C NMR (100MHz, DMSO-d6) δ 169.1,164.0,149.9,144.5,
129.8,117.1,111.3,104.5,54.8,54.4,53.1,33.5,27.5;IR (ATR, pure) 3438,1680,1654,
1610,1605,1516,1490,1434,1379,1263,1234,1216,1177,1156,1115,1089,1038,1018,
952,870cm-1;MS(ES+) m/z (relative intensity) 619 ([M+Na]+., 10), 597 ([M+H]+., 52), 445 (12), 326
(11);HRMS[M+H]+.Theoretical C29H32N4O10M/z 597.2191 has found (ES+)m/z597.2205。
Method B: by suspension of the 10%Pd/C (7.5g, 10%w/w) in DMF (40mL) be added to nitro ester 6 (75g,
104mmol) in the solution in DMF (360mL).It is more than 8 hours that the suspension is hydrogenated in Parr hydrogenation apparatus.Hydrogen absorption stops
After only, reaction process is monitored by LC/MS.Solid Pd/C is removed by filtration, and by under vacuum (being lower than 10mbar)
Filtrate is concentrated in 40 DEG C of rotary evaporations, to provide comprising trace DMF and remain the dark oil of charcoal.At 40 DEG C, in water-bath, (rotation is steamed
Hair bath) on residue absorbed into (digestion, digest) in EtOH (500mL), and the suspension being obtained by filtration by diatomite
It liquid and is washed with ethyl alcohol (500mL), to generate limpid filtrate.Hydrazine hydrate (10mL, 321mmol) is added in solution
And the reaction mixture is heated under reflux.It after 20 minutes, observes that white precipitate is formed, and allows to flow back and continue in addition
30 minutes.Allow for mixture to be cooled to room temperature, and precipitating is recovered by filtration, with diethyl ether (the 2:1 volume ratio of precipitating)
Washing and the drying in vacuum desiccator, to provide 7 (50g, 81%).The analysis data of method B: the analysis obtained with method A
Data it is identical (optical activity,1H NMR, LC/MS and TLC).
(f) 1,1 '-[[(propane -1,3- diyl) two oxygroups] bis- (11aS, 2R) -2- (t-butyldimethylsilyloxies
Base) -7- methoxyl group -1,2,3,10,11,11a- hexahydro -5H- pyrrolo- [2,1-c] [1,4]-benzodiazepine- 5,11- two
Ketone] (8)
TBSCl (27.6g, 182.9mmol) and imidazoles (29.9g, 438.8mmol) are added under 0 DEG C (ice/acetone)
Four lactams 7 (21.8g, 36.6mmol) are in the turbid solution in anhydrous DMF (400mL).Allow to stir in a nitrogen atmosphere
Mixture 3 hours, which passed through LC/MS (3.90min (ES+) m/z (relative intensity) 825 ([M+H] later+., 100) and judgement
Confirmation reaction is completed.Reaction mixture is poured on ice (~1.75L), and allows it to be warming up to room temperature under stiring.Pass through
The white precipitate that vacuum filter is collected, uses H2O, diethyl ether washs, and dry in vacuum desiccator, pure to provide
8 (30.1g, 99%).[α]23 D=+234 ° of (c=0.41, CHCl3);1H NMR (400MHz, CDCl3) δ 8.65 (s, 2H, NH),
7.44 (s, 2H), 6.54 (s, 2H), 4.50 (p, 2H, J=5.38Hz), 4.21-4.10 (m, 6H), 3.87 (s, 6H), 3.73-
3.63 (m, 4H), 2.85-2.79 (m, 2H), 2.36-2.29 (m, 2H), 2.07-1.99 (m, 2H), 0.86 (s, 18H), 0.08
(s, 12H);13C NMR (100MHz, CDCl3) δ 170.4,165.7,151.4,146.6,129.7,118.9,112.8,105.3,
69.2,65.4,56.3,55.7,54.2,35.2,28.7,25.7,18.0, -4.82 and -4.86;IR (ATR, CHCl3) 3235,
2955,2926,2855,1698,1695,1603,1518,1491,1446,1380,1356,1251,1220,1120,1099,
1033cm-1;MS(ES+) m/z (relative intensity) 825 ([M+H]+ ., 62), 721 (14), 440 (38);HRMS[M+H]+.It is theoretical
C41H60N4O10Si2M/z 825.3921 has found (ES+)m/z825.3948。
(g) 1,1 '-[[(propane -1,3- diyl) two oxygroups] bis- [(11aS, 2R) -2- (t-butyldimethylsilyloxies
Base) -7- methoxyl group -10- ((2- (trimethyl silyl) ethyoxyl) methyl) -1,2,3,10,11,11a- hexahydro -5H- pyrroles
And [2,1-c] [1,4]-benzodiazepine5,11- diketone] (9)
Under -30 DEG C (dry ice/ethylene glycol), in a nitrogen atmosphere by n-BuLi (the 1.6M solution of the 68.3mL in hexane,
It 109mmol) is added dropwise to four lactams 8 (30.08g, 36.4mmol) in the stirred suspension in anhydrous THF (600mL).
Reaction mixture is stirred for 1 hours at such a temperature (being reddish orange now) for permission, at this point, SEMCl is added dropwise
The solution of (19.3mL, 18.2g, 109mmol) in anhydrous THF (120mL).Reaction mixture is allowed to be to slowly warm up to room
Temperature, and stir 16 hours in a nitrogen atmosphere.Pass through TLC (EtOAc) and LC/MS (4.77min (ES+) m/z (relative intensity)
1085([M+H]+., 100) and judgement, it reacts and is considered as completion.THF is removed by evaporating under vacuum, and obtained residual is dissolved
In EtOAc (750mL), H is used2O (250mL), salt water (250mL) washing, dry (MgSO4), filtered under vacuum and evaporation, with
It is provided as four lactams, the 9 (max of the thick N10-SEM- protection of oilym39.5g, 100%).Make product carry out next step and
Without purifying.[α]23 D=+163 ° of (c=0.41, CHCl3);1H NMR (400MHz, CDCl3) δ 7.33 (s, 2H), 7.22 (s,
2H), 5.47 (d, 2H, J=9.98Hz), 4.68 (d, 2H, J=9.99Hz), 4.57 (p, 2H, J=5.77Hz), 4.29-4.19
(m, 6H), 3.89 (s, 6H), 3.79-3.51 (m, 8H), 2.87-2.81 (m, 2H), 2.41 (p, 2H, J=5.81Hz), 2.03-
1.90 (m, 2H), 1.02-0.81 (m, 22H), 0.09 (s, 12H), 0.01 (s, 18H);13C NMR (100MHz, CDCl3)δ
170.0,165.7,151.2,147.5,133.8,121.8,111.6,106.9,78.1,69.6,67.1,65.5,56.6,
56.3,53.7,35.6,30.0,25.8,18.4,18.1, -1.24, -4.73;IR (ATR, CHCl3) 2951,1685,1640,
1606,1517,1462,1433,1360,1247,1127,1065cm-1;MS(ES+) m/z (relative intensity) 1113 ([M+Na]+ .,
48), 1085 ([M+H]+., 100) and 1009 (5), 813 (6);HRMS[M+H]+.Theoretical C53H88N4O12Si4M/z 1085.5548, hair
Existing (ES+)m/z 1085.5542。
(h) 1,1 '-[[(propane -1,3- diyl) two oxygroups] bis- [(11aS, 2R) -2- hydroxyl -7- methoxyl group -10- ((2-
(trimethyl silyl) ethyoxyl) methyl) -1,2,3,10,11,11a- hexahydro -5H- pyrrolo- [2,1-c] [1,4] benzo two
Azepine5,11- diketone]] (10)
TBAF (150mL, 1.0M solution in THF, 150mmol) is added to thick double-silyl ester 9 at room temperature
[84.0g(maxm56.8g), 52.4mmol] in the solution of the stirring in THF (800mL).After stirring 1 hour, pass through TLC
(5:5v/v CHCl3/ MeOH) analysis reaction mixture display reaction completion.At room temperature, it is removed under reduced pressure by evaporation
THF, and obtained residual is dissolved in EtOAc (500mL) and uses NH4Cl (300mL) washing.It is washed with salt water (60mL)
It washs, dry (MgSO4), filtering and the organic layer for evaporating combination under reduced pressure, to provide crude product.It is pure by flash chromatography
Change (gradient eluent: 100%CHCl3To 96:4v/v CHCl3/ MeOH) it is produced as the four pure lactams 10 of white foam
(36.0g, 79%).LC/MS3.33min (ES+) m/z (relative intensity) 879 ([M+Na]+., 100), 857 ([M+H]+., 40);
[α]23 D=+202 ° of (c=0.34, CHCl3);1H NMR (400MHz, CDCl3) δ 7.28 (s, 2H), 7.20 (s, 2H), 5.44 (d,
2H, J=10.0Hz), 4.72 (d, 2H, J=10.0Hz), 4.61-4.58 (m, 2H), 4.25 (t, 4H, J=5.83Hz), 4.20-
4.16 (m, 2H), 3.91-3.85 (m, 8H), 3.77-3.54 (m, 6H), 3.01 (br s, 2H, OH), 2.96-2.90 (m, 2H),
2.38 (p, 2H, J=5.77Hz), 2.11-2.05 (m, 2H), 1.00-0.91 (m, 4H), 0.00 (s, 18H);13C NMR
(100MHz, CDCl3) δ 169.5,165.9,151.3,147.4,133.7,121.5,111.6,106.9,79.4,69.3,
67.2,65.2,56.5,56.2,54.1,35.2,29.1,18.4, -1.23;IR (ATR, CHCl3) 2956,1684,1625,
1604,1518,1464,1434,1361,1238,1058,1021cm-1;MS(ES+) m/z (relative intensity) 885 ([M+29]+.,
70), 857 ([M+H]+., 100), 711 (8), 448 (17);HRMS[M+H]+.Theoretical C41H60N4O12Si2M/z 857.3819, hair
Existing (ES+)m/z 857.3826。
(i) 1,1 '-[[(propane -1,3- diyl) two oxygroups] bis- [(11aS) -7- methoxyl group -2- oxo -10- ((2- (three
Methyl silicane base) ethyoxyl) methyl) -1,2,3,10,11,11a- hexahydro -5H- pyrrolo- [2,1-c] [1,4] benzodiazepine *
It is miscellaneous5,11- diketone]] (11)
At Ar, by glycol 10 (25.6g, 30mmol, 1 equivalent), NaOAc (6.9g, 84mmol, 2.8 equivalent) and TEMPO
(188mg, 1.2mmol, 0.04 equivalent) is dissolved in DCM (326mL).- 8 DEG C (internal temperatures) are cooled to, and 15
By batch addition TCCA (9.7g, 42mmol, 1.4 equivalent) in minute.After 30 minutes, TLC (EtOAc) and LC/MS [3.60min.
(ES+) m/z (relative intensity) 854.21 ([M+H]+., 40), (ES-) m/z (relative intensity) 887.07 ([M-H+Cl]-., 10)]
Indicator Reaction is completed.It adds cold DCM (200mL), and in sodium bicarbonate/hypo solution (1:1v/v with saturation;
200mL × 2) washing before, pass through diatomite filter plates mixture.Use MgSO4Organic layer is dried, filtered, and vacuum is removed
Solvent is removed, to generate yellow/orange sponge (25.4g, 99%).LC/MS [3.60min. (ES+) m/z (relative intensity)
854.21([M+H]+., 40);[α]20 D=+291 ° of (c=0.26, CHCl3);1H NMR (400MHz, CDCl3) δ 7.32 (s, 2H),
7.25 (s, 2H), 5.50 (d, 2H, J=10.1z), 4.75 (d, 2H, J=10.1Hz), 4.60 (dd, 2H, J=9.85,
3.07Hz), 4.31-4.18 (m, 6H), 3.89-3.84 (m, 8H), 3.78-3.62 (m, 4H), 3.55 (dd, 2H, J=19.2,
2.85Hz), 2.76 (dd, 2H, J=19.2,9.90Hz), 2.42 (p, 2H, J=5.77z), 0.98-0.91 (m, 4H), 0.00
(s, 18H);13C NMR (100MHz, CDCl3) δ 206.8,168.8,165.9,151.8,148.0,133.9,120.9,111.6,
107.2,78.2,67.3,65.6,56.3,54.9,52.4,37.4,29.0,18.4, -1.24;IR (ATR, CHCl3) 2957,
1763,1685,1644,1606,1516,1457,1434,1360,1247,1209,1098,1066,1023cm-1;MS(ES+)m/
Z (relative intensity) 881 ([M+29]+., 38), 853 ([M+H]+., 100), 707 (8), 542 (12);HRMS[M+H]+.It is theoretical
C41H56N4O12Si2M/z 853.3506 has found (ES+)m/z 853.3502。
(j) 1,1 '-[[(propane -1,3- diyl) two oxygroups] bis- (11aS) -7- methoxyl group -2- [[(trifluoromethyl) sulphonyl
Base] oxygroup] -10- ((2- (trimethyl silyl) ethyoxyl) methyl) -1,10,11,11a- tetrahydro -5H- pyrrolo- [2,1-
C] [1,4]-benzodiazepine5,11- diketone (12)
Under -45 DEG C (dry ice/acetonitrile), in a nitrogen atmosphere, with 1 part by anhydrous 2,6- lutidines (5.15mL,
4.74g, 44.2mmol) injection diketone 11 (6.08g, 7.1mmol) being vigorously stirred in solution in anhydrous DCM (180mL).Fastly
Speed injects the anhydrous trifluoromethanesulfanhydride anhydride (7.2mL, 12.08g, 42.8mmol) taken out from the bottle of fresh opening dropwise, together
When maintain the temperature at -40 DEG C or less.Allow that reaction mixture is stirred for 1 hours at -45 DEG C, at this point, TLC (50/50v/v just oneself
Alkane/EtOAc) show that starting material is completely depleted.Cold reaction mixture is diluted with DCM (200mL) immediately, and is acutely shaken
It shakes, with water (1 × 100mL), 5% citric acid solution (1 × 200mL), the NaHCO being saturated3(200mL), salt water (100mL) are washed
It washs, and dry (MgSO4).Under reduced pressure filtering and evaporation provide crude product, by flash column chromatography (gradient elution: 90:
10v/v n-hexane/EtOAc to 70:30v/v n-hexane/EtOAc) crude product is purified to be provided as the diene alcohol of yellow colored foam
Triflate (salt) (5.5g, 70%).LC/MS 4.32min (ES+) m/z (relative intensity) 1139 ([M+Na]+., 20);
[α]24 D=+271 ° of (c=0.18, CHCl3);1H NMR (400MHz, CDCl3) δ 7.33 (s, 2H), 7.26 (s, 2H), 7.14 (t,
2H, J=1.97Hz), 5.51 (d, 2H, J=10.1Hz), 4.76 (d, 2H, J=10.1Hz), 4.62 (dd, 2H, J=11.0,
3.69Hz), 4.32-4.23 (m, 4H), 3.94-3.90 (m, 8H), 3.81-3.64 (m, 4H), 3.16 (ddd, 2H, J=16.3,
11.0,2.36Hz), 2.43 (p, 2H, J=5.85Hz), 1.23-0.92 (m, 4H), 0.02 (s, 18H);13C NMR (100MHz,
CDCl3) δ 167.1,162.7,151.9,148.0,138.4,133.6,120.2,118.8,111.9,107.4,78.6,67.5,
65.6,56.7,56.3,30.8,29.0,18.4, -1.25;IR (ATR, CHCl3) 2958,1690,1646,1605,1517,
1456,1428,1360,1327,1207,1136,1096,1060,1022,938,913cm-1;MS(ES+) m/z (relative intensity
1144([M+28]+., 100), 1117 ([M+H]+., 48), 1041 (40), 578 (8);HRMS[M+H]+.It is theoretical
C43H54N4O16Si2S2F6M/z 1117.2491 has found (ES+)m/z 1117.2465。
Embodiment 1
(a) (S)-trifluoromethanesulfonic acid 8- (3- (((S) -2- (4- aminophenyl) -7- methoxyl group -5,11- dioxo -10-
((2- (trimethyl silyl) ethyoxyl) methyl) -5,10,11,11a- tetrahydro -1H- benzo [e] pyrrolo- [1,2-a] [1,
4] diaza8- yl) oxygroup) propoxyl group) -7- methoxyl group -5,11- dioxo -10- ((2- (trimethyl silyl) second
Oxygroup) methyl) -5,10,11,11a- tetrahydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza2- base ester (13)
By Pd (PPh3)4(116.9mg, 0.101mmol) be added to double-enol triflate 12 (5.65g,
5.06mmol), 4- aminophenyl boronic acid pinacol ester (1g, 4.56mmol), Na2CO3(2.46g, 23.2mmol), MeOH
In the stirring mixture of (37mL), toluene (74mL) and water (37mL).Permission is stirred to react mixing at 30 DEG C in a nitrogen atmosphere
Object 24 hours, after the time, all borates were depleted.Then before taking out residual from EtOAc (150mL), evaporation
Reaction mixture uses H to drying2O (2 × 100mL), salt water (150mL) washing, dry (MgSO4), it filters under reduced pressure
And evaporation, to provide crude product.Pass through purified by flash chromatography (gradient elution: 80:20v/v hexane/EtOAc to 60:40v/v
Hexane/EtOAc) provide product 13 (2.4g, 45%) for weak yellow foam.LC/MS 4.02min (ES+) m/z is (relatively strong
Degree) 1060.21 ([M+H]+., 100);1H-NMR:(CDCl3, 400MHz) δ 7.40 (s, 1H), 7.33 (s, 1H), 7.27 (bs,
3H), 7.24 (d, 2H, J=8.5Hz), 7.15 (t, 1H, J=2.0Hz), 6.66 (d, 2H, J=8.5Hz), 5.52 (d, 2H, J=
10.0Hz), 4.77 (d, 1H, J=10.0Hz), 4.76 (d, 1H, J=10.0Hz), 4.62 (dd, 1H, J=3.7,11.0Hz),
4.58 (dd, 1H, J=3.4,10.6Hz), 4.29 (t, 4H, J=5.6Hz), 4.00-3.85 (m, 8H), 3.80-3.60 (m,
4H), 3.16 (ddd, 1H, J=2.4,11.0,16.3Hz), 3.11 (ddd, 1H, J=2.2,10.5,16.1Hz), 2.43 (p,
2H, J=5.9Hz), 1.1-0.9 (m, 4H), 0.2 (s, 18H).13C-NMR:(CDCl3, 100MHz) and δ 169.8,168.3,
164.0,162.7,153.3,152.6,149.28,149.0,147.6,139.6,134.8,134.5,127.9,127.5,
125.1,123.21,121.5,120.5,120.1,116.4,113.2,108.7,79.8,79.6,68.7,68.5,67.0,
66.8,58.8,58.0,57.6,32.8,32.0,30.3,19.7,0.25.
(b) (S) -2- (4- aminophenyl) -8- (3- (((S) -2- cyclopropyl -7- methoxyl group -5,11- dioxo -10-
((2- (trimethyl silyl) ethyoxyl) methyl) -5,10,11,11a- tetrahydro -1H- benzo [e] pyrrolo- [1,2-a] [1,
4] diaza8- yl) oxygroup) propoxyl group) -7- methoxyl group -10- ((2- (trimethyl silyl) ethyoxyl) methyl) -1H-
Benzo [e] pyrrolo- [1,2-a] [1,4] diaza5,11 (10H, 11aH)-diketone (14)
Under an argon atmosphere, by triphenylarsine (0.24g, 0.8mmol), silver oxide (I) (1.02g, 4.4mmol), cyclopropyl
Ylboronic acid (0.47g, 5.5mmol) and starting material 13 (1.15g, 1.1mmol) are dissolved in dioxane (30mL).With pestle and
Mortar grinder tripotassium phosphate (2.8g, 13.2mmol), and be quickly added in reaction mixture.Reaction mixture is emptied,
And with argon cleaning 3 times, and it is heated to 71 DEG C.Bis- (chlorination benzonitrile) palladiums (II) (84mg, 0.22mmol) are added, and are emptied
Reaction vessel and with argon cleaning 3 times.After ten minutes, extract a small amount of sample for by TLC (80:20v/v ethyl acetate/oneself
Alkane) and LC/MS analysis.After 30 minutes, reaction carries out (LC/MS analysis instruction starting material is totally consumed) completely, Yi Jitong
The filter plates reactant crossing diatomite and being washed with ethyl acetate (400mL).With water (2x200mL) and salt water (2x200mL)
Wash filtrate.Use MgSO4Dry organic layer, vacuum filter remove solvent.Pass through silica gel column chromatography (30:70v/v hexane/acetic acid
Ethyl ester) purify the product 14 (0.66g, 63%) provided as orange/yellow solid.Method 1, LC/MS (3.85min (ES+)m/
Z (relative intensity) 952.17 ([M+H]+, 100).1H NMR (400MHz, CDCl3) δ 7.36 (d, 2H, J=8.4Hz), 7.30 (s,
1H), 7.25-7.19 (m, 4H), 6.68 (s, 1H), 6.62 (d, 2H, J=8.4Hz), 5.49 (dd, 2H, J=5.6,10.0Hz),
4.73 (app.t, 2H, J=10.8Hz), 4.54 (dd, 1H, J=3.2,10.4Hz), 4.40 (dd, 1H, J=3.2,10.4Hz),
4.29-4.23 (m, 4H), 3.91-3.85 (m, 7H), 3.80-3.71 (m, 2H), 3.70-3.61 (m, 2H), 3.38-3.32 (m,
1H), 3.12-3.01 (m, 1H), 2.50-2.69 (m, 1H), 2.40 (q, 2H, J=5.6Hz), 1.50-1.43 (m, 1H), 0.99-
0.71 (m, 6H), 0.54-0.59 (m, 2H), 0.00 (s, 18H) ppm.
(c) (S) -2- (4- aminophenyl) -8- (3- (((S) -2- cyclopropyl -7- methoxyl group -5- oxo -5,11a- dihydro -
1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza8- yl) oxygroup) propoxyl group) -7- methoxyl group -1H- benzo [e] pyrrole
Cough up simultaneously [1,2-a] [1,4] diaza5 (11aH) -one (15)
Under an argon atmosphere, the bis- lactams 14 (0.66g, 0.69mmol) of SEM are dissolved in THF (23mL) and are cooled down
To -78 DEG C.It is added dropwise in 5 minutesSolution (1M in 1.7mL, THF) while monitoring temperature.20 points
Zhong Hou extracts a small amount of sample, and is washed with water and analyzes for LC/MS.Addition water (50mL) simultaneously removes cryostat.It extracts organic
Layer, and washed with salt water (60mL).Use CH2Cl2The water layer that/MeOH (90/10v/v) (2 × 50mL) washing combines.Use MgSO4It is dry
The organic layer of constipation conjunction, filtering, and solvent is removed in vacuum.Crude product is dissolved in MeOH (48mL), CH2Cl2(18mL) and water
In (6mL), and enough silica gel is added to form dense suspension.After stirring 5 days, is filtered and suspended by sinter funnel
Liquid, and use CH2Cl2/ MeOH (9:1) (~200mL) washing is eluted completely until product.It has been washed with salt water (2x70mL)
Machine layer, uses MgSO4Dry, vacuum filter removes solvent.Pass through silica gel chromatography (100%CHCl3To 96:4v/v
CHCl3/ MeOH) provide product 15 (302mg, 66%) for yellow solid.Method 1, LC/MS (2.42min (ES+) m/z (phase
To intensity) 660.74 ([M+H]+, 30).1H NMR (400MHz, CDCl3) δ 7.86 (d, 1H, J=3.6Hz), 7.78 (d, 1H, J
=3.6Hz), 7.58-7.44 (m, 3H), 7.34-7.20 (m, 3H), 6.88-6.66 (m, 4H), 4.35-4.15 (m, 6H),
3.95-3.75 (m, 7H), 3.39-3.22 (m, 1H), 3.14-3.04 (m, 1H), 2.93-2.85 (m, 1H), 2.46-2.36 (m,
2H), 1.49-1.41 (m, 1H), 0.80-0.72 (m, 2H), 0.58-0.51 (app.s, 2H) ppm.
(d) ((2S) -1- (((2S) -1- ((4- (8- (3- ((2- cyclopropyl -7- methoxyl group -5- oxo -5,11a- dihydro -
1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza8- yl) oxygroup) propoxyl group) -7- methoxyl group -5- oxo -5,11a-
Dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza2- yl) phenyl) amino) -1- oxopropan -2- base) ammonia
Base)-3- methyl-1-oxo-butanes-2- base) allyl carbamate (16)
In the degassing round-bottomed flask filled with argon gas, by HO-Ala-Val-alloc (149.6mg, 0.549mmol) and
EEDQ (135.8mg, 0.549mmol) is dissolved in dry CH2Cl2In the 9:1 mixture of/MeOH (5mL).It is wrapped up and being burnt with aluminium foil
Bottle, and before adding starting material 15 (302mg, 0.457mmol), allow to be stirred at room temperature reaction mixture 1 hour.
Before removing volatile matter by rotary evaporation under reduced pressure, reaction mixture other 40 hours are stirred at room temperature (after reaction
It is LC/MS, RT starting material 2.32min, (ES+660.29([M+H]+., 100)).Pass through silica gel chromatographic column (100%CHCl3Extremely
90/10v/v CHCl3/ MeOH) direct purification crude product, pure products (16) are provided with 42% yield (174mg).Method 2, LC/
MS (2.70min (ES+) m/z (relative intensity) 914.73 ([M+H]+, 60), 660.43 (60), 184.31 (100).
(e) (2S) -2- amino-N- ((2S) -1- ((4- (8- (3- ((2- cyclopropyl -7- methoxyl group -5- oxo -5,11a-
Dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza8- yl) oxygroup) propoxyl group) -7- methoxyl group -5- oxo -
5,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza2- yl) phenyl) amino) -1- oxopropan -2-
Base) -3- methylbutyryl amine (17)
In the round-bottomed flask filled with argon gas, before adding pyrrolidines (41 μ L, 0.21mmol), by starting material 16
(170mg, 0.185mmol) is dissolved in dry CH2Cl2In (5mL).In addition Pd (PPh3)4(14mg, 0.084mmol) it
Before, flask is purged/refilled three times with argon gas, and repeat flushing operation.After 1 hour, observe that starting material is consumed completely
To the greatest extent (reaction after be LC/MS), and by Et2O (50mL), which is added to reaction mixture, to be allowed to stir until product is analysed from solution
Out.Filter solid is crossed by sinter funnel, and uses Et2O washes twice (2x25mL).Flask, and consolidating separation are collected in displacement
Body is dissolved in CHCl3In (100mL or until all products all pass through sinter funnel).Then it is removed under reduced pressure by rotary evaporation
Volatile matter is removed to provide crude product 17, (168mg) will be used directly in a subsequent step.LC/MS method 2
(2.70min (ES+) m/z (relative intensity) 830.27 ([M+H]+, 50), 660.13 (80), 171.15 (100)).
(f) N- ((R) -1- (((S) -1- ((4- ((S) -8- (3- ((oxo -5 (S) -2- cyclopropyl -7- methoxyl group -5-,
11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza8- yl) oxygroup) propoxyl group) -7- methoxyl group -5- oxygen
Generation -5,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza2- yl) phenyl) amino) -1- oxo third
Alkane-2- base) amino)-3- methyl-1-oxo-butanes-2- base)-1- (3- (2,5- dioxo-2,5- dihydro-1H- pyrroles-1- base)
Third amino) eight oxa- heptacosane -27- amide (18) of -3,6,9,12,15,18,21,24-.
In the round-bottomed flask for being purged and being filled with argon gas, by starting material 17 (154mg, 0.185mmol) and
EDCI.HCl (110mg, 0.185mmol) is dissolved in dry CH2Cl2In (5mL).In addition PEG8Maleimide
Before (35.6mg, 0.185mmol), mixture is stirred at room temperature 1 hour, and is stirred to react mixture other 16 hours
(or until reaction completion, being monitored by LC/MS).Use CH2Cl2(50mL) diluting reaction solution, and with MgSO4Before drying
Use H2O (50mL) and salt water (50mL) wash organic matter, filter and remove solvent by rotary evaporation under reduced pressure, thick to provide
Product.Silica gel column chromatography (100%CHCl3To 85/15v/v CHCl3/ MeOH) the desired product (135mg) of purifying generation, still
The unreacted PEG that (passing through LC/MS, 2.21min, method 2) has observed trace remaining8Maleimide.Automatic reverse phase silica gel
Chromatography (H2O/CH3CN) be successfully removed impurity (referring to the general information of condition), provide pure final product (18, starting
In the 37mg pure products of 110mg, 33%).Overall productivity=17%.Method 2, (2.58min (ES+) m/z is (relatively strong by LC/MS
Degree) 1404.03 ([M+H]+, 20), 702.63 (100)).1H NMR (400MHz, CDCl3) δ 7.91 (t, J=3.5Hz, 1H),
7.80 (d, J=4.0Hz, 1H), 7.75 (d, J=8.8Hz, 1H), 7.69 (d, J=8.7Hz, 1H), 7.54-7.50 (m, 2H),
7.45 (s, 1H), 7.39-7.31 (m, 2H), 6.87 (d, J=10.5Hz, 2H), 6.76 (s, 1H), 6.72-6.68 (m, 2H),
4.74-4.62 (m, 1H), 4.45-4.17 (m, 7H), 3.95 (s, 3H), 3.94 (s, 3H), 3.67-3.58 (m, 34H), 3.54
(m, 2H), 3.42 (dd, J=10.2,5.2Hz, 2H), 3.16-3.07 (m, 1H), 2.92 (dd, J=16.1,4.1Hz, 1H),
2.62-2.49 (m, 4H), 2.48-2.39 (m, 2H), 2.37-2.25 (m, 1H), 1.92 (s, 1H), 1.52-1.44 (m, 3H),
1.10-0.93 (m, 6H), 0.79 (dd, J=9.2,5.3Hz, 2H), 0.57 (dd, J=9.2,5.3Hz, 2H) are not observed
NH。
Embodiment 2
(a) (R) -2- ((R) -2- ((((9H- fluorenes -9- base) methoxyl group) carbonyl) amino) -3- methylbutylamino) propionic acid
(20b)
By HO-Ala-Val-H 20a (350mg, 1.86mmol) and Na2CO3(493mg, 4.65mmol) is dissolved in distillation
H2In O (15mL), and before addition dioxane (15mL) mixture is cooled to 0 DEG C (part that amino-acid salt occurs is heavy
It forms sediment).With vigorous stirring, through 10 minutes, Fmoc-Cl (504mg, 1.95mmol) is added dropwise in dioxane (15mL)
Solution.Before removing ice bath, 0 DEG C the mixture stirred to get 2 hours, then persistently stir 16 hours.Lead under reduced pressure
Rotation evaporation of solvent is crossed, and residue is dissolved in water (150mL).PH is adjusted to 2 from 9 with 1N HCl, is then used
EtOAc (3x100mL) aqueous layer extracted.The organic matter merged is washed with salt water (100mL), uses MgSO4It dries, filters and is depressurizing
Volatile matter is removed to provide pure HO-Ala-Val-Fmoc 20b (746mg, 97% yield) by rotary evaporation down.LC/
MS2.85min (ES+) m/z (relative intensity) 410.60;1H-NMR (400MHz, CDCl3) δ 7.79 (d, J=7.77Hz, 2H),
7.60 (d, J=7.77Hz, 2H), 7.43 (d, J=7.5Hz, 2H), 7.34 (d, J=7.5Hz, 2H), 6.30 (bs, 1H), 5.30
(bs, 1H), 4.71-7.56 (m, 1H), 4.54-4.36 (m, 2H), 4.08-3.91 (m, 1H), 2.21-2.07 (m, 1H), 1.50
(d, J=7.1Hz, 3H), 1.06-0.90 (m, 6H).
(b) ((S)-3- methyl-1-oxo-1- (((S)-1- oxo-1- ((4- (4,4,5,5- tetramethyl-1,3,2- dioxy
Miscellaneous borine -2- base) phenyl) amino) propane -2- base) amino) butane -2- base) carbamic acid (9H- fluorenes -9- base) methyl ester
((9H-fluoren-9-yl)methyl((S)-3-methyl-1-oxo-1-(((S)-1-oxo-1-((4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)amino)propan-2-yl)amino)butan-2-
yl)carbamate)(20)
At room temperature, 4- aminophenyl boronic acid pinacol ester (146.9mg, 0.67mmol) is added to and has previously stirred 30
Minute the flask with argon cleaning in HO-Ala-Val-Fmoc 20b (330mg, 0.8mmol), DCC (166mg,
0.8mmol) and DMAP (5mg, catalyst) is in the solution in anhydrous DCM (8mL).Then it is mixed to allow to be stirred at room temperature reaction
Object is closed to stay overnight.Along with LCMS and TLC after reaction.Use CH2Cl2(50mL) diluted reaction mixture, and with MgSO4Drying
Before use H2O and salt water washing organic matter filter under reduced pressure and remove solvent by rotary evaporation.Crude product drying is supported on
On silica gel chromatographic column (hexane/EtOAc, 6:4), and it is separated into 88% yield (360mg) pure products 20 of white solid.
(c) trifluoromethanesulfonic acid 8- (3- ((2- (4- ((S) -2- ((S) -2- ((((9H- fluorenes -9- base) methoxyl group) carbonyl) ammonia
Base) -3- methylbutylamino) the third amino) phenyl) -7- methoxyl group -5,11- dioxo -10- ((2- (trimethyl silyl) second
Oxygroup) methyl) -5,10,11,11a- tetrahydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza8- yl) oxygroup) third
Oxygroup) -7- methoxyl group -5,11- dioxo -10- ((2- (trimethyl silyl) ethyoxyl) methyl) -5,10,11,11a- four
Hydrogen -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza2- base ester (21)
It will double-triflate 12 (2.03g, 1.81mmol), pinacol borate (1g, 1.63mmol) and Na2CO3
(881mg, 8.31mmol) is dissolved in toluene/MeOH/H2In the mixture of O (2:1:1,40mL).Adding four (triphenylphosphines)
Before palladium (0) (41mg, 0.035mmol), is purged with argon gas and fill reaction flask, and extremely by reaction mixture heated overnight
30℃.Solvent is removed under reduced pressure, and residual is extracted in H2It is extracted in O (100mL) and with EtOAc (3x100mL).With
Salt water (100mL) washs combined organic matter, uses MgSO4It dries, filters and passes through rotary evaporation under reduced pressure and remove volatile matter.
By silica gel chromatographic column (hexane/EtOAc, 8:2to 25:75) purification of crude product to provide pure the 21 of 33% yield (885mg).
LC/MS 3.85min (ES+) m/z (relative intensity) 1452.90;1H NMR (400MHz, CDCl3) δ 7.78-7.16 (m, 17H),
7.13 (s, 1H), 6.51-6.24 (m, 1H), 5.51 (dd, J=10.0,5.1Hz, 2H), 5.36-5.11 (m, 1H), 4.74 (dd,
J=10.1,4.4Hz, 2H), 4.70-4.53 (m, 2H), 4.47 (d, J=6.4Hz, 1H), 4.37 (d, J=7.2Hz, 1H),
4.27 (m, 4H), 4.20-4.14 (m, 1H), 3.90 (s, 3H), 3.89 (s, 3H), 3.77 (ddd, J=16.7,9.0,6.4Hz,
3H), 3.71-3.61 (m, 2H), 3.24-2.91 (m, 3H), 2.55-2.33 (m, 2H), 2.22-2.07 (m, 1H), 1.52-1.37
(m, 3H), 1.04-0.86 (m, 10H), 0.00 (s, 18H).
(d) ((2S) -1- (((2S) -1- ((4- (8- (3- ((2- cyclopropyl -7- methoxyl group -5,11- dioxo -10- ((2-
(trimethyl silyl) ethyoxyl) methyl) -5,10,11,11a- tetrahydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] two
Azepine8- yl) oxygroup) propoxyl group) -7- methoxyl group -5,11- dioxo -10- ((2- (trimethyl silyl) ethyoxyl)
Methyl -5,10,11,11a- tetrahydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza2- yl) phenyl) amino) -1-
Oxopropan-2- base) amino)-3- methyl-1-oxo-butanes-2- base) carbamic acid (9H- fluorenes-9- base) methyl ester (22)
((9H-fluoren-9-yl)methyl((2S)-1-(((2S)-1-((4-(8-(3-((2-cyclopropyl-7-methoxy-
5,11-dioxo-10-((2-(trimethylsilyl)ethoxy)methyl)-5,10,11,11a-tetrahydro-1H-
benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)propoxy)-7-methoxy-5,11-dioxo-
10-((2-(trimethylsilyl)ethoxy)methyl)-5,10,11,11a-tetrahydro-1H-benzo[e]
pyrrolo[1,2-a][1,4]diazepin-2-yl)phenyl)amino)-1-oxopropan-2-yl)amino)-3-
methyl-1-oxobutan-2-yl)carbamate)
Under an argon atmosphere, triphenylarsine (42mg, 0.137mmol) is added to PBD- triflate 21
(250mg, 0.172mmol), cyclopropylboronic acid (73.9mg, 0.86mmol), silver oxide (159mg, 0.688mmol) and tricresyl phosphate
Potassium (438mg, 2.06mmol) is in the mixture in dry dioxane (10mL).It is reacted 3 times, and added double with argon cleaning
(benzonitrile) palladium chloride (II) (13.2mg, 0.034mmol).Before it will react and be warming up to 75 DEG C, reacted 3 times with argon cleaning
More than, and stirring 10 minutes.By diatomite filter plates reaction mixture, then rinsed with ethyl acetate.Under reduced pressure
Solvent is removed by rotary evaporation.The residual made carries out flash column chromatography (silica gel;1% methanol/chloroform).It collects and merges
Pure part, and excessive eluent is removed to provide desired product 22 (132mg, 50% production by rotary evaporation under reduced pressure
Rate).LC/MS3.83min (ES+) m/z (relative intensity) 1345.91;1H NMR (400MHz, CDCl3) δ 7.88-7.14 (m,
17H), 6.69 (s, 1H), 6.45-6.25 (m, 1H), 5.57-5.41 (m, 2H), 5.34-5.14 (m, 1H), 4.78-4.67 (m,
2H), 4.62-4.55 (m, 1H), 4.50-4.45 (m, 2H), 4.51-4.44 (m, 1H), 4.31-4.21 (m, 4H), 4.16 (m,
1H), 3.92 (s, 3H), 3.86 (s, 3H), 3.82-3.71 (m, 2H), 3.66 (m, 3H), 3.40-3.28 (m, 1H), 3.07 (m,
1H), 2.70-2.57 (m, 1H), 2.47-2.36 (m, 2H), 2.15 (m, 1H), 1.51-1.40 (m, 3H), 1.03-0.87 (m,
11H), 0.77-0.71 (m, 2H), 0.60-0.54 (m, 2H), 0.00 (t, J=3.0Hz, 18H).
(e) ((2S) -1- (((2S) -1- ((4- (8- (3- ((2- cyclopropyl -7- methoxyl group -5- oxo -5,11a- dihydro -
1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza8- yl) oxygroup) propoxyl group) -7- methoxyl group -5- oxo -5,11a-
Dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza2- yl) phenyl) amino) -1- oxopropan -2- base) ammonia
Base)-3- methyl-1-oxo-butanes-2- base) carbamic acid (9H- fluorenes-9- base) methyl ester (23)
It under an argon atmosphere, will at -78 DEG C(0.5mL, the 1M in THF) is added dropwise to SEM
Double lactams 22 (265mg g, 0.19mmol) are in the solution in THF (10mL).Complete addition in 5 minutes to keep reacting
The internal temperature of mixture is constant.After twenty minutes, equal part reaction is quenched with water to analyze for LC/MS, it should be analysis shows that having reacted
At.Addition water (20mL) into reaction mixture and removes cryostat.Organic layer is extracted with EtOAc (3x30mL), and uses salt water
(50mL) washs combined organic matter, uses MgSO4It dries, filters and solvent is removed by rotary evaporation under reduced pressure.It will slightly produce
Object is dissolved in MeOH (12mL), CH2Cl2To form dense stirred suspension in (6mL) and water (2mL) and enough silica gel.
After 5 days, suspension is filtered by sinter funnel, and use CH2Cl2/ MeOH (9:1) (200mL) washing is washed completely until product
It is de-.Organic layer is washed with salt water (2x70mL), uses MgSO4It dries, filters and solvent is removed by rotary evaporation under reduced pressure.It is logical
Cross silica gel column chromatography (100%CHCl3To 96%CHCl3/ 4%MeOH) purifying provide product 23, be yellow solid (162mg,
78%).LC/MS 3.02min (ES+) m/z (relative intensity) 1052.37.
(f) (2S) -2- amino-N- ((2S) -1- ((4- (8- (3- ((2- cyclopropyl -7- methoxyl group -5- oxo -5,11a-
Dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza8- yl) oxygroup) propoxyl group) -7- methoxyl group -5- oxo -
5,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza2- yl) phenyl) amino) -1- oxopropan -2-
Base) -3- methylbutyryl amine (17)
Excessive addition piperidines (0.2mL, 2mmol) is to the bis- lactams 23 (76mg, 0.073mmol) of SEM- in DMF (1mL)
Solution in.Allow to be stirred at room temperature mixture 20 minutes, at this point, reaction is carried out to completion (monitoring by LC/MS).With
CH2Cl2(75mL) releases dilute reaction mixture, and uses H2O (3x75mL) washing organic phase is until completely remove piperidines.With
MgSO4Dry organic phase filters under reduced pressure and removes excessive solvent to provide crude product 17, directly under by rotary evaporation
It is used in one step.LC/MS 2.32min (ES+) m/z (relative intensity) 830.00.
(g) N- ((2S) -1- (((2S) -1- ((4- (8- (3- ((2- cyclopropyl -7- methoxyl group -5- oxo -5,11a- two
Hydrogen -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza8- yl) oxygroup) propoxyl group) oxo-5-7- methoxyl group-5-,
11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza2- yl) phenyl) amino) -1- oxopropan -2-
Base) amino)-3- methyl-1-oxo-butanes-2- base)-1- (3- (2,5- dioxo-2,5- dihydro-1H- pyrroles-1- base) third ammonia
Base) eight oxa- heptacosane -27- amide (18) of -3,6,9,12,15,18,21,24-.
Under an argon atmosphere, EDCI hydrochloride (14mg, 0.0732mmol) is added to maleimide-PEG8Acid
(43.4mg, 0.0732mmol) is in dry CH2Cl2In suspension in (5mL).Addition PBD 17 (60.7mg,
Before 0.0732mmol), mixture is stirred at room temperature 1 hour.Lasting stirring completes (usually 5 hours) until reaction.With
CH2Cl2Diluting reaction, and with MgSO4H is used before dry2O and salt water washing organic phase filter and pass through rotation under reduced pressure
Evaporation removes excessive solvent.By careful silica gel chromatograph (from 100%CHCl3Start to 9:1CHCl3/ MeOH is slowly eluted)
Purified product carries out reverse-phase chromatography then to remove unreacted maleimide-PEG8Acid.With 17.6% (21.8mg's)
Yield separation product 18.LC/MS 2.57min (ES+) m/z (relative intensity) 1405.30;1H NMR (400MHz, CDCl3)δ
7.91 (t, J=3.5Hz, 1H), 7.80 (d, J=4.0Hz, 1H), 7.75 (d, J=8.8Hz, 1H), 7.69 (d, J=8.7Hz,
1H), 7.54-7.50 (m, 2H), 7.45 (s, 1H), 7.39-7.31 (m, 2H), 6.87 (d, J=10.5Hz, 2H), 6.76 (s,
1H), 6.72-6.68 (m, 2H), 4.74-4.62 (m, 1H), 4.45-4.17 (m, 7H), 3.95 (s, 3H), 3.94 (s, 3H),
3.67-3.58 (m, 34H), 3.54 (m, 2H), 3.42 (dd, J=10.2,5.2Hz, 2H), 3.16-3.07 (m, 1H), 2.92
(dd, J=16.1,4.1Hz, 1H), 2.62-2.49 (m, 4H), 2.48-2.39 (m, 2H), 2.37-2.25 (m, 1H), 1.92 (s,
1H), 1.52-1.44 (m, 3H), 1.10-0.93 (m, 6H), 0.79 (dd, J=9.2,5.3Hz, 2H), 0.57 (dd, J=9.2,
5.3Hz, 2H), NH is not observed.
Embodiment 3
(a) trifluoromethanesulfonic acid (S) -7- methoxyl group -8- (3- (((S) -7- methoxyl group -2- (4- (4- methylpiperazine-1-yl)
Phenyl) -5,11- dioxo -10- ((2- (trimethyl silyl) ethyoxyl) methyl) -5,10,11,11a- tetrahydro -1H- pyrrole
Cough up simultaneously [2,1-c] [1,4] benzodiazepine8- yl) oxygroup) propoxyl group) -5,11- dioxo -10- ((2- (trimethyl first silicon
Alkyl) ethyoxyl) methyl) -5,10,11,11a- tetrahydro-1 H-pyrrolo simultaneously [2,1-a] [1,4] benzodiazepine2- base ester
(24)((S)-7-methoxy-8-(3-(((S)-7-methoxy-2-(4-(4-methylpiperazin-1-yl)phenyl)-
5,11-dioxo-10-((2-(trimethylsilyl)ethoxy)methyl)-5,10,11,11a-tetrahydro-1H-
pyrrolo[2,1-c][1,4]benzodiazepin-8-yl)oxy)propoxy)-5,11-dioxo-10-((2-
(trimethylsilyl)ethoxy)methyl)-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]
benzodiazepin-2-yl trifluoromethanesulfonate)
By Pd (PPh3)4(20.6mg, 0.018mmol) be added to double-enol triflate 12 (500mg,
0.44mmol), N methyl piperazine borate (100mg, 0.4mmol), Na2CO3(218mg, 2.05mmol), MeOH (2.5mL),
In the stirring mixture of toluene (5mL) and water (2.5mL).It is small that permission is stirred to react mixture 24 at 30 DEG C in a nitrogen atmosphere
When, after the time, all borates are depleted.Then before taking out residual in EtOAc (100mL), evaporation reaction mixing
Object uses H to drying2O (2 × 50mL), salt water (50mL) washing, dry (MgSO4), filter and evaporated under reduced pressure to mention
For crude product.Pass through purified by flash chromatography (gradient elution: 80:20v/v hexane/EtOAc to 60:40v/v hexane/EtOAc)
Product 24 is provided, is weak yellow foam (122.6mg, 25%).
LC/MS 3.15min (ES+) m/z (relative intensity) 1144 ([M+H]+, 20%).
(b) ((S) -1- (((S) -1- ((4- ((S) -7- methoxyl group -8- (3- (((S) -7- methoxyl group -2- (4- (4- methyl
Piperazine -1- base) phenyl) -5,11- dioxo -10- ((2- (trimethyl silyl) ethyoxyl) methyl) -5,10,11,11a-
Tetrahydro-1 H-pyrrolo simultaneously [2,1-c] [1,4] benzodiazepine8- yl) oxygroup) propoxyl group) -5,11- dioxo -10- ((2-
(trimethyl silyl) ethyoxyl) methyl) -5,10,11,11a- tetrahydro-1 H-pyrrolo simultaneously [2,1-a] [1,4] benzodiazepine2- yl) phenyl) amino) -1- oxopropan -2- base) amino) -3- methyl-oxo butane -2- base) carbamic acid (9H- fluorenes -
9- yl) methyl ester (25)
By PBD- triflate 24 (359mg, 0.314mmol), pinacol borate 20 (250mg, 0.408mmol)
Toluene/MeOH/H is dissolved in triethylamine (0.35mL, 2.51mmol)2In the mixture of O (2:1:1,3mL).In addition four (three
Phenylphosphine) before palladium (0) (21.7mg, 0.018mmol), with argon cleaning and microwave container is filled, and by reaction mixture
It is placed in 80 DEG C of microwave 10 minutes.Then, CH is added2Cl2(100mL), and with MgSO4Water is used before dry
(2x50mL) and salt water (50mL) wash organic matter, filter and remove volatile matter by rotary evaporation under reduced pressure.Pass through silica gel
Chromatographic column (CHCl3/ MeOH, 100% to 9:1) purification of crude product, to provide 25 pure (200mg, 43% yields).LC/MS
3.27min (ES+) m/z (relative intensity) 1478 ([M+H]+, 100%).
(c) ((S) -1- (((S) -1- ((4- ((S) -7- methoxyl group -8- (3- (((S) -7- methoxyl group -2- (4- (4- methyl
Piperazine -1- base) phenyl) -5- oxo -5,11a- dihydro -1H- pyrrolo- [2,1-c] [1,4] benzodiazepine8- yl) oxygen
Base) propoxyl group) -5- oxo -5,11a- dihydro -1H- pyrrolo- [2,1-a] [1,4] benzodiazepine2- yl) phenyl) ammonia
Base)-1- oxopropan-2- base) amino)-3- methyl-1-oxo-butanes-2- base) carbamic acid (9H- fluorenes-9- base) methyl ester
(26)
It under an argon atmosphere, will at -78 DEG CThe solution of (0.34mL, the 1M in THF) adds dropwise
The bis- lactams 25 (200mg g, 0.135mmol) of SEM- are added in the solution in THF (5mL).In 5 minutes complete addition with
Keep the internal temperature of reaction mixture constant.After twenty minutes, equal part reaction is quenched with water to analyze for LC/MS, the analysis is aobvious
Show that reaction is completed.Addition water (20mL) into reaction mixture and removes cryostat.With EtOAc (3x30mL) extract organic layer and
The organic matter merged is washed with salt water (50mL), uses MgSO4It dries, filters and solvent is removed by rotary evaporation under reduced pressure.
Crude product is dissolved in MeOH (6mL), CH2Cl2It is outstanding to form dense stirring in (3mL) and water (1mL) and enough silica gel
Supernatant liquid.After 5 days, suspension is filtered by sinter funnel, and use CH2Cl2/ MeOH (9:1) (100mL) is washed until product quilt
Elution completely.Organic layer is washed with salt water (2x50mL), uses MgSO4It dries, filters and is removed under reduced pressure by rotary evaporation
Solvent.Pass through silica gel column chromatography (100%CHCl3To 96%CHCl3/ 4%MeOH) purifying provides product 26, and it is yellow solid
(100mg, 63%).LC/MS 2.67min (ES+) m/z (relative intensity) 1186 ([M+H]+, 5%).
(d) (S) -2- amino-N- ((S) -1- ((4- ((R) -7- methoxyl group -8- (3- (((R) -7- methoxyl group -2- (4- (4-
Methylpiperazine-1-yl) phenyl) -5- oxo -5,11a- dihydro -1H- pyrrolo- [2,1-c] [1,4] benzodiazepine8- yl)
Oxygroup) propoxyl group) -5- oxo -5,11a- dihydro -1H- pyrrolo- [2,1-a] [1,4] benzodiazepine2- yl) phenyl) ammonia
Base) -1- oxopropan -2- base) -3- methylbutyryl amine (27)
Excessive piperidines (0.1mL, 1mmol) is added to PBD 26 (36.4mg, 0.03mmol) in DMF (0.9mL)
In solution.Allow to be stirred at room temperature mixture 20 minutes, at this point, reaction is carried out to completion (monitoring by LC/MS).With
CH2Cl2(50mL) releases dilute reaction mixture, and uses H2O (3x50mL) washing organic phase is until completely remove piperidines.With
MgSO4Dry organic phase filters under reduced pressure and removes excessive solvent to provide crude product 27, directly under by rotary evaporation
It is used in one step.LC/MS 2.20min (ES+) m/z (relative intensity) 964 ([M+H]+, 5%).
(e) 6- (2,5- dioxo -2,5- dihydro -1H- pyrroles -1- base)-N- ((S) -1- (((S) -1- ((4- ((S) -7-
Methoxyl group -8- (3- (((S) -7- methoxyl group -2- (4- (4- methylpiperazine-1-yl) phenyl) -5- oxo -5,11a- dihydro -1H-
Pyrrolo- [2,1-c] [1,4] benzodiazepine8- yl) oxygroup) propoxyl group) -5- oxo -5,11a- dihydro -1H- pyrrolo-
[2,1-a] [1,4] benzodiazepine2- yl) phenyl) amino)-1- oxopropan-2- base) amino)-3- methyl-1-oxo
Butane -2- base) caproamide (28)
Under an argon atmosphere, EDCI hydrochloride (4.7mg, 0.03mmol) is added to 6- maleimidohexanoic acid
(6.5mg, 0.03mmol) is in dry CH2Cl2In suspension in (3mL).Before addition PBD 27 (34mg, thick), in room temperature
Lower stirring mixture 1 hour.Lasting stirring completes (6 hours) until reaction.Use CH2Cl2Diluting reaction, and with MgSO4It is dry
H is used before2O and salt water washing organic phase filter and remove excessive solvent by rotary evaporation under reduced pressure.By careful
Silica gel chromatograph is (from 100%CHCl3Start to 9:1CHCl3/ MeOH is slowly eluted) purified product, carry out reverse-phase chromatography then to remove
Remove unreacted maleimide-PEG8Acid.Product 28 has been separated with 41% (14.6mg) yield on two steps.LC/MS
2.40min (ES+) m/z (relative intensity) 1157 ([M+H]+, 5%).
The alternative synthesis of embodiment 4- compound 25
By PBD- triflate 21 (469mg, 0.323mmol), pinacol borate (146.5mg, 0.484mmol)
And Na2CO3(157mg, 1.48mmol) is dissolved in toluene/MeOH/H2In the mixture of O (2:1:1,10mL).In addition four (three
Phenylphosphine) before palladium (0) (7.41mg, 0.0064mmol), reaction flask is purged with argon gas, and reaction mixture is heated to
30 DEG C overnight.Solvent is removed under reduced pressure, and residual is extracted in H2It is extracted in O (50mL) and with EtOAc (3x50mL).
The organic matter merged is washed with salt water (100mL), uses MgSO4It dries, filters and is removed under reduced pressure by rotary evaporation and volatilized
Object.Pass through silica gel column chromatography (CHCl3100% to CHCl3/ MeOH 95%:5%) purification of crude product, it is provided with 33% yield
25 pure (885mg).LC/MS 3.27min (ES+) m/z (relative intensity) 1478 ([M+H]+, 100%).
Embodiment 5
(a) (S) -2- (4- aminophenyl) -8- (3- (((S) -2- (benzo [d] [1,3] dioxole -5- base) -7-
Methoxyl group -5,11- dioxo -10- ((2- (trimethyl silyl) ethyoxyl) methyl) -5,10,11,11a- tetrahydro -1H- pyrrole
Cough up simultaneously [2,1-c] [1,4] benzodiazepine8- yl) oxygroup) propoxyl group) -7- methoxyl group -10- ((2- (trimethyl silyl
Base) ethyoxyl) methyl) -1H- pyrrolo- [2,1-c] [1,4] benzodiazepine5,11 (10H, 11aH)-diketone (29)
In a nitrogen atmosphere, by 3,4- (methylene-dioxy) phenylboric acid (356mg, 2.1mmol, 1.3 equivalent), TEA
(1.8mL, 12.9mmol, 8 equivalent) and triflate/aniline 13 (1.75g, 1.7mmol, 1 equivalent) are dissolved in ethyl alcohol
In the mixture of (7mL), toluene (13mL) and water (2mL).It empties reaction mixture and is adding four (triphenyl phasphine) palladiums (0)
(114mg, 0.1mmol, 0.06 equivalent) in the past, is rinsed 3 times with Ar.Flask is emptied again and is rinsed 3 times with Ar, and at 80 DEG C
It is heated 8 minutes in microwave, wherein being within 30 seconds pre- mixing time.TLC (80:20v/v ethyl acetate/hexane) analysis instruction starting
Material is totally consumed.It is washed with methylene chloride (50mL) diluted reaction mixture and with water (50mL).Use MgSO4Drying is organic
Layer, vacuum filter remove solvent.By silica gel column chromatography (60:40 to 20:80v/v hexane/ethyl acetate) purifying provide for
The product 29 (1.21g, 71%) of yellow solid.LC/MS(3.92min(ES+) m/z (relative intensity) 1032.44 ([M+H]+,
100)。
(b) (S) -2- (4- aminopropyl) -8- (3- (((S) -2- (benzo [d] [1,3] dioxole -5- base) -7-
Methoxyl group -5- oxo -5,11a- dihydro -1H- pyrrolo- [2,1-c] [1,4] benzodiazepine8- yl) oxygroup) propoxyl group)-
7- methoxyl group -1H- pyrrolo- [2,1-c] [1,4] benzodiazepine5 (11aH) -one (30)
Under an ar atmosphere, the bis- lactams 29 (0.25g, 0.24mmol, 1 equivalent) of SEM are dissolved in THF (8mL) and cold
But to -78 DEG C.It is added dropwise in 5 minutes(1M in 0.6mL, THF, 2.5 equivalents), while monitoring temperature
Degree.After twenty minutes, a small amount of sample is extracted, and checks (work-up) for lcms analysis.It adds water (50mL), removes cryostat, and
And solution is washed with ethyl acetate (50mL).Extraction organic layer is simultaneously washed with salt water (60mL), uses MgSO4It is dry, vacuum filter
And remove solvent.Crude product is dissolved in EtOH (15mL), CH2Cl2In (7.5mL) and water (2.5mL), and add enough
Silica gel is to form dense suspension.After stirring 5 days, filtered by sinter funnel, and use CH2Cl2/MeOH(9:1)
(100mL) washing is eluted completely until product.Organic layer is washed with salt water (2x50mL), uses MgSO4Dry, vacuum filter is removed
Remove solvent.Pass through silica gel column chromatography (CHCl3, 1% to 4%MeOH gradient) and purify the product 30 provided as yellow solid
(94mg, 53%).LC/MS(2.53min(ES+) m/z (relative intensity) 739.64 ([M]+, 70).
(c) ((S) -1- (((S) -1- ((4- ((S) -8- (3- (((S) -2- (benzo [d] [1,3] dioxole -5-
Base) -7- methoxyl group -5- oxo -5,11a- dihydro -1H- pyrrolo- [2,1-c] [1,4] benzodiazepine8- yl) oxygroup) third
Oxygroup) -7- methoxyl group -5- oxo -5,11a- dihydro -1H- pyrrolo- [2,1-a] [1,4] benzodiazepine2- yl) phenyl)
Amino)-1- oxopropan-2- base) amino)-3- methyl-1-oxo-butanes-2- base) allyl carbamate (31)
Under an ar atmosphere, stirring alanine-valine-Alloc (180mg, 0.66mmol, 1.2 equivalent) and anhydrous CH2Cl2
EEDQ (163mg, 0.66mmol, 1.2 equivalent) in (21mL) and methanol (1mL).By PBD 30, (407mg, 0.55mmol, 1 work as
Amount) it is dissolved in anhydrous CH2Cl2In (21mL) and methanol (1mL), and add it in reaction.After stirring 5 days at room temperature, LC/
MS shows principal product and is formed.Passing through column chromatography (CH2Cl2With 1% to 6%MeOH gradient) purifying before, solvent is removed in vacuum,
To be produced as the product 31 (184mg, 34%) of yellow solid.LC/MS(2.95min(ES+) 994.95 ([M of m/z (relative intensity)
+H]+, 60).
(d) (S) -2- amino-N- ((S) -1- ((4- ((S) -8- (3- (((S) -2- (benzo [d] [1,3] dioxane penta
Alkene -5- base) -7- methoxyl group -5- oxo -5,11a- dihydro -1H- pyrrolo- [2,1-c] [1,4] benzodiazepine8- yl) oxygen
Base) propoxyl group) -7- methoxyl group -5- oxo -5,11a- dihydro -1H- pyrrolo- [2,1-a] [1,4] benzodiazepine2- yl)
Phenyl) amino) -1- oxopropan -2- base) -3- methylbutyryl amine (32)
Under an ar atmosphere, imines 31 (100mg, 0.1mmol, 1 equivalent) is dissolved in anhydrous DCM (10mL) (auxiliary with
One drips methanol to help to dissolve).Before being flushed three times in emptying flask and with Ar, be added dropwise pyrrolidines (30 μ L,
0.15mmol, 1.5 equivalents).Before emptying flask and being flushed three times with Ar, Pd (PPh is added3)4(7mg, 6 μm of ol, 0.06 works as
Amount).After 1 hour, LC/MS analysis instruction product formation is completely disappeared with starting material.Add Et2O (60mL) is mixed to reaction
It closes in object, and stirs it until all products have been precipitated from solution.It is filtered and is precipitated by sinter funnel, and use Et2O washing
(2x20mL) twice.Displacement collect flask, and dissolution and by using CHCl3(100mL) sinter washs isolated solid.Very
Sky removes solvent to be provided as the crude product 32 of yellow solid, directly uses the crude product 32 in the next step.LC/MS
(1.14min(ES+) m/z (relative intensity) 910.40 ([M+H]+, 67).
(e) N- ((S) -1- (((S) -1- ((4- ((S) -8- (3- (((S) -2- (benzo [d] [1,3] dioxole -
5- yl) -7- methoxyl group -5- oxo -5,11a- dihydro -1H- pyrrolo- [2,1-c] [1,4] benzodiazepine -8- base) oxygroup) third
Oxygroup) -7- methoxyl group -5- oxo -5,11a- dihydro -1H- pyrrolo- [2,1-c] [1,4] benzodiazepine2- yl) phenyl)
Amino)-1- oxopropan-2- base) amino)-3- methyl-1-oxo-butanes-2- base)-1- (3- (bis- oxygroup-2,5- two of 2,5-
Hydrogen -1H- pyrroles -1- base) the third amino) eight oxa- heptacosane -27- amide (33) of -3,6,9,12,15,18,21,24-.
Imines 32 (92mg, 0.1mmol, 1.1 equivalent) is dissolved in CHCl3In (6mL), helped by an anhydrous MeOH of drop
Hydrotropy solution.Add maleimide-PEG8Sour (53mg, 0.09mmol, 1 equivalent), then add EEDQ (33mg,
0.14mmol, 1.5 equivalents).It is vigorously mixed at room temperature for it at Ar, is formed until LC/MS analysis shows principal product.Vacuum is removed
Solvent is removed, and by silica gel column chromatography (CHCl3 and 1% to 10%MeOH gradient) partial purification crude product, generates 33 (81mg).
Further by preparative HPLC purified material, to be produced as 33 (26.3mg, 18%) of yellow solid.Quick formic acid operation:
LC/MS (1.39min (ES+) m/z (relative intensity) 1485.00 ([M+H]+, 64).
Embodiment 6
(a) ((S) -1- (((S) -1- ((4- ((S) -8- (3- (((S) -2- (benzo [d] [1,3] dioxo cyclopentene -5-
Base) -7- methoxyl group -5,11- dioxo -10- ((2- (trimethyl silyl) ethyoxyl) methyl) -5,10,11,11a- four
Hydrogen -1H- pyrrolo- [2,1-c] [1,4] benzodiazepine8- yl) oxygroup) propoxyl group) -7- methoxyl group -5,11- dioxo -
10- ((2- (trimethyl silyl) ethyoxyl) methyl) -5,10,11,11a- tetrahydro-1 H-pyrrolo simultaneously [2,1-a] [1,4] benzene
And diaza2- yl) phenyl) amino) -1- oxopropan -2- base) amino) -3- methyl-oxo butane -2- base) amino first
Sour (9H- fluorenes -9- base) methyl ester (34)
Under an ar atmosphere, by triflate 21 (0.5g, 0.35mmol, 1 equivalent), 3,4- (methylenedioxy) phenyl
Boric acid (75mg, 0.45mmol, 1.3 equivalent) and Na2CO3(0.17g, 1.6mmol, 4.5 equivalent) be dissolved in toluene (11mL),
In EtOH (5.5mL) and water (5.5mL).Flask is emptied, and is flushed three times with Ar.Add Pd (PPh3)4(24mg,
0.02mmol, 0.06 equivalent), and empty flask again and flushed three times with Ar.It is heated to 30 DEG C and is stirred overnight.LC/
MS analysis shows starting material and completely disappears.Solvent is removed in vacuum, and will residual before being washed with ethyl acetate (60mLx3)
It is dissolved in water (60mL).The organic layer combined is washed with salt water (50mL), uses MgSO4Dry, vacuum filter removes solvent.It is logical
Cross column chromatography (50:50 to 25:75v/v hexane/ethyl acetate) purifying provide for yellow solid product 34 (310mg,
64%).LC/MS(1.44min(ES-) m/z (relative intensity) 1423.35 ([M-H]-., 79).
(b) ((S) -1- (((S) -1- ((4- ((S) -8- (3- (((S) -2- (benzo [d] [1,3] dioxole -5-
Base) -7- methoxyl group -5- oxo -5,11a- dihydro -1H- pyrrolo- [2,1-c] [1,4] benzodiazepine8- yl) oxygroup) third
Oxygroup) -7- methoxyl group -5- oxo -5,11a- dihydro -1H- pyrrolo- [2,1-a] [1,4] benzodiazepine2- yl) phenyl)
Amino)-1- oxopropan-2- base) amino)-3- methyl-1-oxo-butanes-2- base) carbamic acid (9H- fluorenes-9- base) methyl ester
(35)
Under an ar atmosphere, the bis- lactams 34 (0.31g, 0.22mmol, 1 equivalent) of SEM are dissolved in THF (10mL) and cold
But to -78 DEG C.It is added dropwise in 5 minutes(1M in 0.5mL, THF, 2.5 equivalents) monitor temperature simultaneously
Degree.After 30 minutes, a small amount of sample is extracted, and check and analyze for LC/MS.It adds water (50mL), removes cryostat, and with acetic acid second
Ester (50mL) washs solution.Extraction organic layer is simultaneously washed with salt water (60mL), uses MgSO4Dry, vacuum filter removes solvent.It will
Crude product is dissolved in EtOH (13.2mL), CH2Cl2In (6.6mL) and water (2.2mL), and it is thick to be formed to add enough silica gel
Close suspension.After stirring 5 days, filtered by sinter funnel, and use CH2Cl2/ MeOH (9:1) (100mL) washing is until producing
Object is eluted completely.Organic layer is washed with salt water (2x50mL), uses MgSO4Dry, vacuum filter removes solvent.Pass through silicagel column
Chromatography (CHCl3, 1% to 4%MeOH gradient) purifying provide pure products 35, be yellow solid (185mg, 75%).LC/MS
(1.70min(ES+) m/z (relative intensity) 1132.85 ([M+H]+, 60).
(c) (S) -2- amino-N- ((S) -1- ((4- ((S) -8- (3- (((S) -2- (benzo [d] [1,3] dioxane penta
Alkene -5- base) -7- methoxyl group -5- oxo -5,11a- dihydro -1H- pyrrolo- [2,1-c] [1,4] benzodiazepine8- yl) oxygen
Base) propoxyl group) -7- methoxyl group -5- oxo -5,11a- dihydro -1H- pyrrolo- [2,1-a] [1,4] benzodiazepine2- yl)
Phenyl) amino) -1- oxopropan -2- base) -3- methylbutyryl amine (32)
It is before being slowly added piperidines (0.2mL, 2mmol, excessive), imines 35 (82mg, 0.07mmol, 1 equivalent) is molten
Solution is in DMF (1mL).The solution is stirred at room temperature 20 minutes, is totally consumed until LC/MS analysis shows starting material.
Use CH2Cl2(50mL) diluted reaction mixture is washed with water (50mLx4), uses MgSO4Dry, vacuum filter removes solvent.?
Product 33 is used in the case where being further purified without next step.LC/MS(1.15min(ES+) m/z (relative intensity)
910.60([M+H]+, 58).
Embodiment 7
(i) (S)-(2- amino -5- methoxyl group -4- ((triisopropylsilyl) oxygroup) phenyl) (2- (((tert-butyl two
Methyl silicane base) oxygroup) methyl) -4- methyl -2,3- dihydro -1H- pyrroles -1- base) ketone (49)
(a) 5- methoxyl group -2- nitro -4- ((triisopropylsilyl) oxygroup) benzaldehyde (42)
Pure tri isopropyl chlorosilane (triisopropylsilylchloride) (56.4mL, 262mmol) is added to miaow
In the mixture of azoles (48.7g, 715.23mmol) and 4- hydroxy-5-methyl oxygroup -2- nitrobenzaldehyde 41 (47g, 238mmol)
(grinding together).Heating mixture is until phenol and imidazoles melt and become solution (100 DEG C).Allow to be stirred to react mixture 15
Minute, it is then allowed to cool, at that time, observes that solid forms (imidazolitm chloride) in bottom of bottle portion.It is anti-with the dilution of 5%EtOAc/ hexane
Answer mixture, and be directly loaded on silica gel, and with 5%EtOAc/ hexane, then with 10%EtOAc/ hexane elution (by
In slight excess, very small amount of unreacted TIPSCl is found in the product).With the solution of 5% ethyl acetate in hexane
Elute required product.Excessive eluent is removed by rotary evaporation under reduced pressure, is then dried under a high vacuum to provide crystallization
Light sensation solid (74.4g, 88%).Purity satisfaction, LC/MS (4.22min (ES+) m/z (relative intensity) 353.88 ([M+H]+.,
100));1H NMR (400MHz, CDCl3) δ 10.43 (s, 1H), 7.60 (s, 1H), 7.40 (s, 1H), 3.96 (s, 3H), 1.35-
1.24 (m, 3H), 1.10 (m, 18H).
(b) 5- methoxyl group -2- nitro -4- ((triisopropylsilyl) oxygroup) benzoic acid (43)
At room temperature, by sodium chlorite (47.3g, 523mmol, 80% industrial grade) and sodium dihydrogen phosphate list alkali
(35.2g, 293mmol) (NaH2PO4) solution in water (800mL) is added to compound 2 (74g, 209mmol) in tetrahydro furan
In the solution muttered in (500mL).Hydrogen peroxide (60%w/w, 140mL, 2.93mol) is added to the two-phase being vigorously stirred immediately
In mixture.Reaction mixture releases gas (oxygen), and the temperature of starting material dissolution and reaction mixture is increased to 45 DEG C.
After 30 minutes, LC/MS display reaction is completed.The cooling reaction mixture in ice bath, and hydrochloric acid (1M) is added so that pH is reduced to 3
(that in many cases, it is found that the step is unnecessary, because it has been acid for reacting last pH;It please examine before extraction
Look into pH).Then, reaction mixture is extracted with ethyl acetate (1L), is washed with brine organic phase (2 × 100mL) and uses magnesium sulfate
It is dry.Organic phase is filtered, and removing excessive solvent by rotary evaporation under reduced pressure to provide quantitative yield is yellow solid
Product 43.LC/MS (3.93min (ES-) m/z (relative intensity) 367.74 ([M-H]-., 100));1H NMR (400MHz,
CDCl3) δ 7.36 (s, 1H), 7.24 (s, 1H), 3.93 (s, 3H), 1.34-1.22 (m, 3H), 1.10 (m, 18H).
(c) ((2S, 4R) -2- (((t-butyldimethylsilyl) oxygroup) methyl) -4- hydroxyl pyrrolidine -1- base)
(5- methoxyl group -2- nitro -4- ((triisopropylsilyl) oxygroup) phenyl) ketone (45)
DCC (29.2g, 141mmol, 1.2 equivalent) is added to sour 3 (43.5g, 117.8mmol, 1 equivalents) and hydroxyl at 0 DEG C
Base benzotriazole hydrate (19.8g, 129.6mmol, 1.1 equivalent) is in the solution in methylene chloride (200mL).Remove cryostat
And allow to react and carry out 30 minutes at room temperature, at this point, quickly adding (2S, 4R) -2-t- butyl diformazan under argon gas at -10 DEG C
Base silanyloxymethyl -4- hydroxyl pyrrolidine 44 (30g, 129.6mmol, 1.1 equivalent) and triethylamine (24.66mL,
176mmol, 1.5 equivalents) in methylene chloride (100mL) solution (it is a large amount of, can be with by the cooling reaction mixture longer time
Shorten the addition time).Allow to be stirred at room temperature reaction mixture 40 minutes to 1 hour, and passes through LC/MS and TLC (EtOAc)
Monitoring.Organic phase is washed by the solid that is filtered to remove over celite, and with cold 0.1M HCL aqueous solution, until what is measured
PH is 4 or 5.Then organic phase is washed with water, then washs organic phase with saturated sodium bicarbonate aqueous solution.Have with magnesium sulfate drying
Machine layer filters and removes excessive solvent by rotary evaporation under reduced pressure.Residue is set to carry out flash column chromatography (silica gel;Gradient:
40/60 ethyl acetate/hexane to 80/20 ethyl acetate/hexane).Excessive solvent is removed by rotary evaporation under reduced pressure to provide
Pure products 45 (the slight impure product of the pure products 66% and 17g of 45.5g, in total 90%).LC/MS, 4.23min (ES+) m/
Z (relative intensity) 582.92 ([M+H]+, 100);1H NMR (400MHz, CDCl3) δ 7.66 (s, 1H), 6.74 (s, 1H), 4.54
(s, 1H), 4.40 (s, 1H), 4.13 (s, 1H), 3.86 (s, 3H), 3.77 (d, J=9.2Hz, 1H), 3.36 (dd, J=11.3,
4.5Hz, 1H), 3.14-3.02 (m, 1H), 2.38-2.28 (m, 1H), 2.10 (ddd, J=13.3,8.4,2.2Hz, 1H),
1.36-1.19 (m, 3H), 1.15-1.05 (m, 18H), 0.91 (s, 9H), 0.17-0.05 (m, 6H), (there are rotational isomers).
(d) (S) -5- (((t-butyldimethylsilyl) oxygroup) methyl) -1- (5- methoxyl group -2- nitro -4- ((three
Isopropyl silyl) oxygroup) benzoyl) pyrrolidines -3- ketone (46)
TCCA (8.82g, 40mmol, 0.7 equivalent) is added to 45 (31.7g, 54mmol, 1 equivalents) and TEMPO at 0 DEG C
(0.85g, 5.4mmol, 0.1 equivalent) is in the agitating solution in dry methylene chloride (250mL).It is vigorously stirred reaction mixing
Object 20 minutes, at this point, TLC (50/50 ethyl acetate/hexane) shows that starting material is totally consumed.It is anti-by diatomite filtering
Mixture is answered, and is washed with saturated sodium bicarbonate aqueous solution (100mL), sodium thiosulfate (9g in 300mL), salt water (100mL)
Filtrate is washed, and dry with magnesium sulfate.Rotary evaporation provides the product 46 of quantitative yield under reduced pressure.LC/MS 4.52min(ES
+) m/z (relative intensity) 581.08 ([M+H]+, 100);1H NMR (400MHz, CDCl3) δ 7.78-7.60 (m, 1H), 6.85-
6.62 (m, 1H), 4.94 (dd, J=30.8,7.8Hz, 1H), 4.50-4.16 (m, 1H), 3.99-3.82 (m, 3H), 3.80-
3.34 (m, 3H), 2.92-2.17 (m, 2H), 1.40-1.18 (m, 3H), 1.11 (t, J=6.2Hz, 18H), 0.97-0.75 (m,
9H), 0.15-0.06 (m, 6H), (there are rotational isomers).
(e) (S)-trifluoromethanesulfonic acid 5- (((t-butyldimethylsilyl) oxygroup) methyl) -1- (5- methoxyl group -2-
Nitro -4- ((triisopropylsilyl) oxygroup) benzoyl) -4,5- dihydro -1H- pyrroles -3- base ester (47)
Under -50 DEG C (acetone/the dry ice bath), there are 2,6- lutidines, (25.6mL, 23.5g, 220mmol, 4 work as
It is amount, dry with molecular sieve) in the case where trifluoromethanesulfanhydride anhydride (27.7mL, 46.4g, 165mmol, 3 equivalent) is injected to acutely
The ketone 46 (31.9g, 55mmol, 1 equivalent) of stirring is in the suspension in anhydrous methylene chloride (900mL).Allow to be stirred to react
Mixture 1.5 hours, fully reacting was shown when LC/MS is at miniature inspection (mini work-up) (water/methylene chloride).By water
It is added in still cold reaction mixture, separates organic layer and is washed with saturated sodium bicarbonate, salt water and magnesium sulfate.It filters organic
Phase, and excessive solvent is removed by rotary evaporation under reduced pressure.Residual is set to be subjected to flash column chromatography (silica gel;10/90v/v acetic acid
Ethyl ester/hexane), it removes excessive eluent and provides product 47 (37.6g, 96%) LC/MS, method 2,4.32min (ES+) m/z
(relative intensity) 712.89 ([M+H]+., 100);1H NMR (400MHz, CDCl3) δ 7.71 (s, 1H), 6.75 (s, 1H), 6.05
(d, J=1.8Hz, 1H), 4.78 (dd, J=9.8,5.5Hz, 1H), 4.15-3.75 (m, 5H), 3.17 (ddd, J=16.2,
10.4,2.3Hz, 1H), 2.99 (ddd, J=16.3,4.0,1.6Hz, 1H), 1.45-1.19 (m, 3H), 1.15-1.08 (m,
18H), 1.05 (s, 6H), 0.95-0.87 (m, 9H), 0.15-0.08 (m, 6H).
(f) (S)-(2- (((t-butyldimethylsilyl) oxygroup) methyl) -4- methyl -2,3- dihydro -1H- pyrroles -
1- yl) (5- methoxyl group -2- nitro -4- ((triisopropylsilyl) oxygroup) phenyl) ketone (48)
Under an argon atmosphere, triphenylarsine (1.71g, 5.60mmol, 0.4 equivalent) is added to triflate 47
(10.00g, 14mmol, 1 equivalent), methyl-boric acid (2.94g, 49.1mmol, 3.5 equivalent), (13g, 56mmol, 4 work as silver oxide
Amount) and tripotassium phosphate (17.8g, 84mmol, 6 equivalent) in the mixture in anhydrous dioxanes (80mL).It is anti-with argon cleaning
It answers 3 times, and two (benzonitrile) palladium chlorides (II) (540mg, 1.40mmol, 0.1 equivalent) is added.Moment be warming up to 110 DEG C it
Before, with argon cleaning reaction 3 times or more (before addition flask, drysyn heat block is warming up to 110 DEG C).After ten minutes, will
Reaction is cooled to room temperature, and passes through diatomite filter plates.Solvent is removed by rotary evaporation under reduced pressure.Make to obtain residue
It is subjected to flash column chromatography (silica gel;10% ethyl acetate/hexane).It collects and merges pure part, and pass through rotation under reduced pressure
Evaporation removes excessive eluent to provide product 48 (4.5g, 55%).LC/MS, 4.27min (ES+) m/z (relative intensity)
579.18([M+H]+., 100);1H NMR (400MHz, CDCl3) δ 7.70 (s, 1H), 6.77 (s, 1H), 5.51 (d, J=
1.7Hz, 1H), 4.77-4.59 (m, 1H), 3.89 (s, 3H), 2.92-2.65 (m, 1H), 2.55 (d, J=14.8Hz, 1H),
1.62 (d, J=1.1Hz, 3H), 1.40-1.18 (m, 3H), 1.11 (s, 9H), 1.10 (s, 9H), 0.90 (s, 9H), 0.11 (d, J
=2.3Hz, 6H).
(g) (S)-(2- amino -5- methoxyl group -4- ((triisopropylsilyl) oxygroup) phenyl) (2- (((tert-butyl two
Methyl silicane base) oxygroup) methyl) -4- methyl -2,3- dihydro -1H- pyrroles -1- base) ketone (49)
At about 15 DEG C, zinc powder (28g, 430mmol, 37 equivalent) is added to compound 48 (6.7g, 11.58mmol) and is existed
5% formic acid is in the solution in ethyl alcohol v/v (70mL).Using the heat release that ice bath control generates to protect the temperature of reaction mixture
It holds at 30 DEG C or less.After 30 minutes, pass through diatomite filter plates reaction mixture.With ethyl acetate dilute filtrate, with water,
Saturated sodium bicarbonate aqueous solution and salt water washing organic phase.With the dry organic phase of magnesium sulfate, filters and pass through rotation under reduced pressure
Evaporative removal excessive solvent.The residual made is subjected to flash column chromatography (silica gel;10% ethyl acetate in hexane).It collects and closes
And pure part, and excessive solvent is removed to provide product 49 (5.1g, 80%) by rotary evaporation under reduced pressure.LC/MS,
4.23min (ES+) m/z (relative intensity) 550.21 ([M+H]+, 100);1H NMR (400MHz, CDCl3) δ 7.28 (s, 1H),
6.67 (s, 1H), 6.19 (s, 1H), 4.64-4.53 (m, J=4.1Hz, 1H), 4.17 (s, 1H), 3.87 (s, 1H), 3.77-
3.69 (m, 1H), 3.66 (s, 3H), 2.71-2.60 (m, 1H), 2.53-2.43 (m, 1H), 2.04-1.97 (m, J=11.9Hz,
1H), 1.62 (s, 3H), 1.26-1.13 (m, 3H), 1.08-0.99 (m, 18H), 0.82 (s, 9H), 0.03-0.03 (m, J=
6.2Hz, 6H).
(ii) (11S, 11aS) -11- ((t-butyldimethylsilyl) oxygroup) -8- ((5- iodo amyl) oxygroup) -
7- methoxyl group -2- methyl -5- oxo -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza
10
(5H)-carboxylic acid allyl esters
(a) (S)-(2- (2- (((t-butyldimethylsilyl) oxygroup) methyl) -4- methyl -2,3- dihydro -1H- pyrrole
Cough up -1- carbonyl) -4- methoxyl group -5- ((triisopropylsilyl) oxygroup) phenyl) allyl carbamate (50)
Under -78 DEG C (acetone/the dry ice bath), there are anhydrous pyridine (0.48mL, 6.00mmol, 2.2 equivalent) the case where
Under, allyl chlorocarbonate (0.30mL, 3.00mmol, 1.1 equivalent) is added to amine 49 (1.5g, 2.73mmol) in anhydrous dichloro
In solution in methane (20mL).After 30 minutes, the bath is removed, and reaction mixture is heated to room temperature.Use methylene chloride
Diluted reaction mixture, and add the copper sulfate solution of saturation.Then the sodium bicarbonate aqueous solution and salt water of sequence saturation
Wash organic layer.With the dry organic phase of magnesium sulfate, filters and excessive solvent is removed to provide production by rotary evaporation under reduced pressure
Object 50, products therefrom 50 directly use in next reaction.LC/MS, 4.45min (ES+) m/z (relative intensity) 632.91 ([M+
H]+, 100).
(b) (S)-(2- (2- (hydroxymethyl) -4- methyl -2,3- dihydro -1H- pyrroles -1- carbonyl) -4- methoxyl group -5-
((triisopropylsilyl) oxygroup) phenyl) allyl carbamate (51)
Crude product 50 is dissolved in acetic acid/methanol/tetrahydrofuran/water (28:4:4:8mL) 7:1:1:2 mixture, and
It is stirred at room temperature.After 3 hours, starting material is observed by LC/MS and is completely disappeared.With ethyl acetate diluted reaction mixture,
And successively with water (2 × 500mL), saturated sodium bicarbonate (200mL) and salt water washing.With the dry organic phase of magnesium sulfate, filtering is simultaneously
Excess ethyl acetate is removed by rotary evaporation under reduced pressure.The residue made is subjected to flash column chromatography (silica gel;In hexane
25% ethyl acetate).It collects and merges pure part and excessive eluent is removed to provide the phase by rotary evaporation under reduced pressure
The product 51 (1g, 71%) of prestige.LC/MS, 3.70min (ES+) m/z (relative intensity) 519.13 ([M+H]+., 95);1H NMR
(400MHz, CDCl3) δ 8.34 (s, 1H), 7.69 (s, 1H), 6.78 (s, 1H), 6.15 (s, 1H), 5.95 (ddt, J=17.2,
10.5,5.7Hz, 1H), 5.33 (dq, J=17.2,1.5Hz, 1H), 5.23 (ddd, J=10.4,2.6,1.3Hz, 1H), 4.73
(tt, J=7.8,4.8Hz, 1H), 4.63 (dt, J=5.7,1.4Hz, 2H), 4.54 (s, 1H), 3.89-3.70 (m, 5H), 2.87
(dd, J=16.5,10.5Hz, 1H), 2.19 (dd, J=16.8,4.6Hz, 1H), 1.70 (d, J=1.3Hz, 3H), 1.38-
1.23 (m, 3H), 1.12 (s, 10H), 1.10 (s, 8H).
(c) (11S, 11aS) -11- hydroxyl -7- methoxyl group -2- methyl -5- oxo -8- ((triisopropylsilyl) oxygen
Base) -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza10 (5H)-carboxylic acid allyl esters (52)
Under an argon, under -78 DEG C (dry ice/acetone batch), by dimethyl sulfoxide (0.35mL, 4.83mmol, 2.5 equivalent)
It is added dropwise to oxalyl chloride (0.2mL, 2.32mmol, 1.2 equivalent) in the solution in anhydrous methylene chloride (10mL).10 minutes
Afterwards, still at -78 DEG C, it is slowly added solution of 51 (1g, the 1.93mmol) in anhydrous methylene chloride (8mL).After 15 minutes, by
(1.35mL passes through drop addition triethylamineMolecular sieve is dry, 9.65mmol, 5 equivalents) and remove dry ice/acetone batch.Make to react
Mixture reaches room temperature and is extracted with cold hydrochloric acid (0.1M), saturated sodium bicarbonate aqueous solution and salt water.It is organic with magnesium sulfate drying
Phase filters and removes excessive methylene chloride by rotary evaporation under reduced pressure to provide product 52 (658mg, 66%).LC/MS,
3.52min (ES+) m/z (relative intensity) (400MHz, CDCl3) δ 7.20 (s, 1H), 6.75-6.63 (m, J=8.8,4.0Hz,
2H), 5.89-5.64 (m, J=9.6,4.1Hz, 2H), 5.23-5.03 (m, 2H), 4.68-4.38 (m, 2H), 3.84 (s, 3H),
3.83-3.77 (m, 1H), 3.40 (s, 1H), 3.05-2.83 (m, 1H), 2.59 (d, J=17.1Hz, 1H), 1.78 (d, J=
1.3Hz, 3H), 1.33-1.16 (m, 3H), 1.09 (d, J=2.2Hz, 9H), 1.07 (d, J=2.1Hz, 9H).
(d) (11S, 11aS) -11- ((t-butyldimethylsilyl) oxygroup) -7- methoxyl group -2- methyl -5- oxo -
8- ((triisopropylsilyl) oxygroup) -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza
10 (5H)-carboxylic acid allyl esters (53)
Under argon gas, at 0 DEG C, by t-butyldimethylsilyl triflate, (0.70mL, 3.00mmol, 3 work as
Amount) compound 52 (520mg, 1.00mmol) and 2 are added to, 6- lutidines (0.46mL, 4.00mmol, 4 equivalent) is in nothing
In solution in water methylene chloride (40mL).After 10min, removes cryostat and reaction mixture is stirred at room temperature 1 hour.With
Water, saturated sodium bicarbonate aqueous solution and salt water extract reaction mixture.With the dry organic phase of magnesium sulfate, filters and lead under reduced pressure
It crosses rotary evaporation and removes excessive solvent.The residual made is subjected to flash column chromatography (silica gel;Gradient, 10% acetic acid second in hexane
Ester 20% ethyl acetate into hexane).It collects and merges pure part and excessive elution is removed by rotary evaporation under reduced pressure
Liquid is to obtain product 53 (540mg, 85%).LC/MS, 4.42min (ES+) m/z (relative intensity) 653.14 ([M+Na]+.,
100);1H NMR (400MHz, CDCl3) δ 7.20 (s, 1H), 6.71-6.64 (m, J=5.5Hz, 2H), 5.83 (d, J=9.0Hz,
1H), 5.80-5.68 (m, J=5.9Hz, 1H), 5.14-5.06 (m, 2H), 4.58 (dd, J=13.2,5.2Hz, 1H), 4.36
(dd, J=13.3,5.5Hz, 1H), 3.84 (s, 3H), 3.71 (td, J=10.1,3.8Hz, 1H), 2.91 (dd, J=16.9,
10.3Hz, 1H), 2.36 (d, J=16.8Hz, 1H), 1.75 (s, 3H), 1.31-1.16 (m, 3H), 1.12-1.01 (m, J=
7.4,2.1Hz, 18H), 0.89-0.81 (m, 9H), 0.25 (s, 3H), 0.19 (s, 3H).
(e) (11S, 11aS) -11- ((t-butyldimethylsilyl) oxygroup) -8- hydroxyl -7- methoxyl group -2- methyl -
5- oxo -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza10 (5H)-carboxylic acid allyl esters
(54)
Lithium acetate (87mg, 0.85mmol) is added to compound 53 (540mg, 0.85mmol) in aqueous dimethyl formyl
In solution in amine (6mL, 50:1DMF/ water).After 4 hours, fully reacting, with ethyl acetate (25mL) diluted reaction mixture
And with aqueous citric acid solution (about pH 3), water and salt water washing.With the dry organic layer of magnesium sulfate, filters and pass through rotation under reduced pressure
Turn evaporation and removes Excess ethyl acetate.The residue made is subjected to flash column chromatography (silica gel;Gradient, in hexane 25% to
75% ethyl acetate).It collects and merges pure part and excessive eluent is removed to be produced by rotary evaporation under reduced pressure
Object 54 (400mg, quantitative).LC/MS, (3.33min (ES+) m/z (relative intensity) 475.26 ([M+H]+, 100).
(f) (11S, 11aS) -11- ((t-butyldimethylsilyl) oxygroup) -8- ((5- iodo amyl) oxygroup) -7-
Methoxyl group -2- methyl -5- oxo -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza10(5H)-
Carboxylic acid allyl esters (55)
Two iodopentanes (0.63mL, 4.21mmol, 5 equivalents) and potassium carbonate (116mg, 0.84mmol, 1 equivalent) are added to
Phenol 54 (400mg, 0.84mmol) is in the solution in acetone (4mL, being dried with molecular sieve).Then, by reaction mixture plus
Heat is to 60 DEG C and stirs 6 hours.Acetone is removed by rotary evaporation under reduced pressure.The residue made is subjected to flash column chromatography
(silica gel;50/50, v/v, hexane/ethyl acetate).It collects and merges pure part and remove excessive eluent to provide 90% production
The 55 of rate.LC/MS, 3.90min (ES+) m/z (relative intensity) 670.91 ([M]+, 100).1H NMR (400MHz, CDCl3)δ
7.23 (s, 1H), 6.69 (s, 1H), 6.60 (s, 1H), 5.87 (d, J=8.8Hz, 1H), 5.83-5.68 (m, J=5.6Hz,
1H), 5.15-5.01 (m, 2H), 4.67-4.58 (m, 1H), 4.45-4.35 (m, 1H), 4.04-3.93 (m, 2H), 3.91 (s,
3H), 3.73 (td, J=10.0,3.8Hz, 1H), 3.25-3.14 (m, J=8.5,7.0Hz, 2H), 2.92 (dd, J=16.8,
10.3Hz, 1H), 2.38 (d, J=16.8Hz, 1H), 1.95-1.81 (m, 4H), 1.77 (s, 3H), 1.64-1.49 (m, 2H),
0.88 (s, 9H), 0.25 (s, 3H), 0.23 (s, 3H).
(iii) (11S, 11aS) -11- ((t-butyldimethylsilyl) oxygroup) -8- hydroxyl -7- methoxyl group -2- first
Base -5- oxo -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza
10 (5H)-carboxylic acid 4- (2-
(1- ((1- (allyloxy) -4- methyl-1,2- dioxo pentane -3- base) amino) -1- oxopropan -2- base) diazanyl) benzyl
Ester (70)
(a) 3- (2- (2- (4- ((((2- ((S) -2- (((t-butyldimethylsilyl) oxygroup) methyl) -4- methyl -
2,3- dihydro -1H- pyrroles -1- carbonyl) -4- methoxyl group -5- ((triisopropylsilyl) oxygroup) phenyl) carbamoyl)
Oxygroup) methyl) phenyl) diazanyl) the third amino) -4- methyl -2- oxopentanoic acid allyl ester (56)
At 5 DEG C (ice baths), triethylamine (2.23mL, 18.04mmol, 2.2 equivalent) is added to amine 49 (4g, 8.20mmol)
With triphosgene (778mg, 2.95mmol, 0.36 equivalent) in the agitating solution in anhydrous tetrahydro furan (40mL).By from anti-
It answers mixture interval to remove part, terminated with methanol and carries out LC/MS analysis to monitor the progress of isocyanates reaction.Once different
The formation of cyanate is completed, then by injecting alloc-Val-Ala-PABOH (4.12g, 12.30mmol, 1.5 equivalent) and three
Solution of the ethamine (1.52ml, 12.30mmol, 1.5 equivalent) in anhydrous tetrahydro furan (40mL) is quickly added to fresh preparation
Isocyanates in.Then mixture is stirred to react 4 hours at 40 DEG C.Excessive solvent is removed by rotary evaporation under reduced pressure.
The residue made is subjected to flash column chromatography (silica gel, gradient, 1% methanol to 5% methanol in chloroform).(use EtOAc and oneself
The substitution chromatographic condition of alkane is also successful).It collects and merges pure part and removed excessively by rotary evaporation under reduced pressure
Eluent is to obtain product 56 (3.9g, 50%).LC/MS, 4.23min (ES+) m/z (relative intensity) 952.36 ([M+H]+.,
100);1H NMR (400MHz, CDCl3) δ 8.62 (br s, 1H), 8.46 (s, 1H), 7.77 (br s, 1H), 7.53 (d, J=
8.4Hz, 2H), 7.32 (d, J=8.5Hz, 2H), 6.76 (s, 1H), 6.57 (d, J=7.6Hz, 1H), 6.17 (s, 1H), 6.03-
5.83 (m, 1H), 5.26 (dd, J=33.8,13.5Hz, 3H), 5.10 (s, 2H), 4.70-4.60 (m, 2H), 4.58 (dd, J=
5.7,1.3Hz, 2H), 4.06-3.99 (m, 1H), 3.92 (s, 1H), 3.82-3.71 (m, 1H), 3.75 (s, 3H), 2.79-2.64
(m, 1H), 2.54 (d, J=12.9Hz, 1H), 2.16 (dq, J=13.5,6.7Hz, 1H), 1.67 (s, 3H), 1.46 (d, J=
7.0Hz, 3H), 1.35-1.24 (m, 3H), 1.12 (s, 9H), 1.10 (s, 9H), 0.97 (d, J=6.8Hz, 3H), 0.94 (d, J
=6.8Hz, 3H), 0.87 (s, 9H), 0.07-0.02 (m, 6H).
(b) 3- (2- (2- (4- ((((2- ((S) -2- (hydroxymethyl) -4- methyl -2,3- dihydro -1H- pyrroles's -1- carbonyl
Base) -4- methoxyl group -5- ((triisopropylsilyl) oxygroup) phenyl) carbamoyl) oxygroup) methyl) phenyl) diazanyl) third
Amino) -4- methyl -2- oxopentanoic acid allyl ester (57)
TBS ether 56 (1.32g, 1.38mmol) is dissolved in acetic acid/methanol/tetrahydrofuran/water (14:2:2:4mL) 7:
In 1:1:2 mixture and allow to be stirred at room temperature.After 3 hours, starting material is not observed by LC/MS.Use ethyl acetate
(25mL) diluted reaction mixture and sequence water, saturated sodium bicarbonate aqueous solution and salt water washing.It is organic with magnesium sulfate drying
Phase filters and removes Excess ethyl acetate by rotary evaporation under reduced pressure.The residue made carries out flash column chromatography (silicon
Glue;2% ethanol/methylene).Collect and merge pure part and under reduced pressure by rotary evaporation remove excessive eluent with
Product 57 (920mg, 80%) needed for providing.LC/MS, 3.60min (ES+) m/z (relative intensity) 838.18 ([M+H]+.,
100)。1H NMR (400MHz, CDCl3) δ 8.55 (s, 1H), 8.35 (s, 1H), 7.68 (s, 1H), 7.52 (d, J=8.1Hz,
2H), 7.31 (d, J=8.4Hz, 2H), 6.77 (s, 1H), 6.71 (d, J=7.5Hz, 1H), 6.13 (s, 1H), 5.97-5.82
(m, J=5.7Hz, 1H), 5.41-5.15 (m, 3H), 5.10 (d, J=3.5Hz, 2H), 4.76-4.42 (m, 5H), 4.03 (t, J
=6.6Hz, 1H), 3.77 (s, 5H), 2.84 (dd, J=16.7,10.4Hz, 1H), 2.26-2.08 (m, 2H), 1.68 (s, 3H),
1.44 (d, J=7.0Hz, 3H), 1.30 (dt, J=14.7,7.4Hz, 3H), 1.12 (s, 9H), 1.10 (s, 9H), 0.96 (d, J
=6.8Hz, 3H), 0.93 (d, J=6.8Hz, 3H).
(c) (11S, 11aS) -11- hydroxyl -7- methoxyl group -2- methyl -5- oxo -8- ((triisopropylsilyl) oxygen
Base) -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza10 (5H)-carboxylic acid 4- (2- (1- ((1-
(allyloxy) -4- methyl-1,2- dioxo pentane -3- base) amino) -1- oxopropan -2- base) diazanyl) benzyl ester (58)
Under an argon, -78 DEG C (dry ice/acetone batch) by dimethyl sulfoxide (0.2mL, 2.75mmol, 2.5 equivalent) dropwise
Oxalyl chloride (0.11mL, 1.32mmol, 1.2 equivalent) is added in the solution in anhydrous methylene chloride (7mL).After ten minutes,
Still at -78 DEG C, it is slowly added solution of 57 (920mg, the 1.10mmol) in anhydrous methylene chloride (5mL).After 15 minutes, by
(0.77mL passes through drop addition triethylamineMolecular sieve is dry, 5.50mmol, 5 equivalents) and remove dry ice/acetone batch.Make to react
Mixture reaches room temperature and is extracted with cold hydrochloric acid (0.1M), saturated sodium bicarbonate aqueous solution and salt water.Have by magnesium sulfate drying
Machine phase filters and removes excessive methylene chloride by rotary evaporation under reduced pressure.The residue made is subjected to quick column
Chromatography (silica gel, gradient, 2% methanol to 5% methanol in methylene chloride).It collects and merges pure part and pass through rotation under reduced pressure
Turn evaporation and removes excessive eluent to provide product 58 (550mg, 60%).LC/MS, 3.43min (ES+) m/z (relative intensity)
836.01([M]+, 100).1H NMR (400MHz, CDCl3) δ 8.39 (s, 1H), 7.52-7.40 (m, 2H), 7.21-7.08 (m, J
=11.5Hz, 2H), 6.67 (s, 1H), 6.60-6.47 (m, J=7.4Hz, 1H), 5.97-5.83 (m, 1H), 5.79-5.66 (m,
1H), 5.38-4.90 (m, 6H), 4.68-4.52 (m, J=18.4,5.5Hz, 4H), 4.04-3.94 (m, J=6.5Hz, 1H),
3.87-3.76 (m, 5H), 3.00-2.88 (m, 1H), 2.66-2.49 (m, 2H), 2.21-2.08 (m, 2H), 1.76 (s, 3H),
1.45 (d, J=7.0Hz, 3H), 1.09-0.98 (m, J=8.9Hz, 18H), 0.96 (d, J=6.7Hz, 3H), 0.93 (d, J=
6.9Hz, 3H).
(d) (11S, 11aS) -11- ((t-butyldimethylsilyl) oxygroup) -7- methoxyl group -2- methyl -5- oxo -
8- ((triisopropylsilyl) oxygroup) -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza
10 (5H)-carboxylic acid 4- (2- (1- ((1- (allyloxy) -4- methyl-1,2- dioxo pentane -3- base) amino) -1- oxo third
Alkane -2- base) diazanyl) benzyl ester (59)
Under argon gas, at 0 DEG C, by t-butyldimethylsilyl triflate, (0.38mL, 1.62mmol, 3 work as
Amount) compound 58 (450mg, 0.54mmol) and 2 are added to, 6- lutidines (0.25mL, 2.16mmol, 4 equivalent) is in nothing
In solution in water methylene chloride (5mL).After 10min, removes cryostat and reaction mixture is stirred at room temperature 1 hour.With
Water, saturated sodium bicarbonate aqueous solution and salt water extract reaction mixture.With the dry organic phase of magnesium sulfate, filters and lead under reduced pressure
It crosses rotary evaporation and removes excessive solvent.The residual made is subjected to flash column chromatography (silica gel;50/50v/v hexane/acetic acid second
Ester).Collect and merge pure part and excessive eluent removed by rotary evaporation under reduced pressure with obtain product 59 (334mg,
65%).LC/MS, 4.18min (ES+) m/z (relative intensity) 950.50 ([M]+, 100).1H NMR (400MHz, CDCl3)δ
8.53 (s, 1H), 8.02 (s, 1H), 7.44 (d, J=7.6Hz, 2H), 7.21 (s, 1H), 7.08 (d, J=8.2Hz, 2H),
6.72-6.61 (m, J=8.9Hz, 2H), 6.16 (s, 1H), 5.97-5.79 (m, J=24.4,7.5Hz, 2H), 5.41-5.08
(m, 5H), 4.86 (d, J=12.5Hz, 1H), 4.69-4.60 (m, 1H), 4.57 (s, 1H), 4.03 (t, J=6.7Hz, 1H),
3.87 (s, 3H), 3.74 (td, J=9.6,3.6Hz, 1H), 2.43-2.09 (m, J=34.8,19.4,11.7Hz, 3H), 1.76
(s, 3H), 1.43 (d, J=6.9Hz, 3H), 1.30-1.21 (m, 3H), 0.97 (d, J=6.7Hz, 3H), 0.92 (t, J=
8.4Hz, 3H), 0.84 (s, 9H), 0.23 (s, 3H), 0.12 (s, 3H).
(e) (11S, 11aS) -11- ((t-butyldimethylsilyl) oxygroup) -8- hydroxyl -7- methoxyl group -2- methyl -
5- oxo -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza10 (5H)-carboxylic acid 4- (2- (1-
((1- (allyloxy) -4- methyl-1,2- dioxo pentane -3- base) amino) -1- oxopropan -2- base) diazanyl) benzyl ester
(60)
Lithium acetate (50mg, 0.49mmol) is added to compound 59 (470mg, 0.49mmol) in aqueous dimethyl formyl
In solution in amine (4mL, 50:1DMF/ water).After 4 hours, fully reacting with ethyl acetate diluted reaction mixture and uses lemon
Lemon acid (about pH 3), water and salt water washing.With the dry organic layer of magnesium sulfate, filters and removed under reduced pressure by rotary evaporation
Measure ethyl acetate.The residue made is subjected to flash column chromatography (silica gel;Gradient, 50/50 to 25/75v/v hexane/acetic acid second
Ester).Collect and merge pure part and excessive eluent removed by rotary evaporation under reduced pressure with obtain product 60 (400mg,
It is quantitative).LC/MS, 3.32min (ES+) m/z (relative intensity) 794.18 ([M+H]+, 100).1H NMR (400MHz, CDCl3)δ
8.53 (s, 1H), 8.02 (s, 1H), 7.44 (d, J=7.6Hz, 2H), 7.21 (s, 1H), 7.08 (d, J=8.2Hz, 2H),
6.72-6.61 (m, J=8.9Hz, 2H), 6.16 (s, 1H), 5.97-5.79 (m, J=24.4,7.5Hz, 2H), 5.41-5.08
(m, 5H), 4.86 (d, J=12.5Hz, 1H), 4.69-4.60 (m, 1H), 4.57 (s, 1H), 4.03 (t, J=6.7Hz, 1H),
3.87 (s, 3H), 3.74 (td, J=9.6,3.6Hz, 1H), 2.43-2.09 (m, J=34.8,19.4,11.7Hz, 3H), 1.76
(s, 3H), 1.43 (d, J=6.9Hz, 3H), 1.30-1.21 (m, 3H), 0.97 (d, J=6.7Hz, 3H), 0.92 (t, J=
8.4Hz, 3H), 0.84 (s, 9H), 0.23 (s, 3H), 0.12 (s, 3H).
(iv) (11S, 11aS) -11- hydroxyl -7- methoxyl group -8- ((5- ((oxo -5 (S) -7- methoxyl group -2- methyl -5-,
11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza
8- yl) oxygroup) amyl) oxygroup) -2- methyl -5-
Oxo -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza
- 10 (5H)-carboxylic acid 4- ((2S, 5S)-
37- (2,5- dioxo-2,5- dihydro-1H- pyrroles-1- base) trioxy--10,13,16-5- isopropyl-2- methyl-4,7,35-,
Eight oxa- -3,6,34- of 19,22,25,28,31-, three azepine heptatriacontane amino) benzyl ester (64) ((11S, 11aS) -4- ((2S,
5S)-37-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5-isopropyl-2-methyl-4,7,35-
trioxo-10,13,16,19,22,25,28,31-octaoxa-3,6,34-triazaheptatri
acontanamido)
benzyl11-hydroxy-7-methoxy-8-((5-(((S)-7-methoxy-2-methyl-5-oxo-5,11a-
dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)pentyl)oxy)-2-methyl-
5-oxo-11,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10(5H)-
carboxylate)
(a) (11S) -8- ((5- (((11S) -10- (((4- (2- (1- ((1- (allyloxy) -4- methyl-1,2- dioxo
Pentane -3- base) amino) -1- oxopropan -2- base) diazanyl) benzyl) oxygroup) carbonyl) -11- ((t-butyl-dimethylsilyl
Base) oxygroup) -7- methoxyl group -2- methyl -5- oxo -5,10,11,11a- tetrahydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4]
Diaza8- yl) oxygroup) amyl) oxygroup) -11- ((t-butyldimethylsilyl) oxygroup) -7- methoxyl group -2- first
Base -5- oxo -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza10 (5H)-carboxylic acid allyls
Ester (61)
Potassium carbonate (70mg, 0.504mmol, 1 equivalent) is added to 55 (370mg, 0.552mmol, 1.2 equivalents) and phenol
60 (400mg, 0.504mmol) are in the solution in dry acetone (25mL).It is stirred to react at 70 DEG C 8 hours.LC/MS shows institute
There is starting material not consume, therefore reaction is made to be stirred at room temperature overnight and be stirred for 2 hours at second day.Pass through under reduced pressure
Rotary evaporation removes acetone.The residue made is subjected to flash column chromatography (silica gel;80% ethyl acetate is to 100% in hexane
Ethyl acetate).It collects and merges pure part and excessive eluent is removed to obtain product 61 by rotary evaporation under reduced pressure
(385mg, 57%).LC/MS, 4.07min (ES+) m/z (relative intensity) 1336.55 ([M+H]+, 50).
(b) (11S) -8- ((5- (((11S) -10- (((4- (2- (1- ((1- (allyloxy) -4- methyl-1,2- dioxo
Pentane -3- base) amino) -1- oxopropan -2- base) diazanyl) benzyl) oxygroup) carbonyl) -11- hydroxyl -7- methoxyl group -2- methyl -
5- oxo -5,10,11,11a- tetrahydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza8- yl) oxygroup) amyl)
Oxygroup) -11- hydroxyl -7- methoxyl group -2- methyl -5- oxo -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4]
Diaza10 (5H)-carboxylic acid allyl esters (62)
Four n-butylamine fluorides (1M, 0.34mL, 0.34mmol, 2 equivalent) are added to 61 (230mg, 0.172mmol) to exist
In solution in anhydrous tetrahydro furan (3mL).After ten minutes, starting material is completely exhausted.It is diluted with ethyl acetate (30mL)
Reaction mixture and with water and salt water sequential purge.With the dry organic phase of magnesium sulfate, filters and pass through rotary evaporation under reduced pressure
Remove Excess ethyl acetate.Obtained residue 62 is used as to the crude mixture of next reaction.LC/MS, 42.87min (ES+) m/
Z (relative intensity) 1108.11 ([M+H]+, 100).
(c) (11S) -11- hydroxyl -7- methoxyl group -8- ((5- ((7- methoxyl group -2- methyl -5- oxo -5,11a- dihydro -
1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza8- yl) oxygroup) amyl) oxygroup) oxo-11-2- methyl-5-,
11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza10 (5H)-carboxylic acid 4- (2- (1- ((1- amino -3-
Methyl-1-oxo-butanes-2- base) amino)-1- oxopropan-2- base) diazanyl) benzyl ester (63)
Tetrakis triphenylphosphine palladium (0) (12mg, 0.01mmol, 0.06 equivalent) is added to thick 62 (0.172mmol) and pyrrole
Alkane (36 μ L, 0.43mmol, 2.5 equivalent) is coughed up in the solution in anhydrous methylene chloride (10mL).Mixture 20 is stirred to react to divide
The dilution of Zhong Bingyong methylene chloride, and sequence saturated aqueous ammonium chloride and salt water washing.Organic phase is dried using magnesium sulfate,
It filters and excessive methylene chloride is removed by rotary evaporation under reduced pressure.Obtained residue 63 is used as the thick of next reaction
Mixture.LC/MS, 42.38min (ES+) m/z (relative intensity) 922.16 ([M+H]+, 40).
(d) (11S, 11aS) -11- hydroxyl -7- methoxyl group -8- ((5- ((oxo -5 (S) -7- methoxyl group -2- methyl -5-,
11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza8- yl) oxygroup) amyl) oxygroup) -2- methyl -5-
Oxo -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza- 10 (5H)-carboxylic acid 4- ((2S, 5S)-
37- (2,5- dioxo-2,5- dihydro-1H- pyrroles-1- base) trioxy--10,13,16-5- isopropyl-2- methyl-4,7,35-,
Eight oxa- -3,6,34- of 19,22,25,28,31-, three azepine heptatriacontane amino) benzyl ester (64)
1- ethyl -3- (3 '-dimethyl aminopropyl) carbodiimide (EDCI, 33mg, 0.172mmol) is added to thick 63
(0.172mmol) and Mal- (PEG)8Sour (100mg, 0.172mmol) is in the solution in anhydrous methylene chloride (10mL).It stirs
It mixes reaction 2 hours and cannot observe the presence of starting material again by LC/MS.With methylene chloride diluting reaction and with water and
Salt water sequential purge.Using the dry organic phase of magnesium sulfate, filters and excessive dichloromethane is removed by rotary evaporation under reduced pressure
Alkane.The residue made is subjected to flash column chromatography (silica gel, 100% chloroform, 10% methanol into chloroform).It collects and merges pure
Part and excessive eluent removed by rotary evaporation under reduced pressure (25%) 60mg, 3 step yields is to provide 64 (E).
Embodiment 8
Compound 65 is the compound 79 of WO 2011/130598.
(11S) -11- hydroxyl -7- methoxyl group -8- (3- ((7- methoxyl group -5- oxo -2- ((E) -propyl- 1- alkene -1- base) -5,
11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza8- yl) oxygroup) propoxyl group) -5- oxo -2-
((E) -propyl- 1- alkene -1- base) -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza10 (5H)-carboxylics
Sour 4- (four oxa- -3,19,22- of 1- iodo -20- isopropyl -23- methyl -2,18,21- trioxy- -6,9,12,15-, three azepine
Lignocerane amino) benzyl ester (66) ((11S) -4- (1-iodo-20-isopropyl-23-methyl-2,18,21-
trioxo-6,9,12,15-tetraoxa-3,19,22-triazatetracosanamido)benzyl11-hydroxy-7-
methoxy-8-(3-((7-methoxy-5-oxo-2-((E)-prop-1-en-1-yl)-5,11a-dihydro-1H-benzo
[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)propoxy)-5-oxo-2-((E)-prop-1-en-1-
yl)-11,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10(5H)-
carboxylate)
By N, N '-diisopropylcarbodiimide (DIC, 4.71 μ L, 0.0304mmol) is added to amine 65 (0.0276mmol)
With iodo-(PEG)4Sour (13.1mg, 0.0304mmol) is in the solution in anhydrous methylene chloride (0.8mL).It is stirred to react 3
Hour and the presence that cannot observe starting material again by LC/MS.Reaction mixture is directly loaded to thin-layer chromatography
(TLC) it is purified on plate and by prep-TLC (10% methanol in chloroform).Pure band is scraped from TLC plate, is extracted in chloroform
In 10% methanol, filters and excessive solvent is removed to obtain 66 (D) (20.9mg, 56%) by rotary evaporation under reduced pressure.LC/
MS, method 2,3.08min (ES+) m/z (relative intensity) 1361.16 ([M+H]+, 100).
The General Experimental Procedures of embodiment 9
Using the 1200 series LC/MS of Agilent with 6110 quadrupole MS of Agilent, obtained with electrospray ionization
Obtain LCMS data.0.1% acetic acid of mobile phase A-in water.Mobile phase B-in acetonitrile 0.1%.Flow velocity is 1.00ml/ points
Clock.Gradient is to rise to 95%B from 5%B through 3 minutes, is maintained at 95%B lower 1 minute, then fell back to 5%B through 6 seconds.Total fortune
The row time is 5 minutes.Column: Phenomenex Gemini-NX 3 μm of C18,30 × 2.00mm.Based on the UV inspection at 254nm
The tomographic map of survey.Mass spectrum is obtained using MS and with cation mode (positive mode).Made based on δ scale with 400MHz
With Bruker AV400, to measure proton nmr chemical shift value.Following abbreviation: s has been used, it is unimodal;D, it is bimodal;T, three
Weight peak;Q, quartet;M, multiplet;Br, it is wide.Coupling constant is reported as unit of Hz.Unless otherwise indicated, Merck is used
Kieselgel silica (Art.9385) carries out column chromatography (passing through fast procedure).It is separated using coupling in Waters 2795HPLC
The Waters Micromass LCT instrument of module acquires mass spectrography (MS) data.With silica gel aluminium sheet (Merck 60, F254) into
Row thin-layer chromatography (TLC).Every other chemicals and solvent purchased from Sigma-Aldrich or Fisher Scientific and
Further purifying is used without such as supply.
Optical activity (Optical is measured with 220 polarimeter of ADP (Bellingham Stanley Ltd.)
Rotation concentration (c) is provided) and as unit of g/100mL.It is measured using numeral melting point instrument (Electrothermal)
Fusing point.IR spectrum is recorded with Perkin-Elmer Spectrum 1000FT IR spectrometer.Bruker is used at 300k
Avance NMR spectrometer obtains at 400 and 100MHz respectively1H and13C H NMR spectroscopy.It is reported relative to TMS (δ=0.0ppm)
Chemical shift is accused, and signal is designated as s (unimodal), d (bimodal), t (triplet), dt (double triplets), dd (bimodal pair
Peak), ddd (bimodal double doublet) or m (multiplet), and be that unit provides coupling constant with hertz (Hz).Using coupling in tool
There is the Waters MicromassZQ instrument of the Waters 2695HPLC of Waters 2996PDA to acquire mass spectrography (MS) number
According to.The Waters Micromass ZQ parameter used is: capillary pressure (kV), 3.38;Cone (V), 35;Extractor (V),
3.0;Source temperature (DEG C), 100;Desolvation temperature (DEG C), 200;Cone flow rate (L/h), 50;Desolvation flow velocity (L/
H), 250.High resolution mass spec method is recorded with Waters Micromass QTOF Global and with cationic W mode
(HRMS) data, wherein introducing the sample into instrument using the Pyrex tip of metal coating.With silica gel aluminium sheet (Merck
60,F254) thin-layer chromatography (TLC) is carried out, and with silica gel (Merck 60,230-400 mesh ASTM) Lai Jinhang flash chromatography.It removes
Except HOBt (NovaBiochem) and supported reagents (Argonaut), every other chemicals and solvent are purchased from Sigma-
Aldrich is simultaneously used without further purifying such as supply.Under a dry nitrogen atmosphere, having existing for appropriate desiccant
Under the conditions of, prepare anhydrous solvent by distilling, andIt is stored on molecular sieve or sodium wire.Petroleum ether refers to boil at 40-60 DEG C
The fraction risen.
General LC/MS condition: it is run using the mobile phase of water (A) (formic acid 0.1%) and acetonitrile (B) (formic acid 0.1%)
HPLC(Waters Alliance 2695).Gradient: Initial Composition 5%B, through 1.0 minutes, then 5%B was arrived in 3 minutes
95%B.At 95%B, composition is kept 0.5 minute, returned to 5%B in 0.3 minute originally.Total gradient runing time is equal to 5 points
Clock.Flow velocity is 3.0mL/ minutes, separates 400 μ L via zero dead volume T shape pipe, is passed into mass spectrograph.Wavelength detection range:
220 to 400nm.Function type: diode array (535 scanning).Column: Onyx Monolithic
C1850×4.60mm。
Embodiment 9
(i) main intermediate
(a)
(a-i) (S) -2- (allyloxycarbonyl amino) -3 Methylbutanoic acid (I2)
Allyl chlorocarbonate (36.2mL, 340.59mmol, 1.2 equivalent) is added dropwise to Valine (I1)
(33.25g, 283.82mmol, 1.0 equivalent) and potassium carbonate (59.27g, 425.74mmol, 1.5 equivalent) in water (650mL) and
In agitating solution in THF (650mL).Reaction mixture is stirred at room temperature 18 hours, solvent is then concentrated under reduced pressure and is used in combination
Diethyl ether (3 × 100mL) extracts surplus solution.Aqueous fractions are acidified to pH 2 with dense HCl and are extracted with DCM (3 × 100mL)
It takes.It is washed with brine the organic matter of merging, uses MgSO4It dries, filters and is concentrated under reduced pressure to be provided as the product of colorless oil
(57.1g, it is assumed that yield 100%).LC/MS(1.966min(ES+)), m/z:202.1 [M+H]+。1H NMR (400MHz, DMSO-
d6) δ 12.57 (br s, 1H), 7.43 (d, 1H, J=8.6Hz), 5.96-5.86 (m, 1H), 5.30 (ddd, 1H, J=17.2,
3.4,1.7Hz), 5.18 (ddd, 1H, J=10.4,2.9,1.6Hz), 4.48 (dt, 2H, J=5.3,1.5Hz), 3.85 (dd,
1H, J=8.6,6.0Hz), 2.03 (oct, 1H, J=6.6Hz), 0.89 (d, 3H, J=6.4Hz), 0.87 (d, 3H, J=
6.5Hz)。
(a-ii) (S) -2- (allyloxycarbonyl amino) -3 Methylbutanoic acid 2,5- dioxo pyrrolidin -1- base ester (I3)
To protection sour I2 (60.6g, 301.16mmol, 1.0 equivalent) and n-hydroxysuccinimide (34.66g,
301.16mmol, 1.0 equivalents) in the agitating solution in anhydrous THF (800mL) add dicyclohexylcarbodiimide (62.14g,
301.16mmol 1 equivalent).At room temperature by reaction stirring 18 hours.Then reaction mixture is filtered, washs solid simultaneously with THF
It is concentrated under reduced pressure the filtrate of merging.Residual is re-dissolved in DCM and is allowed to rest for 30 minutes at 0 DEG C.Filter suspension
And it is washed with cold DCM.Product (the 84.7g, it is assumed that 100% produces that the filtrate being concentrated under reduced pressure provides as thick colorless oil
Rate), next step is used for without being further purified.LC/MS(2.194min(ES+)), m/z:321.0 [M+Na]+。1H
NMR (400MHz, DMSO-d6) δ 8.0 (d, 1H, J=8.3Hz), 5.97-5.87 (m, 1H), 5.30 (ddd, 1H, J=17.2,
3.0,1.7Hz), 5.19 (ddd, 1H, J=10.4,2.7,1.4Hz), 4.52 (dt, 2H, J=5.3,1.4Hz), 4.32 (dd,
1H, J=8.3,6.6Hz), 2.81 (m, 4H), 2.18 (oct, 1H, J=6.7Hz), 1.00 (d, 6H, J=6.8Hz),
(a-iii) (S) -2- ((S) -2- (allyloxycarbonyl amino) -3- methylbutylamino) propionic acid (I4)
Solution of the succinimide ester I3 (12.99g, 43.55mmol, 1.0 equivalent) in THF (50mL) is added to L-
Alanine (4.07g, 45.73mmol, 1.05 equivalent) and NaHCO3(4.02g, 47.90mmol, 1.1 equivalent) is at THF (100mL)
And H2In solution in O (100mL).When removing THF under reduced pressure, stir the mixture at room temperature 72 hours.Use lemon
PH is adjusted to 3-4 with precipitate white glue (gum) by acid.After ethyl acetate (6 × 150mL) extraction, H is used2O (200mL) washing
Combined organic matter, uses MgSO4It dries, filters and is concentrated under reduced pressure.With diethyl ether development to be provided as the product of white powder simultaneously
By filtering and using diethyl ether (5.78g, 49%) washing to collect the product.LC/MS(1.925min(ES+)), m/z:273.1
[M+H]+。1H NMR (400MHz, DMSO-d6) δ 12.47 (br s, 1H), 8.17 (d, 1H, J=6.8Hz), 7.16 (d, 1H, J=
9.0Hz), 5.95-5.85 (m, 1H), 5.29 (dd, 1H, J=17.2,1.7Hz), 5.17 (dd, 1H, J=10.4,1.5Hz),
4.46 (m, 2H), 4.18 (quin, 1H, J=7.2Hz), 3.87 (dd, 1H, J=9.0,7.1Hz), 1.95 (oct, 1H, J=
6.8Hz), 1.26 (d, 3H, J=7.3Hz), 0.88 (d, 3H, J=6.8Hz), 0.83 (d, 3H, J=6.8Hz)
(a-iv) (S)-1- ((S)-1- (4- (methylol) phenylamino)-1- oxo propyl- 2- base amino)-3- methyl-1-oxygen
For butyl- 2- aminocarbamic acid allyl ester (I5)
EEDQ (5.51g, 22.29mmol, 1.05 equivalent) is added to aminobenzyl alcohol (2.74g, 22.29mmol, 1.05
Equivalent) and acid I4 (5.78g, 21.23mmol, 1 equivalent) in the solution in anhydrous THF (100mL) and be stirred at room temperature 72
Hour.Then, reaction mixture is concentrated under reduced pressure and develops resulting brown solid with diethyl ether and filters, then with excessive two
Ether is washed to be provided as the product (7.1g, 88%) of pale solid.LC/MS(1.980min(ES+)), m/z:378.0 [M+
H]+。1H NMR (400MHz, DMSO-d6) δ 9.89 (br s, 1H), 8.13 (d, 1H, J=7.0Hz), 7.52 (d, 2H, J=
8.5Hz), 7.26 (m, 1H), 7.23 (d, 2H, J=8.5Hz), 5.91 (m, 1H), 5.30 (m, 1H), 5.17 (m, 1H), 4.46
(m, 2H), 5.09 (t, 1H, J=5.6Hz), 4.48 (m, 2H), 4.42 (m, 3H), 3.89 (dd, 1H, J=8.6,6.8Hz),
1.97 (m, 1H), 1.30 (d, 3H, J=7.1Hz), 0.88 (d, 3H, J=6.8Hz), 0.83 (d, 3H, J=6.7Hz).(b)
Four oxa- -3- azepine octadecane -18- of 1- iodo -2- oxo -6,9,12,15- is sour (I7)
Solution of the iodoacetic anhydride (0.250g, 0.706mmol, 1.1 equivalent) in anhydrous DCM (1mL) is added to ammonia
Base-PEG(4)Acid I6 (0.170g, 0.642mmol, 1.0 equivalent) is in the solution in DCM (1mL).It stirs in the dark at room temperature
Mixture is mixed to stay overnight.With 0.1M HCl, water washing reaction mixture, MgSO is used4It dries, filters and is concentrated under reduced pressure.By quick
(silica gel, the solution of 3% methanol and 0.1% formic acid in chloroform to 10% methanol and 0.1% formic acid are molten in chloroform for chromatography
Liquid) residue is purified to be provided as the product (0.118g, 42%) of orange oil.LC/MS(1.623min(ES+)), m/z:
433.98[M+H]+。1H NMR (400MHz, CDCl3) δ 8.069 (s, 1H), 7.22 (br s, 1H), 3.79 (t, 2H, J=
5.8Hz), 3.74 (s, 2H), 3.72-3.58 (m, 14H), 3.50-3.46 (m, 2H), 2.62 (t, 2H, J=5.8Hz).
(ii) (11S, 11aS) -11- (t-butyldimethylsilyloxy base) -8- (3- iodo propoxyl group) -7- methoxyl group -
5- oxo -2- ((E) -propyl- 1- alkenyl) -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza
10
(5H)-carboxylic acid allyl esters (74)
(a) (S)-trifluoromethanesulfonic acid 5- ((t-butyldimethylsilyl oxygroup) methyl) -1- (5- methoxyl group -2- nitre
Base -4- (triisopropyl siloxy) benzoyl) -4,5- dihydro -1H- pyrroles -3- base ester (47)
At -50 DEG C, trifluoromethanesulfanhydride anhydride (28.4g, 100.0mmol, 3.0 equivalent) is added dropwise in 25 minutes to play
Ketone 46 (19.5g, 30.0mmol, 1.0 for containing 2,6- lutidines (14.4g, 130.0mmol, 4.0 equivalent) of strong stirring
Equivalent) in the solution in DCM (550mL).It is stirred to react mixture 1.5 hours, LC/MS Indicator Reaction is completed at this time.Successively
Organic phase is washed with water (100mL), saturated sodium bicarbonate (150mL), salt water (50mL) and uses MgSO4Dry organic phase, decompression
It filters and is concentrated.By flash chromatography (silica gel, 90/10v/v n-hexane/EtOAc) purifying residual to be provided as light yellow oil
Product (19.5g, 82%).LC/MS(4.391min(ES+)), m/z:713.25 [M+H]+。1H NMR (400MHz, CDCl3)δ
7.68 (s, 1H), 6.72 (s, 1H), 6.02 (t, 1H, J=1.9Hz), 4.75 (m, 1H), 4.05 (m, 2H), 3.87 (s, 3H),
3.15 (ddd, 1H, J=16.2,10.3,2.3Hz), 2.96 (ddd, 1H, J=16.2,4.0,1.6Hz), 1.28-1.21 (m,
3H), 1.07 (d, 18H, J=7.2Hz), 0.88 (s, 9H), 0.09 (s, 3H), 0.08 (s, 3H).
(b) (S, E)-(2- ((t-butyldimethylsilyl oxygroup) methyl) -4- (propyl- 1- alkenyl) -2,3- dihydro -
1H- pyrroles -1- base) (5- methoxyl group -2- nitro -4- (triisopropyl siloxy) phenyl) ketone (67)
In a nitrogen atmosphere, tetrakis triphenylphosphine palladium (0) (0.41g, 0.35mmol, 0.03 equivalent) is added to fluoroform
Sulphonic acid ester 47 (8.4g, 11.8mmol, 1.0 equivalent), E-1- propylene -1- ylboronic acid (1.42g, 16.5mmol, 1.4 equivalent) and phosphorus
Sour potassium (5.0g, 23.6mmol, 2.0 equivalent) is in the mixture in anhydrous dioxanes (60mL).At 25 DEG C, mixture is stirred
120 minutes, LC/MS showed fully reacting at this time.Ethyl acetate (120mL) and water (120mL) is added, removes organic phase, uses salt
Water (20mL) washing, uses MgSO4It is dry, it is filtered under diminished pressure and is concentrated.Pass through flash chromatography (silica gel, 95/5v/v n-hexane/EtOAc
Residual is purified to 90/10v/v n-hexane/EtOAc) to be provided as the product (4.96g, 70%) of yellow colored foam.LC/MS
(4.477min(ES+)), m/z:605.0 [M+H]+。1H NMR (400MHz, CDCl3) δ 7.67 (s, 1H), 6.74 (s, 1H),
(5.93 d, 1H, J=15.4Hz), 5.67 (s, 1H), 4.65 (m, 1H), 4.04 (m, 2H), 3.86 (s, 3H), 2.85 (m, 1H),
2.71 (m, 1H), 1.72 (dd, 3H, J=6.8,1.0Hz), 1.30-1.22 (m, 3H), 1.07 (d, 18H, J=7.2Hz), 0.87
(s, 9H), 0.08 (s, 3H), 0.07 (s, 3H).
(c) (S, E)-(2- amino -5- methoxyl group -4- (triisopropyl siloxy) phenyl) (2- ((tert-butyl diformazan
Base silicyl oxygroup) methyl) -4- (propyl- 1- alkenyl) -2,3- dihydro -1H- pyrroles -1- base) ketone (68)
Temperature is maintained between 25-30 DEG C using ice bath, in 20 minutes, by zinc powder, (22.0g, 0.33mol, 37 work as
Amount) acrylic intermediate 67 (5.5g, 9.1mmol, 1.0 equivalent) is partially added in 5%v/v formic acid/ethyl alcohol (55mL)
In solution.After 30 minutes, pass through the short bed filtration reaction mixture of diatomite.Diatomite is washed simultaneously with ethyl acetate (65mL)
Successively the organic phase merged is washed with water (35mL), saturated sodium bicarbonate (35mL) and salt water (10mL).Use MgSO4Drying is organic
Phase is filtered under diminished pressure and is concentrated.It is pale yellow to be provided as by flash chromatography (silica gel, 90/10v/v n-hexane/EtOAc) purifying residual
The product (3.6g, 69.0%) of color oil.LC/MS(4.439min(ES+)), m/z:575.2 [M+H]+。1H NMR (400MHz,
CDCl3) δ 6.75 (m, 1H), 6.40 (br s, 1H), 6.28 (m, 1H), 6.11 (d, 1H, J=15.4Hz), 5.53 (m, 1H),
4.67 (m, 1H), 4.36 (m, 2H), 3.93 (br s, 1H), 3.84 (br s, 1H), 3.73 (s, 3H), 2.86 (dd, 1H, J=
15.7,10.4Hz), 2.73 (dd, 1H, J=15.9,4.5Hz), 1.80 (dd, 3H, J=6.8,1.3Hz), 1.35-1.23 (m,
3H), 1.12 (d, 18H, J=7.3Hz), 0.89 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H).
(d) (S, E) -2- (2- ((t-butyldimethylsilyl oxygroup) methyl) -4- (propyl- 1- alkenyl) -2,3- two
Hydrogen -1H- pyrroles -1- carbonyl) -4- methoxyl group -5- (triisopropyl siloxy) phenylcarbamic acid allyl ester (69)
At -78 DEG C, allyl chlorocarbonate (0.83g, 6.88mmol, 1.1 equivalent) is added to containing anhydrous pyridine
Solution of the amine 68 (3.6g, 6.26mmol, 1.0 equivalent) of (1.09g, 13.77mmol, 2.2 equivalent) in anhydrous DCM (80mL)
In.It removes dry ice and reaction mixture is warming up to room temperature.After being stirred for 15 minutes, LC/MS shows fully reacting.Successively use
0.01N HCl (50mL), saturated sodium bicarbonate (50mL), salt water (10mL) wash organic phase, use MgSO4It is dry, it is filtered under diminished pressure
And be concentrated to generate light yellow oil, the oil does not have to be further purified and be used in next step (4.12g, it is assumed that yield 100%).
LC/MS(4.862min(ES+)), m/z:659.2 [M+H]+。
(e) (S, E) -2- (2- (hydroxymethyl) -4- (propyl- 1- alkenyl) -2,3- dihydro -1H- pyrroles -1- carbonyl) -4- first
Oxygroup -5- (triisopropyl siloxy) phenylcarbamic acid allyl ester (70)
Crude intermediate 69 (it is assumed that yield 100%, 4.12g, 6.25mmol, 1.0 equivalent) is dissolved in acetic acid (70mL), first
In the mixture of alcohol (10mL), THF (10mL) and water (20mL) and it is stirred at room temperature.After 6 hours, ethyl acetate is used
(500mL) diluted reaction mixture is simultaneously successively washed with water (2 × 500mL), saturated sodium bicarbonate (300mL) and salt water (50mL)
It washs.Use MgSO4Dry organic phase, is filtered under diminished pressure and is concentrated.Pass through flash chromatography (silica gel, 1/99v/v methanol/DCM to 5/95v/
V methanol/DCM) residue is purified to be provided as the product of yellow oil and recycle the unreacted starting material of 1g.Make the material
It is subjected to reaction condition as described above, but stirs 16h.Post-processing and after purification, separate other product (2.7g,
79%, 2 steps), LC/MS (3.742min (ES+), m/z:545.2 [M+H]+。1H NMR (400MHz, CDCl3) δ 8.38 (m, 1H),
7.72 (m, 1H), 6.81 (s, 1H), 6.37 (m, 1H), 6.10 (d, 1H, J=15.8Hz), 5.97 (m, 1H), 5.53 (m, 1H),
5.36 (ddd, 1H, J=17.2,3.1,1.5Hz), 5.25 (ddd, 1H, J=10.4,2.5,1.3Hz), 4.78 (m, 1H), 4.65
(dt, 2H, J=5.7,1.3Hz), 3.84 (m, 3H), 3.79 (s, 3H), 3.04 (dd, 1H, J=16.7,10.5Hz), 2.40
(dd, 1H, J=16.0,4.5Hz), 1.82 (dd, 3H, J=6.8,1.0Hz), 1.36-1.26 (m, 3H), 1.14 (d, 18H, J=
7.3Hz)。
(f) (11S, 11aS) -11- hydroxyl -7- methoxyl group -5- oxo -2- ((E) -propyl- 1- alkenyl) -8- (triisopropyl first
Siloxy) -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza10 (5H)-carboxylic acid allyls
Ester (71)
Under nitrogen atmosphere, anhydrous dimethyl sulfoxide (1.16g, 14.87mmol, 3.0 equivalent) is added dropwise to grass at -78 DEG C
Acyl chlorides (0.94g, 7.43mmol, 1.5 equivalent) is in the solution in DCM (25mL).- 78 DEG C are kept the temperature at, after ten minutes,
Solution of the primary alconol 70 (2.7g, 4.96mmol, 1.0 equivalent) in DCM (20mL) is added dropwise.After other 15 minutes, nothing is added
Water triethylamine (2.5g, 24.78mmol, 5.0eq) and reaction mixture is heated to room temperature.Successively with the HCl of cold 0.1N
(50ml), saturated sodium bicarbonate (50mL), salt water (10mL) washing reaction mixture simultaneously use MgSO4Dry organic layer, was depressurized
It filters and is concentrated to be produced as the product of yellow oil, the product does not have to be further purified and be used for (2.68g, it is assumed that produce in next step
Rate 100%).LC/MS(3.548min(ES+)), m/z:543.2 [M+H]+。
(g) (11S, 11aS) -11- (t-butyldimethylsilyloxy base) -7- methoxyl group -5- oxo -2- ((E) -propyl-
1- alkenyl) -8- (triisopropylsilyl oxygroup) -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] phenodiazine
It is miscellaneous10 (5H)-carboxylic acid allyl esters (72)
Under nitrogen atmosphere, at 0 DEG C, by tert-butyl dimethyl silyl triflate, (3.93g, 14.87mmol, 3.0 work as
Amount) it is added to carbinolamine 71 (it is assumed that yield 100%, 2.68g, 4.96mmol, 1.0 equivalent) and 2,6- lutidines
(2.12g, 19.83mmol, 4.0 equivalent) is in the solution in anhydrous DCM (40mL).After ten minutes, reaction mixture is heated
To room temperature and it is further stirred for 60 minutes.It is successively washed with water (10mL), saturated sodium bicarbonate (10mL) and salt water (5mL) organic
Phase uses MgSO4It is dry, it is filtered under diminished pressure and is concentrated.It is purified by flash chromatography (silica gel, chloroform to 2/98v/v alcohol/chloroform) residual
Excess is to be provided as the product (2.0g, 63%, 2 step) of yellow oil.LC/MS(4.748min(ES+)), m/z:657.2 [M+H]+。1H NMR (400MHz, CDCl3) δ 7.19 (s, 1H), 6.86 (m, 1H), 6.66 (s, 1H), 6.22 (d, 1H, J=15.4Hz),
5.81 (d, 1H, J=8.8Hz), 5.78 (m, 1H), 5.48 (m, 1H), 5.11 (d, 1H, J=5.0Hz), 5.08 (m, 1H), 4.58
(dd, 1H, J=13.4,5.4Hz), 4.35 (dd, 1H, J=13.2,5.7Hz), 3.83 (s, 3H), 3.76 (s, 1H), 3.00
(dd, 1H, J=15.6,11.0Hz), 2.53 (m, 1H), 1.81 (dd, 3H, J=6.8,0.9Hz), 1.30-1.18 (m, 3H),
1.08 (d, 9H, J=2.3Hz), 1.06 (d, 9H, J=2.3Hz), 0.86 (s, 9H), 0.25 (s, 3H), 0.18 (s, 3H).
(h) (11S, 11aS) -11- (t-butyldimethylsilyl oxygroup) -8- hydroxyl -7- methoxyl group -5- oxo -2-
((E) -propyl- 1- alkenyl) -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza- 10 (5H)-carboxylic acids
Allyl ester (73)
At 25 DEG C, two hydrations lithium acetate (0.31g, 3.04mmol, 1.0eq) are added to diaza72 (2.0g,
3.04mmol, 1.0eq) in the solution in aqueous DMF (20mL) and stir 4 hours.With ethyl acetate (200mL) diluting reaction
Mixture uses MgSO successively with 0.1M citric acid (50mL, pH 3), water (50mL) and salt water (10mL) washing4It is dry, decompression
It filters and is concentrated.It is purified by flash chromatography (silica gel, 50/50v/v n-hexane/EtOAc to 25/75v/v n-hexane/EtOAc)
Residual is to provide product as light yellow solid (0.68g, 45%).LC/MS(3.352min(ES+)), m/z:501.1 [M+H]+。1H
NMR (400MHz, CDCl3) δ 7.02 (s, 1H), 6.66 (m, 1H), 6.53 (s, 1H), 6.03 (d, 1H, J=15.5Hz), 5.80
(s, 1H), 5.63 (d, 1H, J=8.9Hz), 5.55 (m, 1H), 5.29 (m, 1H), 4.87 (m, 2H), 4.39 (dd, 1H, J=
13.5,4.2Hz), 4.20 (dd, 1H, J=13.2,5.7Hz), 3.73 (s, 3H), 3.59 (m, 1H), 2.81 (dd, 1H, J=
16.1,10.5Hz), 2.35 (d, 1H, J=15.7Hz), 1.61 (d, 3H, J=6.4Hz), 0.67 (s, 9H), 0.05 (s, 3H),
0.00 (s, 3H).
(i) (11S, 11aS) -11- (t-butyldimethylsilyl oxygroup) -8- (3- iodo propoxyl group) -7- methoxy
Base -5- oxo -2- ((E) -propyl- 1- alkenyl) -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza
10 (5H)-carboxylic acid allyl esters (74)
By diiodo propane (0.295g, 1.00mmol, 5.0 equivalent) and potassium carbonate (0.028g, 0.20mmol, 1.0 equivalent)
Phenol 33 (0.100g, 0.020mmol, 1.0 equivalent) is added in the solution in dry acetone (5ml).By reaction mixture
It is heated 6 hours at 60 DEG C, LC/MS shows fully reacting at this time.Reaction mixture is concentrated under reduced pressure to drying and by fast
Fast chromatography (silica gel, 75/25v/v n-hexane/EtOAc to 50/50v/v n-hexane/EtOAc) purification residues are colourless to be provided as
The product (0.074g, 56%) of oil.LC/MS(3.853min(ES+)), m/z:669.0 [M+H]+。1H NMR (400MHz,
CDCl3) δ 7.26 (s, 1H), 6.90 (s, 1H), 6.68 (s, 1H), 6.24 (d, 1H, J=15.3Hz), 5.87 (d, 1H, J=
8.9Hz), 5.78 (m, 1H), 5.53 (m, 1H), 5.12 (m, 2H), 4.65 (m, 2H), 4.41 (m, 1H), 4.11 (m, 1H), 3.93
(s, 3H), 3.81 (m, 1H), 3.40 (t, 2H, J=6.7Hz), 3.05 (dd, 1H, J=16.3,10.1Hz), 2.57 (m, 1H),
2.34 (m, 2H), 1.84 (d, 3H, J=6.6Hz), 0.92 (s, 9H), 0.28 (s, 3H), 0.26 (s, 3H).
(iii) (11S, 11aS) -11- (t-butyldimethylsilyloxy base) -8- hydroxyl -7- methoxyl group -5- oxo -2-
((E) -propyl- 1- alkenyl) -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza
- 10 (5H)-carboxylic acids
4- ((S) -2- ((S) -2- (allyloxy carbonyl ammonia base) -3- methylbutylamino) the third amino) benzyl ester (79)
(a) ((S) -1- (((S) -1- ((4- ((((2- ((S) -2- (((t-butyldimethylsilyl) oxygroup) first
Base) -4- ((E) -propyl- 1- alkene -1- base) -2,3- dihydro -1H- pyrroles -1- carbonyl) -4- methoxyl group -5- ((triisopropyl monosilane
Base) oxygroup) phenyl) carbamoyl) oxygroup) methyl) phenyl) amino)-1- oxopropan-2- base) amino)-3- methyl-1-
Oxo-butanes -2- base) allyl carbamate (75)
Under 5 DEG C (ice bath), by triethylamine (0.256ml, 1.84mmol, 2.2 equivalent) be added to amine 68 (0.480g,
0.835mmol, 1.0 equivalents) and stirring of the triphosgene (0.089g, 0.301mmol, 0.36 equivalent) in anhydrous THF (15mL)
In solution.It is anti-to monitor isocyanates by removing part from reaction mixture interval, being terminated with methanol and carrying out lcms analysis
The progress answered.Once the reaction of isocyanates is completed, then by injection by alloc-Val-Ala-PABOH I5 (0.473g,
1.25mmol, 1.5 equivalents) and solution of the triethylamine (0.174ml, 1.25mmol, 1.5 equivalent) in anhydrous THF (10mL) it is fast
Speed is added in freshly prepared isocyanates.At 40 DEG C, reaction stirring 4 hours is then stirred at room temperature overnight.Decompression
Be concentrated mixture and by flash chromatography (silica gel, 20/80v/v n-hexane/EtOAc to 50/50v/v n-hexane/EtOAc, then
1/99v/v DCM/MeOH to 5/95v/v DCM/MeOH) it purifies to provide yellow solid product (0.579g, 71%).LC/
MS(4.468min(ES+)), m/z:978.55 [M+H]+。1H NMR (400MHz, CDCl3) δ 8.63 (br s, 1H), 8.42 (s,
1H), 7.78 (br s, 1H), 7.53 (d, 2H, J=8.1Hz), 7.31 (d, 2H, J=8.6Hz), 6.76 (s, 1H), 6.59 (d,
1H, J=7.6Hz), 6.36 (br s, 1H), 6.04 (d, 1H, J=15.9Hz), 5.90 (m, 1H), 5.55 (m, 1H), 5.33-
5.21 (m, 3H), 5.10 (s, 2H), 4.66 (m, 2H), 4.57 (dd, 2H, J=5.6,1.0Hz), 3.98 (dd, 1H, J=7.3,
6.8Hz), 3.90 (m, 1H), 3.81 (m, 1H), 3.78 (s, 3H), 2.82 (dd, 1H, J=15.4,9.6Hz), 2.72 (dd, 1H,
J=15.9,3.5Hz), 2.17 (m, 1H), 1.78 (dd, 3H, J=6.5,0.8Hz), 1.46 (d, 3H, J=7.1Hz), 1.29
(m, 3H), 1.11 (d, 18H, J=7.1Hz), 0.97 (d, 3H, J=6.8Hz), 0.92 (d, 3H, J=6.8Hz), 0.83 (s,
9H), 0.04 (s, 3H), 0.01 (s, 3H).
(b) ((S) -1- (((S) -1- ((4- ((((2- ((S) -2- (methylol) -4- ((E) -propyl- 1- alkene -1- base) -2,3-
Dihydro -1H- pyrroles -1- carbonyl) -4- methoxyl group -5- ((triisopropylsilyl) oxygroup) phenyl) carbamoyl) oxygroup)
Methyl) phenyl) amino)-1- oxopropan-2- base) amino)-3- methyl-1-oxo-butanes-2- base) allyl carbamate
(76)
By silyl ether 75 (1.49g, 1.52mmol, 1.0 equivalent) be dissolved in acetic acid/methanol/tetrahydrofuran/water (14:
In 7:1:1:2 mixture 2:2:4ml) and it is stirred at room temperature.After 2 hours, with EtOAc (100mL) diluting reaction, successively use
Water, sodium bicarbonate aqueous solution washing, are then washed with brine.Then MgSO is used4Dry organic phase, is filtered under diminished pressure and is concentrated.It is logical
Flash chromatography (silica gel, 100/0, then 99/1 to 92/8v/v DCM/ methanol) purifying residue is crossed to be provided as orange solids
Product (1.2g, 92%).LC/MS(3.649min(ES+)), m/z:865.44 [M+H]+。1H NMR (400MHz, CDCl3)δ
8.44 (s, 1H), 8.35 (s, 1H), 7.69 (br s, 1H), 7.53 (d, 2H, J=8.7Hz), 7.32 (d, 2H, J=8.3Hz),
6.78 (s, 1H), 6.56 (m, 2H), 6.32 (br s, 1H), 6.05 (d, 1H, J=14.9Hz), 5.90 (m, 1H), 5.56 (m,
1H), 5.30 (m, 2H), 5.22 (m, 1H), 5.10 (d, 2H, J=3.1Hz), 4.73 (m, 1H), 4.64 (m, 1H), 4.57 (d,
2H, J=5.8Hz), 4.01 (m, 1H), 3.79 (m, 2H), 3.76 (s, 3H), 2.98 (dd, 1H, J=16.3,10.2Hz), 2.38
(dd, 1H, J=16.6,4.1Hz), 2.16 (m, 1H), 1.78 (dd, 3H, J=6.8,0.9Hz), 1.46 (d, 3H, J=
7.1Hz), 1.29 (m, 3H), 1.11 (d, 18H, J=7.4Hz), 0.97 (d, 3H, J=6.7Hz), 0.92 (d, 3H, J=
6.8Hz)。
(c) (11S, 11aS) -11- hydroxyl -7- methoxyl group -5- oxo -2- ((E) -propyl- 1- alkenyl) -8- (triisopropyl first
Siloxy) -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza10 (5H)-carboxylic acid 4- ((S)-
2- ((S) -2- (allyloxy carbonyl ammonia base) -3- methylbutylamino) third amino) benzyl ester (77)
Under nitrogen atmosphere, anhydrous dimethyl sulfoxide (0.180g, 2.3mmol, 3.0 equivalent) is added dropwise to grass at -78 DEG C
Acyl chlorides (0.147g, 1.1mmol, 1.5 equivalent) is in the solution in DCM (10mL).Temperature is maintained -78 DEG C, after twenty minutes,
Solution of the primary alconol 76 (0.666g, 0.77mmol, 1.0 equivalent) in DCM (10mL) is added dropwise.After other 15 minutes, it is added
Anhydrous triethylamine (0.390g, 3.85mmol, 5.0 equivalent) and reaction mixture is warming up to room temperature.Successively with cold 0.1N
HCl (10mL), saturated sodium bicarbonate (10mL) and salt water (5mL) washing reaction mixture.Then MgSO is used4Drying is organic
Layer, is filtered under diminished pressure and is concentrated.Then by flash chromatography (silica gel, 50/50v/v n-hexane/EtOAc to 25/75v/v n-hexane/
EtOAc) purifying residual is to provide white solid product (0.356g, 54%).LC/MS(3.487min(ES+)), m/z:
862.2[M+H]+。1H NMR (400MHz, CDCl3) δ 8.34 (br s, 1H), 7.47 (d, 2H, J=7.6Hz), 7.17 (s, 1H),
7.14 (d, 2H, J=7.5Hz), 6.86 (br s, 1H), 6.65 (br s, 1H), 6.42 (d, 1H, J=7.6Hz), 6.22 (d,
1H, J=14.4Hz), 5.80 (m, 1H), 5.40 (m, 1H), 5.53 (m, 1H), 5.32 (m, 1H), 5.21 (d, 2H, J=
9.6Hz), 5.06 (d, 1H, J=12.3Hz), 4.90 (m, 1H), 4.58 (m, 3H), 3.98 (m, 1H), 3.84 (m, 1H), 3.81
(s, 3H), 3.50 (m, 1H), 3.05 (dd, 1H, J=16.0,10.3Hz), 2.76 (m, 1H), 2.15 (m, 1H), 1.80 (dd,
3H, J=6.7,0.8Hz), 1.44 (d, 3H, J=7.1Hz), 1.16 (m, 3H), 1.01 (d, 18H, J=6.6Hz), 0.96 (d,
3H, J=6.8Hz), 0.92 (d, 3H, J=6.8Hz).
(d) (11S, 11aS) -11- (t-butyldimethylsilyloxy base) -7- methoxyl group -5- oxo -2- ((E) -propyl-
1- alkenyl) -8- (triisopropyl siloxy) -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza10 (5H)-carboxylic acid 4- ((S) -2- ((S) -2- (allyloxy carbonyl ammonia base) -3- methylbutylamino) the third amino) benzyl ester
(78)
Under nitrogen atmosphere, at 0 DEG C, by t-butyldimethylsilyl triflate (0.46g, 1.74mmol,
3.0 equivalents) it is added to secondary alcohol 77 (0.5g, 0.58mmol, 1.0 equivalent) and 2,6- lutidines (0.25g, 2.32mmol,
4.0 equivalents) in the solution in anhydrous DCM (10mL).After ten minutes, reaction mixture is heated to room temperature and be further stirred for
120 minutes.Then organic phase successively is washed with water (10mL), saturated sodium bicarbonate (10mL) and salt water (5mL), uses MgSO4It is dry
It is dry, it is filtered under diminished pressure and is concentrated.By flash chromatography (silica gel, 50/50v/v n-hexane/EtOAc) purifying residual to be provided as white
The product (0.320g, 57%) of solid.LC/MS(4.415min(ES+)), m/z:976.52 [M+H]+。1H NMR (400MHz,
CDCl3) δ 8.31 (br s, 1H), 7.48 (d, 2H, J=8.0Hz), 7.21 (s, 1H), 7.14 (d, 2H, J=8.3Hz), 6.89
(s, 1H), 6.65 (s, 1H), 6.38 (d, 1H, J=7.3Hz), 6.25 (d, 1H, J=14.6Hz), 5.93 (m, 1H), 5.85 (d,
1H, J=8.8Hz), 5.50 (m, 1H), 5.34 (m, 1H), 5.24 (m, 2H), 5.15 (d, 1H, J=12.5Hz), 4.86 (d, 1H,
J=12.2Hz), 4.62 (m, 3H), 4.01 (m, 1H), 3.86 (s, 3H), 3.78 (m, 1H), 3.04 (m, 1H), 2.56 (m, 1H),
2.20 (m, 1H), 1.84 (dd, 3H, J=6.6,0.7Hz), 1.48 (d, 3H, J=6.8Hz), 1.20 (m, 3H), 1.05 (d, 9H,
J=2.9Hz), 1.03 (d, 9H, J=2.9Hz), 0.99 (d, 3H, J=6.8Hz), 0.95 (d, 3H, J=6.8Hz), 0.88 (s,
9H), 0.27 (s, 3H), 0.14 (s, 3H).
(e) (11S, 11aS) -11- (t-butyldimethylsilyl oxygroup) -8- hydroxyl -7- methoxyl group -5- oxo -2-
((E) -propyl- 1- alkenyl) -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza- 10 (5H)-carboxylic acids
4- ((S) -2- ((S) -2- (allyloxy carbonyl ammonia base) -3- methylbutylamino) the third amino) benzyl ester (79)
At 25 DEG C, two hydrations lithium acetate (0.010g, 0.10mmol, 1.0 equivalent) are added to silyl ether 78
(0.100g, 0.10mmol, 1.0 equivalent) is 3 hours in the solution in aqueous DMF (2mL).Then dilute with ethyl acetate (20mL)
Reaction mixture is released, successively with 0.1M citric acid (20mL, pH 3), water (20mL) and salt water (5mL) washing, uses MgSO4It is dry,
It is filtered under diminished pressure and is concentrated.By flash chromatography (silica gel, 5/95v/v methanol/DCM) purification residues to be provided as light yellow oil
Product (0.070g, 83%).LC/MS(3.362min(ES+)), m/z:820.2 [M+H]+。1H NMR (400MHz, CDCl3)δ
8.39 (s, 1H), 7.48 (d, 2H, J=8.2Hz), 7.25 (s, 1H), 7.12 (d, 2H, J=8.1Hz), 6.88 (s, 1H), 6.68
(s, 1H), 6.47 (d, 1H, J=7.6Hz), 6.24 (d, 1H, J=15.2Hz), 6.03 (s, 1H), 5.92 (m, 1H), 5.84 (d,
1H, J=8.9Hz), 5.50 (m, 1H), 5.34 (m, 1H), 5.26 (m, 2H), 5.18 (d, 1H, J=12.3Hz), 4.80 (d, 1H,
J=12.4Hz), 4.66-4.60 (m, 3H), 4.02 (m, 1H), 3.95 (s, 3H), 3.81 (m, 1H), 3.03 (m, 1H), 2.57
(m, 1H), 2.19 (m, 1H), 1.84 (dd, 3H, J=6.8,0.8Hz), 1.48 (d, 3H, J=7.1Hz), 1.00 (d, 3H, J=
6.8Hz), 0.95 (d, 3H, J=6.8Hz), 0.87 (s, 9H), 0.26 (s, 3H), 0.12 (s, 3H).
(iv) (11S, 11aS) -11- hydroxyl -7- methoxyl group -8- (3- ((S) -7- methoxyl group -5- oxo -2- ((E) -propyl-
1- alkenyl) -5,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza
8- base oxygroup) propoxyl group) -5- oxygen
Generation -2- ((E) -propyl- 1- alkenyl) -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza
10(5H)-
Carboxylic acid 4- (four oxa- -3 (20S, 23S) -1- iodo -20- isopropyl -23- methyl -2,18,21- trioxy- -6,9,12,15-,
19,22- tri- azepine lignocerane amino) benzyl ester (66, D)
(a) (11S, 11aS) -8- (3- ((11S, 11aS) -10- ((4- ((R) -2- ((R) -2- (allyloxy carbonyl ammonia
Base) -3- methylbutylamino) the third amino) benzyloxy) carbonyl) -11- (t-butyldimethylsilyloxy base) -7- methoxyl group -5-
Oxo -2- ((E) -propyl- 1- alkenyl) -5,10,11,11a- tetrahydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza
8- base oxygroup) propoxyl group) -11- (t-butyldimethylsilyloxy base) -7- methoxyl group -5- oxo -2- ((E) -propyl- 1- alkene
Base) -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza10 (5H)-carboxylic acid allyl esters (80)
Potassium carbonate (0.030g, 0.21mmol, 1.0 equivalent) is added to phenol 79, and (0.175g, 0.21mmol, 1.0 work as
Amount) and iodine connector 74 (0.214g, 0.32mmol, 1.5 equivalent) in the solution in acetone (10mL).By reaction mixture in nitrogen
It is heated 17 hours in sealing triangular flask under atmosphere at 75 DEG C.Reaction mixture is concentrated under reduced pressure to drying and by quick
Chromatography (silica gel, 2/98v/v methanol/DCM to 5/95v/v methanol/DCM) is purified to be provided as the product of light yellow solid
(0.100g, 35%).LC/MS(4.293min(ES+)), m/z:1359.13 [M]+。
(b) (11S, 11aS) -8- (3- ((11S, 11aS) -10- ((4- ((R) -2- ((R) -2- (allyloxy carbonyl ammonia
Base) -3- methylbutylamino) the third amino) benzyloxy) carbonyl) -11- hydroxyl -7- methoxyl group -5- oxo -2- ((E) -propyl- 1- alkene
Base) -5,10,11,11a- tetrahydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza8- base oxygroup) propoxyl group)-
11- hydroxyl -7- methoxyl group -5- oxo -2- ((E) -propyl- 1- alkenyl) -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a]
[1,4] diaza10 (5H)-carboxylic acid allyl esters (81)
By four n-butylamine fluorides (1M, 0.22mL, 0.22mmol, 2 equivalent) be added to silyl ether 80 (0.150g,
0.11mmol, 1.0 equivalents) in the solution in anhydrous THF (2mL).Reaction mixture is stirred at room temperature 20 minutes, at this time
LC/MS Indicator Reaction is complete.It is sequentially washed with ethyl acetate (10mL) diluted reaction mixture and with water (5mL) and salt water (5mL)
It washs.Use MgSO4Dry organic phase, is filtered under diminished pressure and is concentrated to leave yellow solid.Pass through flash chromatography (silica gel, 6/94v/v first
Alcohol/DCM to 10/90v/v methanol/DCM) it is purified to be provided as the product of light yellow solid (0.090g, 73%).LC/MS
(2.947min(ES+)), m/z:1154.0 [M+Na]+。1H NMR (400MHz, CDCl3) δ 8.39 (br s, 1H), 7.39 (d,
2H, J=7.6Hz), 7.18 (d, 2H, J=10.6Hz), 7.10 (m, 3H), 6.86 (d, 2H, J=10.0Hz), 6.74 (s, 1H),
6.55 (s, 1H), 6.22 (dd, 2H, J=15.3,6.6Hz), 5.85 (m, 2H), 5.74 (m, 3H), 5.52 (m, 2H), 5.22 (m,
1H), 5.00 (m, 2H), 4.57 (m, 6H), 4.41 (m, 2H), 4.09 (m, 4H), 3.85 (m, 11H), 3.06 (m, 2H), 2.76
(m, 2H), 2.20 (m, 2H), 2.08 (m, 1H), 1.79 (d, 6H, J=6.4Hz), 1.40 (d, 3H, J=6.1Hz), 0.90 (m,
6H)。
(c) (11S, 11aS) -11- hydroxyl -7- methoxyl group -8- (3- ((S) -7- methoxyl group -5- oxo -2- ((E) -propyl- 1-
Alkenyl) -5,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza8- base oxygroup) propoxyl group) -5- oxygen
Generation -2- ((E) -propyl- 1- alkenyl) -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza10(5H)-
Carboxylic acid 4- ((R) -2- ((R) -2- amino -3- methylbutylamino) the third amino) benzyl ester (65)
Tetrakis triphenylphosphine palladium (0) (0.005g, 0.005mmol, 0.06 equivalent) is added to double-carbinolamine 81
(0.090g, 0.08mmol, 1.0 equivalent) and pyrrolidines (16 μ L, 0.20mmol, 2.5 equivalent) are molten in anhydrous DCM (5mL)
In liquid.After twenty minutes, with DCM (10mL) diluted reaction mixture and successively with saturated aqueous ammonium chloride (5mL) and salt water
(5mL) washing, uses MgSO4It is dry, it is filtered under diminished pressure and removes solvent with remaining pale-yellow solid crude product, without being further purified
It is used for next step (0.075g, it is assumed that 100% yield).LC/MS(2.060min(ES+)), m/z:947.2 [M+H]+。
(d) (11S, 11aS) -11- hydroxyl -7- methoxyl group -8- (3- ((S) -7- methoxyl group -5- oxo -2- ((E) -propyl- 1-
Alkenyl) -5,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza8- base oxygroup) propoxyl group) -5- oxygen
Generation -2- ((E) -propyl- 1- alkenyl) -11,11a- dihydro -1H- benzo [e] pyrrolo- [1,2-a] [1,4] diaza10(5H)-
Carboxylic acid 4- (four oxa- -3 (20S, 23S) -1- iodo -20- isopropyl -23- methyl -2,18,21- trioxy- -6,9,12,15-,
19,22- tri- azepine lignocerane amino) benzyl ester (66, D)
By EDCI (0.015g, 0.08mmol, 1.0 equivalent) be added to amine 65 (it is assumed that 100% yield, 0.075g,
0.08mmol, 1.0 equivalents) and iodo-acetamide-PEG4Acid I7 (0.034g, 0.08mmol, 1.0 equivalent) is in anhydrous dichloromethane
It is stirred to react in solution in alkane (5mL) and in the dark.After 50 minutes, the iodo-acetamide-EG of additional amount is added4Acid I7
The EDCI (0.003g, 0.016mmol, 0.2 equivalent) of (0.007g, 0.016mmol, 0.2 equivalent) and additional amount.2.5 is small in total
Shi Hou with methylene chloride (15mL) diluted reaction mixture and is successively washed with water (10mL) and salt water (10mL).Use MgSO4It is dry
Dry organic phase is filtered under diminished pressure and is concentrated.It is purified by flash chromatography (silica gel, chloroform 100% to 90:10v/v chloroform: methanol)
The residue arrived.Merge pure part to provide product (0.0254g, 23%, 2 step).It collects crude product part and passes through preparation
Type TLC (silica gel, 90:10v/v chloroform: methanol) is purified to provide the product (0.0036g, 3%, 2 step) of second batch.LC/MS
(2.689min(ES+)), m/z:681.01/2 [M+2H]+。
Embodiment 10: the activity of the compound of release
K562 measurement
At 37 DEG C, containing 5%CO2Humid atmosphere in, K562 human chronic's marrow leukaemia cell is maintained at supplement
Have in the RPM11640 culture medium of 10% fetal calf serum and 2mM glutamine and 37 DEG C in the dark, with the medicine of given dose
Object is incubated for 1 hour or 96 hours.It is terminated by centrifugation (5min, 300g) and is incubated for and washs cell one with the culture medium of no drug
It is secondary.After drug-treated appropriate, cell is transferred to (10 in the microtiter plate in the hole 96-4Cells/well, 8 holes/sample).It will
The plate is maintained at 37 DEG C, containing 5%CO2Humid atmosphere dark place.Measurement is with living cells by yellow soluble tetrazolium salts (bromination
3- (4,5- dimethylthiazole -2- base) -2,5- diphenyl -2H- tetrazolium (MTT, Aldrich-Sigma)) it is reduced to insoluble purple
Based on the ability of Se formazan precipitating.Next plate is incubated for 4 days (to allow to control cell in quantitative aspects increase about 10
Times), plate to each hole and is further incubated for 5h by 20 μ L MTT solution (5mg/mL in the physiological saline of phosphate-buffered).So
Plate 5min is centrifuged with 300g afterwards, most of culture mediums are sucked out from cell precipitation, leave 10-20 holes μ L/.It is added into every hole
DMSO (200 μ L) and stirred sample are to ensure to be thoroughly mixed.Then in Titertek Multiscan ELISA microplate reader
Optical density is read under the wavelength of 550nm and constructs dose-response curve.For every curve, by IC50Value is read as will be final
Dosage needed for optical density is reduced to the 50% of control value.
In the measurement, compound R elC has the IC less than 0.1pM50。
In the measurement, compound R elE has the IC of 0.425nM50。
Embodiment 11: the formation of conjugate
General antibody binding step
In reduction buffer solution, (example: phosphate buffered saline PBS, histidine buffer solution, sodium borate buffer are molten
Liquid, TRIS buffer solution) in antibody is diluted to 1-5mg/mL.By freshly prepared TCEP (three (2- carboxyethyl) phosphonium salt hydrochlorates)
Solution be added in the cysteine disulphide bridges of selective reduction.The amount of TCEP and reduction (reducing, reduction)
Targeting is horizontal proportional, in 1 to 4 molar equivalent/antibody, generates 2 to 8 reactive mercaptan.After 37 DEG C of reduction a few hours,
Mixture is cooled to room temperature and the agent-linker of excessive addition (A, B, C, D, E) is (final as diluted DMSO solution
DMSO content is up to 10% volume/reaction mixture volume).Mixture reasonable time is jiggled at 4 DEG C or at room temperature,
Elongated is 1-3 hours.It is combining finally, excess reactivity mercaptan can be with " mercaptan capping reagent " (such as N- ethyl maleimide
Amine (NEM)) reaction.It is combined using the centrifugal filter concentrated antibody with 10kDa or higher Molecular weight cut-off value-drug
Then object is purified by tangential flow filtration (TFF) or fast protein liquid chromatogram (FPLC).Using with UV- visible light, fluorescence
Or reverse chromatograms (RP) or hydrophobic interaction chromatography (HIC) that mass spectrograph detection combines, high performance liquid chromatography (HPLC) can be passed through
Or ultra performance liquid chromatography (UHPLC) analysis determines corresponding antibody-drug conjugates to assess drug/Antibody ratio (DAR);
The size exclusion combined is detected using with UV- visible light, fluorescence or mass spectrograph, HPLC or UHPLC analysis aggregation water can be passed through
Gentle monomer purity.It can be determined by the combination of spectrum (being absorbed at 280,214 and 330nm) and biochemical measurement final
Conjugate concentration (bicinchonic acid assay BCA;Smith,P.K.,et al.(1985)
Anal.Biochem.150(1):76–85;Use the IgG antibody of known concentration as reference).Usually used under aseptic condition
0.2 μm of Filter Sterile filters antibody-drug conjugates and stores it in+4 DEG C, -20 DEG C or -80 DEG C.
DAR is determined
Original antibody is gone back by 10 μ L borate buffer solutions (100mM, pH 8.4) of addition and 5 μ L DTT (0.5M in water)
Or ADC (35 μ L in about 35 μ g) and 37 DEG C heat 15 minutes.With the acetonitrile of 1 volume: water: formic acid (49%:49%:2%v/v)
Dilute sample and in being injected to UPLC system (Shimadzu Nexera), 80 DEG C of 3.6 μ XB- of Widepore
In C18150 × 2.1mm (P/N00F-4482-AN) column (Phenomenex Aeris), flow rate 1ml/min, with 75%
Buffer solution A (water, trifluoroacetic acid (0.1%v/v) (TFA), 25% buffer solution B (acetonitrile: water: TFA90%:10%:0.1%
V/v it) balances.25% to 55% buffer solution gradient elution bond material is used in 10min.The UV at 214nm is integrated to absorb
Peak.Next peak identified to each ADC or antibody: natural antibody light chain (L0), natural antibody heavy chain (H0) and being added with medicine
Each of these chains of object-connector are (for the light chain with a drug labeled as L1 and for having 1,2 or 3 company
The heavy chain of the agent-linker connect is labeled as H1, H2, H3.It for identification include the piece of agent-linker by the UV chromatography at 330nm
Section (that is, L1, H1, H2, H3).
Calculate the PBD/ protein molar ratios of light chain and heavy chain:
Final DAR is calculated according to following:
DAR measurement is carried out at 214nm, because of the minimum interference that 214nm absorbs agent-linker.
Generate the ADC for being directed to PSMA
By antibody A (including variable domains, be the SEQ ID NO.3 pairs of with SEQ ID NO.4) and drug connector A
In conjunction with being 2.62 with the DAR for obtaining Conj A-A and measuring.
By antibody A (including variable domains, be the SEQ ID NO.3 pairs of with SEQ ID NO.4) and drug connector B
In conjunction with being 2.43 with the DAR for obtaining Conj A-B and measuring.
By antibody A (including variable domains, be the SEQ ID NO.3 pairs of with SEQ ID NO.4) and drug connector D
In conjunction with being 2.35 with the DAR for obtaining Conj A-D and measuring.
By antibody A (including variable domains, be the SEQ ID NO.3 pairs of with SEQ ID NO.4) and drug connector E
In conjunction with being 2.34 with the DAR for obtaining Conj A-E and measuring.
It is described below other ADC.
DeJ591 is comprising with the VH structural domain according to the sequence of SEQ ID NO.3 and with according to SEQ ID NO.4
Sequence VL structural domain anti-PSMA antibody.
By the way that deJ591 antibody is bound to the ADC that drug connector A, E or D generate targeting PSMA.Obtained ADC is listed in down
In table, it is next to the DAR measured.The non-PSMA targeting ADC of control is generated using B12 AntiHIV1 RT activity gp120 antibody.
ADC | DAR | Concentration [mg/ml] | Yield [%] |
deJ591-A | 2.35 | 2.72 | 66 |
deJ591-E | 2.76 | 2.65 | 72 |
deJ591-D | 2.0 | 1.42 | 59 |
B12-A | 2.06 | 1.47 | 49 |
B12-E | 1.88 | 1.34 | 68 |
B12-D | 2.26 | 1.17 | 48 |
The vitro cytotoxicity of embodiment 12:ADC
Cell culture
Generous donation of the LNCaP and PC3 cell from John Hartley professor (UCL).Cell culture medium is supplement
There are Pidolidone and the RPMI 1640 of 10%FBS.Cell is grown in 37 DEG C, 5%CO2, in moist incubator.
Cytotoxicity detection
Suspended cell culture (at most 1 × 10 is determined by expecting that (Trypan) indigo plant 1:1 is mixed with platform6/ ml) concentration and
Survival ability and with hemacytometer rolling counters forward transparent (work)/indigo plant (dead) cell.Cell suspending liquid is diluted to required
Inoculum density (usually 105/ ml) and distributed into 96 hole flat undersides.Alma indigo plant is measured, by 100 holes μ l/ point
It fits in black holes plate.MTS is measured, by the distribution of 50 holes μ l/ in transparent orifice plate.Pass through the ADC dilution that will be sterile filtered
The stock solution (1ml) of ADC (20 μ g/ml) is prepared into cell culture medium.By the cell that 100 μ l are continuously transferred to 900 μ l
In culture medium, one group of 8 × 10 times of dilution of preparation deposit ADC in 24 orifice plates.By each ADC dilution (for alma
Blue 100 holes μ l/, for 50 hole μ l/ MTS) it distributes into 4 repeating holes of 96 orifice plates comprising cell suspending liquid.Control wells are only
Receive the culture medium of same volume.After being incubated for 4 days, pass through alma indigo plant or MTS analysis measurement cell viability.
It will(Invitrogen, catalog number DAL1025) distributes into each hole (20 hole μ l/) simultaneously
At 37 DEG C in supply CO2Couveuse in be incubated for 4 hours.Go out measured hole fluorescence in excitation 570nm, transmitting 585nm., by 4
ADC processing hole in mean fluorecence compared with the mean fluorecence in 4 control wells (100%) ratio calculation cell survival rate
(%).
MTS (Promega, catalog number G5421) is distributed into each hole to (20 hole μ l/) and at 37 DEG C in supply CO2
Couveuse in be incubated for 4 hours.It measures and absorbs at 490nm.The average absorption and 4 control wells in hole handled by 4 ADC
In average absorption compared to (100%) calculate cell survival rate (%).The average data for repeating experiment by 3 groups generates dose response
Curve and the dosage that data are fitted to S-shaped having a variable slope by using Prism (GraphPad, San Diego, CA)
Response curve determines EC50。
Vitro cytotoxicity
The above deJ591ADC is tested to the effect of LNCaP cell.Use PC3 cell as PSMA negative control.
Fig. 1 shows vitro efficacy of the deJ591ADC in LNCaP cell.What it is with LNCap cell incubation deJ591ADC is
10 times of dilutions of column (μ g/mL).The measurement of alma indigo plant is finally carried out in the incubation stage and calculates cell survival rate.Image represents three
A average value for repeating experiment.
All three deJ591ADC of test show the significant cytotoxicity (Fig. 1) to LNCaP cell.
deJ591-A | deJ591-E | deJ591-D | |
EC50μg/mL | 0.01856 | 0.006856 | 0.004897 |
Identical experiment is repeated with PSMA-ve cell (PC3), is shown without the cytotoxic effect (Fig. 2) of concentration dependant.
The AntiHIV1 RT activity gp120 antibody (B12) that identical head (warhead) will be connected to is used as negative control ADC.Such as with
On, with 10 times of dilutions of series (μ g/mL) of LNCap cell incubation B12ADC.Alma indigo plant survey is finally carried out in the incubation stage
Determine and calculates cell survival rate.Image in Fig. 3 and Fig. 4 indicates the average value of three repetition experiments.
Three kinds of non-binding B12ADC conjugates show the substantially less than effect of the deJ591 of equal value in conjunction with A, E and D respectively.
Identical experiment is repeated with PSMA-ve cell (PC3), is shown without the cytotoxic effect (Fig. 4) of concentration dependant again.
The internal anti-tumor activity of embodiment 13-ADC
Using the measurement of cell line LNCaP derived from PSMA+ (ve) human prostate cancer deJ591-A ADC in murine heterotropic
In vivo efficacy in transplantation model.The AntiHIV1 RT activity gp120 antibody (B12) for being connected to identical drug connector is combined as non-PSMA
Control.
Researching and designing
Drug and treatment:
Group number | Animal/group | ADC | Dosage level (mg/kg) | Dose volume (ml/kg) |
1 | 10 | [only carrier] | - | - |
2 | 10 | deJ591-A | 0.3 | 10 |
3 | 10 | deJ591-A | 1.0 | 10 |
4 | 10 | B12-A | 0.3 | 10 |
5 | 10 | B12-A | 1.0 | 10 |
Step:
CR female NCr nu/nu mouse is set, there is the I x I at side of body portion (flank) in 0%Matrigel sc
LNCaP-SPN tumour cell.
Cell infusion volume is 0.1mL/ mouse.
The age of from date: 8 to 12 weeks.
When tumour reaches 100-150mm3Average-size when, matched in pairs and start to treat.
Weight: qd × 5, then bi-wk is to the end.
Calliper to measure: bi-wk is to the end.
Immediately any adverse reaction or death are reported.
Be euthanized have single observation to > 30% weight loss or three times continuously measure > 25% weight loss
Any individual animals.
Any group for measuring the average weight mitigation or > 10% death rate with > 20% twice can be stopped being administered.
The group that is not euthanized simultaneously allows to restore.In the group with > 20% weight saving, euthanasia is reached into single weight loss terminal
Individual.If treatment group relevant to weight loss restores to the 10% of original weight, can with relatively low-dose or
The dosage regimen of lower frequency continues to be administered.The exception that non-treatment weight % can be allowed to restore on the basis of case analysis
(exception)。
Terminal TGD.Animal will be separately monitored.Experimental endpoints are for 2000mm3Gross tumor volume or 60 days, whichever
First reach.Respondent can carry out more long.When reaching terminal, be euthanized animal.
Universal method approach
Calculating for group mean tumour volume, application are regular once:, will when animal is withdrawn from the study due to tumor size
Final gross tumor volume for animal record is included with data, the average external volume for calculated for subsequent time point.Error rod figure
Indicate average standard error (SEM).When being less than the reservation of 50% animal in group under study for action, not by gross tumor volume value based on
Calculation group mean tumour volume.It is analyzed using Prism (GraphPad, San Diego, CA) for graphical representation and data.
As a result
Fig. 5 shows the deJ591-A in LNCaP heteroplastic transplantation model.When every experimental group mean tumour volume reaches
0.1cm3When, it is administered to mouse and they is treated by the IV in tail vein with the ADC single dose of 0.3 and 1mg/kg.Number
According to mean tumour volume (+/- SEM) of the expression from every group of 10 mouse.
It is active (Fig. 5) that the deJ591-A of each concentration shows effective antitumour.DeJ591-A is shown noticeably greater than
The anti-tumor activity of non-binding ADC (B12-A) control.
Abbreviation
Ac acetyl group
Acm acetylamino methyl
Alloc allyloxy carbonyl
Bis- dimethyl dicarbonate butyl ester of Boc
T-Bu tert-butyl
Bzl benzyl, wherein Bzl-OMe is methoxy-benzyl and Bzl-Me is methylbenzyl
Cbz or Z benzyloxy-carbonyl, wherein Z-Cl and Z-Br is chlorobenzyloxycarbonyl and bromo-benzyloxy carbonyl respectively
DMF N,N-dimethylformamide
Dnp dinitrophenyl
DTT dithiothreitol (DTT)
Fmoc 9H- fluorenes-ylmeth-oxycarbonyl
Imp N-10 imines blocking group: 3- (2- methoxy ethoxy) propionic ester-Val-Ala-PAB
MC-OSu maleimidocaproyl-O-N- succinimide
Moc methoxycarbonyl
MP maleimide propionamide
Mtr 4- methoxyl group -2,3,6- trimethylphenysulfonyl
PAB is to aminobenzyloxycarbonyl
PEG ethyleneoxy
PNZ is to nitrobenzylamino formic acid esters
Psec 2- (phenyl sulfonyl) ethoxy carbonyl
TBDMS t-butyldimethylsilyl
TBDPS t-butyldiphenylsilyl
Teoc 2- (trimethyl silyl) ethoxy carbonyl
Tos tosyl
Troc 2,2,2- tri-chloroethoxy base carbonyl chloride
Trt trityl
Xan xanthyl
Claims (14)
1. a kind of conjugate of following formula:
ConjA:
,
ConjD:
,
Or ConjE:
Wherein, Ab is the antibody for being bound to PSMA, and the antibody includes to have according to SEQ ID NO. 1,3,5,7,8,9 or 10
In any sequence VH structural domain;And
Wherein, the drugloading rate (p) of drug (D) to antibody (Ab) is 1 to 8 integer.
2. conjugate according to claim 1, wherein the antibody further include have according to SEQ ID NO. 2,
4, the VL structural domain of sequence any in 6,11,12,13,14,15,16,17 or 18.
3. conjugate according to claim 2, wherein the VH structural domain and the VL structural domain have following pairs of
Sequence:
Pairs of SEQ ID NO.1 and SEQ ID NO.4 pairs of SEQ ID NO.3 and SEQ ID with SEQ ID NO.2
NO.6 pairs of SEQ ID NO.5 and SEQ ID NO.11 pairs of SEQ ID NO.7 and SEQ ID NO.12 pairs of SEQ
ID NO.7 and SEQ ID NO.13 pairs of SEQ ID NO.7 and SEQ ID NO.14 pairs of SEQ ID NO.7 and SEQ
It is ID NO.15 pairs of SEQ ID NO.7, SEQ ID NO.7 pairs of with SEQ ID NO.16, pairs of with SEQ ID NO.17
SEQ ID NO.7, with SEQ ID NO.18 pairs of SEQ ID NO.7, with SEQ ID NO.11 pairs of SEQ ID
NO.8 and SEQ ID NO.12 pairs of SEQ ID NO.8 and SEQ ID NO.13 pairs of SEQ ID NO.8 and SEQ ID
NO.14 pairs of SEQ ID NO.8, with SEQ ID NO.15 pairs of SEQ ID NO.8, it is pairs of with SEQ ID NO.16
SEQ ID NO.8 and SEQ ID NO.17 pairs of SEQ ID NO.8 and SEQ ID NO.18 pairs of SEQ ID NO.8,
Pairs of SEQ ID NO.9 and SEQ ID NO.12 pairs of SEQ ID NO.9 and SEQ ID with SEQ ID NO.11
NO.13 pairs of SEQ ID NO.9, with SEQ ID NO.14 pairs of SEQ ID NO.9, it is pairs of with SEQ ID NO.15
SEQ ID NO.9 and SEQ ID NO.16 pairs of SEQ ID NO.9 and SEQ ID NO.17 pairs of SEQ ID NO.9,
Pairs of SEQ ID NO.9 and SEQ ID NO.11 pairs of SEQ ID NO.10 and SEQ ID with SEQ ID NO.18
NO.12 pairs of SEQ ID NO.10, with SEQ ID NO.13 pairs of SEQ ID NO.10, it is pairs of with SEQ ID NO.14
SEQ ID NO.10 and SEQ ID NO.15 pairs of SEQ ID NO.10 and SEQ ID NO.16 pairs of SEQ ID
The NO.10 and SEQ ID NO.17 pairs of SEQ ID NO.10 or SEQ ID NO.10 pairs of with SEQ ID NO.18.
4. conjugate according to any one of claim 1 to 3, wherein the antibody is complete antibody.
5. conjugate according to claim 1, wherein the antibody is humanization, removes immune or resurfacing.
6. conjugate according to claim 5, wherein the antibody is humanization below, removes immune or resurfacing
Version: (i) include the VH structural domain SEQ ID NO.1 pairs of with VL structural domain SEQ ID NO.2 antibody;(ii)WO02/
J519 antibody disclosed in 098897;(iii) antibody secreted by hybridoma ATCC accession number HB-12109;(iv) include and VL
The antibody of structural domain SEQ ID NO. 6 pairs of VH structural domain SEQ ID NO. 5;(v) J415 disclosed in WO02/098897
Antibody;(vi) antibody secreted by hybridoma ATCC accession number HB-12126.
7. conjugate according to claim 1, wherein the drugloading rate (p) is 1,2,3 or 4.
8. conjugate according to claim 7, the mixture including the antibody-drug conjugates compound, wherein institute
Drug loading/the antibody stated in the mixture of antibody-drug conjugates compound is 2 to 5.
9. conjugate according to any one of claim 1 to 8 answering in the drug that preparation is used to use in the treatment
With.
10. a kind of pharmaceutical composition includes conjugate described in any item of the claim 1 to 8 and pharmaceutically acceptable load
Body or excipient.
11. pharmaceutical composition described in any one of claim 10 further includes the chemotherapeutics of therapeutically effective amount.
12. conjugate according to any one of claim 1 to 8 is in preparation for the proliferative disease in subject
Purposes in drug used in treatment.
13. purposes described in claim 12, wherein the disease is cancer.
14. pharmaceutical composition described in any one of claim 10 is in preparation for treating the purposes in patient in the drug of cancer.
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261712928P | 2012-10-12 | 2012-10-12 | |
US201261712924P | 2012-10-12 | 2012-10-12 | |
US61/712,928 | 2012-10-12 | ||
US61/712,924 | 2012-10-12 | ||
US201361784525P | 2013-03-14 | 2013-03-14 | |
US201361784460P | 2013-03-14 | 2013-03-14 | |
US201361784477P | 2013-03-14 | 2013-03-14 | |
US61/784,477 | 2013-03-14 | ||
US61/784,460 | 2013-03-14 | ||
US61/784,525 | 2013-03-14 | ||
PCT/EP2013/071341 WO2014057113A1 (en) | 2012-10-12 | 2013-10-11 | Pyrrolobenzodiazepine - anti-psma antibody conjugates |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105102003A CN105102003A (en) | 2015-11-25 |
CN105102003B true CN105102003B (en) | 2019-03-05 |
Family
ID=49641717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380065405.7A Expired - Fee Related CN105102003B (en) | 2012-10-12 | 2013-10-11 | Tall and erect-anti-PSMA antibody conjugates of Pyrrolobenzodiazepines |
Country Status (22)
Country | Link |
---|---|
US (1) | US10751346B2 (en) |
EP (1) | EP2906253B9 (en) |
JP (1) | JP6270859B2 (en) |
KR (1) | KR101986404B1 (en) |
CN (1) | CN105102003B (en) |
AU (1) | AU2013328619B2 (en) |
BR (1) | BR112015008173A2 (en) |
CA (1) | CA2887894C (en) |
CY (1) | CY1120916T1 (en) |
DK (1) | DK2906253T3 (en) |
ES (1) | ES2690067T3 (en) |
HR (1) | HRP20181646T2 (en) |
HU (1) | HUE041274T2 (en) |
LT (1) | LT2906253T (en) |
MX (1) | MX364326B (en) |
NZ (1) | NZ707486A (en) |
PL (1) | PL2906253T3 (en) |
PT (1) | PT2906253T (en) |
RS (1) | RS57694B1 (en) |
SI (1) | SI2906253T1 (en) |
TR (1) | TR201815418T4 (en) |
WO (1) | WO2014057113A1 (en) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
BR112012026801B8 (en) | 2010-04-15 | 2021-05-25 | Medimmune Ltd | targeted pyrrolobenzodiazepine conjugates, pharmaceutical composition, use thereof for treatment of a proliferative or autoimmune disease and drug binding |
NZ602933A (en) | 2010-04-15 | 2014-09-26 | Seattle Genetics Inc | Pyrrolobenzodiazepines used to treat proliferative diseases |
CA2849039C (en) | 2011-09-20 | 2018-09-18 | Spirogen Sarl | Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates |
EA028457B1 (en) | 2011-10-14 | 2017-11-30 | Медимьюн Лимитед | Pyrrolobenzodiazepines |
CA2850264C (en) | 2011-10-14 | 2019-11-05 | Spirogen Sarl | Pyrrolobenzodiazepines |
AU2012322613B2 (en) | 2011-10-14 | 2016-04-21 | Medimmune Limited | Pyrrolobenzodiazepines and targeted conjugates |
WO2013055990A1 (en) | 2011-10-14 | 2013-04-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
CA2885305C (en) | 2012-10-12 | 2019-11-12 | Spirogen Sarl | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
SI3470086T1 (en) | 2012-10-12 | 2021-03-31 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
EP2839860B1 (en) | 2012-10-12 | 2019-05-01 | MedImmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
CN105102003B (en) | 2012-10-12 | 2019-03-05 | Adc疗法责任有限公司 | Tall and erect-anti-PSMA antibody conjugates of Pyrrolobenzodiazepines |
WO2014096365A1 (en) | 2012-12-21 | 2014-06-26 | Spirogen Sàrl | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
AU2013366493B2 (en) | 2012-12-21 | 2017-08-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
BR112015021965B1 (en) | 2013-03-13 | 2022-05-03 | Medimmune Limited | Pyrrolobenzodiazepine conjugates and compounds, pharmaceutical composition, use thereof for the treatment of a proliferative disease and method of synthesis of said compounds |
KR102057755B1 (en) | 2013-03-13 | 2019-12-19 | 메디뮨 리미티드 | Pyrrolobenzodiazepines and conjugates thereof |
GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
EP3054983B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
SI3191135T1 (en) | 2014-09-12 | 2021-01-29 | Genentech, Inc. | Anti-her2 antibodies and immunoconjugates |
GB201416112D0 (en) * | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
CA2968447A1 (en) | 2014-11-25 | 2016-06-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates and their use to treat neoplasms |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
GB201506393D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
MA43345A (en) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
GB201601431D0 (en) * | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
JP7093767B2 (en) | 2016-08-11 | 2022-06-30 | ジェネンテック, インコーポレイテッド | Pyrrolobenzodiazepine prodrug and its antibody conjugate |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
WO2018107109A1 (en) * | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Novel anti-kremen2 antibodies and methods of use |
CA3050085A1 (en) | 2017-01-20 | 2018-07-26 | Juno Therapeutics Gmbh | Cell surface conjugates and related cell compositions and methods |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
JP6671555B2 (en) | 2017-02-08 | 2020-03-25 | アーデーセー セラピューティクス ソシエテ アノニム | Pyrrolobenzodiazepine antibody conjugate |
AU2018219654B2 (en) | 2017-02-08 | 2019-10-10 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
CN109790171B (en) | 2017-03-29 | 2022-07-26 | 乐高化学生物科学股份有限公司 | Pyrrolobenzodiazepine dimer precursors and ligand-linker conjugate compounds thereof |
AU2018250336A1 (en) | 2017-04-07 | 2019-09-26 | Juno Therapeutics, Inc. | Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods |
JP2020517609A (en) | 2017-04-18 | 2020-06-18 | メディミューン リミテッド | Pyrrolobenzodiazepine complex |
CA3057748A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
EP3612235A1 (en) * | 2017-04-20 | 2020-02-26 | ADC Therapeutics SA | Combination therapy with an anti-psma antibody-drug conjugate |
CN110582303A (en) | 2017-04-20 | 2019-12-17 | Adc治疗有限公司 | Combination therapy with anti-CD 25 antibody-drug conjugates |
CA3064681A1 (en) | 2017-06-14 | 2018-12-20 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-cd25 adc |
WO2019034764A1 (en) * | 2017-08-18 | 2019-02-21 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
CN117003875A (en) | 2017-09-29 | 2023-11-07 | 第一三共株式会社 | Antibody or functional fragment thereof, polynucleotide, expression vector, host cell, sugar chain reconstruction antibody, pharmaceutical composition and application |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
US20210283141A1 (en) * | 2018-05-25 | 2021-09-16 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US20220347309A1 (en) | 2018-12-19 | 2022-11-03 | Adc Therapeutics Sa | Pyrrolobenzodiazepine resistance |
GB201820725D0 (en) | 2018-12-19 | 2019-01-30 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine resistance |
JP2022516911A (en) * | 2019-01-03 | 2022-03-03 | レゴケム バイオサイエンシズ, インク. | Pyrrolobenzodiazepine dimer compounds with improved stability and their uses |
KR20200084802A (en) | 2019-01-03 | 2020-07-13 | 주식회사 레고켐 바이오사이언스 | Pyrrolobenzodiazepine dimer compounds with improved safety and its use |
GB201908128D0 (en) | 2019-06-07 | 2019-07-24 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
CN114222588A (en) | 2019-08-12 | 2022-03-22 | 雷杰纳荣制药公司 | Macrophage stimulating 1 receptor (MST1R) variants and uses thereof |
GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
WO2023088966A1 (en) * | 2021-11-19 | 2023-05-25 | Adc Therapeutics Sa | Anti-psma conjugates |
WO2023173096A1 (en) * | 2022-03-11 | 2023-09-14 | Sigma-Aldrich Co. Llc | Pyrrolobenzodiazepine intermediates and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7514078B2 (en) * | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
Family Cites Families (352)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3361742A (en) | 1964-12-07 | 1968-01-02 | Hoffmann La Roche | 5-oxo-1h-pyrrolo-[2, 1-c][1, 4]-benzodiazepin-2-crylamides |
US3523941A (en) | 1967-03-06 | 1970-08-11 | Hoffmann La Roche | Benzodiazepine compounds and process for their preparation |
US3524849A (en) | 1967-10-27 | 1970-08-18 | Hoffmann La Roche | Process for the preparation of pyrrolo-benzodiazepine acrylamides and intermediates useful therein |
FR2027356A1 (en) | 1968-12-30 | 1970-09-25 | Fujisawa Pharmaceutical Co | Benzodiazepinone antibiotics |
JPS4843755B1 (en) | 1969-06-26 | 1973-12-20 | ||
IL33558A (en) | 1968-12-30 | 1973-10-25 | Fujisawa Pharmaceutical Co | Antibiotic pyrrolo-benzodiazepine compound,its derivatives and processes for their production |
JPS6053033B2 (en) | 1976-12-28 | 1985-11-22 | 財団法人微生物化学研究会 | New anticancer antibiotic mazethramycin and its production method |
JPS585916B2 (en) | 1977-12-27 | 1983-02-02 | 株式会社ミドリ十字 | New benzodiazepine compounds |
JPS5615289A (en) | 1979-07-17 | 1981-02-14 | Green Cross Corp:The | Novel benzodiazepinnbased compound 3 |
JPS57131791A (en) | 1980-12-31 | 1982-08-14 | Fujisawa Pharmaceut Co Ltd | Benzodiazepine derivative and its preparation |
CA1185602A (en) | 1981-02-27 | 1985-04-16 | Emilio Kyburz | Imidazodiazepines |
CA1173441A (en) | 1981-02-27 | 1984-08-28 | Hoffmann-La Roche Limited | Imidazodiazepines |
CA1184175A (en) | 1981-02-27 | 1985-03-19 | Walter Hunkeler | Imidazodiazepines |
JPS58180487A (en) | 1982-04-16 | 1983-10-21 | Kyowa Hakko Kogyo Co Ltd | Antibiotic dc-81 and its preparation |
US4427588A (en) | 1982-11-08 | 1984-01-24 | Bristol-Myers Company | Process for conversion of oxotomaymycin to tomaymycin |
US4427587A (en) | 1982-11-10 | 1984-01-24 | Bristol-Myers Company | Total synthesis of antitumor antibiotics BBM-2040A and BBM-2040B |
JPS59152329A (en) | 1983-02-17 | 1984-08-31 | Green Cross Corp:The | Local disorder inhibitor |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
FR2586683B1 (en) | 1985-08-29 | 1988-07-01 | Centre Nat Rech Scient | NOVEL NEOTHRAMYCIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS |
US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
JP2660201B2 (en) | 1988-08-05 | 1997-10-08 | 塩野義製薬株式会社 | Novel pyrrolo [1,4] benzodiazepine derivatives and senile dementia drugs |
CA2023779A1 (en) | 1989-08-23 | 1991-02-24 | Margaret D. Moore | Compositions and methods for detection and treatment of epstein-barr virus infection and immune disorders |
JPH053790A (en) | 1990-04-19 | 1993-01-14 | Fujisawa Pharmaceut Co Ltd | Dehydropeptidase-i |
US5256643A (en) | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
AU9016591A (en) | 1990-10-25 | 1992-05-26 | Tanox Biosystems, Inc. | Glycoproteins associated with membrane-bound immunoglobulins as antibody targets on B cells |
US5543503A (en) | 1991-03-29 | 1996-08-06 | Genentech Inc. | Antibodies to human IL-8 type A receptor |
DE69231223T3 (en) | 1991-03-29 | 2008-01-17 | Genentech, Inc., South San Francisco | HUMAN PF4A RECEPTORS AND THEIR USE |
US5440021A (en) | 1991-03-29 | 1995-08-08 | Chuntharapai; Anan | Antibodies to human IL-8 type B receptor |
FR2676230B1 (en) | 1991-05-07 | 1993-08-27 | Centre Nat Rech Scient | NOVEL PYRROLO [1,4] -BENZODIAZEPINES DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM. |
JP3050424B2 (en) | 1991-07-12 | 2000-06-12 | 塩野義製薬株式会社 | Human endothelin receptor |
US5264557A (en) | 1991-08-23 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Polypeptide of a human cripto-related gene, CR-3 |
US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
US6011146A (en) | 1991-11-15 | 2000-01-04 | Institut Pasteur | Altered major histocompatibility complex (MHC) determinant and methods of using the determinant |
US6153408A (en) | 1991-11-15 | 2000-11-28 | Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale | Altered major histocompatibility complex (MHC) determinant and methods of using the determinant |
GB9205051D0 (en) | 1992-03-09 | 1992-04-22 | Cancer Res Campaign Tech | Pyrrolobenzodiazepine derivatives,their preparation,and compositions containing them |
FR2696176B1 (en) | 1992-09-28 | 1994-11-10 | Synthelabo | Piperidine derivatives, their preparation and their therapeutic application. |
IL107366A (en) | 1992-10-23 | 2003-03-12 | Chugai Pharmaceutical Co Ltd | Genes coding for megakaryocyte potentiator |
US5644033A (en) | 1992-12-22 | 1997-07-01 | Health Research, Inc. | Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment |
US5869445A (en) | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
GB9316162D0 (en) | 1993-08-04 | 1993-09-22 | Zeneca Ltd | Fungicides |
US5773223A (en) | 1993-09-02 | 1998-06-30 | Chiron Corporation | Endothelin B1, (ETB1) receptor polypeptide and its encoding nucleic acid methods, and uses thereof |
EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
US5750370A (en) | 1995-06-06 | 1998-05-12 | Human Genome Sciences, Inc. | Nucleic acid encoding human endothlein-bombesin receptor and method of producing the receptor |
JPH08336393A (en) | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | Production of optically active gamma-substituted-beta-hydroxybutyric ester |
US5707829A (en) | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
US20020193567A1 (en) | 1995-08-11 | 2002-12-19 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
JP3646191B2 (en) | 1996-03-19 | 2005-05-11 | 大塚製薬株式会社 | Human gene |
US6218519B1 (en) | 1996-04-12 | 2001-04-17 | Pro-Neuron, Inc. | Compounds and methods for the selective treatment of cancer and bacterial infections |
AU722499B2 (en) | 1996-05-17 | 2000-08-03 | Schering Corporation | Human B-cell antigens, related reagents |
AU739028B2 (en) | 1996-09-27 | 2001-10-04 | Bristol-Myers Squibb Company | Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells |
US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
US5945511A (en) | 1997-02-20 | 1999-08-31 | Zymogenetics, Inc. | Class II cytokine receptor |
US7033827B2 (en) | 1997-02-25 | 2006-04-25 | Corixa Corporation | Prostate-specific polynucleotide compositions |
US20030185830A1 (en) | 1997-02-25 | 2003-10-02 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US6541212B2 (en) | 1997-03-10 | 2003-04-01 | The Regents Of The University Of California | Methods for detecting prostate stem cell antigen protein |
US6261791B1 (en) | 1997-03-10 | 2001-07-17 | The Regents Of The University Of California | Method for diagnosing cancer using specific PSCA antibodies |
WO1998040403A1 (en) | 1997-03-10 | 1998-09-17 | The Regents Of The University Of California | Psca: prostate stem cell antigen |
US6555339B1 (en) | 1997-04-14 | 2003-04-29 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human protein-coupled receptors |
US6319688B1 (en) | 1997-04-28 | 2001-11-20 | Smithkline Beecham Corporation | Polynucleotide encoding human sodium dependent phosphate transporter (IPT-1) |
WO1998051824A1 (en) | 1997-05-15 | 1998-11-19 | Abbott Laboratories | Reagents and methods useful for detecting disease of the urinary tract |
US6890749B2 (en) | 1997-05-15 | 2005-05-10 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
US20030060612A1 (en) | 1997-10-28 | 2003-03-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US20020034749A1 (en) | 1997-11-18 | 2002-03-21 | Billing-Medel Patricia A. | Reagents and methods useful for detecting diseases of the breast |
US6110695A (en) | 1997-12-02 | 2000-08-29 | The Regents Of The University Of California | Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1 |
DE69939527D1 (en) | 1998-03-13 | 2008-10-23 | Burnham Inst | TARGETING LINKS FOR DIFFERENT ORGANS AND TISSUE |
EP1078092B1 (en) | 1998-05-13 | 2011-08-03 | Epimmune Inc. | Expression vectors for stimulating an immune response and methods of using the same |
US20020187472A1 (en) | 2001-03-09 | 2002-12-12 | Preeti Lal | Steap-related protein |
US20030064397A1 (en) | 1998-05-22 | 2003-04-03 | Incyte Genomics, Inc. | Transmembrane protein differentially expressed in prostate and lung tumors |
CN1250293C (en) | 1998-05-22 | 2006-04-12 | 第一制药株式会社 | Drug composites |
EP1093600B1 (en) | 1998-07-08 | 2004-09-15 | E Ink Corporation | Methods for achieving improved color in microencapsulated electrophoretic devices |
GB9818731D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
GB9818732D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collection of compounds |
WO2000012130A1 (en) | 1998-08-27 | 2000-03-09 | Smithkline Beecham Corporation | Rp105 agonists and antagonists |
GB9818730D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collections of compounds |
PT1193270E (en) | 1998-08-27 | 2003-10-31 | Spirogen Ltd | PYRROLOBENZODIAZEPINAS |
JP4689781B2 (en) | 1998-09-03 | 2011-05-25 | 独立行政法人科学技術振興機構 | Amino acid transport protein and its gene |
AU5963699A (en) | 1998-10-02 | 2000-04-26 | Mcmaster University | Spliced form of (erb)b-2/neu oncogene |
WO2001057188A2 (en) | 2000-02-03 | 2001-08-09 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
US6858710B2 (en) | 1998-12-17 | 2005-02-22 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US6468546B1 (en) | 1998-12-17 | 2002-10-22 | Corixa Corporation | Compositions and methods for therapy and diagnosis of ovarian cancer |
US6962980B2 (en) | 1999-09-24 | 2005-11-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US20020119158A1 (en) | 1998-12-17 | 2002-08-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US20030091580A1 (en) | 2001-06-18 | 2003-05-15 | Mitcham Jennifer L. | Compositions and methods for the therapy and diagnosis of ovarian cancer |
AU776672B2 (en) | 1998-12-30 | 2004-09-16 | Beth Israel Deaconess Medical Center | Characterization of a calcium channel family |
DE60044665D1 (en) | 1999-01-29 | 2010-08-26 | Corixa Corp | HER2 / NEW FUSION PROTEINS |
GB9905124D0 (en) | 1999-03-05 | 1999-04-28 | Smithkline Beecham Biolog | Novel compounds |
US7109292B2 (en) | 1999-03-08 | 2006-09-19 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
US7312303B2 (en) | 1999-05-11 | 2007-12-25 | Genentech, Inc. | Anti-PRO4980 antibodies |
US6268488B1 (en) | 1999-05-25 | 2001-07-31 | Barbas, Iii Carlos F. | Prodrug activation using catalytic antibodies |
AU4952600A (en) | 1999-06-03 | 2000-12-28 | Takeda Chemical Industries Ltd. | Screening method with the use of cd100 |
DK2283866T3 (en) | 1999-06-25 | 2015-05-18 | Genentech Inc | METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES |
US6302318B1 (en) | 1999-06-29 | 2001-10-16 | General Electric Company | Method of providing wear-resistant coatings, and related articles |
US20030119113A1 (en) | 1999-07-20 | 2003-06-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7297770B2 (en) | 1999-08-10 | 2007-11-20 | Genentech, Inc. | PRO6496 polypeptides |
US7294696B2 (en) | 1999-08-17 | 2007-11-13 | Genentech Inc. | PRO7168 polypeptides |
US6909006B1 (en) | 1999-08-27 | 2005-06-21 | Spirogen Limited | Cyclopropylindole derivatives |
EP1208202A2 (en) | 1999-09-01 | 2002-05-29 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030232056A1 (en) | 1999-09-10 | 2003-12-18 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US20030129192A1 (en) | 1999-09-10 | 2003-07-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US20030206918A1 (en) | 1999-09-10 | 2003-11-06 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
ES2309012T3 (en) | 1999-10-29 | 2008-12-16 | Genentech, Inc. | COMPOSITIONS OF THE ANTI-PSCA ANTIBODY AND ITS PROCEDURES AGAINST CANCERIGENE CELLS THAT EXPRESS PSCA. |
ES2586850T3 (en) | 1999-11-29 | 2016-10-19 | The Trustees Of Columbia University In The City Of New York | Isolation of five novel genes encoding new Fc receptor-type melanomas involved in the pathogenesis of lymphoma / melanoma |
EP1248800A2 (en) | 1999-11-30 | 2002-10-16 | Corixa Corporation | Compositions and methods for therapy and diagnosis of breast cancer |
CA2393738A1 (en) | 1999-12-10 | 2001-06-14 | Epimmune Inc. | Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions |
NZ502058A (en) | 1999-12-23 | 2003-11-28 | Ovita Ltd | Isolated mutated nucleic acid molecule for regulation of ovulation rate |
US6610286B2 (en) | 1999-12-23 | 2003-08-26 | Zymogenetics, Inc. | Method for treating inflammation using soluble receptors to interleukin-20 |
DE60030769T2 (en) | 1999-12-23 | 2007-10-25 | Zymogenetics, Inc., Seattle | PROCESS FOR TREATMENT OF IGNITION |
ATE407950T1 (en) | 1999-12-23 | 2008-09-15 | Zymogenetics Inc | SOLUBLE INTERLEUKIN-20 RECEPTOR |
US7608681B2 (en) | 1999-12-24 | 2009-10-27 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
US20040001827A1 (en) | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
US7294695B2 (en) | 2000-01-20 | 2007-11-13 | Genentech, Inc. | PRO10268 polypeptides |
WO2001053463A2 (en) | 2000-01-21 | 2001-07-26 | Corixa Corporation | COMPOUNDS AND METHODS FOR PREVENTION AND TREATMENT OF HER-2/neu ASSOCIATED MALIGNANCIES |
US20030224379A1 (en) | 2000-01-21 | 2003-12-04 | Tang Y. Tom | Novel nucleic acids and polypeptides |
US20030104562A1 (en) | 2000-02-11 | 2003-06-05 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030219806A1 (en) | 2000-02-22 | 2003-11-27 | Millennium Pharmaceuticals, Inc. | Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor |
AU2001238596A1 (en) | 2000-02-22 | 2001-09-03 | Millennium Pharmaceuticals, Inc. | 18607, a novel human calcium channel |
US20040052793A1 (en) | 2001-02-22 | 2004-03-18 | Carter Paul J. | Caspase activivated prodrugs therapy |
US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
US20040005561A1 (en) | 2000-03-01 | 2004-01-08 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
WO2001066689A2 (en) | 2000-03-07 | 2001-09-13 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
JP2004521602A (en) | 2000-03-24 | 2004-07-22 | ファハリ サッチオグリュ | Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
JP2003530325A (en) | 2000-03-31 | 2003-10-14 | イーペーエフ ファルマシューティカルス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Diagnostics and agents for the investigation of cell surface proteomes of tumors and inflammatory cells, and the treatment of tumor and inflammatory diseases, preferably with the aid of specific chemokine receptor analysis and chemokine receptor / ligand interactions |
US7279294B2 (en) | 2000-04-03 | 2007-10-09 | The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services, Nih | Tumor markers in ovarian cancer |
CN1420929A (en) | 2000-04-07 | 2003-05-28 | 阿瑞那制药公司 | Non-endogenous, constitutively activated known G protein-coupled receptors |
WO2001088133A2 (en) | 2000-05-18 | 2001-11-22 | Lexicon Genetics Incorporated | Human semaphorin homologs and polynucleotides encoding the same |
AU2001274888A1 (en) | 2000-05-19 | 2001-12-03 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
AU2001275437A1 (en) | 2000-06-09 | 2001-12-17 | Idec Pharmaceuticals Corporation | Gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomas |
JP2004523203A (en) | 2000-06-16 | 2004-08-05 | インサイト・ゲノミックス・インコーポレイテッド | G protein-coupled receptor |
AU2001273151A1 (en) | 2000-06-30 | 2002-01-14 | Incyte Genomics, Inc. | Human extracellular matrix and cell adhesion polypeptides |
CA2406649A1 (en) | 2000-06-30 | 2002-01-10 | Human Genome Sciences, Inc. | B7-like polynucleotides, polypeptides, and antibodies |
MXPA02012749A (en) | 2000-06-30 | 2003-10-06 | Amgen Inc | B7-like molecules and uses thereof. |
WO2002006339A2 (en) | 2000-07-03 | 2002-01-24 | Curagen Corporation | Proteins and nucleic acids encoding same |
US20040044179A1 (en) | 2000-07-25 | 2004-03-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU2001283507A1 (en) | 2000-07-27 | 2002-02-13 | Mayo Foundation For Medical Education And Research | B7-h3 and b7-h4, novel immunoregulatory molecules |
ATE396266T1 (en) | 2000-07-28 | 2008-06-15 | Ulrich Wissenbach | TRP8 CANCER MARKER |
US7229623B1 (en) | 2000-08-03 | 2007-06-12 | Corixa Corporation | Her-2/neu fusion proteins |
WO2002013847A2 (en) | 2000-08-14 | 2002-02-21 | Corixa Corporation | Methods for diagnosis and therapy of hematological and virus-associated malignancies |
CN1537164A (en) | 2000-08-14 | 2004-10-13 | Compositions and methods for therapy and diagnosis of Her-2/neu associated malignancies | |
GB0020953D0 (en) | 2000-08-24 | 2000-10-11 | Smithkline Beecham Biolog | Vaccine |
EP1311674A2 (en) | 2000-08-24 | 2003-05-21 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP1346040A2 (en) | 2000-09-11 | 2003-09-24 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
US20030119121A1 (en) | 2000-09-15 | 2003-06-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
DE60141546D1 (en) | 2000-09-15 | 2010-04-22 | Zymogenetics Inc | Polypeptides containing the extracellular domain of IL-20RA and / or IL-20RB |
US6613567B1 (en) | 2000-09-15 | 2003-09-02 | Isis Pharmaceuticals, Inc. | Antisense inhibition of Her-2 expression |
AU9272401A (en) | 2000-09-18 | 2002-03-26 | Biogen Inc | Cripto mutant and uses thereof |
UA83458C2 (en) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf) |
US6660742B2 (en) | 2000-09-19 | 2003-12-09 | Taiho Pharmaceutical Co. Ltd. | Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins |
AU2002215345A1 (en) | 2000-10-13 | 2002-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer |
EP1407017B1 (en) | 2000-11-07 | 2009-06-03 | ZymoGenetics, Inc. | Human tumor necrosis factor receptor |
US20020150573A1 (en) | 2000-11-10 | 2002-10-17 | The Rockefeller University | Anti-Igalpha-Igbeta antibody for lymphoma therapy |
US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
WO2002061087A2 (en) | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides |
WO2002054940A2 (en) | 2001-01-12 | 2002-07-18 | University Of Medicine & Dentistry Of New Jersey | Bone morphogenetic protein-2 in the treatment and diagnosis of cancer |
US20030119133A1 (en) | 2001-01-16 | 2003-06-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030119125A1 (en) | 2001-01-16 | 2003-06-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2002059377A2 (en) | 2001-01-24 | 2002-08-01 | Protein Design Labs | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
WO2002060317A2 (en) | 2001-01-30 | 2002-08-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of pancreatic cancer |
WO2002064798A1 (en) | 2001-02-12 | 2002-08-22 | Bionomics Limited | Dna sequences differentially expressed in tumour cell lines |
US20030087250A1 (en) | 2001-03-14 | 2003-05-08 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
AU2002311787A1 (en) | 2001-03-28 | 2002-10-15 | Zycos Inc. | Translational profiling |
US6362331B1 (en) | 2001-03-30 | 2002-03-26 | Council Of Scientific And Industrial Research | Process for the preparation of antitumor agents |
WO2003008537A2 (en) | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
US6820011B2 (en) | 2001-04-11 | 2004-11-16 | The Regents Of The University Of Colorado | Three-dimensional structure of complement receptor type 2 and uses thereof |
JP5232350B2 (en) | 2001-04-17 | 2013-07-10 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー | Repeat sequence of CA125 gene and its use for diagnostic and therapeutic intervention |
AU2002309583A1 (en) | 2001-04-18 | 2002-11-05 | Protein Desing Labs, Inc. | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
PT1390389E (en) | 2001-04-26 | 2009-04-03 | Biogen Idec Inc | Cripto blocking antibodies and uses thereof |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
EP1515982A4 (en) | 2001-05-09 | 2005-10-26 | Corixa Corp | Compositions and methods for the therapy and diagnosis of prostate cancer |
US20030078399A1 (en) | 2001-05-11 | 2003-04-24 | Sloan-Kettering Institute For Cancer Research | Nucleic acid sequence encoding ovarian antigen, CA125, and uses thereof |
SI2116259T1 (en) | 2001-05-24 | 2012-11-30 | Zymogenetics Inc | TACI-immunoglobulin fusion proteins |
WO2002098897A2 (en) * | 2001-06-01 | 2002-12-12 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
US7157558B2 (en) | 2001-06-01 | 2007-01-02 | Genentech, Inc. | Polypeptide encoded by a polynucleotide overexpresses in tumors |
WO2003000842A2 (en) | 2001-06-04 | 2003-01-03 | Curagen Corporation | Novel proteins and nucleic acids encoding same |
AU2002314901A1 (en) | 2001-06-04 | 2002-12-16 | Eos Biotechnology, Inc. | Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer |
EP1456650B1 (en) | 2001-06-05 | 2010-10-06 | Exelixis, Inc. | Gfats as modifiers of the p53 pathway and methods of use |
CA2449275A1 (en) | 2001-06-05 | 2002-12-12 | Exelixis, Inc. | Dgks as modifiers of the p53 pathway and methods of use |
US7235358B2 (en) | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
US7125663B2 (en) | 2001-06-13 | 2006-10-24 | Millenium Pharmaceuticals, Inc. | Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer |
JP2005508144A (en) | 2001-06-18 | 2005-03-31 | イオス バイオテクノロジー,インコーポレイティド | Ovarian cancer diagnostic method, composition and method for screening ovarian cancer modulator |
US7189507B2 (en) | 2001-06-18 | 2007-03-13 | Pdl Biopharma, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
WO2003004989A2 (en) | 2001-06-21 | 2003-01-16 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
US20030108958A1 (en) | 2001-06-28 | 2003-06-12 | Rene De Waal Malefyt | Biological activity of AK155 |
AU2002314433A1 (en) | 2001-07-02 | 2003-01-21 | Licentia Ltd. | Ephrin-tie receptor materials and methods |
US20040076955A1 (en) | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
WO2003003984A2 (en) | 2001-07-05 | 2003-01-16 | Curagen Corporation | Novel proteins and nucleic acids encoding same |
WO2003055439A2 (en) | 2001-07-18 | 2003-07-10 | The Regents Of The University Of California | Her2/neu target antigen and use of same to stimulate an immune response |
US20030108963A1 (en) | 2001-07-25 | 2003-06-12 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer |
MXPA04001050A (en) | 2001-08-03 | 2004-07-08 | Genentech Inc | Tacis and br3 polypeptides and uses thereof. |
CA2457819A1 (en) | 2001-08-14 | 2003-02-27 | The General Hospital Corporation | Nucleic acid and amino acid sequences involved in pain |
US20030092013A1 (en) | 2001-08-16 | 2003-05-15 | Vitivity, Inc. | Diagnosis and treatment of vascular disease |
WO2003018621A2 (en) | 2001-08-23 | 2003-03-06 | Oxford Biomedica (Uk) Limited | Genes |
AU2002357643A1 (en) | 2001-08-29 | 2003-04-14 | Vanderbilt University | The human mob-5 (il-24) receptors and uses thereof |
US20030124579A1 (en) | 2001-09-05 | 2003-07-03 | Eos Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
ES2532757T3 (en) | 2001-09-06 | 2015-03-31 | Agensys, Inc. | Nucleic acid and corresponding protein called STEAP-1 useful in the treatment and detection of cancer |
WO2003025138A2 (en) | 2001-09-17 | 2003-03-27 | Protein Design Labs, Inc. | Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer |
US20050004017A1 (en) | 2001-09-18 | 2005-01-06 | Yuval Reiss | Methods and compositions for treating hcap associated diseases |
KR101008758B1 (en) | 2001-09-18 | 2011-01-14 | 제넨테크, 인크. | Compositions and Methods for the Diagnosis and Treatment of Tumor |
CA2460621A1 (en) | 2001-09-19 | 2003-03-27 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
WO2003026493A2 (en) | 2001-09-28 | 2003-04-03 | Bing Yang | Diagnosis and treatment of diseases caused by mutations in cd72 |
WO2003029277A2 (en) | 2001-10-03 | 2003-04-10 | Rigel Pharmaceuticals, Inc. | Modulators of lymphocyte activation and migration |
US20040249144A1 (en) | 2001-10-03 | 2004-12-09 | Zairen Sun | Regulated breast cancer genes |
US20050089957A1 (en) | 2001-10-19 | 2005-04-28 | Audrey Goddard | Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders |
US20040241703A1 (en) | 2002-08-19 | 2004-12-02 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US20050123925A1 (en) | 2002-11-15 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7825089B2 (en) | 2001-10-24 | 2010-11-02 | National Jewish Health | Three-dimensional structures of TALL-1 and its cognate receptors and modified proteins and methods related thereto |
ATE349554T1 (en) | 2001-10-31 | 2007-01-15 | Alcon Inc | BONE MORPHOGENIC PROTEINS (BMP), BMP RECEPTORS AND BMP BINDING PROTEINS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF GLAUCOMA |
WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
US20030232350A1 (en) | 2001-11-13 | 2003-12-18 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
US20050123536A1 (en) | 2001-11-20 | 2005-06-09 | Che-Leung Law | Treatment of immunological disorders using anti-dc30 antibodies |
EP1448226A1 (en) | 2001-11-29 | 2004-08-25 | Genset S.A. | Agonists and antagonists of prolixin for the treatment of metabolic disorders |
AU2002349784A1 (en) | 2001-12-03 | 2003-06-17 | Asahi Kasei Pharma Corporation | Nf-kappab activating genes |
EP1504099A4 (en) | 2001-12-10 | 2006-05-10 | Nuvelo Inc | Novel nucleic acids and polypeptides |
US20030134790A1 (en) | 2002-01-11 | 2003-07-17 | University Of Medicine And Dentistry Of New Jersey | Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer |
US20050041271A1 (en) | 2002-01-16 | 2005-02-24 | Ito Tomoyoshi | Moving image holography reproducing device and color moving image holography reproducing device |
US7452675B2 (en) | 2002-01-25 | 2008-11-18 | The Queen's Medical Center | Methods of screening for TRPM4b modulators |
EP1476120B1 (en) | 2002-02-21 | 2010-09-29 | Duke University | Treatment methods using anti-cd22 antibodies |
CA2476518A1 (en) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
WO2003074674A2 (en) | 2002-03-01 | 2003-09-12 | Exelixis, Inc. | MSRAs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
WO2003101400A2 (en) | 2002-06-04 | 2003-12-11 | Avalon Pharmaceuticals, Inc. | Cancer-linked gene as target for chemotherapy |
US6660856B2 (en) | 2002-03-08 | 2003-12-09 | Kaohsiung Medical University | Synthesis of pyrrolo[2,1-c][1,4]benzodiazepine analogues |
EP2258712A3 (en) | 2002-03-15 | 2011-05-04 | Multicell Immunotherapeutics, Inc. | Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs |
CA2486490A1 (en) | 2002-03-19 | 2003-12-31 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
EP1579186A4 (en) | 2002-03-21 | 2008-10-08 | Sunesis Pharmaceuticals Inc | Identification of kinase inhibitors |
US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
JP2005520566A (en) | 2002-03-22 | 2005-07-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Cripto specific antibodies |
AU2003245239A1 (en) | 2002-03-25 | 2003-11-03 | Uab Research Foundation | FC receptor homolog, reagents, and uses thereof |
AU2003222103A1 (en) | 2002-03-28 | 2003-10-13 | Idec Pharmaceuticals Corporation | Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas |
US20030194704A1 (en) | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
WO2003087306A2 (en) | 2002-04-05 | 2003-10-23 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer |
WO2003087768A2 (en) | 2002-04-12 | 2003-10-23 | Mitokor | Targets for therapeutic intervention identified in the mitochondrial proteome |
EP2011886A3 (en) | 2002-04-16 | 2009-02-11 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
WO2003089904A2 (en) | 2002-04-17 | 2003-10-30 | Baylor College Of Medicine | Aib1 as a prognostic marker and predictor of resistance to encocrine therapy |
AU2003228869A1 (en) | 2002-05-03 | 2003-11-17 | Incyte Corporation | Transporters and ion channels |
EP1572925A4 (en) | 2002-05-15 | 2007-08-15 | Avalon Pharmaceuticals | Cancer-linked gene as target for chemotherapy |
AU2003232453A1 (en) | 2002-05-30 | 2003-12-19 | David K. Bol | Human solute carrier family 7 member 11 (hslc7a11) |
AU2003240495A1 (en) | 2002-06-04 | 2003-12-19 | Incyte Corporation | Diagnostics markers for lung cancer |
SG145559A1 (en) | 2002-06-06 | 2008-09-29 | Oncotherapy Science Inc | Genes and polypeptides relating to human colon cancers |
WO2003104270A2 (en) | 2002-06-06 | 2003-12-18 | Ingenium Pharmaceuticals Ag | Dudulin 2 genes, expression products, non-human animal model: uses in human hematological disease |
AU2003249691A1 (en) | 2002-06-07 | 2003-12-22 | Avalon Pharmaceuticals, Inc | Cancer-linked gene as target for chemotherapy |
WO2003105758A2 (en) | 2002-06-12 | 2003-12-24 | Avalon Pharmaceuticals, Inc. | Cancer-linked gene as target for chemotherapy |
CA2487809A1 (en) | 2002-06-18 | 2003-12-24 | Archemix Corp. | Aptamer-toxin molecules and methods for using same |
US20040249130A1 (en) | 2002-06-18 | 2004-12-09 | Martin Stanton | Aptamer-toxin molecules and methods for using same |
WO2004000221A2 (en) | 2002-06-20 | 2003-12-31 | The Regents Of The University Of California | Compositions and methods for modulating lymphocyte activity |
EP1534331B1 (en) | 2002-06-21 | 2014-10-29 | Johns Hopkins University School of Medicine | Membrane associated tumor endothelium markers |
DE10229834A1 (en) | 2002-07-03 | 2004-01-29 | Zinser Textilmaschinen Gmbh | Drafting system for spinning machines with a downstream compacting device |
AU2003281515A1 (en) | 2002-07-19 | 2004-02-09 | Cellzome Ag | Protein complexes of cellular networks underlying the development of cancer and other diseases |
MXPA05000940A (en) | 2002-07-25 | 2005-05-16 | Genentech Inc | Taci antibodies and uses thereof. |
ES2556641T3 (en) | 2002-07-31 | 2016-01-19 | Seattle Genetics, Inc. | Drug conjugates and their use to treat cancer, an autoimmune disease or an infectious disease |
AU2003294210A1 (en) | 2002-07-31 | 2004-05-04 | Seattle Genetics, Inc | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
AU2003251471A1 (en) | 2002-08-06 | 2004-02-25 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 5(cxcr5) |
JP2004121218A (en) | 2002-08-06 | 2004-04-22 | Jenokkusu Soyaku Kenkyusho:Kk | Method for testing bronchial asthma or chronic obstructive pulmonary disease |
US7504211B2 (en) | 2002-08-27 | 2009-03-17 | Bristol-Myers Squibb Company | Methods of using EPHA2 for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells |
WO2004020595A2 (en) | 2002-08-29 | 2004-03-11 | Five Prime Therapeutics, Inc. | Novel human polypeptides encoded by polynucleotides |
WO2004019993A1 (en) | 2002-08-30 | 2004-03-11 | Ramot At Tel Aviv University Ltd. | Self-immolative dendrimers releasing many active moieties upon a single activating event |
AU2002951346A0 (en) | 2002-09-05 | 2002-09-26 | Garvan Institute Of Medical Research | Diagnosis of ovarian cancer |
MXPA05002455A (en) | 2002-09-06 | 2005-06-03 | Mannkind Corp | Epitope sequences. |
EP1581648A2 (en) | 2002-09-09 | 2005-10-05 | Nura, Inc. | G protein coupled receptors and uses thereof |
JP2004113151A (en) | 2002-09-27 | 2004-04-15 | Sankyo Co Ltd | Oncogene and its application |
AU2003278002A1 (en) | 2002-10-03 | 2004-04-23 | Mcgill Univeristy | Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics |
WO2004032842A2 (en) | 2002-10-04 | 2004-04-22 | Van Andel Research Institute | Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers |
US20040138269A1 (en) | 2002-10-11 | 2004-07-15 | Sugen, Inc. | Substituted pyrroles as kinase inhibitors |
EP2364716A3 (en) | 2002-11-08 | 2012-01-11 | Genentech, Inc. | Compositions and methods for the treatment of natural killer cell related diseases |
US20040146907A1 (en) | 2002-11-13 | 2004-07-29 | Genentech, Inc. | Methods and compositions for detecting dysplasia |
US7705045B2 (en) | 2002-11-14 | 2010-04-27 | Syntarga, B.V. | Prodrugs built as multiple self-elimination-release spacers |
GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
AU2003294355A1 (en) | 2002-11-15 | 2004-06-15 | The Board Of Trustees Of The University Of Arkansas | Ca125 gene and its use for diagnostic and therapeutic interventions |
CA2505601C (en) | 2002-11-15 | 2014-10-28 | Musc Foundation For Research Development | Complement receptor 2 targeted complement modulators |
US20080213166A1 (en) | 2002-11-20 | 2008-09-04 | Biogen Idec Inc. | Novel Gene Targets and Ligands that Bind Thereto for Treatment and Diagnosis of Colon Carcinomas |
EP1624753B1 (en) | 2002-11-21 | 2012-01-25 | The University of Utah Research Foundation | Purinergic modulation of smell |
AU2003298786A1 (en) | 2002-11-26 | 2004-06-18 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
EP1581641A4 (en) | 2002-12-06 | 2006-11-15 | Diadexus Inc | Compositions, splice variants and methods relating to ovarian specific genes and proteins |
US20040157278A1 (en) | 2002-12-13 | 2004-08-12 | Bayer Corporation | Detection methods using TIMP 1 |
JP4898120B2 (en) | 2002-12-20 | 2012-03-14 | アボット バイオセラピューティクス コーポレイション | Antibodies against GPR64 and methods of use thereof |
US20050249671A9 (en) | 2002-12-23 | 2005-11-10 | David Parmelee | Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof |
JP2007520995A (en) | 2003-01-08 | 2007-08-02 | ブリストル−マイヤーズ スクイブ カンパニー | Biomarkers and methods for determining susceptibility to epidermal growth factor receptor modulators |
US20050227301A1 (en) | 2003-01-10 | 2005-10-13 | Polgen | Cell cycle progression proteins |
WO2004063355A2 (en) | 2003-01-10 | 2004-07-29 | Protein Design Labs, Inc. | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer |
WO2004065577A2 (en) | 2003-01-14 | 2004-08-05 | Bristol-Myers Squibb Company | Polynucleotides and polypeptides associated with the nf-kb pathway |
WO2004065576A2 (en) | 2003-01-15 | 2004-08-05 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the treatment of urological disorder using differential expressed polypeptides |
JP2009520459A (en) | 2003-02-14 | 2009-05-28 | サイグレス ディスカバリー, インコーポレイテッド | Therapeutic target in cancer |
US20030224411A1 (en) | 2003-03-13 | 2003-12-04 | Stanton Lawrence W. | Genes that are up- or down-regulated during differentiation of human embryonic stem cells |
WO2004087717A1 (en) | 2003-03-31 | 2004-10-14 | Council Of Scientific And Industrial Research | Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines as potential antitumour agents and process thereof |
GB0321295D0 (en) | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
WO2005040170A2 (en) | 2003-10-22 | 2005-05-06 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto |
GB0416511D0 (en) | 2003-10-22 | 2004-08-25 | Spirogen Ltd | Pyrrolobenzodiazepines |
KR101438983B1 (en) | 2003-11-06 | 2014-09-05 | 시애틀 지네틱스, 인크. | Monomethylvaline compounds capable of conjugation to ligands |
US20050288491A1 (en) | 2004-02-17 | 2005-12-29 | Wilson David S | Super-humanized antibodies against respiratory syncytial virus |
US7375078B2 (en) | 2004-02-23 | 2008-05-20 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
GB0404578D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
EP1720881B9 (en) | 2004-03-01 | 2013-04-17 | Spirogen Sàrl | 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepins |
GB0404574D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Amino acids |
GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
DE102004010943A1 (en) | 2004-03-03 | 2005-09-29 | Degussa Ag | Process for the preparation of N-protected 4-ketproline derivatives |
JP5166861B2 (en) | 2004-03-09 | 2013-03-21 | スピロゲン リミティッド | Pyrrolobenzodiazepine |
FR2869231B1 (en) | 2004-04-27 | 2008-03-14 | Sod Conseils Rech Applic | THERAPEUTIC COMPOSITION CONTAINING AT LEAST ONE PYRROLOBENZODIAZEPINE DERIVATIVE AND FLUDARABINE |
GB0410725D0 (en) | 2004-05-13 | 2004-06-16 | Spirogen Ltd | Pyrrolobenzodiazepine therapeutic agents |
PL1791565T3 (en) | 2004-09-23 | 2016-10-31 | Cysteine engineered antibodies and conjugates | |
US7849909B2 (en) | 2004-12-24 | 2010-12-14 | Showa Denko K.K. | Production method of thermoelectric semiconductor alloy, thermoelectric conversion module and thermoelectric power generating device |
US20080206239A1 (en) | 2005-02-03 | 2008-08-28 | Antitope Limited | Human Antibodies And Proteins |
CA2605507C (en) | 2005-04-19 | 2016-06-28 | Seattle Genetics, Inc. | Humanized anti-cd70 binding agents and uses thereof |
DE602006011300D1 (en) | 2005-04-21 | 2010-02-04 | Spirogen Ltd | PYRROLOBENZODIAZEPINE |
ATE427949T1 (en) | 2005-10-05 | 2009-04-15 | Spirogen Ltd | 4-A4-(5-OXO-2,3,5,11A-TETRAHYDRO-5H-PYRROLO A2, 1-CUA1,4UBENZODIAZEPINE-8-YLOXY)-BUTYRYLAMINOU-1 - PYRROLE-2-CARBONATE ALKYL ESTER DERIVATIVES AND RELATED COMPOUND FOR THE TREATMENT OF A PROLIFERATIVE DISEASE |
NZ567140A (en) | 2005-10-07 | 2011-09-30 | Exelixis Inc | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
ES2374964T3 (en) | 2006-01-25 | 2012-02-23 | Sanofi | CYTOTOXIC AGENTS UNDERSTANDING NEW TOMAIMYCIN DERIVATIVES. |
AU2007274738B2 (en) | 2006-07-18 | 2013-11-28 | Sanofi-Aventis | Antagonist antibody against EphA2 for the treatment of cancer |
US20080112961A1 (en) | 2006-10-09 | 2008-05-15 | Macrogenics, Inc. | Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
EP2609932B1 (en) | 2006-12-01 | 2022-02-02 | Seagen Inc. | Variant target binding agents and uses thereof |
CA2683568A1 (en) | 2007-05-08 | 2008-11-20 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
SI2019104T1 (en) | 2007-07-19 | 2013-12-31 | Sanofi | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use |
BRPI0818780A2 (en) | 2007-10-19 | 2015-04-22 | Genentech Inc | Cysteine-Designed Anti-Tenb2 Antibodies and Antibody Drug Conjugates |
PL2842575T3 (en) | 2008-03-18 | 2018-02-28 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
GB0813432D0 (en) | 2008-07-22 | 2008-08-27 | Spirogen Ltd | Pyrrolobenzodiazepines |
KR101631610B1 (en) | 2008-10-15 | 2016-06-17 | 짐머 게엠베하 | Intramedullary nail |
GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
GB0819097D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
KR101984053B1 (en) | 2009-02-05 | 2019-05-30 | 이뮤노젠 아이엔씨 | Novel benzodiazepine derivatives |
FR2949469A1 (en) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | ANTICANCER DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
AU2010289527C1 (en) | 2009-09-01 | 2014-10-30 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
CA2775350A1 (en) | 2009-09-24 | 2011-03-31 | Seattle Genetics, Inc. | Dr5 ligand drug conjugates |
US9040526B2 (en) | 2010-02-09 | 2015-05-26 | Bristol-Myers Squibb Company | Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity |
IT1398164B1 (en) * | 2010-02-10 | 2013-02-14 | Givi S R L Unipersonale | COUPLING SYSTEM FOR SUITCASES FOR MOTORCYCLES |
BR112012026801B8 (en) * | 2010-04-15 | 2021-05-25 | Medimmune Ltd | targeted pyrrolobenzodiazepine conjugates, pharmaceutical composition, use thereof for treatment of a proliferative or autoimmune disease and drug binding |
WO2011130598A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
GB201006340D0 (en) * | 2010-04-15 | 2010-06-02 | Spirogen Ltd | Synthesis method and intermediates |
NZ602933A (en) | 2010-04-15 | 2014-09-26 | Seattle Genetics Inc | Pyrrolobenzodiazepines used to treat proliferative diseases |
WO2011130615A2 (en) | 2010-04-15 | 2011-10-20 | Dr. Reddy's Laboratories Ltd. | Preparation of lacosamide |
WO2012112708A1 (en) | 2011-02-15 | 2012-08-23 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and methods of preparation |
CA2849039C (en) | 2011-09-20 | 2018-09-18 | Spirogen Sarl | Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates |
AU2012322613B2 (en) | 2011-10-14 | 2016-04-21 | Medimmune Limited | Pyrrolobenzodiazepines and targeted conjugates |
EA028457B1 (en) | 2011-10-14 | 2017-11-30 | Медимьюн Лимитед | Pyrrolobenzodiazepines |
EA029046B1 (en) | 2011-10-14 | 2018-02-28 | Медимьюн Лимитед | Pyrrolobenzodiazepines and intermediates for the preparation thereof, synthesis methods thereof |
WO2013055990A1 (en) | 2011-10-14 | 2013-04-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
CA2850264C (en) | 2011-10-14 | 2019-11-05 | Spirogen Sarl | Pyrrolobenzodiazepines |
US11135303B2 (en) | 2011-10-14 | 2021-10-05 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
AR091700A1 (en) | 2012-07-09 | 2015-02-25 | Genentech Inc | ANTI-CD79B ANTIBODIES AND IMMUNOCATION |
SG11201500087VA (en) | 2012-07-09 | 2015-02-27 | Genentech Inc | Immunoconjugates comprising anti-cd22 antibodies |
CA2879665A1 (en) | 2012-08-02 | 2014-02-06 | Genentech, Inc. | Anti-etbr antibodies and immunoconjugates |
EP2839860B1 (en) | 2012-10-12 | 2019-05-01 | MedImmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
CN105102003B (en) | 2012-10-12 | 2019-03-05 | Adc疗法责任有限公司 | Tall and erect-anti-PSMA antibody conjugates of Pyrrolobenzodiazepines |
SI3470086T1 (en) | 2012-10-12 | 2021-03-31 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
CA2885305C (en) | 2012-10-12 | 2019-11-12 | Spirogen Sarl | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
AU2013366493B2 (en) * | 2012-12-21 | 2017-08-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
KR102057755B1 (en) | 2013-03-13 | 2019-12-19 | 메디뮨 리미티드 | Pyrrolobenzodiazepines and conjugates thereof |
-
2013
- 2013-10-11 CN CN201380065405.7A patent/CN105102003B/en not_active Expired - Fee Related
- 2013-10-11 US US14/434,812 patent/US10751346B2/en active Active
- 2013-10-11 JP JP2015536162A patent/JP6270859B2/en not_active Expired - Fee Related
- 2013-10-11 SI SI201331199T patent/SI2906253T1/en unknown
- 2013-10-11 BR BR112015008173A patent/BR112015008173A2/en not_active IP Right Cessation
- 2013-10-11 RS RS20181128A patent/RS57694B1/en unknown
- 2013-10-11 AU AU2013328619A patent/AU2013328619B2/en not_active Ceased
- 2013-10-11 PL PL13795435T patent/PL2906253T3/en unknown
- 2013-10-11 KR KR1020157012364A patent/KR101986404B1/en active IP Right Grant
- 2013-10-11 TR TR2018/15418T patent/TR201815418T4/en unknown
- 2013-10-11 DK DK13795435.0T patent/DK2906253T3/en active
- 2013-10-11 HU HUE13795435A patent/HUE041274T2/en unknown
- 2013-10-11 CA CA2887894A patent/CA2887894C/en not_active Expired - Fee Related
- 2013-10-11 MX MX2015004416A patent/MX364326B/en active IP Right Grant
- 2013-10-11 EP EP13795435.0A patent/EP2906253B9/en active Active
- 2013-10-11 PT PT13795435T patent/PT2906253T/en unknown
- 2013-10-11 LT LTEP13795435.0T patent/LT2906253T/en unknown
- 2013-10-11 ES ES13795435.0T patent/ES2690067T3/en active Active
- 2013-10-11 WO PCT/EP2013/071341 patent/WO2014057113A1/en active Application Filing
- 2013-10-11 NZ NZ707486A patent/NZ707486A/en not_active IP Right Cessation
-
2018
- 2018-10-11 HR HRP20181646TT patent/HRP20181646T2/en unknown
- 2018-10-23 CY CY181101089T patent/CY1120916T1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7514078B2 (en) * | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
Also Published As
Publication number | Publication date |
---|---|
CY1120916T1 (en) | 2019-12-11 |
AU2013328619A1 (en) | 2015-04-23 |
EP2906253A1 (en) | 2015-08-19 |
CA2887894C (en) | 2019-10-29 |
ES2690067T3 (en) | 2018-11-19 |
KR101986404B1 (en) | 2019-06-07 |
DK2906253T3 (en) | 2018-10-22 |
MX2015004416A (en) | 2015-10-15 |
MX364326B (en) | 2019-04-23 |
NZ707486A (en) | 2018-09-28 |
KR20150085813A (en) | 2015-07-24 |
BR112015008173A2 (en) | 2017-11-28 |
TR201815418T4 (en) | 2018-11-21 |
CN105102003A (en) | 2015-11-25 |
HRP20181646T1 (en) | 2018-12-14 |
EP2906253B9 (en) | 2019-04-10 |
PT2906253T (en) | 2018-11-05 |
JP2015534577A (en) | 2015-12-03 |
EP2906253B1 (en) | 2018-08-01 |
LT2906253T (en) | 2018-10-10 |
HRP20181646T2 (en) | 2019-08-09 |
JP6270859B2 (en) | 2018-01-31 |
AU2013328619B2 (en) | 2016-11-17 |
ES2690067T9 (en) | 2019-06-19 |
US10751346B2 (en) | 2020-08-25 |
HUE041274T2 (en) | 2019-05-28 |
WO2014057113A1 (en) | 2014-04-17 |
PL2906253T3 (en) | 2019-02-28 |
SI2906253T1 (en) | 2018-11-30 |
US20150283258A1 (en) | 2015-10-08 |
CA2887894A1 (en) | 2014-04-17 |
RS57694B1 (en) | 2018-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105102003B (en) | Tall and erect-anti-PSMA antibody conjugates of Pyrrolobenzodiazepines | |
CN105102004B (en) | Pyrrolobenzodiazepines Zhuo-anti-CD22 antibody conjugate | |
CN105102068B (en) | Pyrrolobenzodiazepines Zhuo-antibody conjugates | |
CN105050661B (en) | Pyrrolobenzodiazepines Zhuo antibody conjugates | |
CN104955485B (en) | Pyrrolobenzodiazepines Zhuo Anti-HER 2 conjugate | |
EP2906250A1 (en) | Pyrrolobenzodiazepine-anti-psma antibody conjugates | |
CN108093640A (en) | Site-specific antibodie-drug conjugate | |
EP2906297A1 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
CN107683146A (en) | Site-specific antibodie drug conjugate | |
CN107548306A (en) | Site-specific antibodie drug conjugate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190305 Termination date: 20201011 |